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Rising global concern about antimicrobial resistance (AMR) has drawn attention to the use of 
antibiotics in livestock. Of particular concern is the excessive, sub-therapeutic use of 
antibiotics for disease prevention, in particular the Critically Important Antimicrobials (CIA), 
which are reserved as a last resort for the most severe and resistant human infections. 
Understanding current usage of antibiotics in these animals is essential to design and 
implement effective interventions that will reduce unnecessary antibiotic use. However, to 
date few studies have assessed the use of antibiotics for pig production in low- and middle-
income countries.  
The aim of the thesis is to investigate patterns of antibiotic use and determinants influencing 
antibiotic use in pig production in Thailand in order to contribute to the development of 
policies to optimise the use of antibiotics in pig production and control AMR. 
Two systematic reviews on antibiotic use in pig production and its associations; and methods 
and measurements for quantification of the use of antibiotics in pig production were 
conducted to explore the antibiotic use in pig production globally. Using mixed methods for 
the empirical research, a survey of pig farmers (n=84), a survey of feed mills (n=31), and 
interviews with veterinarians (n=5) were undertaken to understand the patterns of antibiotic 
use. A total of 31 in-depth interviews were conducted with different categories of actors: pig 
farmers (n=13), drug retailers (n=5), veterinarians (n=7), government officers (n=3) and 
representatives of animal and human health associations (n=2) to explore determinants 
influencing antibiotic use in pig production in Thailand.    
Evidence revealed several practices associated with antibiotic use in pig production in 
Thailand, which may contribute to the emergence and threat of AMR to people including a 
high proportion of pig farmers using antibiotics for disease prevention and using antibiotics 
in the CIA category; and a large volume of antibiotics being administered in the form of 
medicated feed. The multi-faceted nature of the views and practices may contribute to misuse 
or overuse of antibiotics in the study locations, including misconceptions about the nature of 
antibiotics and AMR (particularly among smallholders), lack of facilities and financial means 
to establish an antibiotic-free farm, lack of sufficient training on AMR and antibiotic 
prescribing for veterinarians, the profit motive of pharmaceutical companies and their ties to 
farm consultants, and lack of sufficient regulatory oversight. 
 8 
Given the concern on the loss of antibiotic effectiveness through the development of AMR, 
collective action is required to improve the practices of all actors towards the optimisation of 
antibiotic use in pig production. For example, farmers need better access to veterinary 
services and reliable information about animal health needs and antibiotics. Further 
development of professional training and clinical guidelines, and the establishment of a code 
of conduct, would help improve antibiotic dispensing practices. In addition, a combination of 
market access rules by the private sector and control through regulations such as establishing 
veterinary antibiotic prescriptions monitoring systems and limiting the pharmaceutical 
industry’s influence on the farmers’ and veterinarians’ decision on the use of antibiotics, 
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SECTION A: BACKGROUND 
Chapter 1 Introduction  
Summary  
In this chapter, I set out the background to Antimicrobial Resistance (AMR) and its 
significance for global health, and I explain the mechanism of AMR emergence and its 
drivers including the use of antibiotics. Antibiotics are used widely in farming and animal 
food production around the world. In this chapter, I describe the use of antibiotics in pig 
production, which is the focus of the research on antibiotic use and AMR presented in this 
thesis. I address the contribution of agricultural to AMR role of agriculture and antibiotic use 
in animal production before describing global policy on AMR.  
Following this, I provide background information about pig production, the AMR and 
antibiotic use in pig production, antibiotic distribution and control of antibiotic in Thailand. 
The chapter concludes with a presentation of the rationale of the thesis, the aim and 








1.1 Antimicrobial resistance: a threat to global health  
Antimicrobial resistance (AMR) is a serious threat to global health. It has become a growing 
concern that creates serious implications for human health which leading to increased death 
rates and health care spending. It is estimated that AMR will claim 10 million deaths annually 
and cost the world up to US$ 100 trillion, equivalent to 2% to 3.5% of Gross Domestic 
Product (GDP) by 2050 (1).  
The discovery of antimicrobials in the 1940s transformed the therapeutic paradigm in health 
care. Since then, antimicrobials have been a vital tool to fight infectious diseases and are one 
of the most important medical interventions in modern medicine. However, the efficacy of 
antimicrobials in health care is increasingly under threat worldwide as a result of the 
emergence and spread of untreatable infections with common bacterial pathogens. The 
situation is worsened by the lack of discovery of any new classes of antimicrobials to treat 
bacterial infection since the 1980s; meanwhile the resistance rate is increasing (2). The World 
Health Organization (WHO) says that, “Without urgent action, we are heading for a ‘post-
antibiotic era’, in which common infections and minor injuries can once again kill.” (3). 
Resistant microbes do not respect international borders. Due to the increase in international 
travel, the vulnerability of any country to disease is arising faster than ever before in human 
history. An example of globalisation driving AMR transmission is seen in the spread of the 
novel carbapenem resistance mechanism of New Delhi metallo‐beta‐lactamase (bla NDM‐1) 
in Enterobacteriaceae. The bla NDM‐1 gene was first reported in 2009 in a Klebsiella 
pneumonia isolated in a Swedish hospital from a patient previously admitted to a hospital in 
India. Later, the isolation of bacterial species carrying the bla NDM‐1 gene was reported in 
several countries worldwide, mostly from patients who had travelled to and from the Indian 
subcontinent (4). This example shows that no one single country can protect the health of its 
population against AMR. International collective action is therefore essential.  
The problem of resistant bacteria is not only a public health challenge for the human health 
sector. AMR has extended far beyond humans because resistant pathogens can spread across 
humans, animals, food and the environment. The drivers of AMR include the use of 
antimicrobials in both humans and livestock. Most classes of antimicrobials used to treat 
bacterial infections in humans are also used in animals. A report in 2015 described the 
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discovery of a plasmid-mediated colistin resistant gene (MCR-1) in commensal Escherichia 
coli from pigs, pork products and humans in China. This raised global concerns due to the 
fact that colistin is a last-resort antimicrobial used to treat severe infections caused by 
multidrug-resistant (MDR) pathogens in hospitals (5). Given the important and 
interdependent human, animal, and environmental dimensions of AMR, this highlights the 
need for a holistic and multi-sectoral approach or a ‘One health’ approach. This means the 
collaboration of multiple disciplines working locally, nationally, and globally to attain 
optimal health for people, animals and our environment (6). The One Health concept also 
recognises that both a cause and solution of AMR encompasses interactions among humans, 
animals and the environment.  
1.2 Mechanisms of the development of AMR   
Antimicrobials are medicinal products that kill or stop the growth of living microorganisms. 
Most antimicrobial drugs are produced naturally by living organisms including plants, 
animals or microorganisms such as environmental fungi and saprophytic bacteria; only few of 
them are entirely synthetic (for example, fluoroquinolones) (7,8). Antimicrobials are 
classified based on the microorganisms they act primarily against, including:  
• Antibacterials1  (active against bacterial infections, often called antibiotics) 
• Antimycobacterial drugs (antibacterials specifically active against tuberculosis and 
other mycobacterial infections) 
• Antivirals (active against viral infections) 
• Antifungals (active against fungal infections) 
• Antiparasital drugs (active against malaria and other infections due to parasites).  
AMR is a natural process where microbes evolve to resist the action of antimicrobials (9,10). 
Some microorganisms are naturally resistant to certain antimicrobials. For example, some 
bacteria have an innate ability to resist the action of some antimicrobials via inherently 
structural or functional characteristics such as the absence of a susceptible target of a specific 
antibiotic, which is called intrinsic resistance (11).   
 
1 In general, this thesis focuses on “antibiotic” which refers to antibacterial. The term “antimicrobials” is 
used when referring to standard terminology such as antimicrobial resistance. 
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Microorganisms can also resist the effects of an antimicrobial to which they were once 
sensitive in other ways, known as acquired AMR. Acquired AMR is driven by several 
mechanisms. Firstly, resistance can occur via a reduction in the intracellular concentration of 
antibiotics by a reduction in antibiotic permeability and efflux. Secondly, bacteria may 
inactivate the antibiotic by modification or degradation of the antibiotic molecule. Thirdly, 
bacteria can modify the antibiotic target sites by modification or protection of the target, and 
change of target expression (10,12,13). Figure 1.1 depicts resistance mechanisms including 
reduced permeability, antimicrobial efflux expression changes, antimicrobial modification, 
target protection, and target modification. Responses to antibiotics in susceptible organisms 
are represented on the left and resistant organisms are represented on the right. Furthermore, 
certain bacteria have evolved resistance through an acquired mechanism, particularly by 
horizontal gene transfer from other resistant organisms in the environment (13,14). AMR 
genes in environmental and commensal bacteria are recognised as a potential reservoir of 
pathogens to humans and animals (15). 
 
 
Figure 1.1 Potential resistance mechanisms in micro-organisms 




1.3 Drivers of AMR  
The exposure of bacteria to antibiotics creates a selection pressure which favours the survival 
and growth of resistant bacteria in populations, contributing to the emergence of AMR. 
Through a range of resistant mechanisms, antibiotics kill the susceptible bacteria while 
resistant bacteria are selected to survive in the presence of the antibiotics and possibly 
continue to grow and multiply. Potential drivers of the emergence of AMR are interlinked 
factors in the context of the health care system and community, including agriculture and the 
environment.  
Antibiotic use is one of the main drivers of AMR. In the human health sector, the high 
volume of antibiotic prescriptions and poor patient adherence to treatment are related to the 
development of AMR. For example, antibiotics are often wrongly prescribed to treat flu or 
common cold symptoms (16). A recent study in the United State (US) showed that nearly 
25% of antibiotic prescriptions were inappropriate2 (17). Moreover, antibiotic self-medication 
is also common in many countries, particularly in low- and middle-income countries 
(LMICs) where antibiotics are sold over the counter (18,19). The risk of AMR increases 
when people do not complete the course or take an insufficient dose, take antibiotics for the 
wrong indications such as for viral infections, or share antibiotics with their friends or family 
(18).  
In my previous research, I identified the complex determinants of the inappropriate use of 
antibiotics in both human health and agricultural sectors (20). The supply and demand of 
antibiotics is the major factor driving the use of antibiotics. The supply side for antibiotics 
that causes problems includes retail sector, health-care sector and agricultural sector. On the 
demand side of antibiotics, people, including farmers, lack knowledge and perceive AMR to 
be a low risk. In some countries, farmers can access active pharmaceutical ingredients for 
direct use on their animals. In addition, inappropriate use of antibiotics is exacerbated by 
 
2 Different terminology has been used to capture a concept regarding the use of antibiotics. Terms have included 
‘rational/irrational’, ‘appropriate/inappropriate’ or ‘prudent/non-prudent’, but these all depend on the perspective 
and there is a lack of a universal standard (137,139,182). In this thesis, the word ‘appropriate’ has been chosen to 
mean the rational/correct/proper use of antibiotics according to the selection, dose, duration which is suitable for 
clinical needs, and is dispensed correctly and taken properly. 
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loose regulatory systems such as a lack of requirements for prescriptions to obtain and use 
antibiotics in both humans and animals. (Figure 1.2). 
Furthermore, the poor quality of antibiotics, including from substandard and falsified drugs, 
also contributes to AMR. Poor quality antibiotics create the conditions for similar 
consequences to the sub-therapeutic level of antibiotic use, both of which promote the 
development of AMR (21). However, there is currently no conclusive evidence on the impact 






Figure 1.2 Complex determinants of the inappropriate use of antibiotics in both human health 
and agricultural sectors 






1.4 Contribution of agriculture to AMR  
Resistant bacteria can be transmitted to people (both consumers and farmers) when they 
consume AMR-contaminated animal products such as inadequately cooked food or when 
they have direct contact with animals and their environment such as through contaminated 
soil and water (23). One of the main routes of AMR contamination to the environment is 
through untreated animal waste from farms. Antibiotics including un-metabolised compounds 
can also reach the environment through medical waste, improper drug disposal from hospitals 
or medicated feed from animal farms. This contributes to resistance in environmental bacteria 
and as a result, soils and surface waters in agricultural areas are contaminated by AMR 
bacteria and AMR genes (24).   
AMR bacteria have been detected in food animals, in carcasses and in food products (25–29). 
AMR bacteria and genes can be also found in manure and in general environments such as 
soil, water, and the air surrounding animal farms (24,30–34). Among the bacteria found, 
AMR zoonotic pathogens included Escherichia coli, Campylobacter spp., Salmonella spp. 
and Staphylococcus aureus. 
The use of antibiotics in food animal production has been recognised as one of the main 
drivers of the emergence of drug-resistant bacteria. In a recent study in seven countries in 
Europe, the level of use of specific antibiotics significantly correlates to the level of 
resistance to certain antibiotics such as fluoroquinolones, sulphonamides, aminopenicillins, 
and tetracycline in commensal E. coli isolates in pigs, poultry and cattle (35). However, 
demonstrating concrete evidence of the link between antibiotic use in livestock and 
transmission to humans is difficult due to a complex causal association. Analysis requires 
identification of AMR in animal products exposed to antibiotics in the production process, 
detecting the association between AMR in animals emerging from the use of antibiotics in 
animal production process, confirming the transmission of the AMR pathogens to humans, 
and diagnosing the cause of disease in humans by the AMR pathogens (36). 
Despite the challenges in demonstrating the association between antibiotic use in livestock 
and AMR in humans, several studies have shown the presence of AMR in foods of livestock 
origin throughout the world and evidence of human infection from AMR in animals (37–40) . 
Previous studies have demonstrated possible transmission of Methicillin-resistant 
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Staphylococcus aureus (MRSA) between animals and humans (37,38), and MRSA is 
considered to be a major cause of healthcare-, community- and livestock-associated 
infections. One study investigated 22 MRSA cases in humans in New Zealand: 4 of them 
reported contact with cattle and sheep and 2 lived on farms with livestock with mecC-
carrying MRSA and some genetic patterns with the human isolates (38). Another study 
showed that the phylogenetic analysis of mecC-MRSA isolated from humans and from 
livestock on the farm were identical. The findings support the premise of zoonotic 
transmission (23). 
The current approach to assessing the association is to examine the level of AMR in bacteria 
in livestock products at the slaughter stage. In European countries, AMR surveillance systems 
have been established to monitor indicator bacteria in livestock including poultry, pigs and 
cattle. In 2017, resistance in zoonotic Salmonella and Campylobacter, and Escherichia coli, 
as well as methicillin-resistant Staphylococcus aureus, were found in livestock and meat 
products (41). In Salmonella isolates, high proportions of isolates were resistant to ampicillin 
(54.9%); sulphonamides (59.1%) and tetracycline (60.8%) in fattening pigs. Some countries 
reported the occurrence of MRSA in livestock and products. Resistance to colistin was 
observed at low levels in Salmonella and E. coli from fattening pigs, calves and meat. 
Evidence of resistance was also associated with resistant bacteria isolates in humans in the 
same report.  
1.5 Antibiotic use and AMR in animal production 
Penicillin, the first antibiotic, was discovered in the 1940s. Since then, antibiotics have 
changed the treatment of bacterial infections for both humans and animals. The different 
mechanisms of antibiotics have an impact in the host’s intestinal flora, intestinal physiology, 
and immune system. Mechanisms include reducing the colonization of intestinal bacteria, 
inhibiting the growth of pathogenic microorganisms, and decreasing the thickness of mucus 
membrane, leading to more absorption of nutrients and reduced fermentation, and 
neutralising the host’s immune response (42,43). 
Antibiotics have been widely used in livestock production since the 1940s (44,45). The 
efficiency of antibiotics to improve animal productivity and enhance animal growth was 
unintentionally discovered. It was first reported in 1946 when chickens were fed 
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streptomycin, and this use of antibiotics enhanced growth and feed efficiency, and reduced 
mortality (46). After this discovery, within a few years, antibiotic use had become common 
practice for animal growth promotion in many countries in Europe and the US, and helped 
meet the demands of a post-war policy to increase livestock production (44,47,48). Since 
1960, the use of antibiotics has spread widely throughout global food production, mostly in 
poultry and pigs, with the aim of keeping animals healthy and increasing productivity. 
Livestock production has also changed, driven in part by an increase in the human population 
globally and greater demand for livestock products, as people became wealthier. Worldwide, 
compared with other meat, pork is one of the most highly-consumed meat at approximately 
35-40 percent of global meat production and is of critical importance in many countries (49). 
Global pork consumption has increased from 23.1 kg per capita in 1961 to 42.2 kg per capita 
in 2011 (50) . The rapid increase in pork production has in part been achieved through supply 
changes with a shift from household farming to intensive commercial industrial systems. 
These new systems often have a high density of animals which can exacerbate the risk of 
infectious diseases and their rapid spread. The area of concern for AMR is that farmers have 
responded in part to these risks by using antibiotics in their pig production systems, and given 
the link between antibiotic use and AMR it becomes critical to understand the reasons for this 
use. 
To understand the use of antibiotics in pig production, the next section explains three key 
areas of antibiotics use which are: the purpose of the use; route of administration and 
pharmaceutical forms; and antibiotic use and common diseases in pigs. 
1.5.1 Purpose of the use of antibiotics 
Antibiotics, since their discovery to be effective in animals, have been used routinely in 
livestock. Apart from therapeutic use to treat disease, it is common practice to use sub-
therapeutic doses of antibiotics in food-animals to control and prevent the spread of infection 
or disease. In many countries, antibiotics are used to promote growth. 
There is a lack of a standard definition on the use of antibiotics. The World Health 
Organization defines ‘therapeutic use’ as the use of antibiotics for treating animals with a 
clinically diagnosed infectious disease (51), while elsewhere the US Food and Drug 
Administration defines ‘therapeutic use’ to include treatment, control (metaphylaxis), and 
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prevention (prophylaxis) of disease (52). In this thesis, the definitions of antibiotic use are 
according to the WHO recommendations.  
Therapeutic use of antibiotics is targeted at animals infected by disease. When the disease is 
diagnosed, the most appropriate antibiotic is selected and applied to animals.  
Sub-therapeutic doses of antibiotics are applied to a group of animals after the diagnosis of 
disease in one of the animals, with the purpose of controlling the spread of infection to 
animals in close contact (metaphylaxis); and preventing disease at points of high-disease risk, 
particularly when animals are under stress (prophylaxis).  
The use of antibiotics for controlling the disease of an individual animal which have already 
infected or may be sub-clinically infected but is in close contact with others, helps to reduce 
the risk of the infection becoming clinically apparent, spreading to other tissues or organs, or 
being transmitted to other animals (metaphylaxis). On a population basis, control refers to the 
use of antibiotics to reduce the incidence of infectious diseases in a group of animals.  
Antibiotic use for disease prevention (prophylaxis) is sometimes used on animals where there 
is no evidence of disease or infection. It is applied based on history, clinical judgment, or 
epidemiological information. In livestock production, there are many points of high-disease 
risk, particularly when animals are under stress including post-vaccination, when moving 
pens or changing feed. The preventive administration of an antibiotic to either an individual 
animal or a group of animals aims to mitigate the risk of acquiring disease or infection. 
Non-therapeutic use of antibiotics is to enhance growth and feed efficiency as an antibiotic 
growth promoter. The term antibiotic growth promoter is used to describe any medicine that 
is administered at a low and sub-therapeutic dose to help growing animals digest their food 
more efficiently, get the maximum benefit from it and allow them to develop into strong and 
healthy animals (53). However, the mechanisms of growth promotion are still not exactly 
known. Possible mechanisms could be improving the digestibility of nutrients, absorption of 
nutrients, and the structure of intestinal flora (54). Table 1.1 summarises the definitions of 
antibiotic use according to indications and animal status.  
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Table 1.1 Definitions of antibiotic use in livestock (51) 
Antibiotic use Indications Animal status  
A. Therapeutic use 
(antibiotic treatment of 
disease) 
Treatment is the administration of an antibiotic 
as a remedy for an individual animal or within 
the group with evidence of infectious disease. 
Sick animals 
B. Sub-therapeutic doses of antibiotics 
- Antibiotic control of 
disease (synonym: 
metaphylaxis) 
Control is the administration of an antibiotic to 
an individual animal in close contact who may 
be sub-clinically infected. It helps to reduce the 
risk of the infection becoming clinically 
apparent, spreading to other tissues or organs, 
or being transmitted to other individuals. On a 
population basis, control is the use of 
antimicrobials to reduce the incidence of 




- Antibiotic prevention of 
disease (synonym: 
prophylaxis) 
Prevention is the administration of an antibiotic 
to animals, none of which has evidence of 
disease or infection based on history, clinical 
judgment, or epidemiological information. In 
livestock production, there are many points of 
high-disease risk, particularly when animals are 
under stress including post-vaccination, 
moving pen or changing feed. The 
administration of an antibiotic to an individual 
animal and a group of animals aims to mitigate 
the risk of acquiring disease or infection. 
Healthy animals 





1.5.2 Route of administration and pharmaceutical forms 
 
Routes of administration are categorised by application location. Enteral administration refers 
to the uptake of medicine through the gastrointestinal tract, mostly through oral 
administration. It also includes administration through the rectum. Parenteral route refers to 
any route of administration apart from the enteral route, and usually refers to injection. The 
main issues determining the selection of the route are the desired effect of the medicine, and 
animal management including for example, animal handling or age of pigs (55,56). Unlike in 
humans, administration of medication by tablets, capsules or liquid formulations is 
uncommon. Antibiotics are commonly applied to the entire group of pigs through the addition 
of antibiotics to their feed (in medicated premix) or water because individual animal 
treatment is impractical. Therefore, oral administration of antibiotics is the most common 
route for a group application in pigs.  Injectable administration is a highly effective route for 
administration to treat sick pigs experiencing difficulties with eating or drinking.  
• An oral solution is commonly used in piglets which can be handled individually for 
medical administration. The solution is usually available for the treatment of 
colibacillosis in piglets (57). 
• Oral powder through water medication (additives to drinking water) allows for the 
treatment of groups of pigs that may have poor appetite but are still drinking. 
However, it is essential to ensure that the water facilities and systems, including water 
flow rates, are sufficient to deliver to all pigs and that there is no leakage of medicated 
water. In addition, the water intake of pigs must be checked to ensure they receive the 
proper dose of antibiotics and it is vital to check water quality. Some substances in 
water can inactivate some antibiotics. For example, oxytetracycline is inactivated by 
high levels of calcium, iron, and magnesium (56). 
• Medicated feed is the main route of antibiotic administration in many countries, 
particularly for preventing and controlling disease in a whole group of pigs. This route 
may not be the most efficient route for administration in sick animals, as sick animals 
may have less appetite or be unable to feed. Medicated feed is produced by either feed 
mills or by a farmer who produces their own feed on the farm (home mixed) by 
mixing medicated premix into feed. However, mixing medicated feed in farms can 
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result in a lack of quality control for ensuring consistent distribution of antibiotics in 
the feed (58). 
1.5.3 Common diseases and antibiotic use in pigs 
A wide range of common diseases are caused by viruses and bacteria in pigs. Age-specific 
diseases and common pathogens are related to antibiotics use. For example, bacterial 
infections causing diarrhoea are commonly found in suckling pigs and nursery pigs, therefore 
antibiotics were commonly used in these pigs for disease prevention (59). 
Some of the pathogens in pigs can be also found in humans such as Escherichia coli, 
Staphylococcus aureus, and Salmonella spp. Moreover, many bacterial pathogens can be 
transmitted between animals and humans, so-called zoonosis (60). Table 1.2 presents 












Table 1.2 Type of farm by phases of pig production, common diseases and pathogens by 
stage of production 
 Common diseases and pathogens 
Sow  • Mastitis, metritis, agalactia syndrome (E. coli) 
• Necrotic enteritis (Clostridium perfringrens type C) [E] 
• Progressive atrophic rhinitis (Pasteurella multocida) [R] 
Suckling and 
nursery pig 
• Neonatal and piglet diarrhoea (E. coli) [E] 
• Post weaning diarrhoea (E. coli, C.perfringrens type A, Salmonella spp.) [E] 
  • Septicemia, endocarditis, arthritis, and pneumonia (Actinobacillus suis) * [R] 
  • Meningitis and arthritis (Streptococcus suis) * 
  • Glasser disease (Haemophilus parasuis) * 
  • Polyserositis, arthritis, low-grade pneumonia (Mycoplasma hyorhinis) * [R] 
Fattener pig • Diarrhoea (Salmonella spp.) [E] 
 • Porcine haemorrhagic enteropathy (Lawsonia intracellulalis) [E] 
  • Swine dysentery (Bachyspira hyodysentary) [E] 
  • Enzootic pneumonia (Mycoplama hyopnuemoniae) [R] 
  • Mycoplasma induced respiratory disease (Pasturella multocida) [R] 
  • Pleuropnuemonia (Actinobacillus pleuropnueumoniae) [R] 
  • Mycoplasma arthritis (Mycopplasma hyosynoviae)  
  • Erysipelas (Erysipelas rhusiopathiae) 
 [E]= enteric infection, [R]=respiratory infection 
*both nursery and finisher phases 





Due to the possible association between antibiotic use in livestock and AMR in humans, there 
are concerns that their level of use is unnecessarily high especially for sub-therapeutic use for 
growth promotion and disease prevention, and particularly for the use of those antibiotics 
highly important for humans. 
High levels of antibiotic use in livestock 
Many reports show a larger proportion of antibiotics used in food-producing animals than 
used in humans. In Europe, it was estimated that 70% of all antibiotics consumption in 30 
European countries was in the animal sector (8,927/12,720 tonnes) (61). Moreover, based on 
the predicted continued rise in global demand for livestock products, global antibiotics 
consumption by livestock is predicted to increase by two thirds over the next ten years (62).  
Sub-therapeutic use for growth promotion and disease prevention 
Many organisations suggest that farmers and the food industry should stop the routine use of 
antibiotics for the prevention of disease and promotion of growth in healthy animals. For 
example, the 2015 European Commission Guidelines for the Prudent Use of Antibiotics in 
Veterinary Medicine state that the routine use of antibiotics for disease prevention should be 
avoided and antibiotics reserved for exceptional case-specific indications (63). The World 
Health Organization (WHO) strongly recommends a restriction of the routine use of 
Medically Important Antibiotics (MIA) for disease prevention and complete restriction of all 
antibiotics for growth promotion in food-producing animals (51). Many countries have 
recently banned the use of growth-promoting antibiotics (64). However, antibiotics are still 
used as growth promoters in some countries. Indeed, 22% (35/153) of World Organisation for 
Animal Health (OIE) member countries reported the use of antibiotic growth promoters in 
2018 (65).  
Use of antibiotics in the same class as humans, particularly the Critically Important 
Antimicrobials (CIA) 
The WHO classifies MIA based on their importance to human medicine including: 1) the 
volume of antibiotic use in humans (high proportion of use in patients and high frequency of 
use in human medicine); 2) antimicrobials for treatment of transmission of AMR; 3) 
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antimicrobials with limited alternatives for treatment of serious bacterial infections in 
humans; and 4) antimicrobials for treatment of infections in humans caused by bacteria that 
may be transmitted to humans from non-human sources, or bacteria that may acquire resistant 
genes from non-human sources (66). There are three groups of MIA:  
1. Critically important antimicrobials (CIA)-highest priority and high priority (Lists of 
CIA are in Appendix 8); 
2. Highly important antimicrobials; 
3. Important antimicrobials. 
Antibiotics used in animals are often the same or in the same class as those used in humans. 
Of particular concern has been the use of CIA which are last-resort antibiotics normally 
reserved for the most severe infections in humans.  
Group treatment  
In livestock, antibiotics are commonly applied to whole groups through medicated feed or 
medicated drinking water (67–71). However, the European Commission recommends that 
administering medication to an entire herd or flock should be avoided whenever possible. 
Sick animals should be isolated and treated individually (for example, by parenteral 
administration) (63).  
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1.6 Global policy on AMR 
To tackle AMR, international organizations recommend several implementation strategies for 
both human health and agriculture. The Global Action Plan on Antimicrobial Resistance 
(GAP-AMR) was adopted in 2015 by all countries through decisions taken at the World 
Health Assembly, the Food and Agricultural Organization Governing Conference and the 
World Assembly of World Organisation for Animal Health Delegates (72). Box 1 describes 
the strategic objectives of the GAP-AMR.  
In 2016, the political commitment to AMR was made at the United Nations General 
Assembly High-Level Meeting (73). Member States committed to develop multi-sectorial 
national action plans on AMR in line with the GAP-AMR and endorsed a concerted ‘One 
Health’ approach which links various sectors and actors in defence of human, animal and 
environmental health. In addition, all Member States agreed to mobilize adequate and 
sustained resources to implement activities tackling AMR and pledged to raise awareness of 
AMR. This is the first time that heads of state committed to collectively solve the AMR 
problem and only the fourth time in the history of the United Nations that a health issue was 
discussed at the United Nations General Assembly.  
In response to the GAP-AMR, each country is required to develop a national action plan. 
Based on the global database for AMR country self-assessment in 2018, only a few countries 
have not yet developed a national action plan on AMR (74,75). 
Box 1.1 Five strategic objectives of the Global Action Plan on AMR 
1. To improve awareness and understanding of antimicrobial resistance through 
effective communication, education and training;  
2. To strengthen the knowledge and evidence base through surveillance and 
research;  
3. To reduce the incidence of infection through effective sanitation, hygiene and 
infection prevention measures;  
4. To optimize the use of antimicrobial medicines in human and animal health; 
and  
5. To develop the economic case for sustainable investment that takes account of 
the needs of all countries, and increase investment in new medicines, 
diagnostic tools, vaccines and other interventions. 
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1.7 Pig production in Thailand 
Thailand is an upper-middle-income country with a population of approximately 69 million. 
In 2018, the average income, measured as GDP per person, was about US$ 7,2733 (76). 
Thailand's economy has been growing steadily over the last few decades. In 2000, Thailand’s 
GDP per person was one third lower than in 2018. However, although GDP has increased 
over time, the contribution of the agricultural sector to GDP has declined over the past decade 
from 12% in 2011 to 8% in 2018 (US$ 42,400 million) (77).  
Pork is one of the most common protein sources in Thailand and the majority of pig products 
were consumed in the domestic market. In 2018, about 10 million pigs were produced by 
about 180,000 pig farms in Thailand (78). Table 1.3 shows the population census of humans 




















3 US $1.00 = 31.5 Baht (As of 20 February 2020) 
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Table 1.3 Key statistics on economic status and pig production in Thailand (2018) 
 
Thailand profiles 
Population census of human 69,428,524a  
GDP (billion US$) 506,514.0a 
GDP per capita (US$) 6,592.9a  
Population census of pig  10,587,303 b  
- Indigenous pig 647,296 b 
- Breeder: sow 927,969 b 
- Breeder: boar 94,225 b 
- Fattener 8,917,813 b 
Households raising pigs  184,717 b 
a Source: https://data.worldbank.org/indicator (2018) (76) 
b Source: http://ict.dld.go.th (2018) (78) 
Globally, demand for livestock as a source of food is growing rapidly due to increases in both 
populations and their incomes. Industrial-scale livestock production has become a major 
response to rapidly growing consumer demands. Industrial-scale livestock production 
systems are common in high-income countries (HICs), leading to livestock-derived foods 
becoming more available, accessible and affordable to all consumers, and contributes to the 
growth of economies. In low- and middle- income countries (LMICs), the livestock 
production system plays a vital role in generating income for livestock producers, which 
benefits a country’s economy as a whole and contributes to the production of food. 
Since the 1960s, pig production in Thailand has shifted increasingly from smallholder 
farming for household consumption to intensive large-scale production for commercial use. 
Pork has become one of the most important sources of animal protein in Thailand, and its 
production has more than doubled in the last 30 years from around 336 thousand tons (4.6 
kilograms/capita) in 1990 to approximately 883 thousand tons (10 kilograms/capita) in 2018 
(79). In 2018, the income of the agricultural sector in Thailand accounted for around US$ 
42,400 million and pig production generated about 10% of this (77). Along with a rapid 
increase in pork demand and production, both the number and the size of intensive pig farms 
have grown significantly.  
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In the past, smallholder farmers, where pig production is not a major income-generating 
activity (sometimes referred to as “backyard farms”), fed their pigs from various sources such 
as leftover food and vegetables. However, feeding pigs with leftover food resulted in poor 
pork quality and provided a lower return, so farmers turned to commercial feed in response to 
pork market demands. Now, commercial feed stores are the most common source of feed on 
smallholder farmers. On commercial farms, farmers either produce their own feed by mixing 
various ingredients (home mixed) or buy commercial feed from feed companies. Pig farms 
differ in how they are managed, including their approach to biosecurity. Smallholder farms 
are often associated with poor hygiene and low biosecurity. By contrast, commercial systems 
usually have higher hygiene and biosecurity measures than smallholder farms (80).  
The majority of pig products (95%) are for domestic consumption (78,81), about 70% of 
which is distributed to the general market, while 20% is sold through supermarkets (82). In 
the supply chain, there are many ways to process pork from farms through to markets. 
Smallholders sell their pigs through middlemen (pig brokers) who contact farmers and 
slaughterhouses, and then sell pork to retailers (butchers). Some local retailers visit 
smallholder farms in local communities to buy pigs in small numbers directly. This then 
becomes fresh pork sales in local markets. However, in the past decade, vertical integration 
by large companies has become increasingly common. The companies use contract farming 
with pig farmers for pork production involving pig slaughter, marketing and retail of pork 
products. 
Thailand has experienced fluctuating pig prices due to an oversupply in 2017 and 2018 (83). 
Many farms, particularly smallholder farms, have closed over the last few years, while 
commercial farms have expanded with integrated pig production and marketing systems. 
Consequently, the Thai pig production system is likely to become more dominated by large 
agro-industrial conglomerates performing integrated operations of animal breeding, feed 
production, and processing meat products (80). In the integrated business system, contract 
farming is common where farmers and contracting companies make an agreement in advance 
on the terms and conditions for the production and the price of products. In general, 
contracting companies provide inputs such as pigs, feed, medicines, and technical support to 
contracted farmers, who provide animal housing and labour. The farmers’ main obligation is 
to produce and deliver the products in relation to the contract and the company pays the 
farmers the agreed price stated in the contract.  
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In 2018, about 180,000 of Thai farms raised about 10 million pigs with 60% of these farms 
being commercial farms (more than 51 pigs on a single farm) and raising more than 90% of 
the pig population4. The rest, 40%, were smallholder farms raising indigenous pig breeds 
comprising 6% of the total pig population (78,81).  
1.8 AMR and antimicrobial use in pig production in Thailand 
With pig production rates and large commercial farms expanding in Thailand, concerns 
around antibiotic use and AMR are also growing. Many studies have reported the occurrence 
of AMR in pathogenic and commensal bacteria isolated from pigs in Thailand. A recent 
review on AMR in South East Asian countries, including Thailand (84), showed that most of 
the published work in Thailand relates to non-typhoidal Salmonella, Escherichia coli (E. 
coli), and Campylobacter spp. and MRSA. Salmonella isolates were resistant to tetracycline 
(85,86), streptomycin (85), sulfamethoxazole (85) and nalidixic acid (86). The majority of    
E. coli isolates were resistant to tetracycline (87–89), ampicillin (87–89), streptomycin 
(88,89) and sulfamethoxazole (89). Multidrug-resistant Salmonella and E. coli isolates were 
also reported (86,87,89,90). Two studies reported AMR among Campylobacter spp. in pigs in 
Thailand. The results presented high resistance to nalidixic acid, ciprofloxacin, erythromycin, 
azithromycin and tetracycline (91,92). Methicillin resistant Staphylococcus aureus was found 
in pig and pork in Thailand (93–96).  
A recent study reported the occurrence of the MCR-1 gene on pig farms in Thailand (97). 
The study examined colistin resistance E. coli in healthy fattening pigs (16-24 weeks) in four 
provinces in Thailand during 2004 -2014. Gene MCR-1 was detected in pigs from three 
provinces. At Nakhon Pathom, the MCR-1 gene was found at 3.5% of faecal samples from 
selected farms in 2012 and at 29.5% in 2013. E. coli isolated from Ratchaburi and Chonburi 
were also found in the MCR-1 gene at 3.5% and 20.7%, respectively. No MCR-1 gene was 
found in Nakhon Ratchasima.  
 
4 Based on the number of pigs on the farm, farms were categorised by size according to the Department of Livestock 
Development (DLD) definition: smallholder farm (less than 50 pigs), and commercial farm subcategorised to small 
commercial farm (from 51 to 500 pigs), medium commercial farm (from 501 to 5,000 pigs), and large commercial farm 
(more than 5,001 pigs).  
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In 2017, the Department of Livestock Development (DLD) established the national 
surveillance system on AMR in food-producing animals with an aim to monitor the trend of 
AMR and promote prudent use of antimicrobials in Thailand (98). The Thailand surveillance 
of AMR includes data on target bacteria such as zoonotic bacteria (Salmonella spp. and 
Campylobacter jejuni) and indicator bacteria (Enterococcus faecium and Enterococcus 
faecalis, and E. coli) collecting from porcine caeca from slaughter houses and pork meat 
samples from both slaughter houses and retail markets (98). The sample size was calculated 
according to the OIE guidelines. The tested antimicrobials were included as follows: colistin, 
ciprofloxacin, cefotaxime and ceftazidime, meropenem, chloramphenicol, sulfamethoxazole 
and trimethoprim, gentamicin and streptomycin, etc.  
In 2018, high levels of resistance in Salmonella spp. and E.coli were detected against 
ampicillin, tetracycline, chloramphenicol and trimethoprim/sulfamethoxazole, while low 
levels of resistance (<10%) against third-generation cephalosporins, ciprofloxacin, and 
colistin. None of Salmonella spp. isolates from all three sources of pigs was resistant against 
meropenem (Figure 1.3). The prevalence of resistance in E. faecium and E. faecalis was high 
against three highest antimicrobials including tetracycline (76.8), erythromycin (75.4%), and 






 Figure 1.3 Prevalence of resistance in Salmonella spp. isolated and E. coli isolated from pork 
samples  
Source: Thailand’s One Health Report on Antimicrobial Consumption and Antimicrobial 





The existing Surveillance of Antimicrobial Consumption in Thailand, called ‘Thailand SAC’, 
was developed in 2016 in response to the National Strategic Plan on AMR. Data from an 
annual report of pharmaceutical operators including importers and manufacturers were used 
to estimate the total national consumption of antimicrobials in humans and animals.  
 In 2018, the total consumption of antimicrobials in food-producing animals was 3,816.3 
tonnes of active pharmaceutical ingredients or 522.1 mg/Population Correction Unit (PCU) 
Thailand (98). According to the class of antimicrobials, penicillins were consumed most 
(40.8%, 212.8 mg/PCUThailand), mainly in the form of amoxicillin (210.4 mg/PCUThailand).. The 
second-ranked consumed antimicrobials belonged to other antibacterials including 
bambermycin, bacitracin and halquinol, accounting for 18.3%. The third-ranked 
antimicrobials consumed were tetracyclines (12.1%), of which chlortetracycline and 
doxycycline were the majority (Figure 1.4). When grouped by pharmaceutical dosage form, 
more than half of veterinary antimicrobials were in the form of medicated premix (59.1%), 
followed by oral powder (36.8%) and injection (2.9%).  
Regarding the World Health Organization list of Critically Important Antimicrobials (CIA), 
55.4% of total veterinary antimicrobials consumed belonged to the CIA. The top-three 
antimicrobials consumed in the highest priority group were colistin, tilmicosin and tylosin 
and the top-three in the high priority group were amoxicillin, neomycin and 
dihydrostreptomycin. 
However, the surveillance data were limited. The consumption data were not stratified by 
animal species or indication, so it was not possible to identify the extent of use in individual 















Figure 1.4 Consumption from veterinary antimicrobials classified by drug class in 2018 
(mg/PCUThailand) 
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1.9 Antibiotic distribution and control of antibiotics in Thailand  
Between 2016 and 2017, I led a study in parallel to my PhD research, to analyse how 
antibiotics are imported, manufactured, distributed and regulated in Thailand. The academic 
article was published in the Bulletin of the World Health Organization in 2018 (Appendix1) 
(100). Based on this research, I extracted the following information. 
In summary, antibiotic distribution in livestock is a complex array of activities including 
marketing, distribution, prescription, and use. A number of different public and private 
stakeholders are involved at different stages of this process, including pharmaceutical 
companies who import, produce and distribute antibiotics, retail pharmacies, health 
professionals and farmers. It also includes feed mills which produce and distribute medicated 
feed to feed stores and farms either directly or through distributor companies. Table 1.4. 













Table 1.4 Process of antibiotic distribution and key actors 
Function 
Actor 
Antibiotic Medicated feed 
Production/ 
importation 




Feed mills, distributor 
companies  



















Figure 1.5 illustrates the antibiotic distribution flow in Thailand. Thailand imports Active 
Pharmaceutical Ingredients (API) for local manufacturing and finished product of antibiotics 
(including medicated premix for producing medicated feed). Once antibiotics are produced 
by manufacturers, they are sold to wholesalers, pharmacies (drug stores), feed mills and 
farms, or distributed through distributors. The wholesalers, distributors and pharmacies need 
to hold a medicines sale license authorised by the Thai-Food and Drug Administration (Thai-
FDA). Feed mills add antibiotics to feed to produce medicated feed and sell it to feed stores 
and animal farms. Both feed mills and feed stores must hold a license authorised by DLD. 
Farmers can buy antibiotics through several channels including distributors, wholesalers, 
pharmacies, and medicated feed from either feed mills or feed stores. By law, Thailand does 
not allow distributors, wholesalers, pharmacies to sell API to feed mills and farmers, and 

























The regulation of antibiotics is generally covered through drug regulations where the main 
aim is to ensure the safety, efficacy, and quality of drugs in both human and animal sectors. 
The main regulatory functions are broadly categorised as licensing of manufacturers, 
importers, wholesalers and retailers; issuing marketing authorization; inspecting of licensees; 
controlling and monitoring the quality of medicines on the market; controlling promotion and 
advertising of medicines; monitoring adverse reactions to medicines; and providing 
independent information on medicines to professionals and the public (101).  
In developing countries, regulations control antibiotic use through the classification of 
antibiotics and the restriction of access to highly important antibiotics through the 
requirement of prescriptions. However, in LMICs, regulatory processes mostly focus on the 
licensing process of medicines (102). Over-the-counter sale of antibiotics is reportedly 
common (103).  
In Thailand, the relevant regulations regarding antibiotics which are described in more detail 
in the report “System analysis of antimicrobial utilisation in humans and animals: actors and 
legal framework” (Appendix 2).There are regulations about antibiotic use in relation to pig 
production systems (Box 1.2). Two main laws govern the distribution of antibiotics for 
humans and animals: the 1967 Drug Act under the responsibility of the Thai-FDA; and the 
2015 Animal Feed Quality Control Act, under the responsibility of the DLD. In addition, the 
non-legal norm on the Good Agricultural Practice (GAP) certification established by the 
government also addresses standard practice on antibiotic use in pig farms. 
The Drug Act was first legislated in 1967; it has been amended four times in 1975, 1979, 
1984 and 1987 and the current version is the Drug Act (1987). The law aims to assure safety, 
efficacy and quality of medicines including antibiotics. The Drug Act classifies medicines 
into four categories and regulates which outlets patients can access. The Drug Act controls 
pharmaceutical operators through licensing in relation to the distribution process including 
importation, manufacture and sale of medicines. It is nevertheless noteworthy that no 
regulation exists to contain the number of medicines distributed through different channels or 
to end-users. 
The Animal Feed Quality Control Act BE 2558 (2015) controls the quality and standard of 
medicated feed including medicated premix used in medicated feed. The Act covers the 
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process of licensing and inspection of medicated feed’s operators covering feed mills, feed 
stores and livestock farms. Veterinary prescriptions and Good Manufacture Practice 
certificates are required for feed mills prior to medicated feed production.  
The Veterinary council and Pharmaceutical council work in accordance with the Veterinary 
Profession Act (2002) and Pharmaceutical Profession Act (2015). Both councils have 
regulatory functions including setting educational standards, licensing, and conducting 
continuing education of health professionals. However, no standards of practice and 
professional ethics specific to antibiotic use for veterinarians are established in Thailand.  
The GAP certificate for pig farms was introduced as a voluntary standard for food safety to 
fulfil trade and government regulatory requirements. The National Bureau of Agricultural 
Commodity and Food Standards is the accreditation body, while the DLD provides 
implementation functions. Farmers submit their application form and relevant documents to 
their provincial livestock office which carries out the approval and an annual inspection. The 
standards range from farm infrastructure, animal feed quality, water quality, farm 







Box 1.2 Regulations and standards in relation to antibiotics in pigs  
Drug Act (1987) 
- Aim: to ensure the safety, efficacy and quality of drugs, which contribute to the 
health protection of consumers. 
- Regulated by Thai-FDA, Ministry of Public Health  
- Five regulatory functions include market authorisation, licensing, inspection, 
quality control and pharmacovigilance 
Animal Feed Quality Control Act (2015) 
- Aim: controls the quality and standard of animal feed including medicated feed 
- Regulated by DLD, Ministry of Agriculture  
- Regulatory functions include licensing, inspection, registration, quality control, and 
post-marketing surveillance  
Professional standards (Veterinary Profession Act (2002) and Pharmaceutical 
Profession Act (2015)) 
- Functions:  
o Setting educational standards  
o Licensing  
o Continuing education of health professionals  
GAP for livestock certificate  
- Voluntary standards for food safety and good production  
- National Bureau of Agricultural Commodity and Food Standards is the 
accreditation body. 
- DLD provides implementation functions.  
- The standards range from farm infrastructure, animal feed quality, water quality, 
farm management, animal health management including the use of antibiotics, 
animal welfare and the environment. 
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Regulations previously described show cross-regulations at different levels. Table 1.5 maps 
regulations according to settings, functions, regulator and tools for enforcement. The Drug 
Act controls the production, importation, distribution, and the sale of antibiotics of 
pharmaceutical companies and pharmacies.  The Animal Feed Quality Control Act regulates 
the production of medicated feed, use of antibiotics, veterinary prescriptions at feed mills and 
animal farms, and the sale of medicated feed at the animal feed store. On farms, practices for 
antibiotic use are controlled under the GAP standard of farm management. The Veterinary 
Profession Act and Pharmaceutical Profession Act controls the dispensing and prescription of 
antibiotics in veterinarians and pharmacists. 
As mandated by the Drug Act (1987), Thai-FDA classified most human and veterinary 
antibiotics as “dangerous drugs”.  They do not legally require a prescription but must be 
dispensed by a licensed pharmacist or veterinarians in licensed pharmacies or pharmaceutical 
companies. Recently, in 2019, a number of restrictions were introduced on the veterinary use 
of certain reserved groups of antibiotics.  A prescription is now needed for the sale of 
quinolones, cephalosporins, macrolides and polymyxin by pharmacies and pharmaceutical 
companies, and also for the sale of  all medicated premix (antibiotic mixed in feed)  (104). In 
addition, some CIA including polymyxin, penicillins, fluoroquinolones, fosfomycin and 
cephalosporins are not allowed to use for disease prevention through medicated feed (105). 
Yet implementation is still at an early stage and compliance has to be monitored closely. The 
introduction of laws and regulations does not always result in the desired outcomes unless 
there is robust institutional capacity for regulatory enforcement. The ineffective functioning 
of the regulatory system has been well documented, including the lack of inspections of the 
supply chain (106). In South East Asia, only a few countries have the capacity to ensure the 
implementation of antibiotic use regulation (107). However, there is no study on regulatory 
capacity to control the use of antibiotics in Thailand.  The appropriate prescribing and 
dispensing of medicines are the responsibility of health professionals, yet neither prescription 
monitoring nor auditing systems are in place.  
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Table 1.5 Regulations and regulators of antibiotic use in relation to pig production systems 
Settings Function Regulation  Regulator Tool for enforcement  
Pharmaceutical 
manufacturers 
Production of antibiotic Drug Act (1987) FDA Pharmaceutical manufacture license, 




sale of antibiotic 
Drug Act (1987) FDA Pharmaceutical import license, 
pharmaceutical sale license 
Feed mill Production of medicated 
feed  
Animal Feed Quality 
Control Act (2015) 
DLD, Provincial Livestock 
Office 
Animal feed manufacturer license (with 
GAP), Inspection (1-2 times/year) 
Pharmacy  Sale of antibiotic  Drug Act (1987) Thai-FDA, Provincial 
Health Office 
Pharmaceutical sale license, Annual 
inspection 
Farm   Use of antibiotic  GAP for livestock 
certificate (voluntary) 
DLD, Provincial Livestock 
Office 
Audit, licensing and relicensing (q 3 
years) 
 Production of medicated 
feed, use of antibiotic, 
veterinary prescription 
Animal Feed Quality 
Control Act (2015) 
DLD, Provincial Livestock 
Office 
Inspection (1-2 times/year) 
Feed store Sale of medicated feed  Animal Feed Quality 
Control Act (2015) 
DLD, Provincial Livestock 
Office 
Animal feed sale license, Inspection (1-
2 times/year) 
Veterinarian  Dispensing and 
prescription of antibiotic 
Veterinary Profession 
Act (2002) 
Veterinary council Licensing, continuing education, 
response to complain 
Pharmacist Prescription of antibiotic Pharmaceutical 
Profession Act (2015) 
Pharmacy council  Licensing, continuing education, 
response to complain 
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1.10 Structure of the thesis 
This PhD thesis is structured in a research paper style along with introductory and 
supplementary materials, in accordance with the guidelines and regulations specified by the 
London School of Hygiene and Tropical Medicine. There are four research papers: two in the 
literature review section and two in the results section. Three out of four of these research 
papers have been published in peer-reviewed journals (one is currently under consideration 
with a journal). The thesis comprises three main sections and 8 chapters (see Figure 1.6).  
In Section A, Chapter 2 indicates aim and objectives of the thesis. Chapter 3 provides a 
description of materials and methods including the study design and the methodological 
considerations for data collection and analysis. Chapter 4 presents a literature review on 
antibiotic use in pig production globally. It covers two published systematic reviews on 
antibiotic use in pig production and its associations, and methods and measurements for 
quantification of the use of antibiotics in pig production. Following this, potential factors 
influencing the use of antibiotics are addressed.  
Section B comprises Chapters 5 and 6, with results presented as two research papers from 
empirical research. The results of the study of the patterns of antibiotic use in pig farms and 
the total amount of antibiotics used in pig production in Thailand from an analysis of the 
mixed-methods study are reported in Chapter 5. Chapter 6 presents the factors contributing to 
the use of antibiotics in pigs in Thailand from the qualitative study.  
Section C includes the conclusion and reflections in Chapter 7 on research findings in relation 
to the aim and objectives of the thesis. Chapter 8 presents key implications of the study, 
including policy recommendations, recommendations for research priorities. Finally, 
additional information is provided in the Appendices. 
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Figure 1.6 Mapping eight chapters in the thesis  
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Chapter 2 Aim and objectives  
Summary  
This chapter presents the overall approach, design and methods. It begins with the thesis aim 
and objectives in section 1. Subsection 2 addresses the study frameworks.  
2.1 Aim and objectives  
The overarching aim of the thesis is to investigate patterns of antibiotic use and determinants 
influencing antibiotic use in pig production in Thailand in order to contribute to the 
development of policies aimed at optimising the use of antibiotics in pig production.  
The specific objectives are: 
2. To critically review the literature on the use of antibiotics in pigs and to identify the 
methods and measurements used to quantify antibiotic use in pigs; 
3. To describe patterns of antibiotic use and estimate the total amount of antibiotics 
used in pig production in Thailand; 
4. To explore the practices and views of pig farmers and other stakeholders about 
determinants influencing antibiotic use in pig production in Thailand; 





2.2 Study framework  
The study framework is presented in Table 2.1. It includes the relationship between the thesis 
objectives, research questions and methodology. The systematic reviews were conducted to 
explore on how antibiotics are used in global pig production and what methods and 
measurements are used to quantify the use of antibiotics in pigs? The empirical research 
comprises of two sub-studies based on study objectives and primary data collection. In the 
rest of the thesis, the term ‘the study’ means the empirical research. 
The 1st sub-study was a mixed-method study to describe the patterns of antibiotic use and 
estimate the total amount of antibiotics used in pig production in Thailand, in order to address 
objective 2. A mixed-methods approach was applied to gain a comprehensive understanding 
by comparing and synthesising both qualitative and qualitative data. A questionnaire survey 
with farmers was conducted to collect data on the patterns of antibiotic use in pigs in selected 
pig farms in a single province. The amount of antibiotics is estimated through secondary 
analysis of a 2017 national survey of feed mills conducted by the International Health Policy 
Program, Ministry of Public Health. Data obtained from feed mills was supplemented by 
interviews with veterinarians working in the feed mill industry to gain a deeper understanding 
of the use of medicated feed.  
The 2nd sub-study was a qualitative study which involved interviews with farmers and other 
stakeholders in line with observations on selected pig farms, in order to address objective 3. 
The purpose was to explore the practices and views of pig farmers and other stakeholders about 
determinants influencing antibiotic use in pig production.  
Evidence generated from the above was synthesised to discuss and identify relevant policy and 
interventions to enhance the rational use of antibiotics in pig production in Thailand, in order 







Table 2.1 Relationship between thesis objectives, research questions and methodology  
Objectives Research questions Methodology 
Objective 1: To critically 
review the literature on the use 
of antibiotics in pigs and to 
identify the methods and 
measurements used to quantify 
antibiotic use in pigs; 
 
- What is known about how antibiotics 
are used and which factors are 
associated with the use of antibiotics 
in global pig production? 
- What methods and measurements are 
used to quantify the use of 
antimicrobials in pigs? 
Systematic reviews 
Objective 2: To describe the 
patterns of antibiotic use and 
estimate the total amount of 
antibiotics used in pig 
production in Thailand. 
- How are antibiotics used in terms of 
types, routes, and purposes in pig 
production? 
- Which farm and farmer characteristics 
are associated with the use of 
antibiotics? 
- What volume of antibiotics is used in 
pig production? 
A mixed-methods study 
- Questionnaire survey of pig 
farmers and feed mills 
- Interviews with veterinarians in 
the feed industry 
Objective 3: To explore the 
practices and views of pig 
farmers and other stakeholders 
about determinants influencing 
antibiotic use in pig production 
in Thailand. 
- What determinants influence the use 
of antibiotics in pig production? 
A qualitative study  
- Interviews with farmers and 
other stakeholders including 
animal drug retailers, 
veterinarians, government 
officers  
- Observation in selected pig 
farms 
Objective 4: To identify 
potentially effective policy 
options to optimise the use of 
antibiotics in pig production in 
Thailand. 
- What are effective policy options to 
optimise the use of antibiotics in pig 
production in Thailand? 
Synthesis of evidence generated 





The study is concerned with exploring how and why antibiotics are used in pig production in 
Thailand. Figure 2.1 summarises the conceptual framework about antibiotic use in pig 
production and factors influencing the use of antibiotics. At the bottom of the figure, patterns 
of antibiotic use in pig production are categorised by type of antibiotics, route of 
administration, purpose of antibiotic use and volume of antibiotic use. The determinants 
influencing the use of antibiotics in pig production involve different levels. The following 






Figure 2.1 Conceptual framework describing the use of antibiotics in pig production and 
factors influencing antibiotic use 
• Type of antibiotics
• Route of administration
• Purpose of antibiotic use
• Volume of antibiotic use 
Patterns of antibiotic use in pig production
• Education level 
• Experience in raising pigs
• Understanding of antibiotics
• Awareness of AMR
• Attitudes on antibiotic use
Antibiotic supply level
• Antibiotic distribution—access to antibiotics and 
medicated feed through pharmacies, feed mills and 
other outlets
• Health professionals: knowledge, awareness on AMR, 
public service, academic brokers
• Pharmaceutical companies: promotion, market sales
• Non-legally binding instruments: 
- Guidelines for antibiotic prescription 
- Contract among food retailer and farmers
- Good Agricultural Practice certificate
• Regulation: Drug Act, Animal Feed Quality Control Act, 
Health Professional Act
• National Strategic Plan on AMR
Pig production systems
• Characteristics of farm: size, income
• Farm management: biosecurity, GAP certification, waste 
disposal, diseases on farm 
• Farm productivity: cost-return of farm 
• Slaughterhouse










Firstly, the question of how antibiotics are used in pig production is addressed through a 
study of pig farms that aims to identify patterns of antibiotic use, focusing on the types of 
antibiotics, the volume of the different types of antibiotics, their intended purpose and routes 
of administration. The types of antibiotic are described in terms of active ingredients 
according to the anatomical therapeutic chemical veterinary (ATCvet) classification system. 
The types also relate to the WHO CIA list for human medicine (66). The volume is calculated 
in kilograms. The routes of administration include injection, oral medication, and medicated 
feed. The purposes of the use include for treatment, for control and prevention of disease and 
for growth promotion. 
Secondly, as the determinants influencing the use of antibiotics in pig production can be 
considered at different levels as illustrated in the conceptual framework. This study 
considered the determinants influencing antibiotic use at three levels: farmer level, systems 
level and policy level.  
At the farmer-level, factors that have been considered include educational level; experience 
in raising pigs; understanding of antibiotics; awareness of AMR; attitudes on antibiotic use. 
At the system level, two systems were considered at the system level, the pig production 
systems and antibiotic supply systems. Factors attributable to pig production systems cover 
farm characteristics, farm management, health status of pigs on farms, farm productivity, 
slaughterhouse, and the role of consumers and food retailers that can stimulate the reduction 
of antibiotic use in pig production. Factors attributable to antibiotic supply systems 
(production, distribution, prescription, sale and use of antibiotics) focuses on access and 
availability of antibiotics, and roles of relevant stakeholders involved in the systems such as 
veterinarians and the pharmaceutical industry.  
Policy and regulations include the drivers associated with the government, regulations and 
policies concerning the use of antibiotics in pig farms. The regulations cover formal legal 
restrictions, enforced by a government authority, to non-legal norms or enforced self-
regulation through professional bodies. To control antibiotic distribution, the Drug Act, 
Animal Feed Control Act and Health Professional Act play a vital role as common legal 




for both health professionals and farmers. Through the National Strategic Plan on AMR, 
several interventions aim to optimize use of antibiotics at pig farms. At farm level, the 
government promotes the good practice of farm management including increased farm 





Chapter 3 Material and methods 
In order to achieve the stated aim and objectives, a wide range of methods was used. This 
chapter describes the study design and outlines a brief description of the methodological 
considerations. Systematic review was used to describe the pattern of antibiotic use in pigs, 
and methods and measurement to quantify antibiotic use in pigs. For the empirical research, a 
mixed-methods study was conducted to explore the use of antibiotics and estimate the total 
amount of antibiotics used in pig production in Thailand. In addition, a qualitative approach 
was used to explore the practices and views of the various key actors associated with the use 
of antibiotics for pig farming in Thailand. Full details of the methodology are presented in 























3.1 Systematic reviews 
 
I conducted two systematic reviews. The studies included in the review focus on antibiotic 
use in global pig production, involving pigs of any age and type of production, with a focus 
or clear explanation of the methodology in pigs or other food producing animals including 
pigs. The studies were reviews, clinical research, pharmacokinetic, biopharmaceutical studies 
and laboratory studies were excluded. 
The operational definitions of the terms used in the reviews are as follows.  
 
Term  Definition  
Antimicrobials According to World Organisation for Animal Health (OIE) definition, an 
antimicrobial is considered as a naturally occurring, semi-synthetic or 
synthetic substance that exhibits antimicrobial activity (it kills or inhibits 
the growth of micro-organisms) at concentrations attainable in vivo. 
Anti-helminthic and substances classed as disinfectants or antiseptics are 
excluded from this definition (108). 
Pig The term refers to all stages of swine production including breeding and 





WHO defines consumption data as quantitative data (amounts of 
antimicrobial) and qualitative data (description of antimicrobial class, 
indication, route of administration, etc.) collected from several sources 
such as import data, wholesale data or aggregated health insurance data. 
Use data refers to estimates derived from patient-level data. It may focus 
on how and why antimicrobials are being used by health care providers 
and patients. Usually, data on consumption is reported when information 
on antimicrobial use in patients is not available. Consumption data 
provides a proxy estimate of the use of antimicrobials (109). 
However, in this study, for simplicity the term “use” is applied to refer 






The online electronic database through LSHTM databases: MEDLINE 
(http://ovidsp.tx.ovid.com; 1946 until present), Scopus (http://www.scopus.com; 1823 until 
present) and Web of Science (http://apps.webofknowledge.com; 1970 until present) were 
searched with restriction of the date of publication between 2000 and 2017 to capture up-to-
date data, using the following search strategy:  
- (antibiotic OR antimicrobial OR antibacterial) AND  
- (livestock OR swine OR pig* OR farrow OR weaner OR finisher OR sow) AND  
- (use OR utilisation OR consum* OR practice OR administration) 
The titles and abstracts were reviewed for relevance to the study question and the full text of 
articles identified as potentially relevant were examined. The reference lists of final papers 
included in the review were searched to identify additional relevant papers. Articles were 
exported into EndNote, de-duplicated and then exported into an excel spreadsheet to permit 
the selection of articles and data extraction. The Critical Appraisal Skills Programme (CASP) 
was applied for quality assessment by two independent reviewers. When there were 
conflicting views, the reviewers will be discussed and seek consensus. 
3.2 Study design and methodological considerations for the empirical 
research 
3.2.1 Study design  
The study applied a convergent parallel mixed-methods design, in order to compare different 
perspectives drawn from quantitative and qualitative data on determinants influencing the use 
of antibiotics. Figure 3.1 summarises the study design and methods used in the study.  
First, mixed methods were used to describe the patterns of antibiotic use and estimate the total 
amount of antibiotics used in pig production in Thailand. The quantitative strand included a 
survey among farmers describing types, routes, and purpose of antibiotics used in pig farms, 
and a survey of feed mills presenting the volume of antibiotics used in pigs. The qualitative 
approach through interviews with veterinarians working in the feed mill industry provided a 
deeper understanding about antibiotics used in medicated feed in relation to common diseases 




was used to explore the practices and views of pig farmers and other stakeholders about 
determinants influencing antibiotic use in pig production. 
Using a mixed methods approach, I was able to compare and integrate findings from 
questionnaire surveys with farmers with the perspective of other stakeholders concerning 












Figure 3.1 Diagram demonstrating the study design using the convergent 
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• Trends in antibiotic use in 
pig farms (including type, 
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• The total national amount 
of antibiotics used in pig 
production through 
medicated feed is 
estimated
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antibiotic use in different 




3.2.2 Setting  
The study was conducted in province A located in the central region of Thailand, which has 
one of the highest pig populations, accounting for about 20% of total annual Thai pig 
production (78). The province has an area of about 5,000 square kilometres and around 
100,000 inhabitants. It is sub-divided into ten districts, some with a high density of pig and 
cattle farms, and others with very low density.  
Data from the study of antibiotic distribution in 2016 (100) demonstrated that there is a wide 
range of types of farm management in this province including smallholder farms managed by 
the individual farmer, smallholder farms managed under a cooperative association and 
commercial contracting farms. This diverse setting supports a range of situations of interest 
that will provide greater in-depth understanding antibiotic use in pigs in Thailand.  
3.2.3 Methodological considerations  
This section gives brief methodology considerations based on the two sub-studies: a mixed-
methods study and a qualitative study. The research methodology for each sub-study is 
explained in full in the next chapters. 
A mixed-methods study  
To describe patterns of antibiotic use in pigs, it is necessary to focus on the active ingredients 
of antibiotics, the quantity of antibiotics used for different purposes and routes of 
administration. Based on my systematic literature review, there are four possible approaches 
to collect antibiotic use data (Table 3.1).  
At farm level, data from prescription records can be accurate in terms of indication and doses 
given to animals. However, it is difficult in countries where no prescription is required for 
antibiotics. Antibiotic treatment records are available on some farms. In prospective data 
collection, a researcher might provide a record book to farmers, but these data are likely to be 
confidential on some farms. In many HICs, data on antibiotic use are available via online 
platforms including antibiotic application (by farmers) and antibiotic prescription (by 




only available for a few farms in LMICs. If no standard programme at a national level exists, 
investment and training is required to develop an online data entering system. In addition, it 
is challenging in countries where no prescription is required for antibiotics. Data from 
pharmaceutical companies and pharmacies are likely to be more practical to collect. 
However, these data cannot capture the number of animals which received antibiotics 
including doses, indications and duration. This data might also be confidential for the 


















Table 3.1 Different approaches for data collection on antibiotic use 
Data source PROS CONS Comments 
FARM VISIT    
- Antibiotic prescription  
(a prescription record at 
farm) 
- Accurate data on 
medicine, indications 
and doses 
- The prescribed 
antibiotics may not 
be used by animals 
- Difficult in countries 
where no prescription 
required for 
antibiotics 
- Antibiotic application 
(treatment record) 
- Indicate the number 
of animals which 
received antibiotics 
- Indicate dose and 
duration  
 - Available on some 
farms. It can be a 
prospective data 
collection. Researcher 
may provide a record 
book to farmers 
- Antibiotic invoice - Easy to access - Difficult to capture 
the number of 
animals which 
received antibiotics 
- Unable to capture 
indications, dose 
and duration  
- May not be available 
in all farms 
ONLINE PLATFORM    
- Antibiotic prescription  
(by veterinarians) 
- Easy to obtain, 
verify and use data for 
analysis 
 - Available in few 
farms in LMIC.  
- If no standard 
programme at a 
national level, it 
requires investment 
and training to 
develop the online 
data entering system 
- Difficult in countries 






Data source PROS CONS Comments 
- Antibiotic application 
(by farmers) 
- Easy to obtain, 
verify and use data for 
analysis 
  - Available in few 
farms in LMIC 
- If no standard 
programme at a 
national level, it 
requires investment 
and training to 
develop the system 
PHARMACEUTICAL COMPANY 
Antibiotic sale - Practical to collect 
data 
- Unable to capture 
the number of 
animals received 
antibiotics 
- Unable to capture 
dose, indications 
and duration  
- All antibiotics sold 
may not apply to 
animals 
- Confidential data for 
a pharmaceutical 
company 
PHARMACY    
Antibiotic prescription, 
Antibiotic sale 
 - Unable to capture 
the number of 
animals received 
antibiotics 
- Unable to capture 
dose and duration  
- All antibiotics sold 
may not apply to 
animals 









Based on the availability of data from different approaches, a questionnaire survey of pig 
farmers, secondary analysis of data from a survey of feed mill operators, and interviews with 
veterinarians were applied in the study to determine the patterns and total amount of 
antibiotic use in pig production in Thailand.  
• Survey of pig farmers  
Initially, I planned to obtain the sampling frame from national data of the DLD database. The 
random sampling methodology therefore would be applied to calculate the number of pig 
farms in the study. The primary sampling is an area (province) and the secondary sampling 
unit is a farm. However, the absence of complete up-to-date lists of pig farms in 2018 at 
district level limited the application of a census and random sampling technique for a sample 
selection of farms (more information is discussed in the strengths and limitations of the study, 
chapter 7).  
Based on the best available data and discussions with each district health office, the three 
districts with the highest number of pig farms were purposively selected and within each 
district, the two sub-districts with the highest number of pig farms were selected. 
The objective of a questionnaire survey of farmers was to assess the use of antibiotics; the 
source of antibiotics (including medicated feed); and how much access to information 
farmers had on animal health management, feed and antibiotic administration. 
The questionnaire was developed based on the relevant literature about antibiotic 
consumption in pig farms (110–112) and modified after the first phase of the interview with a 
small set of farmers, to ensure suitability to the local context in Thailand. The questions 
covered the following areas:  
- General information on farmer: gender, age, educational level 
- Characteristics of farms 
§ The size of farm is categorised based on the number of pigs on the farm 
according to the Department of Livestock Development (DLD) definition: 




small commercial farm (from 51 to 500 pigs), medium commercial farm (from 
501 to 5,000 pigs), and large commercial farm (more than 5,001 pigs); 
§ Good Agricultural Practices for the pig farm are introduced as voluntary 
standards for food safety and livestock production. The farm standards range 
from farm infrastructure, animal feed quality, water quality, farm management, 
and animal health management including the use of antibiotics; 
§ A contracted farm is classified to be where the contracting company provides 
pigs, feed, medicines, and technical support to farmers and farmers provide 
animal housing and labour. A non-contract farmer is independent of contracting 
companies;  
§ The type of pig production is grouped into farrow-to-finish (breeder, suckling 
piglet, nursery pig, fattener), fattening (fattener-only), and breeding (breeder-
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- Destination of pig products: pig broker, pork retailer, consumer, other farms, 
household own consumption; 
- Antibiotics and medicated feed used:  
§ The types of antibiotic are described according to the ATCvet classification 
system;  
§ Antibiotics are also categorised by WHO CIA for human medicine; 
§ Routes of administration included injection medication, oral solution, oral power 
through water medication (medicated drinking water) and feed medication 
(medicated feed); 
§ Purposes of antibiotic use are categorised as therapeutic use (treatment of 
disease), preventive use (sub-therapeutic doses of antibiotics) including for 
control of disease (metaphylaxis) and prevention of disease (prophylaxis), and 
non-therapeutic use. 
- Sources of antibiotics and medicated feed (pharmaceutical company, pharmacy, 
internet, feed mill, feed store; 
- Knowledge and awareness about antibiotics and AMR; 
- Perceptions of the factors regarding the use of antibiotics. 
The questionnaire is in Appendix 3.1. Data collection, data management and analysis of 
farmer survey are explained in full in chapter 5. 
• Survey of feed mills 
The survey of feed mill operators aimed to collect information about the production of 
medicated feed at a national level and included information about the type and volume of 
antibiotics mixed in medicated feeds. In order to determine the total amount of antibiotics 
used in pig production, the initial plan was to collect data through records of antibiotic 
administration on farms. However, it became clear that this would not be adequate. First, 
farmers had no recording system on the use of medicated feed. Second, there was a potential 
recall bias by farmers during interview. Third, there were no labels with the antibiotics’ 
names and concentration levels on the feed package (although there were feed codes on the 
feed packages, these codes were not specific to antibiotic contents). Fourth, farmers were not 
willing to disclose information in relation to the use of antibiotics. Limitations in estimating 
















Data recording at farm
Cannot retrieve antibiotic information from the  
feed products
• No label of antibiotic on the package of feed 
stuffs.
• The feed codes are not specific to antibiotics 
content in feed.







Given these limitations, data from a national survey of feed mill operators for feed production 
in 2017 were used for the secondary data analysis. The national survey of feed mills was 
conducted by the International Health Policy Program as part of the Thailand Surveillance of 
Antimicrobial Consumption in humans and animals (Thailand SAC) (81). Thailand SAC was 
developed in 2017 in response to the National Strategic Plan on AMR. Data from an annual 
report of pharmaceutical operators including importers and manufacturers were used to 
estimate the total national consumption of antimicrobials in humans and animals. Given the 
limitations of Thailand SAC, data are not available to disaggregate by animal species. In 
2017, the working group decided to collect data of antibiotics used in medicated feed 
(medicated premix) because about half of antimicrobials used in food-producing animals was 
in the form of medicated premix (81).  
Data extracted for the analysis from the survey forms included the following variables:  
- Name of the antibiotic (medicated premix) according to the anatomical therapeutic 
chemical veterinary (ATCvet) classification system; 
- Thailand FDA market authorization identification number; 
- Type and amount of antibiotic added to the feed; 
- Unit of measurement: kilograms; 
- Stage of pig production: breeding pigs (sows), pigs less than 25 kg (suckling and 
nursery pigs) and fatteners. 
A full explanation of the sample population, data collection and data management and 
analysis of feed mill survey is in chapter 5. 
• Interviews with veterinarians in the feed industry  
The interview with veterinarians in the feed industry was conducted to understand the use of 
medicated feed in pig farms. The Thai Feed Mill Association was asked to propose a list of 
veterinarians working at the feed mills, who were members of the Thai Feed Mill 
Association, to participate in the study. All of the interviews were conducted face-to-face in 
Thai through semi-structured interviews. A full description of data collection, data 




A qualitative study  
A qualitative approach was used to explore determinants influencing antibiotics use. The 
interviews were conducted with pig farmers and other stakeholders including animal drug 
detailers, food animal industry veterinarians and government officers concerning antibiotic 
control to explore their views about the practices of antibiotic use, and its drivers in pig 
production.  
Interviews were used with open questions to reconstruct meanings of antibiotic use through 
actors’ practices, perceptions, attitudes and motivations (113). There was little information 
about the use of antibiotics in pigs in Thailand; therefore, data from the key-informants 
supplemented the interview questionnaire to try to obtain information about potential factors 
influencing the use of antibiotics.  
To design the interview guide, interviews were conducted with a small set of farmers, such as 
a representative of a pig farmer association or a representative of a pig cooperative 
association. Based on the study framework and the first phase of interviews, the interview 
guide covers the potential factors contributing to antibiotic use:  
- Animal health and farm management;  
- Pig production and market demand; 
- Relationship with other farmers 
- Regulation and policy on antibiotic use. 
Farmers respondents in the farmer survey of antibiotic usage were asked to participate in the 
interview and farmers who did not use antibiotics in their farms in the studied area were 
purposively selected through a snowball sampling technique. The interviews took the form of 
an interactive discussion between the researcher and farmer participant with an average 
duration of 120 minutes. The researcher then conducted direct observation on the farm after 
the interview, in order to add more depth to the analysis and findings (114). This also helped 
validate the information given by interview respondents such as comparing data collected 
during the interview with farmworkers’ actual practices observed on the farm. For the 
observations, I looked at activities of farmworkers, labels of the feed, medicines used by 




Animal drug detailers, food animal feed industry veterinarians and government officers were 
interviewed to assess the context in which pig farms operate and to explore other additional 
and related information. Each interviewee was selected using purposive sampling. Animal 
drug detailers who were working in the study area were identified by farmers and contacted 
for the interview. Relevant organisations such as government authorities in the field of 
antibiotic control, animal feed mill associations, veterinary associations, and health 
professional councils were asked to propose lists of their staffs or members who could 
provide information about the use of antibiotics in pig production. The researcher contacted 
each potential informant identified to see if they were able and willing to participate in the 
study. Animal drug retailers and food animal industry veterinarians were interviewed outside 
their shops and offices, and officers were interviewed in their offices. Each interview took 
one to three hours. 
To gather in-depth data, I conducted the interviews and observations to ensure a good 
relationship between myself and the key informants. Details of the qualitative methodology is 
explained in full in chapter 6. 
3.2.4 Ethical considerations 
The study is approved by the ethical committees of the Institute for the Development of 
Human Research Protection at Ministry of Public Health, Thailand (reference number: 
IHRP2018007); and the London School of Hygiene and Tropical Medicine research ethics 
committee (reference number: 14860). Informed consent was obtained for all interviews. In 
keeping with confidentiality agreements, no name and affiliation of the respondents were 







Chapter 4 Literature review     
Summary 
To inform the empirical research, I conducted two systematic literature reviews of antibiotic 
use in pig production. The aim of the first review was to gain a comprehensive overview of 
antibiotic use in global pig production. The results are presented in the first paper entitled 
“Patterns of antibiotic use in global pig production: A systematic review”. The paper was 
published in Veterinary and Animal Science in April 2019. A further systematic review 
sought to understand the methods for quantification of antibiotic use and was undertaken in 
order to guide data collection in my empirical research to estimate the total amount of 
antibiotics used in pig production in Thailand. The paper was published in Preventive 
Veterinary Medicine in September 2018. Both systematic reviews are presented in subsection 
2. Based on a further review of the literature, subsection 3 highlights potential factors 
influencing the use of antibiotics among different stakeholders at three different levels: 
individual level, systems level, and policy and regulation level. Finally, subsection 4 presents 












4.1 Systematic literature review of antibiotic use in pig production  
The literature review covered two main areas: a description of the patterns of antibiotic use 
and methods for quantification of antibiotic use in global pig production. In accordance with 
objective 1 of this study, the first review aims to describe what is known about how 
antibiotics are used and which factors are associated with the use of antibiotics in global pig 
production. The second review was conducted to identify the methods and measurements 
which are applied to quantify the use of antibiotics and identify the current quantity of 
antibiotics used in pigs. 
4.1.1 Patterns of antibiotic use in global pig production: A systematic review  
Understanding the current patterns of antibiotic use in livestock is important due to concerns 
about AMR. This systematic review aims to analyse and synthesise the available published 
information on patterns of antibiotic use in pigs. It describes the patterns of antibiotic use 
including classes and active ingredients of the antibiotic; the route of administration; the 
purpose of use including treatment, metaphylaxis, prophylaxis and growth promotion; and the 
frequency of use by different farms and different stages of pig production. 
The studies included in the systematic review were conducted between 2000 and 2017; this 
time period was selected in order to get up-to-date information on antibiotic use in pig 
production. The analysis also considers the geographical gap of the studies conducted in 
HICs and LMICs.  
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A B S T R A C T
This review assesses the evidence for patterns of antibiotic use in pig on the basis of papers published in peer-
reviewed journals in English between 2000 and 2017. Thirty-six articles were identified and reviewed, of which
more than 85% of studies were conducted in Europe and North America. Penicillins and Tetracyclines groups
were the most commonly used antibiotics in many countries. Oral medication in suckling and post-weaning
periods were the most common applications of antibiotic administration in pig production. Antibiotic use is
driven by age-specific diseases and the common pathogens causing these conditions where epidemiological
profiles varied greatly across countries. In addition, the type and size of farm were associated with antibiotic use
with finisher and larger farms using more antibiotics than farrow-to-finish and smaller farms. There is variation
in the use of the highest priority critically important antimicrobials in humans across studies. However, this
review indicates that they are still commonly used in pig production, for treatment and prevention of infection.
This evidence calls for global e!orts on the prudent use of antibiotics in response to the emergence of anti-
microbial resistance (AMR) in the agricultural sector.
1. Introduction
Antibiotics have been used routinely in farm animal production since
the 1950s, in particular during intensive farming, in order to keep animals
healthy and to increase productivity. The use of antibiotics in animals has
raised concerns that the selective pressure on the bacteria population pro-
motes antibiotic resistance. Despite the di"culties in demonstrating the
transmission of resistant bacteria from animals to humans, many studies
have shown evidence of human infection from resistant bacteria in animals
(Liu et al., 2018; McCrackin et al., 2016; Nhung, Cuong, Thwaites, &
Carrique-Mas, 2016). The discovery of a plasmid-mediated colistin resistant
gene (MCR-1) in commensal Escherichia coli from pigs, pork products and
humans in China, triggered global concern (Liu et al., 2016). Colistin is
considered a last resort antibiotic as it is one of the only antibiotics active in
severe infections caused by hospital acquired multidrug-resistant (MDR)
pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii and
Enterobacteriaceae (Catry et al., 2015).
Antibiotics in the same class usually have a similar mode of therapeutic
action, with a range of e!ectiveness. Many classes of antibiotic used for
humans are also used in food animals. The World Health Organisation
(WHO) produces a list of all antimicrobials grouped into 3 categories based
on their importance in treating human infections. (World Health
Organization, 2017). The classes of drugs included in the list of critically
important antimicrobials (CIA) for human medicine contain the last-resort
antibiotics to treat severe infections caused by multidrug-resistant (MDR).
The CIA list of Highest Priority Critically Important Antimicrobial includes
Quinolones, 3rd and higher generation Cephalosporins, Macrolides and
Ketolides, Glycopeptides and Polymixins class which includes colistin
(World Health Organization, 2017). This WHO CIA list is referred to in the
rest of this report.
In animals, the use of antibiotics is common for not only treatment, but
also for controlling the spread of infection (metaphylaxis), preventing in-
fection (prophylaxis) particularly in periods of stress and vulnerability to
infections, and improvement of feed e"ciency and promotion of animal
growth (Aarestrup, 2005). According to American Veterinary Medical As-
sociation, the term “therapeutic” includes treatment, control, and preven-
tion of disease (Association American Veterinary Medical, 2019). The use of
antibiotics as a growth promoter is considered non-therapeutic. Many
countries including USA, Canada and Australia have implemented policies
and regulations that medically important antimicrobials are prescription
only medicines by licensed veterinarians (Australian Veterinary Association,
Guideline for prescribing, authorising and dispensing veterinary medicines,
2005; Government of Canada, 2018; US Food and Drug Administration,
2011). The use of antibiotics for growth promotion has been banned in the
European Union since 2006 (Regulation (EC) No 1831/2003 of the
European Parliament and of the councel on additives for use in animal
https://doi.org/10.1016/j.vas.2019.100058
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nutrition, 2003). In contrast, other countries – including China and Brazil
which are the large livestock producing and exporting countries – do not
prohibit the use of antibiotics for growth promotion (Maron, Smith, &
Nachman, 2013).
Despite the concerns about the relationship between the use of anti-
biotics and AMR in food animals and AMR in humans, there are limited
studies exploring the use of antibiotic in livestock and the factors that in-
fluence how farmers use them. To promote the prudent use of antibiotics in
livestock, it is vital to have a better understanding of the current situation.
This systematic review aims to analyse and synthesise the available pub-
lished information on the pattern of antibiotic use in pigs.
2. Method
2.1. Scope of study and research question
This study focuses on antibiotics. Before conducting the systematic re-
view, the terms and explanations to be included were considered as follows.
According to World Organisation for Animal Health (OIE) definition, an
antimicrobial is considered as a naturally occurring, semi-synthetic or
synthetic substance that exhibits antimicrobial activity (to kill or inhibit the
growth of micro-organisms) at concentrations attainable in vivo. Anti-hel-
minthic and substances classed as disinfectants or antiseptics are excluded
from this definition (World Organisation for Animal Health, 2011). In this
study the word ‘pigs’ refers to all stages of swine production including
breeding and gestation, farrowing, nursery and feeding and finishing. The
word ‘pattern’ explains the use of antibiotics in terms of active ingredient;
the route of administration such as injection or medicated feed; the purpose
of the use including treatment, metaphylaxis, prophylaxis and growth
promotion; and the frequency of the use by di!erent farms and di!erent
stages of life cycle of pig production. The research questions in the review is:
“What are the patterns of antibiotic use in terms of classes, routes of ad-
ministration and purpose of the use and its associations with pig produc-
tion?”.
2.2. Identifying relevant literature
The study applied the “SPIDER” tool, designed specifically to
identify relevant quantitative studies (Cooke, Smith, & Booth, 2012). It
covers the following: Sample: pig; Phenomenon of Interest: antibiotic
use in pigs; Design: Observational studies; Evaluation: pattern of anti-
biotic use including active ingredient of antibiotic, route of adminis-
tration, purpose of use including treatment, control, prevention and
growth promotion; and Research: Quantitative research.
Literature on the use of antibiotics in pigs was systematically reviewed
between July to October 2017. Relevant scientific papers published in
English peer-reviewed journals were identified using the keyword combi-
nations (antibiotic OR antimicrobial OR antibacterial) AND (livestock OR
swine OR pig* OR farrow OR weaner OR finisher OR sow) AND (use OR
utilisation OR consum* OR practice OR administration).
The online electronic database through LSHTM databases: MEDLINE
(http://ovidsp.tx.ovid.com; 1946 until present), Scopus (http://www.
scopus.com; 1823 until present) and Web of Science (http://apps.
webofknowledge.com; 1970 until present) were searched with restriction
of the date of publication between 2000 and 2017 to capture up-to-date
data. To ensure a wide range of articles from di!erent sources, additional
searches were sourced through the reference lists of key articles.
2.3. Eligibility assessment of studies and inclusion criteria
Prior to a study being included within the review, the following
criteria were considered: publication in English, and focus on antibiotic
usage in pigs with high and moderate ranking of a quality assessment.
Citations of all identified studies were downloaded into a reference
management software (EndNote X8.0.2). In the first screening step, the
duplicated studies were removed, through consideration of the title and the
abstract by comparison with the keywords. Full texts were further con-
sidered. Reviews, clinical research, pharmacokinetic, biopharmaceutical
and experimental studies were excluded. In addition, studies focusing on
antibiotic activity, specific diseases related to drug recommendations, as-
sociations of antibiotic use with antimicrobial resistance, relationship be-
tween interventions and antibiotic use, and e!ects of antibiotic treatment to
AMR, animal productivity and animal management were excluded.
Studies included in the qualitative synthesis were those that presented
the pattern of antimicrobial use, and medium (50–75%) and high-ranking
quality assessment (>75%). If a study explored data over many periods of
time, then the updated data was selected for the review.
2.4. Quality assessment
The Critical Appraisal Skills Programme (CASP) was applied for
quality assessment) (Critical Appraisal Skills Programme, 2014). They
were aggregated into a quality score based on four criteria: aim,
method, result and application of the literature; Yes, No and Cannot tell
are the assessment outcomes. With eleven questions, the score was
categorised into three groups: weak means <50% having “yes” an-
swers, moderate means 50–75% having “yes” answers, and high means
>75% having “yes” answers (see Table B.1 of annex). If the assessment
by the reviewer was ‘no’ or ‘cannot tell’, the score for that question was
zero; the score for yes was one. In this review, the studies were ranked
by quality criteria. The quality ranking was classified into three groups:
High meant >75% of all eleven sub-criteria were met, moderate meant
50–75% were met and weak meant <50% of criteria were met.
2.5. Data extraction and synthesis
Fig. 1 shows the review process. All relevant articles in full texts
were reviewed and summarised using a standardised data extraction
table in an Excel spreadsheet.
3. Results
3.1. Eligible studies
Our search strategies identified a total of 2588 articles
(Appendix A). After duplicates were removed and an initial review of
titles and abstracts for relevance was conducted and 118 articles were
found to be eligible for full-text screening on the basis of the inclusion
criteria. Sixty-eight studies were found to be relevant and retained.
Further screening excluded 31 papers; of which 16 papers were not
related to pattern and factors influencing antibiotic use; two papers had
inappropriate study design; four papers focused on specific diseases
using recommended antibiotics and relationship between interventions
and antibiotic use; and ten papers were not related to pigs. Finally, 36
studies were included in this systematic review. Fig. 1 showed the flow
diagram of the process in screening papers.
3.2. Study characteristics
As shown in Table 1, twenty-seven of studies (75%) were conducted
between 2010 and 2017; the remaining 9 studies were conducted be-
tween 2000 and 2010 (25%). Most studies (72%) were conducted in
Europe, with four studies in North America (11%), three in Asia (8%),
and one each in Africa (3%) and Australia (3%). Diverse sources of data
were used for the study such as farm surveys (39%), national databases
(19%), farm-based survey and prescription data (14%), prescription
data (8%), antibiotic application records (8%), veterinary survey (6%),
pharmaceutical producer survey (3%) and farm-based survey and na-
tional data (3%). Among total studies reviewed, 9 studies (25%) were
nationally representative. The result of the quality assessment of 36
studies showed that 21 (58%) and 15 (42%) of studies are of high and
medium quality respectively (see Table B.1 in Annex).
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3.3. Patterns of antibiotic use in pigs
3.3.1. Patterns of antibiotic use
3.3.1.1. Classes and active ingredients of antibiotic. Some studies
reported antibiotic use by active ingredient and others only by the
class. In many studies the most common used antibiotic classes were the
Penicillins and Tetracyclines. Benzylpenicillins consisted 61% of total
use in a farm study in Sweden (Sjölund et al., 2016). Aminopenicillins
were commonly reported accounting for 30–40% of total antibiotic use
in studies from Sweden, Germany and Canada (Glass-kaastra et al.,
2013; Sjölund et al., 2016; Van Rennings et al., 2015). Twelve studies
reported that Tetracyclines class was the most commonly used
including studies from Denmark, Japan, Netherlands, Australia, Spain
and France (Bondt, Jensen, Puister-Jansen, & van Geijlswijk, 2013; Bos
et al., 2013; Casal, Mateu, Mejía, & Martín, 2007; Chauvin, Beloeil,
Orand, Sanders, & Madec, 2002; Dupont, Diness, Fertner, Kristensen, &
Stege, 2017; Hosoi, Asai, Koike, Tsuyuki, & Sugiura, 2014; Jordan et al.,
2009; Vieira, Pires, Houe, & Emborg, 2011), and was as high as 54.4%
in a study from Germany (Merle et al., 2013). Within the Tetracyclines
class, doxycycline was used 62.3% of total use in the study in Austria
(Moreno, 2012). The share of chlortetracycline use was 23.9% in a farm
study in Vietnam (Van Cuong et al., 2016), and formed the majority of
antibiotics use in all pig stages in the United States (Apley, Bush,
Morrison, Singer, & Snelson, 2012). In the farm study in Switzerland,
the most common antibiotic class was the reductase inhibitors and
combinations class” of drugs, specifically sulfadimidine, sulfathiazole
and trimethoprim, accounting for 62.1% (Arnold, Gassner, Giger, &
Zwahlen, 2004) while Bacitracin was the most reported of antibiotic use
(24.8%) in the farm study in Vietnam (Van Cuong et al., 2016).
Fattening farms in the study from Austria applied Lincosamides in
71.9% of antibiotic use (Trau!er, Griesbacher, Fuchs, & Köfer, 2014).
The use of highest priority Critically Important Antimicrobials in hu-
mans was also reported di"erently across countries. The studies from France
and Austria reported the use of Macrolides at 20% and at 7.4% of total use
Fig. 1. Flow diagram of the screening process of the literature.
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(Chauvin et al., 2002; Trau!er, Obritzhauser, Raith, Fuchs, & Köfer, 2014).
Based on the electronic drug application records from 75 pig farms in
Austria, Fluoroquinolones were reported at 2.4% of total use, third and
fourth generation Cephalosporins were 2.2% of total use (Trau!er et al.,
2014), while the use of Fluoroquinolones at 5% and third generation Ce-
phalosporins at 11% were reported from 47 pig farms in the study in Bel-
gium (Sjölund et al., 2016). The study in 60 French pig herds received
colistin in 30% of total antibiotic use (Sjölund et al., 2016), 12.2% in the
study in Vietnam using the internet-based survey of commercial feed pro-
ducer (Van Cuong et al., 2016), 33% and 61% in the survey in 45 farrow-to-
finish farms and 67 fattening farms in Spain (Moreno, 2012) and 34.4% in
fattening farms in 75 pig farms in Austria (Trau!er et al., 2014).
3.3.1.2. Routes of administration. Generally, oral medication was the
most common route of antibiotic administration in pig production.
Several studies reported more than 90% of antibiotic substances were
administered orally via both feed and water (Chauvin et al., 2002;
Merle et al., 2012; Raji", Reid-Smith, Deckert, Dewey, & McEwen,
2006; Van Rennings et al., 2015). About 70–90% of the oral use was
reported in many countries, for example 87% in the study from France
(Sjölund et al., 2016), 86% in the study from Austria (Trau!er et al.,
2014), 73% in the study from Denmark (Dupont et al., 2017), 71% in
the study from Germany (Sjölund et al., 2016) and 70% in the study
from Belgium (Sjölund et al., 2016). In the UK farm study, 60–75% of
the farmers had used medicated feeds for their weaners (Stevens et al.,
2007). Another study indicated that oral use of antibiotics was higher
than parenteral indication (97.43% VS 2.46%) (Merle et al., 2013).This
is in contrast to another study that farmers applied very low levels of
oral antibiotics, 13% of all routes (Sjölund et al., 2016).
A wide range of active ingredients was commonly used for oral medi-
cation, including: colistin (Filippitzi, Callens, Pardon, Persoons, & Dewulf,
2014; Moreno, 2012; Timmerman et al., 2006), amoxicillin(Filippitzi et al.,
2014; Timmerman et al., 2006), sulfonamides (Bondt et al., 2013;
Timmerman et al., 2006), oxycycline (Bondt et al., 2013), doxycycline
(Moreno, 2012; Timmerman et al., 2006), chlortetracycline, lincomy-
cin,tiamulin, tylosin, and penicillin G (in water) (Rosengren et al., 2008).
However, ceftiofur (Filippitzi et al., 2014; Timmerman et al., 2006),
enrofloxacin (Moreno, 2012), amoxycillin (Moreno, 2012; Timmerman
et al., 2006), penicillin (Moreno, 2012; Rosengren et al., 2008) and tulz-
tromycin (Filippitzi et al., 2014) were commonly used for parenteral
medication.
The oral administration of antibiotics (either through feed or water) was
commonly used for group treatment, while injection was the commonly
applied for treatment of individual sick animals (Sjölund, Backhans, Greko,
Emanuelson, & Lindberg, 2015; Trau!er et al., 2014). A study showed that
90% of group treatment was administered between birth and ten weeks of
age; while only 20% of group treatment was administered during the fat-
tening period (Callens et al., 2012). Group treatments were primarily ad-
ministered via oral medication in weaners and via parenteral route for in-
dividual sucking piglets (Filippitzi et al., 2014), particularly after castration
or when diarrhoea occurred (Timmerman et al., 2006). In one study re-
ported ninety-four percent of group treatment at farm for a respiratory in-
fection (prior to a definitive diagnosis) was carried out with tetracycline,
beta-lactams and sulphonamides while 90% of group treatment at farm for
enteric disease used colistin (Casal et al., 2007).
3.3.1.3. Indications: treatment, metaphylaxis, prophylaxis and growth
promotion. Few studies in this review reported the indication for
antibiotics use. A vast majority, 93% of total antibiotics administered
were for prophylaxis, whereas metaphylaxis or treatments were much
smaller at 7% of total antibiotics in Belgium (Callens et al., 2012; Filippitzi
et al., 2014). Main therapy indications in farrow-to-finish and fattening
farms were metaphylactic/prophylactic measures (Trau!er et al., 2014).
Chlrotetracycline and carbadox were the most commonly used antibiotics
for growth promotion, prevention and treatment of infectious diseases and
tiamulin was commonly used for prevention and treatment of infectious
diseases (Apley et al., 2012).
Only few studies reported the use of antibiotic by distinguishing
between metaphylaxis and prophylaxis (Callens et al., 2012; Filippitzi
et al., 2014), which ‘prophylactic use’ means treatment of healthy pigs
to prevent disease from occurring and ‘metaphylactic use’ means
treatment of clinically healthy pigs in the same group where some
animals had showed clinical symptoms of disease. Based on American
Veterinary Medical Association, both ‘prophylaxis’ and ‘metaphylaxis’
means therapeutic (Association American Veterinary Medical, 2019)
and commonly described as “preventative use” as a general term.
However, both terms are not applied in certain situations such as the
use of antibiotics within a group of animals without definite diagnosis.
3.3.2. Association between the use of antibiotics and pig production
3.3.2.4. Phase of pig production. Six studies examined the association of
antibiotic use and the phase of pig production. Antibiotics were commonly
used during suckling and post-weaning periods. One study reported more
than 80% of antibiotics were applied to pigs at less than ten weeks of age
(Callens et al., 2012). Four studies reported that weaners received the most
antibiotics (Chauvin et al., 2002; Fertner et al., 2015; Jensen, Emborg, &
Aarestrup, 2012; Sjölund et al., 2016). However, another study showed that
treatment of suckling piglets was more common than weaners
(Sjölund et al., 2016), and similar findings were reported in two studies
(Merle et al., 2013; Van Rennings et al., 2015).
Based on the cross-sectional study conducted among 227 farrow-to-
finish pig herds in four European countries, there was a significant asso-
ciation between antibiotic use across di#erent age categories. The lowest
use of antibiotics among fatteners reported in France and Sweden, while the
least use in breeders reported in Belgium and Germany (Sjölund et al.,
2016). Similarly, the studies from Denmark and France reported the least
application of antibiotics in sows, with about 26% and 17% of total use in
all phases respectively (Chauvin et al., 2002; Jensen et al., 2012). Another
study using veterinary prescription data reported almost zero use of anti-
biotic among the finishers in Denmark (Fertner et al., 2015). However, one
study from Belgium reported that the use of antibiotics was higher in the
farrowing period than fattening period (Callens et al., 2012). Another study
showed that eight veterinarians in Saskatchewan and Alberta applied more
Table 1










Data source of antibiotics
Farm based survey 14 (39%)
National database (consumption/sale/prescription) 7 (19%)
Farm based survey and prescription data 5 (14%)
Prescription data 3 (8%)
Antibiotic application records 3 (8%)
Veterinarian survey 2(6%)
Pharmaceutical producer survey 1 (3%)
Farm based survey and national data 1 (3%)
Quality assessment by authors
High (>75%) 21 (58%)
Moderate (50–74%) 15 (42%)
a Europe: Denmark (n=7), Germany (n=6), Belgium (n=5), France
(n=3), Netherlands (n=3), Sweden (n=3), Switzerland (n=3), Austria
(n=2), Spain (n=2), UK (n=1).
b North America: Canada (n=3), USA (n=1).
c Asia: Vietnam (n=2), Japan (n=1).
d Africa: Sudan (n=1).
e Australia: Australia (n=1).






















































































































































































































































Number of studies reporting data sources of active by geographical areas.
Europe (27) North America (4) Asia (3) Africa (1) Australia (1)
Farm based survey (14) 11 (Callens et al., 2012; Casal et al., 2007; Dupont et al., 2017; Jensen, Jorsal, & Toft,
2017; Moreno, 2012; Sjölund et al., 2016, 2015; Stevens et al., 2007; Timmerman et al.,
2006; Visschers et al., 2014, 2015)
1 (Raji$ et al., 2006) 1 (Kim et al., 2013) 1 (Eltayb et al., 2012) –
National database (consumption/sale/
prescription) (7)
5 (Aarestrup, Vibeke, Jacobsen, & Wegener, 2010; Bondt et al., 2013; Bos et al., 2013;
Jensen et al., 2012; Vieira et al., 2011) (Bondt et al., 2013; Bos et al., 2013; de Jong
et al., 2014; Jensen et al., 2012)
1 (Apley et al., 2012) 1 (Hosoi et al., 2014) – –
Farm based survey and prescription data
(5)
4 (Merle et al., 2012, 2013, 2014; Van Rennings et al., 2015) – – – 1 (Jordan et al., 2009)
Prescription data (3) 2 (Arnold et al., 2004; Fertner et al., 2015) 1 (Glass-kaastra et al., 2013) – – –
Antibiotic application records (3) 3 (Trau"er et al., 2014; Trau"er et al., 2014; van der Fels-Klerx et al., 2011) – – – –
Veterinarian survey (2) 1 (Chauvin et al., 2002) 1 (Rosengren et al., 2008) – – –
Pharmaceutical producer survey (1) – – 1 (Van Cuong et al.,
2016)
– –






Number of studies reporting use of antibiotic class and active ingredient, by phase of pig production.
Antibiotic class and active ingredient Total studies (N) Phase of pig production
Breeders Sucking piglet Weaner Fattener/finisher
Penicillins 2 (Jensen et al., 2012; Raji! et al.,
2006)
2 (Jensen et al., 2012; Raji! et al.,
2006)
– 2 (Jensen et al., 2012; Raji! et al.,
2006)
2 (Jensen et al., 2012; Raji! et al.,
2006)
– Benzylpenicillins 2 (Sjölund et al., 2015, 2016) 1 (Sjölund et al., 2016) 2 (Sjölund et al., 2015, 2016) 1 (Sjölund et al., 2016) 1 (Sjölund et al., 2016)
– Aminopenicillin 5 (Dupont et al., 2017; Jensen et al.,
2012; Sjölund et al., 2015, 2016; Van
Rennings et al., 2015)
5 (Dupont et al., 2017; Jensen et al.,
2012; Sjölund et al., 2015, 2016;
Van Rennings et al., 2015)
4 (Dupont et al., 2017; Sjölund
et al., 2015, 2016; Van
Rennings et al., 2015)
5 (Jensen et al., 2012, 2017, Sjölund
et al., 2015, 2016; Van Rennings
et al., 2015)
4 (Jensen et al., 2012; Sjölund et al.,




2 (Dupont et al., 2017; Sjölund et al.,
2015)
2 (Dupont et al., 2017; Sjölund
et al., 2015)
2 (Dupont et al., 2017; Sjölund
et al., 2015)
1 (Sjölund et al., 2015) 2 (Dupont et al., 2017; Sjölund et al.,
2015)
–Amoxicillin-clavalunic acid 1 (Jensen et al., 2017) – – 1 (Jensen et al., 2017) –
Tetracyclines 5 (Jensen et al., 2017, 2012; Sjölund
et al., 2016; Van Rennings et al.,
2015; Merle et al., 2012)
4 (Jensen et al., 2012; Merle et al.,
2012; Sjölund et al., 2016; Van
Rennings et al., 2015)
3 (Merle et al., 2014; Sjölund
et al., 2016; Van Rennings
et al., 2015)
4 (Jensen et al., 2012, 2017; Sjölund
et al., 2016; Van Rennings et al.,
2015)
4 (Jensen et al., 2012; Merle et al.,
2014; Sjölund et al., 2016; Van
Rennings et al., 2015)
–Doxycycline 2 (Dupont et al., 2017; Sjölund et al.,
2015)
– – 1 (Dupont et al., 2017) 2 (Dupont et al., 2017; Sjölund et al.,
2015)
–Chlortetracycline 4 (Apley et al., 2012; Dupont et al.,
2017; Raji! et al., 2006; Van Rennings
et al., 2015)
2 (Raji! et al., 2006; Van Rennings
et al., 2015)
1 (Van Rennings et al., 2015) 4 (Apley et al., 2012; Dupont et al.,
2017; Raji! et al., 2006; Van Rennings
et al., 2015)
3 (Apley et al., 2012; Raji! et al.,
2006; Van Rennings et al., 2015)
–Oxytetracycline 3 (Apley et al., 2012; Raji! et al.,
2006; Sjölund et al., 2015)
2 (Raji! et al., 2006; Sjölund et al.,
2015)
1 (Sjölund et al., 2015) 3 (Apley et al., 2012; Raji! et al.,
2006; Sjölund et al., 2015)
3 (Apley et al., 2012; Raji! et al.,
2006; Sjölund et al., 2015)
Sulphonamides 1 (Merle et al., 2014) 1 (Merle et al., 2014) 1 (Merle et al., 2014) 1 (Merle et al., 2014)
–Trimethoprim–sulphonamides 5 (Dupont et al., 2017; Jensen et al.,
2017, 2012; Sjölund et al., 2015,
2016)
4 (Dupont et al., 2017; Jensen et al.,
2012; Sjölund et al., 2015, 2016)
3 (Dupont et al., 2017; Sjölund
et al., 2015, 2016)
4 (Jensen et al., 2012, 2017, Sjölund
et al., 2015, 2016)
3 (Jensen et al., 2012; Sjölund et al.,
2015, 2016)
–Sulfadiazine 1 (Van Rennings et al., 2015) 1 (Van Rennings et al., 2015) 1 (Van Rennings et al., 2015) 1 (Van Rennings et al., 2015) 1 (Van Rennings et al., 2015)
Macrolides 4 (Jensen et al., 2012; Merle et al.,
2014; Sjölund et al., 2015, 2016)
4 (Jensen et al., 2012; Merle et al.,
2014; Sjölund et al., 2015, 2016)
3 (Merle et al., 2014; Sjölund
et al., 2015, 2016)
3 (Jensen et al., 2012; Sjölund et al.,
2015, 2016)
4 (Jensen et al., 2012; Merle et al.,
2014; Sjölund et al., 2015, 2016)
–Tylosin 5 (Apley et al., 2012; Dupont et al.,
2017; Raji! et al., 2006; Sjölund et al.,
2015; Van Rennings et al., 2015)
2 (Raji! et al., 2006; Van Rennings
et al., 2015)
1 (Van Rennings et al., 2015) 5 (Apley et al., 2012; Dupont et al.,
2017; Raji! et al., 2006; Sjölund et al.,
2015; Van Rennings et al., 2015)
5 (Apley et al., 2012; Dupont et al.,
2017; Raji! et al., 2006; Sjölund et al.,
2015; Van Rennings et al., 2015)
–Tilmicosin 2 (Apley et al., 2012; Raji! et al.,
2006)
– – 1 (Apley et al., 2012) 2 (Apley et al., 2012; Raji! et al.,
2006)
Pleuromutilins 2 (Merle et al., 2014; Sjölund et al.,
2016)
2 (Merle et al., 2014; Sjölund et al.,
2016)
2 (Merle et al., 2014; Sjölund
et al., 2016)
1 (Sjölund et al., 2016) 2 (Merle et al., 2014; Sjölund et al.,
2016)
–Tiamulin 4(Apley et al., 2012; Dupont et al.,
2017; Raji! et al., 2006; Sjölund et al.,
2015)
1 (Dupont et al., 2017) 1 (Dupont et al., 2017) 3 (Apley et al., 2012; Dupont et al.,
2017; Sjölund et al., 2015)
4 (Apley et al., 2012; Dupont et al.,
2017; Raji! et al., 2006; Sjölund et al.,
2015)
Lincosamides
–Lincosamides 4 (Apley et al., 2012; Merle et al.,
2014; Raji! et al., 2006; Sjölund et al.,
2016)
1 (Merle et al., 2014; Raji! et al.,
2006; Sjölund et al., 2016)
2 (Merle et al., 2014; Sjölund
et al., 2016)
4 (Apley et al., 2012; Jensen et al.,
2017; Raji! et al., 2006; Sjölund et al.,
2016)
4 (Apley et al., 2012; Merle et al.,
2014; Raji! et al., 2006; Sjölund et al.,
2016)
–Lincosamides and spectinomycin 3 (Jensen et al., 2012; Raji! et al.,
2006; Sjölund et al., 2016)
3 (Jensen et al., 2012; Raji! et al.,
2006; Sjölund et al., 2016)
1 (Sjölund et al., 2016) 3 (Jensen et al., 2012; Raji! et al.,
2006; Sjölund et al., 2016)
3 (Jensen et al., 2012; Raji! et al.,
2006; Sjölund et al., 2016)
Polymyxin
Colistin 5 (Jensen et al., 2012, 2017, Sjölund
et al., 2015, 2016; Van Rennings
et al., 2015)
3 (Jensen et al., 2012; Sjölund
et al., 2016; Van Rennings et al.,
2015)
3 (Sjölund et al., 2015, 2016;
Van Rennings et al., 2015)
5 (Jensen et al., 2012, 2017, Sjölund
et al., 2015, 2016; Van Rennings
et al., 2015)
3 (Jensen et al., 2012; Sjölund et al.,
2016; Van Rennings et al., 2015)
Aminoglycosides 4 (Jensen et al., 2012; Merle et al.,
2014; Sjölund et al., 2016)
3 (Jensen et al., 2012; Merle et al.,
2014; Sjölund et al., 2016)
2 (Merle et al., 2014; Sjölund
et al., 2016)
3 (Jensen et al., 2012, 2017;
Sjölund et al., 2016)
4 (Jensen et al., 2012; Merle et al.,
2014; Sjölund et al., 2016)
Amphenicols 2 (Jensen et al., 2012; Sjölund et al.,
2016)
2 (Jensen et al., 2012; Sjölund
et al., 2016)
1 (Sjölund et al., 2016) 2 (Jensen et al., 2012; Sjölund et al.,
2016)
2 (Jensen et al., 2012; Sjölund et al.,
2016)





Pig density had a positive association with the use of antibiotics (Bos
et al., 2013; Stevens et al., 2007). The number of sows presented on the
farm has a positive correlation with the amount of antibiotic use (van der
Fels-Klerx et al., 2011). Di!erent findings in few studies showed that small
herd size had significantly higher antibiotic use than moderate and large
herd size (Vieira et al., 2011); and the number of pigs in farms had no
association with the use of antibiotics (Casal et al., 2007) and the use of
growth promoters (Stevens et al., 2007). One study reported that industrial
production system had higher antibiotic use than a semi-industrial pro-
duction system and small farm holders (Kim et al., 2013).
There was only one study that documented the association between
vaccination and antibiotic use. The vaccination of suckling piglets and
weaners was significantly associated with the greater use of in-feed
antibiotics (Stevens et al., 2007). In terms of farm management, one
study found that weaner production in indoor pig farming systems had
higher use of antibiotics in medicated feed (64–74%) than the outdoor
farming (60%); it is noted that UK is the only country that raise com-
mercial sow outdoor(Stevens et al., 2007). One study showed that im-
proved farm sanitation and management contributes to a reduction in
antibiotic consumption without productivity losses (Fertner et al.,
2015); however, another study reported that the use of antibiotics had
no association with farm management (Casal et al., 2007).
3.3.2.7. Other factors. Other factors also contribute to the use of
antibiotics. The volume of tetracycline used in the spring was five-
fold higher than other seasons (Van Rennings et al., 2015). In the study
from the UK, there was a large variations of in-feed antibiotics in
weaners and growers, and in individual weaners in di!erent pork
quality assurance schemes (Stevens et al., 2007). In term of farm
location, farms located in high pig-density areas have a positive
correlation with the amount of antibiotic use (van der Fels-Klerx
et al., 2011).
Only one study examined the educational status of farmers, and
there was a significant association between low education and poor
knowledge on antibiotic use (Eltayb, Barakat, Marrone, Shaddad, & Sta,
2012). Farmers perceived that use of antibiotic contributes to their
profitability from raising pigs (Stevens et al., 2007).
4. Discussion
Understanding the current pattern of antibiotic use in livestock is im-
portant in order to support optimal antibiotic use, which may potentially
slow down the emergence of AMR in animal production. Studies on anti-
biotic use have increased considerably over the last decade, and in this
review, the majority of studies were conducted between 2010 and 2017.
Most of the studies were conducted in Europe, particularly in high-income
countries (HICs) where there are higher research capacities and data
availability. Due to the population size, demand for animal-source food is
higher among low- and middle-income countries (LMICs) than in HICs
(Robinson & Pozzi, 2011). More evidence on consumption of antibiotics in
LMICs is required for proper and timely responses to AMR such as opti-
mizing consumptions and uses of antibiotics.
4.1. Pattern of antibiotic use
Common classes of antibiotics used varied across countries. Overall,
Penicillins and Tetracyclines class were the most commonly used antibiotic
in pigs. These findings were similar to another review which reported
Penicillins, Tetracyclines and Macrolides were the most common use in pig
production (Cuong, Padungtod, Thwaites, & Carrique-Mas, 2018). This was
probably because they are relatively cheap and cost-e!ective compared to
other antibiotics (“OIE LIST OF ANTIMICROBIALS OF VETERINARY IMP-
ORTANCE Criteria used for categorisation List of antimicrobials,” 2007).
Penicillins have bactericidal actions against Gram-negative and Gram-po-
sitive pathogens (Lobanovska & Pilla, 2017). They were commonly used for
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infections in a broad range of animal species. Tetracyclines were widely
used for the treatment of respiratory diseases caused by Actinobacillus
pleuropneumonia and Pasteurella multocida; however, resistance to tetra-
cyclines is common. For example, 22% of Pasteurella multocida, 15% of Ac-
tinobacillus pleuropneumoniae and 82% of Streptococcus suis were reported to
be resistant to tetracyclines (de Jong et al., 2014).
This review confirms that antibiotics of veterinary importance de-
fined in the highest priority critically important antimicrobials in
human in WHO's list (World Health Organization, 2017), were still
commonly used in swine production.
The use of antibiotics without definitive diagnosis and proper indica-
tions has raised global concern, especially with the emergence of AMR in
the agricultural sector. The first attempt to withdraw non-therapeutic an-
tibiotics was in the UK in 1969 when the Swann Joint Committee suggested
restricting the use of medicated feed at a sub-therapeutic level in livestock
(Swann, Baxter, & Field, 1969). Many countries have banned antibiotic use
for growth promotion. However, this review shows that the use of anti-
biotics for infection prevention is still globally common in pig production, in
order to prevent production loss in particular in intensive industrial
farming. The standard prophylactic protocol for the whole herd can be more
convenient to administer and less labour-intensive to manage than treat-
ment of individual sick animals.
4.2. Antibiotics choice and route of administration associated with specific
diseases and age groups
Choices of antibiotics were driven by age-specific diseases and the
common pathogens for these conditions. Gastrointestinal and respiratory
tract infections are common in pigs at all stages and are easily transmitted
within and between herds. However, some specific diseases are more
common in weaners such as septicaemia caused by Actinobacillus suis and
Mycoplasma infection than others. In finishers, diarrhoea, porcine hae-
morrhagic enteropathy (Lawsonia intracellulalis) and swine dysentery
(Bachyspira hyodysentary) are common pathogens causing gastrointestinal
infection, whereas enzootic pneumonia (Mycoplama hyopnuemoniae), my-
coplasma induced respiratory disease (Pasturella multocida), pleur-
opnuemonia (Actinobacillus pleuropnueumoniae) are common pathogens
causing respiratory infection (Burch, 2013). Type of bacteria in animal are
drivers for type of antibiotic use (Jordan et al., 2009).
Colistin was most commonly used for gastrointestinal conditions in
piglets and weaners, tylosin in fatteners and sows (Van Rennings et al.,
2015). Farmers used Pleuromutilins for respiratory tract infections in sow
and piglets (Jensen et al., 2012) and beta-lactam antibiotics in piglets,
weaners and fattening pigs (Van Rennings et al., 2015). However, the
choice of antibiotics depends on market availability and cost in di!erent
countries. For example, while the most common respiratory pathogens in
Danish swine production, Actinobacillus pleuropneumoniae, Pasturella multo-
cida, and Streptococcus suis infections are fully susceptible to penicillin
(Aarestrup, Oliver Duran, & Burch, 2008), penicillin only constitutes a
minor share of the prescriptions for respiratory disease, whereas Tetra-
cyclines and Pleuromutilins are widely used. Possibly they have relatively
lower costs; aminopenicillins are more expensive and parenteral use of
benzylpenicillins is less convenient in administration (Jensen et al., 2012).
Choices of antibiotic are also guided by route of administration. Oral
application is a major route in weaners and fatteners, whereas parenteral is
applied more in sows than piglets and fatteners, such as through the use of
benzylpenicillin (Merle et al., 2014). In finishers, however, parenteral
benzylpenicillins are applied to individual treatment of sick pigs, although
other drugs such as tylosin and lincomycin are mainly administered through
feed (Raji" et al., 2006; Rosengren et al., 2008).
4.3. The use of antibiotic associated with farm management
Farm management can be associated with antibiotic use, such as the
type of farm, size of farm and vaccination status. This review shows that
finisher farms used higher volumes of antibiotics than farrow-to-finish
farms (24,30), in particular for metaphylactic and prophylactic mea-
sures, and growth promotion (Casal et al., 2007; Trau#er et al., 2014).
Large farms were more likely to use medicated feeds compared to
smaller-sized farms (Bos et al., 2013; Kim et al., 2013; Stevens et al., 2007;
van der Fels-Klerx et al., 2011). One possible explanation of the high use of
antibiotics is that larger-sized farms have a greater risk of transmission of
pathogens within herds than smaller farms, although this review is incon-
clusive as contradictory findings were reported (Vieira et al., 2011). How-
ever, there are multiple factors which influence the use of antibiotics, such
as farm biosecurity practices, density, level of stress in the herd, vaccination
status, quality of feed, farmer knowledge and disease prevalence rates. Good
farm biosecurity such as all-in all-out production and a single supplier of
weaners has been identified as common practice in herds which lead to a
reduction in disease transmissions and lower antibiotic use (Fertner et al.,
2015) . Vaccination has been recommended as an alternative strategy to
prevent disease contributing to optimizing antibiotic usage (Postma et al.,
2015). It has shown beneficial return of investment despite the costs for
vaccines (Alarcon, Rushton, Nathues, & Wieland, 2013). However, the
higher use of in-feed antibiotics was significantly associated with the vac-
cination of pigs in some age groups including suckling piglets, weaners and
sows (Stevens et al., 2007). This finding can be confounded by other factors
such as poor bio-security and farm management, low health status of the
herd and high disease prevalence.
4.4. The use of antibiotic associated with other factors
The use of antibiotics was highly dependent on the farm manage-
ment and person in charge of the daily routines. The initiation of
treatment depended on the ability of early detection of diseased ani-
mals and the level of farmers’ perceptions and responses to the clinical
signs in animals (Fertner et al., 2015). Farmers were likely to have a
limited understanding of antibiotics, particularly those in low- and
middle-income countries. One study in Cambodia indicated that none of
the farmers demonstrated an understanding about the action and in-
dication for antibiotics (Om & Mclaws, 2016). A study in Sudan found a
significant association between farmers’ low education level and poor
knowledge on antibiotic use and AMR awareness (Eltayb et al., 2012).
All these challenges can lead to inappropriate use of antibiotics.
Veterinarians play important roles in animal health and antibiotic
stewardship; and often farmers rely on veterinarian's advice on pig health,
choices and use of antibiotics (Visschers et al., 2015). Despite their critical
role, veterinarians’ prescription decisions are based on “expert opinion” or
views from “opinion leaders” or from internet sources, rather than scientific
and peer-reviewed data (Vandeweerd et al., 2012) or laboratory resistant
profiles. Representatives from pharmaceutical companies, when serving as
advisors to farmers on disease management, may have conflict of interests
to o!er their products. In Belgium, on average, 43% of the income among
pig veterinarians came from selling pharmaceutical products (Maes et al.,
2010) for which prudent use of antibiotics can be at risk due to potential
conflict of interests.
The prevalence of pathogens in pigs and levels of resistance and sus-
ceptibility to di!erent antibiotics is an important evidence to guide anti-
biotic selection and support prudent use. Despite critical contributions,
nearly half of all veterinarians in a study in 25 European countries (44.3%)
seldom collect a sample for bacterial identification and drug sensitivity tests
in laboratory (De Briyne, Atkinson, Pokludová, Borriello, & Price, 2013). In
addition, law and enforcement and availability of antibiotics influences the
use of antibiotics. Sweden and Denmark's law restricts the use of fluor-
oquinolones and third and fourth generation Cephalosporins in pigs
(Guidelines for the prudent use of antimicrobials in veterinary medicine. Practical
examples., 2015).
4.5. Limitations of the review
There are a number of limitations which need to be considered in
interpreting the findings from this review. This review covers 36 studies
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published in English; where studies in non-English speaking countries
may o!er di!erent or similar findings. More than 85% of the studies
reviewed were conducted of in Europe and North America, limiting the
relevance of the findings to LMIC. Diversity in study design is a major
challenge for an in-depth comparative analysis and synthesis; a few
studies could be considered nationally representative, while others
were small scale studies. These challenges require careful interpreta-
tion. Di!erent data collection methods including face-to-face interviews
with farmers, internet-based surveys, and mail surveys to pig farmers or
veterinarians may a!ect the validity of the findings. Use of antibiotics
based on survey questionnaires cannot detect the misuse and o!-label
use, where other approaches are needed such as prescription reviews.
As noted in our recent review there is also huge variability in how
studies have measured the quantity of antibiotic use making it very
di"cult to make any comparisons. Some studies measure the use of
antibiotics as a percentage of total use, while other studies calculated in
specific units such as animal daily dose. Some studies reported the use
by class of antibiotic, while other studies reported active ingredient of
antibiotic (Lekagul, Tangcharoensathien, & Yeung, 2018). The EU is
developing a standard unit for antibiotic measurement, called defined
daily dose for animal (DDDvets) of active ingredient which take into
account di!erences in dosing, pharmaceutical forms and routes of ad-
ministration used (European Medicines Agency, 2015).
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Appendix A
I. Search Strategy
Structured Database Search (Search terms and results)
! MEDLINE: N=703 articles
- (Antibiotic.mp. or exp Anti-Bacterial Agents) (704,921)
- (Antimicrobial agents.mp. or Anti-Infective Agents) (61,091)
- (livestock or swine or pig* or farrow or weaner or sow).mp. [mp=title, abstract, original title, name of substance word, subject heading word,
keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (519,570)
- (Use* or usage or consume or consumption or practiceor or administration or oral or feed or injection).mp. [mp=title, abstract, original title,
name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary
concept word, unique identifier, synonyms] (6635,975)
! Scopus: N=808 articles
(TITLE-ABS-KEY (antibiotic OR antimicrobial OR antibacterial) AND TITLE-ABS-KEY (livestock OR swine OR pig* OR farrow OR weaner OR finisher OR
sow) AND TITLE-ABS-KEY (use OR utilisation OR consum* OR practice OR administration)) AND (LIMIT-TO (PUBYEAR, 2017) OR LIMIT-TO (PUBYEAR,
2016) OR LIMIT-TO (PUBYEAR, 2015) OR LIMIT-TO (PUBYEAR, 2014) OR LIMIT-TO (PUBYEAR, 2013) OR LIMIT-TO (PUBYEAR, 2012) OR LIMIT-TO
(PUBYEAR, 2011) OR LIMIT-TO (PUBYEAR, 2010) OR LIMIT-TO (PUBYEAR, 2009) OR LIMIT-TO (PUBYEAR, 2008) OR LIMIT-TO (PUBYEAR, 2007) OR
LIMIT-TO (PUBYEAR, 2006) OR LIMIT-TO (PUBYEAR, 2005) OR LIMIT-TO (PUBYEAR, 2004) OR LIMIT-TO (PUBYEAR, 2003) OR LIMIT-TO (PUBYEAR,
2002) OR LIMIT-TO (PUBYEAR, 2001) OR LIMIT-TO (PUBYEAR, 2000)) AND (LIMIT-TO (DOCTYPE, "ar") OR LIMIT-TO (DOCTYPE, "sh")) AND (LIMIT-TO
(SUBJAREA, "AGRI") OR LIMIT-TO (SUBJAREA, "VETE")) AND (LIMIT-TO (LANGUAGE, "English")) AND (LIMIT-TO (SRCTYPE, "j"))
! Web of Science: N=1070 articles
TOPIC: (antibiotic or antimicrobial or antibacterial) AND TOPIC: (livestock or swine or pig or farrow or weaner or finisher or sow) AND TOPIC:
(use or utilisation or consum* or practice or administration)
Refined by: PUBLICATION YEARS: (2016 OR 2006 OR 2015 OR 2005 OR 2014 OR 2004 OR 2012 OR 2002 OR 2013 OR 2003 OR 2017 OR 2000 OR
2011 OR 2001 OR 2009 OR 2010 OR 2007 OR 2008) AND WEB OF SCIENCE CATEGORIES: (VETERINARY SCIENCES) AND DOCUMENT TYPES:
(ARTICLE)
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=1970–2018
Table A.1
Search terminology to be used in literature review.
Search term
I Antimicrobial (Free text) OR antimicrobial (MeSH term) OR antibacterial (Free text) OR antibacterial (MeSH term) OR antibiotic (Free text) OR antibiotic (MeSH term)
II Livestock (Free text) OR swine (Free text) OR pig* (Free text) OR farrow (Free text) OR weaner (Free text) OR finisher (Free text) OR sow (Free text)
III Use (Free text) OR utilisation (Free text) OR consum* (Free text) OR practice (Free text) OR administration (Free text)





Quality assessment of included studies.
Author, year Q1 Method Result Application Rank*
Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11
2017
Dupont et al. (2017) Y Y Y Y Y Y Y Y Y Y Y H
Jensen, Jorsal, and Toft (2017) Y Y Y Y Y Y Y Y Y Y Y H
2016
Van Cuong et al. (2016) Y Y N N Y Y Y Y Y Y Y H
Sjölund et al. (2016) Y Y N N Y Y Y Y Y Y Y H
2015
Fertner et al. (2015) Y CT N N Y N Y Y Y Y Y M
Van Rennings et al. (2015) Y Y Y N Y Y Y Y Y Y Y H
Visschers et al. (2015) Y Y N N Y Y Y Y Y Y Y H
(Sjölund et al.( 2015) Y Y Y N Y Y Y Y Y Y Y H
2014
Filippitzi et al. (2014) Y Y CT N CT CT Y Y Y Y Y M
Hosoi et al. (2014) Y Y CT N N N Y N Y Y Y M
Merle et al. (2014) Y Y N N Y N Y Y Y Y Y M
Trau!er et al. (2014) Y Y N N Y N Y Y Y Y Y M
Trau!er et al. (2014) Y Y N N Y N Y Y Y Y Y M
Visschers et al. (2014) Y Y CT Y Y Y Y Y Y Y Y H
2013
Bondt et al. (2013) Y Y Y CT CT Y Y Y Y Y Y H
Bos et al. (2013) Y Y Y Y Y Y Y Y Y Y Y H
Glass-kaastra et al. (2013) Y Y N N Y CT Y Y Y Y Y M
Kim et al. (2013) Y Y N N Y CT Y Y Y Y Y M
Merle, et al. (Merle et al., 2013) Y Y N N Y N Y Y Y Y Y M
2012
Apley et al. (2012) Y Y Y N Y Y Y N Y Y Y H
Callens et al. (2012) Y Y Y N Y Y Y Y Y Y Y H
Eltayb et al. (2012) Y Y CT N Y CT Y N Y Y Y M
Merle et al. (2012) Y Y N N Y N Y Y Y Y Y M
Moreno (2012) Y Y Y N Y Y Y Y Y Y Y H
2011
JJensen et al. (2012) Y Y N N Y Y Y Y Y Y Y H
van der Fels-Klerx et al. (2011) Y Y Y N Y Y N Y N Y Y M
Vieira et al. (2011) Y Y Y Y Y Y Y Y Y Y Y H
Aarestrup, Vibeke, Jacobsen, and Wegener (2010) Y Y Y Y Y Y Y Y Y Y Y H
2009
Jordan et al. (2009) Y Y Y Y Y Y Y Y Y Y Y H
2008
Rosengren et al. (2008) Y CT N N Y N Y Y Y Y Y M
2007
Casal et al. (2007) Y Y N N Y Y Y Y Y Y Y M
Stevens et al. (2007) Y Y N N Y N Y Y Y Y Y M
2006
Raji" et al. (2006) Y Y N N Y Y Y Y Y Y Y M
Timmerman et al. (2006) Y Y Y Y Y Y Y Y Y Y Y H
2004
Arnold et al. (2004) Y Y Y N Y Y Y Y Y Y Y H
2002
Chauvin et al. (2002) Y Y Y N Y Y Y Y Y Y Y H
Note:
Q1 = Did the study address a clearly focused issue?.
Q2=Did the authors use an appropriate method to answer their question?.
Q3=Were the subjects recruited in an acceptable way?.
Q4=Were the measures accurately measured to reduce bias?.
Q5=Were the data collected in a way that addressed the research issue?.
Q6=Did the study have enough participants to minimize the play of chance?.
Q7=How are the results presented and what is the main result?.
Q8=Was the data analysis su#ciently rigorous?.
Q9= Is there a clear statement of findings?.
Q10=Can the results be applied to the local population?.
Q11=How valuable is the research?.
Y=Yes (clearly described).
N=No (Not described).
CT=Cannot tell (described but with limited detail.
! Score >75=high (H), 50–74=medium (M) and <50= low (L) *score >75=high (H), 50–74=medium (M) and <50=low (L).
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4.1.2 The use of antimicrobials in global pig production: A systematic review of 
methods for quantification 
The measurement of antibiotic consumption varies widely in terms of types of data, methods, 
and units of measurement. The systematic review aims to describe and compare the methods 
and measurements that have been used to quantify antibiotic use in pigs. Having standardised 
measurements of antibiotic consumption will help to monitor the impact of interventions 
aimed at reducing the amount of antibiotic use in livestock. The findings of the review were 
also used to inform the approach I used to collecting data on antibiotic use in pig production 
in Thailand.  
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The use of antimicrobials in global pig production: A systematic review of
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A B S T R A C T
Background: Overuse of antimicrobials in both humans and animals is recognized as one of the main drivers of
Antimicrobial Resistance (AMR); and the optimisation of their use has been advocated as a key strategy for
dealing with AMR. The measurement of antimicrobial use is vital for the design, monitoring and evaluation of
such strategies. This systematic review describes and compares methods and measurements used to quantify
antimicrobial use in pigs in order to inform e!orts to standardize measurement.
Methods: The peer-reviewed literature was systematically searched using four online databases: MEDLINE,
ScienceDirect, Scopus and Web of Science. Eligibility criteria for inclusion in the review included: articles
published in English, involving pigs of any age and types of production, providing quantitative data on anti-
microbial use, containing a clear description of the methodology, and having moderate to high rank in the
quality assessment.
Results: Of 2,362 abstracts reviewed, a total of 25 studies were included based on the eligibility criteria. All
studies were published between 2001 and 2017. Twenty of the studies were conducted in eight European
countries. Twelve studies estimated antimicrobial use and eight studies were primarily methodological papers
comparing di!erent methods or variables, or developing new methods. The two main sources of antimicrobial
use data were farm surveys and national sales data.
A large variety of units of measurement was found. In this review, the ten measurements identified were
categorized into four groups: 1) antimicrobials use measured by milligrams of active substance per animal
weight; 2) antimicrobials use measured by daily dose per weight at treatment; 3) antimicrobial use measured by
daily dose per treatment period; and 4) antimicrobials use measured by daily dose per period at risk of treat-
ment.
Conclusion: There is no global standardized measurement of antimicrobial use in pigs. Given the importance of
monitoring the use antimicrobials, we recommend that at a minimum, all countries should develop macro-level
monitoring using national sales data and report use by milligram of active ingredients per Population Correcting
Unit. Monitoring in specific animal species requires the development of systems to capture prescription at na-
tional or farm level. Findings from monitoring antimicrobial use may help to guide e!ective interventions for
optimising use of antimicrobials, as recommended by the WHO Global Action Plan on AMR.
1. Background
Antimicrobial Resistance (AMR) is an increasingly serious threat to
global public health. Overuse of antimicrobials can accelerate the
emergence of antimicrobial resistance (World Health Organization,
2015b). In livestock industries, large amounts of antimicrobials are
used for both therapeutic and non-therapeutic purposes including
growth promotion (Aarestrup, 2005). In response to global concerns
https://doi.org/10.1016/j.prevetmed.2018.09.016
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about AMR, in 2008, the World Organization for Animal Health (OIE)
launched guidelines on the prudent use of antimicrobials in veterinary
medicines, which describes the respective responsibilities of relevant
stakeholders such as veterinarians, regulators, pharmaceutical in-
dustries, animal producers and consumers (World Organisation for
Animal Health (OIE), 2008).
Measuring antimicrobial use is critical to understanding the mag-
nitude and profile of antimicrobial resistance in countries.
Measurement is the first step to detecting whether there is excessive and
inappropriate use and monitoring whether policies aimed at optimizing
use are successful. Recognising this, international organizations such as
FAO, OIE and WHO, have recommended that countries develop systems
for monitoring antimicrobial consumption (World Health Organization,
2015a, OIE, 2016; FAO, 2016). The World Health Organization (WHO)
guidelines defines antimicrobial “consumption” data captured from
aggregate sales data such as form importer, local manufacturer or
wholesales, whilst data on antimicrobial “use” are collected from pa-
tient-level data such as medical records and prescriptions (World
Health Organization, 2017). Whilst there has been significant progress
in the monitoring of antimicrobial use and consumption in the human
health sector, action in the animal health sector has lagged behind
(Schar et al., 2018). Some European countries established national
programs for the surveillance of antimicrobial consumption in animals
for more than 20 years ago, specifically DANMAP in Denmark in 1995
(Statens Serum Institut, 2012), MARAN in Netherlands in 1998
(Anonymous, 2012) and SWEDRES-SVARM (SWEDRES and SVARM,
2014). The European Medicines Agency established the European Sur-
veillance of Veterinary Antimicrobial Consumption (ESVAC) project in
2009 (Agency, 2017). ESVAC compiles, verifies and reports on anti-
microbial consumption of veterinary antimicrobial agents in 29 Eur-
opean countries. Data are collected through a network of national focal
points. Furthermore, ESVAC has been striving to set up a standardised
methodology to allow for cross country comparisons. The monitoring of
antimicrobial consumption serves various objectives. It monitors time
trends of antimicrobial use, compares use by di!erent antimicrobial
classes, identifies high users and promotes more prudent use, and stu-
dies the association between level of usage and bacterial resistance
(Collineau et al., 2017).
Currently, there is a wide variation in the availability and type of
data, methods and use measurement across countries. The lack of uni-
formity hampers cross-country comparisons (Collineau et al., 2017). In
order to guide the strengthening of existing monitoring systems and the
development of new ones to facilitate cross-country comparisons, it is
essential to understand the di!erent existing methods, their strengths,
limitations and operational feasibility.
This systematic review will describe and compare methods and
measurement to quantify antimicrobial use in pigs, in order to con-
tribute to the process of future guideline development of monitoring the
antimicrobial use.
2. Method
2.1. Scope of study and research question
The operational definitions of the terms used in this review are as
follows.
Term Definition
Antimicrobials According to OIE definition, an antimicrobial is
considered as a naturally occurring, semi-
synthetic or synthetic substance that exhibits
antimicrobial activity (it kills or inhibits the
growth of micro-organisms) at concentrations
attainable in vivo. Anti-helminthic and
substances classed as disinfectants or
antiseptics are excluded from this definition
(World Organisation for Animal Health (OIE),
2015).
Pig The term refers to all stages of swine production
including breeding and gestation, farrowing




As explained above WHO defines “use” data as
estimates derived from patient-level data. It
may focus on how and why antimicrobials are
being used by health care providers and
patients. “Consumption” data are usually
reported when information on antimicrobial
use in patients is not available. It can be
collected from several sources such as import
data, wholesale data or aggregated health
insurance data. Consumption data provides a
proxy estimate of the use of antimicrobials
(World Health Organization, 2017).
However, in this study, for simplicity the term
“use” is applied to refer to both use at farm
level and consumption at aggregate national or
sub-national level.
Biomass The weight or total quantity of living organisms
of one animal species or of all the species in the
community. Using biomass for antimicrobial
consumption aims to compare the weight of
animals between di!erent species and between
human and animals.
This review covers use of antimicrobials in pigs, with the following
research question: “What methods and measurements are used to
quantify the use of antimicrobials?”
2.2. Search strategy
2.2.1. SPIDER tool
A “SPIDER” tool was applied in order to specifically identify re-
levant quantitative and mixed-method studies. It covers the Sample,
Phenomenon of interest, Design, Evaluation and Research type) (Cooke
et al., 2012).
S: 1) Surveys based on end-point antimicrobial usage: veterinary
prescription, usage by pig farmer
2) Antimicrobial sales data (from pharmaceutical operators, such as
importer,
manufacturer, wholesaler)
P and I: Antimicrobial use in pigs D: Observational studies, inter-
vention studies
E: Methods used for the measurement of antimicrobial use R:
Quantitative study
2.2.2. Eligibility assessment of studies and inclusion criteria
The following inclusion criteria were considered:
(i) the paper was published in, or translated into, the English lan-
guage,
(ii) the study involved pigs of any age and type of production,
(iii) the study provided quantitative data on antimicrobial use with a
focus or clear explanation of the methodology in pigs or other food
producing animals including pigs,
(iv) The study had moderate to high ranking of a quality assessment.
2.2.3. Search protocol
Literature on the use of antimicrobials in pigs was systematically
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reviewed between May to August 2017. Relevant scientific papers
published in English peer-reviewed journal were identified using the
keywords combinations in the title, abstract and content. All search
terms were combined, see Table 1.
2.2.3.1. Structured Database Search. Online electronic databases were
searched in English language literature with restriction of the date of
publication being after 2000: MEDLINE (http://ovidsp.tx.ovid.com;
1946 until present), ScienceDirect (http://www.sciencedirect.com;
1996 until present), Scopus (http://www.scopus.com; 1823 until
present) and Web of Science (http://apps.webofknowledge.com; 1970
until present). The initial scope of the search focused on low- and
middle-income countries. Due to the limited number of publications, it
was expanded to cover studies in high-income countries.
2.2.3.2. Grey literature. In addition to the structured database searches,
articles were sourced through searches from the reference lists of key
articles identified as in line with the research questions and inclusion
criteria. This combination ensured that a wide range of articles from
di!erent sources was retrieved.
2.2.4. Screening relevant records
After the searches, the duplicate studies and inconsistencies be-
tween titles, abstracts and keywords were removed. Then, full texts
were reviewed; those which were reviews, clinical research, pharma-
cokinetic, biopharmaceutical studies and laboratory studies were ex-
cluded.
Studies were excluded for the following reasons:
- No report on pattern or volume of antimicrobial use in pigs
- Inappropriate study design: such as review, clinical research, phar-
macokinetic and biopharmaceutical studies
- Focus on laboratory study, on human health or antimicrobial ac-
tivity, relationship with AMR, specific disease related to drug re-
commendation
- Measurements of antimicrobial levels in farm waste, faeces and
environment, residue in animal products
- Low level of quality from assessment (< 50%)
2.3. Quality assessment
The methodological quality of the studies was assessed using an
instrument adapted from the Critical Appraisal Skills Programme
(CASP) (Critical Appraisal Skills Programme (CASP), 2014). The four
criteria of quality assessment were a) aim, b) method, c) result and d)
application. The answer to the four criteria are either ‘yes’, or ‘no’ or
‘cannot tell’. Each criterion has certain a number of sub-criteria, there
were in total eleven sub-criteria for quality assessment; see Table A2
(annex). If the assessment by the two independent reviewers (AS and
VT) was ‘no’ or ‘cannot tell’, the score for that question was zero; the
score for yes was one. When there were conflicting views, the reviewers
discussed and sought consensus. In this review, the studies were ranked
by quality criteria. The quality ranking was classified into three groups:
High meant> 75% of all eleven sub-criteria were met, moderate meats
50–75% were met, weak meant< 50% were met.
2.4. Data extraction and synthesis
The full text of all relevant articles was reviewed and summarised
using a standardised data extraction table in Excel which supported the
sifting, sorting and annotation of primary source materials and data.
Data extraction was categorised by three sets of variables: a) context
variables: author, year of publication, year of study, title, journal,
geographical area, objective and b) methodology variables: type of
study, data source, sampling technique, sample size, methods for anti-
microbial use measurement. See Table A1 in annex for variables as-
sessed in the study.
3. Results
3.1. Search processes
The search from the four database and hand search identified 2362
articles. After screening and removal of duplications, 90 manuscripts
remained for further screening. Of these 90 manuscripts, 37 manu-
scripts were selected on the basis of the inclusion criteria. Of these 37
manuscripts, seven articles described antimicrobials without essential
information on the pattern or volume of antimicrobials use; these were
excluded. Two articles were not included, because they were review
articles. Another three articles were excluded as they only focused on
the association between specific groups of antimicrobial and AMR. No
studies were excluded due to low rank of quality assessment (< 50%).
In summary, a total of 12 studies were excluded from the set of 37
studies, leaving 25 manuscripts that met the inclusion criteria and were
included in this systematic review. Fig. 1 describes flow of screening
processes.
3.2. Description of the studies
Of the 25 studies, 22 studies were published between 2010 and
2016, with the remaining three being published between 2000 and
2010. One study analysed global level use data and the others reported
data from 12 countries. Twenty studies were from eight European
countries of which six were conducted in Denmark; two were multi-
country studies; one study in Belgium, France, Germany and Sweden,
and the other included Denmark and Netherlands. Two studies were
conducted in African countries (South Africa and Kenya). Another two
studies reported data from China and Japan. See Table 2 for char-
acteristic of these studies.
The quality assessment is reported in Table A2 of the Annex. In
general, the hypotheses and the objectives of the study were clearly
described. Fifteen (60%) studies were ranked as high quality (meeting
more than 75% of all eleven sub-criteria). Ten remaining studies were
of moderate quality. None had low quality assessment.
3.3. Methods for measuring antimicrobial use
A large variation in terms of the methodological approaches and
units of measurement of antimicrobial use was found.
3.3.1. Types of studies and data sources
As shown in Table 2, eight studies were primarily methodological,
for example comparing antimicrobial use by using di!erent methods or
variables (Carmo et al., 2017; Dupont et al., 2016; Taverne et al., 2015;
Trau"er et al., 2014a; Bondt et al., 2013; Timmerman et al., 2006) or
developing new methodologies (Ferner et al., 2014; van Rennings et al.,
2015). Twelve studies aimed to estimate antimicrobial use (Jensen
et al., 2004; Mitema et al., 2001b; Sjolund et al., 2016; Krishnasamy
Table 1
Search terminology to be used in literature review.
Search term
I antimicrobial (Free text) OR antimicrobial (MeSH term) OR antibacterial
(Free text) OR antibacterial (MeSH term) OR antibiotic (Free text) OR
antibiotic (MeSH term)
II livestock (Free text) OR swine (Free text) OR pig* (Free text) OR farrow
(Free text) OR weaner (Free text) OR finisher (Free text) OR sow (Free text)
III use (Free text) OR utilisation (Free text) OR consum* (Free text) OR practice
(Free text) OR administration (Free text)
IV measure* (Free text) OR indicator (Free text) OR surveillance (Free text) OR
survey (Free text) OR monitor (Free text)
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et al., 2015; Sjolund et al., 2015; Van Boeckel et al., 2015; Hauck et al.,
2014; Hosoi et al., 2014; Bos et al., 2013; Callens et al., 2012; Eagar
et al., 2012; Merle et al., 2012). One study examined both improving
the national surveillance and measuring the antimicrobial use
(Filippitzi et al., 2014). The remainder of studies assessed the associa-
tion between the use of antimicrobials and farm management practice
(Fertner et al., 2015; Vieira et al., 2011; Arnold et al., 2004).
Eleven studies (44%) presented data at national level (Carmo et al.,
2017; Dupont et al., 2016; Krishnasamy et al., 2015; Van Boeckel et al.,
2015; Filippitzi et al., 2014; Hauck et al., 2014; Hosoi et al., 2014;
Bondt et al., 2013; Jensen et al., 2012; Eagar et al., 2012; Mitema et al.,
2001b). Fourteen studies (56%) presented data at sample farm level
(Sjolund et al., 2016; Fertner et al., 2015; van Rennings et al., 2015;
Sjolund et al., 2015; Taverne et al., 2015; Ferner et al., 2014; Trau!er
et al., 2014a, b; Bos et al., 2013; Callens et al., 2012; Merle et al., 2012;
Vieira et al., 2011; Timmerman et al., 2006; Arnold et al., 2004) with
four of these studies complete farm data at a national level (Sjolund
et al., 2016; Taverne et al., 2015; Bos et al., 2013; Vieira et al., 2011).
Data on antimicrobial use were collected from various sources. Of
25 studies, seven collected data through farm surveys (Sjolund et al.,
2016, 2015; Ferner et al., 2014; Trau!er et al., 2014a, b; Callens et al.,
2012; Timmerman et al., 2006), six compiled national data from the
surveillance of antimicrobial consumption(Carmo et al., 2017; Dupont
et al., 2016; Taverne et al., 2015; Van Boeckel et al., 2015; Filippitzi
et al., 2014; Bondt et al., 2013; Vieira et al., 2011), four collected data
through veterinary prescriptions (Fertner et al., 2015; Bos et al., 2013;
Jensen et al., 2012; Arnold et al., 2004), and four from a review of sales
of pharmaceutical products (Carmo et al., 2017; Hauck et al., 2014;
Hosoi et al., 2014; Eagar et al., 2012; Mitema et al., 2001b). Three
studies drew information from more than one data source (van
Rennings et al., 2015; Filippitzi et al., 2014; Merle et al., 2012) and one
study used data on food animal antimicrobial utilisation from the US,
estimating the quantity of antimicrobials used in China (Krishnasamy
et al., 2015).
Twenty-two studies (88%) reported antimicrobial use by major
classes, while three studies (12%) reported in aggregation all classes of
antimicrobial (Ferner et al., 2014; Fertner et al., 2015; Van Boeckel
et al., 2015). Twenty studies (80%) reported the use of antimicrobials
specific to pigs or other animal species but five studies (20%) only re-
ported total use in all animal species (Van Boeckel et al., 2015; Ferner
et al., 2014; Hauck et al., 2014; Eagar et al., 2012; Mitema et al.,
2001a).
3.3.2. Numerators: the amount of antimicrobial use
Measuring numerators varied greatly, for example, by milligrams or
kilograms of active ingredient and other more sophisticated adjust-
ments such as defined daily dose, daily product dose, animal daily dose,
used daily dose, prescribed daily dose, (see detail in Fig. 2).
Fig. 1. Flow diagram of the review process.
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3.3.3. Denominators: the number or mass of animals
For denominator data, eight studies used national level animal po-
pulation which was retrieved from government agencies such as
National Statistics, Central registry for livestock (Carmo et al., 2017;
Dupont et al., 2016; Taverne et al., 2015; Filippitzi et al., 2014; Hosoi
et al., 2014; Bondt et al., 2013; Jensen et al., 2012; Vieira et al., 2011).
Two studies applied data from the Food and Agriculture Organization
(FAOSTAT) (Krishnasamy et al., 2015; Van Boeckel et al., 2015). For
the twelve studies at farm level, the number of animals reported by a
certain production type and the time period during the study period
(Sjolund et al., 2016; Fertner et al., 2015; van Rennings et al., 2015;
Sjolund et al., 2015; Ferner et al., 2014; Trau!er et al., 2014a,
Trau!er et al., 2014b, Bos et al., 2013; Callens et al., 2012; Merle et al.,
2012; Timmerman et al., 2006; Arnold et al., 2004).
Several studies applied di"erent standard weights for animal
(Carmo et al., 2017). For example, the weights of an animal at treat-
ment in Denmark (32) were: weaner 15 kg, slaughtered pig 50 kg and
sows 200 kg. In Austria (26) weights were: piglets 1.5–10 kg, weaners
10-30 kg, fattened pigs< 60 kg, and sow and boar> 60 kg. In Sweden
(18) weights were: sucking piglets 7 kg, weaners 7 kg, fatteners 35 kg
and adult pigs 220 kg (Sjolund et al., 2015).
3.3.4. Unit of measurement: indicators used
Of the total 25 studies, there were ten di"erent units of measure-
ment. Nine studies calculated the total volume of antimicrobials used in
the country per year (Carmo et al., 2017; Krishnasamy et al., 2015; van
Rennings et al., 2015; Ferner et al., 2014; Filippitzi et al., 2014; Hauck
et al., 2014; Eagar et al., 2012; Merle et al., 2012; Mitema et al.,
2001b). Five of these studies (Hauck et al., 2014; Merle et al., 2012;
Mitema et al., 2001b; Carmo et al., 2017; Filippitzi et al., 2014) cal-
culated the volume of antimicrobial substances by multiplying the
number of packages (package size) with the potency (strength of active
substance) for each antimicrobial. One study (Eagar et al., 2012) cal-
culated the volume of antimicrobials in kilograms of active pharma-
ceutical ingredient from the reports provided by pharmaceutical com-
panies, while two other studies (van Rennings et al., 2015), Ferner
et al., (2014) used treatment data at the farms. Only one study at-
tempted to estimate non-therapeutic antimicrobial use in livestock. This
was done by multiplying the number of animals in di"erent phases of
production by the estimated feed consumed per day and the duration in
days in each phase that the swine received antimicrobials through feed
and doses of antimicrobials in the feed (Krishnasamy et al., 2015).
3.3.4.1. Antimicrobials use measured by milligrams of active substance per
animal weight. Six studies used some measure of the biomass of animals
in order to indicate the intensity of antimicrobial use (Carmo et al.,
2017; Van Boeckel et al., 2015; Filippitzi et al., 2014; Hosoi et al., 2014;
Trau!er et al., 2014a, b). Biomass is the total weight of live animals.
Two studies (Trau!er et al., 2014a, b) calculated biomass at farms by
multiplying the number of animals and the average weight. One study
estimated biomass by using the carcass weight, which is the whole-body
weight of a slaughtered animal after blood is drained, evisceration and
skinning (Hosoi et al., 2014).
Biomass can be calculated by using a population correction units
(PCU). The PCU provides a better measurement of animal weight ex-
posed to antimicrobial treatment: one PCU is equivalent to one kilo-
gram of biomass of live animal or slaughtered animals where the animal
had been exposed to antimicrobials throughout their lifecycle. For ex-
ample, gross weight at slaughter was 150 kg, but the PCU was 65 kg and
25 kg for slaughtered and fattening pigs (Agency, 2013). Two studies
(Carmo et al., 2017; Filippitzi et al., 2014) calculated the total national
PCU, with reference to the guidelines produced by ESVAC, by multi-
plying the numbers of livestock animals and slaughtered animals by the
theoretical weight at the time they were exposed to antimicrobial
treatment. Another study estimated the PCU by multiplying the num-
bers of live animals in a production period and a ratio of carcass weight
to live weight of animals (Van Boeckel et al., 2015).
3.3.4.2. Antimicrobials use measured by daily dose per weight at
treatment. The daily dosage is a measure of the amount of a specific
active pharmaceutical ingredient (e.g. in milligrams) required to treat
one kilogram of animal in one day with that antimicrobial preparation,
and is based on the average dosage of a medicine per kilogram per day
for a specific type of animal.
Defined Daily Dose (DDD) is a technical unit of measurement of
antimicrobial consumption in humans, calculated by standard DDD-
value. In animals, measuring antimicrobial by defined daily dosage is
calculated by using a specified dose of medicine (Animal Daily Dose
value (ADD-value)), so called Animal Daily Dose (ADD) (Dupont et al.,
2016; Fertner et al., 2015; Taverne et al., 2015; Ferner et al., 2014;
Trau!er et al., 2014a, b; Bondt et al., 2013; Jensen et al., 2012) or by
using the mean authorised dosage (Taverne et al., 2015; Bos et al.,
2013; Merle et al., 2012) so called Daily Doses Animal (DDDA).
The ADD-value is specifically defined as the average maintenance
dose per day for a drug used for its main indication for each animal
species. The ADD-value was used in Denmark and Austria. They were
Table 2












High (> 75%) 15 (60%)
Moderate (50–74%) 10 (40%)
Unit of analysis
National level 11 (44%)
Farm level 14 (56%)
Data collection on antimicrobial use
Farm based survey 7 (28%)
National data 6 (24%)
Prescription data 4 (16%)
Pharmaceutical product sold review 4 (16%)
Mixed method (> 1 data source) 3 (12%)
Data from another countryb 1 (4%)
Report by type of antimicrobials
Sum of all antimicrobials 3 (12%)
Disaggregated by classes 22 (88%)
Report by animal species
Sum of antimicrobials in all animal species 5 (20%)
Specific in pig/ disaggregated by animal species 20 (80%)
Unit of measurement used (N=40)
- Volume 9 (23%)
- Volume per biomass 6 (15%)
- Daily Product Dose (DPD) 3 (8%)
- Animal Daily Dose (ADD) 8 (20%)
- Defined Daily Doses per Animal year (DDDA) 3 (8%)
- Used Daily Dose (UDD) 3 (8%)
- Prescribed Daily Dose (PDD) 1 (3%)
- Treatment incidence rate 1 (3%)
- Treatment frequency 1 (3%)
- Treatment incidence 5 (13%)
a Including two multi-country studies.
b The study estimated the quantity of antimicrobials used in animal feeds in
China by using antimicrobial utilisation data from the US livestock production.
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based on the dose recommendations of each medicinal product regis-
tered in a country for each antimicrobial agent, administration route
and animal species and when appropriate, also age group (Dupont
et al., 2016; Fertner et al., 2015; Taverne et al., 2015; Ferner et al.,
2014; Trau!er et al., 2014a, b; Bondt et al., 2013; Jensen et al., 2012).
For the DDDA, antimicrobial use is equal to the amount of active
substances divided by the total weight of the number of livestock in the
farm and mean authorised dosage. Other studies applied the same
formula but called the unit of measurement di"erently as Animal
Defined Daily Dose (ADDD) (Bos et al., 2013) and Daily Dose per an-
imal year (nDDay) (Merle et al., 2012). One study used Defined Animal
Daily Dosage (DADD), which is a measure established at the level of the
active ingredient, route of administration and pharmaceutical form and
not at the level of a specific antimicrobial class (Taverne et al., 2015).
Product-related Daily Doses (PrDD) or Daily Product Dose (DPD)
calculated the daily dose to an assumed factor of 0.8, correcting for the
fact that the maximum doses are not used in every treatment (Ferner
et al., 2014); this means only 80% of the maximal dosage of the active
substances were administered per day per kilogram biomass (Trau!er
et al., 2014a, b).
3.3.4.3. Antimicrobial use measured by daily dose per treatment
period. The Used Daily Dose (UDD) is the actual administered daily
dose per kilogram biomass of a drug based on administered data
reported by the farmer at farm level by a specific study. The formula for
the UDD calculation is the weight of active substance divided by the
number of treated animals, multiplied by the average weight of animals
and treatment duration. Three studies applied UDD (Carmo et al., 2017;
Trau!er et al., 2014a,b, Timmerman et al., 2006).
One study quantified antimicrobial use as a Prescribed Daily Dose
(PDD). This was calculated for each active pharmaceutical ingredient
and for each prescription according to the amount of active pharma-
ceutical ingredient per prescription (mg) divided by the average weight
of the animals multiplied by the number of animals and treatment
period (Arnold et al., 2004).
3.3.4.4. Antimicrobials use measured by daily dose per period at risk of
treatment. To compare each administered antimicrobial in specific
individual species, the treatment incidence was used in five studies
(Sjolund et al., 2016, 2015; Filippitzi et al., 2014; Callens et al., 2012;
Timmerman et al., 2006). It was defined as the number of pigs per 1000
pigs that are treated daily with one ADD or UDD, which is equivalent to
how many pigs per 1000 pigs receive a dose of antimicrobials each day.
In order to calculate the treatment incidence, the total UDD or ADD is
divided by the treatment period, standard weight and population, then
multiplied by 1000. One study applied ‘treatment incidence’ rate for
slaughtered pigs by dividing the number of ADD by 100 slaughtered
pigs at risk (Vieira et al., 2011).
One study calculated ‘treatment frequency’ by using the sum of all
UDD divided by population size. It identified how many days, on
average, an animal in a herd is treated with one active pharmaceutical
ingredient (van Rennings et al., 2015).
3.3.5. Volume of antimicrobial use
As described above, this review uncovered a large variation in how
antimicrobial use was measured, and the actual magnitudes of use. The
annual antimicrobial use in pigs ranged from 20,000 kg to72,300 kg at
di"erent farm and country levels. One study estimated 34 million
kilograms of antimicrobials was found in medicated feed in pigs in
China due to the massive number of livestock (Krishnasamy et al.,
2015). However, more than one million kilograms were quantified in
the studies in food animals in Germany (Hauck et al., 2014) and South
Africa (Eagar et al., 2012) and about 63 million kilograms globally (Van
Boeckel et al., 2015). On the other hand, lower use was documented in
Kenya where only 15,000 kg of antimicrobials were used in one year in
all animal species (Mitema et al., 2001b). A wide range of volume per
biomass was reported, ranged from 33.9mg per biomass in Austria
(Trau!er et al., 2014a) with about 400mg per biomass in Japan (Hosoi
et al., 2014).
The ADD varied from lower than one (Fertner et al., 2015) to 16
ADD (Taverne et al., 2015) in di"erent phases of pig production and
countries. Treatment incidence per 1000 pigs at risk per day ranged
from lower than 10 (Carmo et al., 2017; Sjolund et al., 2016, 2015) to
more than 200 treatment incidences (Sjolund et al., 2016; Callens et al.,
2012).
However, careful interpretation across countries is needed as these
Fig. 2. describe the ten di"erent measurements, categorised in four groups.
aActual consumption data which calculated antimicrobial per a number of treated animal; bAdditional measurement: calculated from ADD, UDD
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measurements are not standardized. Also, the magnitudes of use are
determined by the type of pig farms, animal demographic and the socio-
economic context of a country. See details in Table 3.
4. Discussion
4.1. Data sources
Two main sources of data emerge from this review: national sales
data and primary data collected through pig farm surveys. In many
European countries, the national monitoring of antimicrobial con-
sumption relies on national sales data of pharmaceutical products, the
disadvantage of sales data is the lack of information on which species
they are being used for, the indication, dose and duration of treatment.
Farm or pharmaceutical company surveys apply prospective long-
itudinal or cross-sectional studies which provide additional detailed use
by species and production types (European Medicines Agency, 2013).
One study applies bottom up approach for national consumption data
estimate, it collects data from some herds and extrapolates to the na-
tional level (Filippitzi et al., 2014). However, this approach could be
inaccurate as the sampled farms are not designed as national re-
presentative samples.
Data sources for animal populations can be retrieved from total
national data collection by government agencies such as slaughter
house and production information, or it can be obtained from other
sources such as the Association of Pig Farmers. Data from international
organizations such as the FAOSTAT database hosted by the Food and
Agriculture Organization is another source of the size of animal popu-
lations (Krishnasamy et al., 2015; Van Boeckel et al., 2015). Even
though, FAOSTAT information is limited such as estimates for non-re-
sponses and incomplete report, and the lack of granularity on number
of animal of species; it can be applied when data at the country is not
available. Using di!erent weights of animals at treatment across studies
resulted in substantial di!erences in use and hinders comparability
(Carmo et al., 2017; Dupont et al., 2016).
4.2. Methods and units of measurement
This systematic review describes methods for measuring anti-
microbial use. All the studies in the review were conducted after 2000.
Table 3
Summary antimicrobial usage data from studies included in this review.
Unit of measurement Antimicrobial usage data
Antimicrobials use measured by milligrams of active substance per
animal weight
- 67,423–72,300 kg;
- 34 (min) to 178.6 (max) mg/biomass (Switzerland) (Carmo et al., 2017)
- 34million kg (in medicated feed) (China) (Krishnasamy et al., 2015)
- 20,373.6 kg (Germany) (van Rennings et al., 2015)
- 63,151, 000 kg (Global level) (Van Boeckel et al., 2015)a
- > 5,400 kg (Austria) (Ferner et al., 2014)a
- 222,500 kg;
- 137mg/biomass (Belgium) (Filippitzi et al., 2014)a
- 1,706 tons (2011) and 1,619 tons (2012) (Germany) (Hauck et al., 2014)a
- 392 to 423mg/ biomass (Japan) (Hosoi et al., 2014)
- 33.89mg/ biomass (Austria) (Trau"er et al., 2014a,b)
- 1,538,443 kg (South Africa)*(Eagar et al., 2012)
- 31,622 kg (Germany) (Merle et al., 2012)
- 14,594 kg (Kenya) (Mitema et al., 2001)a
Antimicrobials use measured by daily dose per weight at treatment
(ADD, DDDA, DPD)
- 9.4, 10.4, 11.6 ADD (Denmark) (Dupont et al., 2016)
- 0.6-7.37 ADD (Denmark) (Fertner et al., 2015)
- 11.78-19.20 DDDA; 10.43 (min) to 16.0 (max) ADD (Netherlands and Denmark) (Taverne et al.,
2015)
- DPD-LU 631,939; ADD-LU 576,242(Austria) (Ferner et al., 2014)a
- 2.51 DPD; 1.95 ADD (Austria) (Trau"er et al., 2014a,b)
- 19 ADD (Netherlands); 14 ADD (Denmark) (27)
- 16.9 DDA, 9.6 DDDA (Netherlands) (Bos et al., 2013)
- 60.86 DDDA (piglet), 28.60 DDDA (fattener), 2.89 DDDA (sow) Germany) (Merle et al., 2012)
- 1.40–2.14 ADD (sow), 5.02–5.90 ADD (weaner), 1.12–1.37 ADD (finisher) (Denmark) (Jensen et al.,
2012)
Antimicrobial use measured by daily dose per treatment period (UDD,
PDD, Treatment incidence rate, Treatment frequency)
- Treatment frequency: 0.86 days (sows), 14.74 days (piglets), 6.62 days (weaners) and 3.67
(fattener) (Germany) (van Rennings et al., 2015)
- 4.88 UDD (Austria) (Trau"er et al., 2014a,b)
- Treatment incidence rate: Tetracycline 0.28–0.70, Macrolide 0.40–0.44 (Denmark) (Vieira et al.,
2011)
- 3.3–6.1 PDD (Switzerland) (Arnold et al., 2004)
Antimicrobials use measured by daily dose per period at risk of
treatment (TI-ADD, TI-UDD)
- TI-ADD (per 1,000 pigs at risk per day): 176 (suckling piglet), 406 (weaner), 33 (fattener), 143
(grower), 16 (breeder) (Belgium); 59 (suckling piglet), 374 (weaner), 7 (fattener), 108 (grower), 22
(breeder) Germany: 245 (suckling piglet), 633 (weaner), 53 (fattener), 243 (grower), 42 (breeder)
(France); 76 (suckling piglet), 21 (weaner), 6 (fattener), 23 (grower), 11 (breeder) (Sweden)
(Sjolund et al., 2016)
- TI-ADD (per 1,000 pigs at risk per day): 54.7 (suckling piglet), 6.2 (weaner), 2.8 (fattener),
14.3(grower), 8.4 (breeder) (Sweden) (Sjolund et al., 2015)
- TI-ADD (per 1,000 pigs at risk per day): 235.8, TI-UDD 200.7 (Belgium) (Filippitzi et al., 2014;
Callens et al., 2012)
- TI-ADD (per 1,000 pigs at risk per day): 178.1, TI-UDD 170.3 (Belgium) (Timmerman et al., 2006)
a Data combined other species.
A. Lekagul et al. 3UHYHQWLYH9HWHULQDU\0HGLFLQH²
 99
Most of the literatures on the pattern of use of antimicrobials are de-
rived from high-income countries in the European region; while very
few studies were conducted in Asia and Africa, which applied the tra-
ditional measurement by weight of active substance per animal weight.
This review indicates that there is no global harmonised system for
measuring antimicrobial use in animals. The proliferation of indicators
using di!erent measurements of both numerators and denominators
hampers cross-country comparisons.
Several studies reported the quantity of use in kilograms of active
ingredient without denominator data. Though simple, its main limita-
tion is that it does not give any indication of intensity of use. To address
this deficiency, measurements of use per weight have been widely used.
However, using kilogram of active ingredients does not take into ac-
count the di!erences in drug strengths, doses administered and phar-
macokinetics. The use of higher strengths, dosage and more treatment
days led to higher antimicrobial use than those which were applied at
lower strengths and dosage (van Rennings et al., 2015).
There is also a large variation in strengths and dosages of anti-
microbials use in human health. In order to standardise the measure-
ment, the DDD was developed and is now used globally to measure
antimicrobial consumption in humans with standardised reporting by
DDD per 1000 inhabitant-days. This facilitates international compar-
ison on antimicrobial use (Natsch et al., 1998). However, a similar
universal standardised unit of DDD measurement has not yet been de-
veloped for veterinary antimicrobial agents; hence di!erent countries
have established their own national ADD-value, based upon medicine
specifications registered by their National Regulatory Authorities. The
di!erent ADD-values for veterinary medicines hampers cross country
comparisons, as using di!erent sets of ADD-values a!ected the estimate
of use (Dupont et al., 2016; Taverne et al., 2015). Moreover, there are
not only di!erent units of measurement, but countries also name their
measurement di!erently, such as ADD in Denmark (Jensen et al., 2004)
and ADDD in Netherlands (NETHMAP and MARAN, 2013).
There has been an attempt to establish a consensus on DDDA for
each active substance and administration route for veterinary anti-
microbial products authorised in four European countries (Postma
et al., 2015); this e!ort has yet to scale up to all European countries.
Another approach to calculate the daily dose is by using an actual dose
administered to animal. Instead of using ADD-value, a DPD is proposed
to by adjusting the recommended maximum daily dose by a factor of
0.8 of maximal dose for specific medicinal products; assuming that the
maximum doses are not used in every treatment (Ferner et al., 2014;
Trau"er et al., 2014a, b).
To di!erentiate antimicrobial use between herds, antimicrobial per
treatment periods were calculated based on real use data at farm level.
In 2006, a measurement called UDD was introduced firstly in a study in
pig farms (Timmerman et al., 2006). The UDD was calculated based on
the definite number of treated animals in a treatment period and the
dosages of antimicrobials to animals in farms; the UDD avoids di!er-
ences between ADD-values and supports comparison of use across
countries and across studies. Moreover, the ratio between UDD/ADD
reflects the appropriateness of dosing where the higher the ratio, the
more excessive the use. Another measurement of antimicrobial use that
takes into account the treatment period was PDD; it reports anti-
microbial use by antimicrobial prescription. PDD also shows the ve-
terinarian’s prescribing pattern. However, antimicrobial prescription is
not always equal to the actual antimicrobial administration (Chauvin
et al., 2001).
There are several methods that relate to the association between the
actual volume of specific antimicrobials used in a specific time period
such as ‘treatment frequency’ (van Rennings et al., 2015) and
‘treatment incidence rate’ (Vieira et al., 2011). Furthermore, the
‘treatment incidence’ has been introduced for a comparison of data
between farms, considering the period at risk of treatment (Sjolund
et al., 2016, 2015; Filippitzi et al., 2014; Callens et al., 2012;
Timmerman et al., 2006). The treatment incidence rate can compare
the antimicrobial use per animal species and details of antimicrobial
use in terms of dosage and route of administration which can be com-
pared between herd and production types. It can be calculated based on
both ADD-values or UDD. However, comparison of ‘treatment in-
cidence’ to other studies should be done with caution when ADD-value
is used (Sjolund et al., 2015).
The wide variation in methods and indicators across the studies, and
the relative lack of swine-specific data prevent this review from making
valid comparisons of antimicrobial use in swine production or doc-
umenting trends.
4.3. European experiences and international recommendations
In European countries, the European Medicines Agency (EMA)
(2014) established the ESVAC project in 2009. The antimicrobial con-
sumption reported by ESVAC members is comparable across countries
by using a standardised measurement of mg of active ingredient per
population correction unit (mg/PCU). The total volume of anti-
microbials used in 30 European countries was 8361.3 tonnes of active
ingredients or 135.5mg/PCU on an average of consumption in food
producing animals in 2015 (European Medicines Agency, 2015).
The ESVAC project has contributed significantly to the standardised
methods for antimicrobial consumption in 30 countries in Europe and
has also spill over e!ects to developing countries, in particular Thailand
(Tangcharoensathien et al., 2017). In addition to the current reporting
of mg per PCU, the ESVAC project has established standardised units of
measurement in three major animal species (pigs, cattle and broilers)
called Defined Daily Dose (DDDvet) and Defined Course Dose (DCDvet).
It aims to harmonize and standardise reporting data on veterinary an-
timicrobial consumption across European countries. The values are
based on an assumed average DDDvet or DCDvet of active substance,
which take into account di!erences in dosing, pharmaceutical forms
and routes of administration used by these three species (European
Medicines Agency, 2015).
To rectify the weakness of national sales data, in 2013, the EMA
recommended that countries conduct farm surveys of veterinary pre-
scriptions or antimicrobial administration records in the logbooks kept
by farmers, specific for di!erent species (see ESVAC guidelines of data
collection at farm level) (European Medicines Agency, 2013). Though
this additional data collection from farms demands substantial re-
sources, infrastructure development and enforcement of veterinary
prescriptions at farm level, the benefit is high as it provides accurate
information on antimicrobial use by classes and animal species and
indications, and evidence can be used to facilitate the development of
specific interventions and improve the specific training and education
in veterinarians and farmers.
To date, the OIE has also relied on antimicrobial sales data as in-
dicators of actual use, and also recommends that OIE member countries
to collect and report data on quantity of antimicrobial consumption in
kilogram of antimicrobial agents for di!erent types of indication
(therapeutic use or growth promotion), di!erent animal species group
and di!erent routes of administration. In the second OIE annual report
in 2017 on the use of antimicrobial agents intended for use in animals,
OIE recommended to use animal biomass as a denominator so that the
quantitative data on antimicrobial agent can be compared among
countries. Animal biomass is calculated as the total weight of the live
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domestic animals, used as a proxy to represent those likely to have
exposed to the quantities of antimicrobial agents reported (World
Organisation for Animal Health (OIE), 2017).
From the review, data of the volume of antibiotic use in low- and
middle-income countries are limited while these countries have a large
livestock production. Only three studies are included in this review,
which includes Kenya (lower-middle-income economies), and China
and South Africa (upper-middle-income economies). Data from South
Africa and Kenya was reported in kilogram of antimicrobials used in all
livestock. Total antibiotics were calculated by the review of sales of
pharmaceutical product. Whereas, the study in China reported anti-
microbials in medicated feed by estimation. The quantity of anti-
microbials was calculated by using antimicrobial utilisation data from
the US livestock production. This review indicates an urgent need to
build up national capacity to develop system which monitors anti-
microbial consumption in LMIC. The monitoring systems of anti-
microbial consumption can be developed in a phased manner (Schar
et al., 2018).
4.4. Policy utilities
Data on antimicrobial usage is needed for a number of reasons such
as monitoring time trends of use and assessing the e!ectiveness of in-
terventions. Ideally it should be disaggregated by di!erent anti-
microbial classes in particular the critically important for human
health. It can also be used to investigate the association between the
magnitude of use and bacterial resistance (Collineau et al., 2017; Schar
et al., 2018).
5. Conclusion
We systematically reviewed the peer-reviewed literatures on the
methods and measurements for antimicrobial use in pigs globally. Ten
di!erent units of measurement were identified from 25 studies of high-
and medium-quality studies; which vary greatly in term of objectives,
data sources and units of measurement both numerators and denomi-
nators. The non-homogeneity of the unit of measurement limits the
cross-study comparative analysis. Additionally, di!erent levels of data
such as from farm surveys and national sales data used by these studies
also produce di!erent magnitude of use across studies.
6. Recommendations
Given the importance of measuring antimicrobial use in monitoring
progress of policies in optimizing use, at a minimum, all developing
countries should develop macro-level monitoring using national sales
data and report consumption by milligram of active ingredients per
biomass, while at the same time, when there are improved capacities,
gradually develop sentinel sites which capture prescription of anti-
microbial use by species with the application of DDDvet and DCDvet.
The EMA initiative on standardised units of measurement in three main
animal species using DDDvet and DCDvet, should be scaled up in
Europe and can be applied by developing countries in responses to the
GAP-AMR which calls for monitoring and optimizing antimicrobial use.
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Variables assessed in the study.
Variables Results
1. Context variables Author, year of publication, year of study, title, journal, geographical area, objective
2. Methodology variables 2.1 Research (Observational study: cohort studies/case–control studies/ cross-sectional surveys/routine-data-based studies);
national report
2.2 Data source: primary data (survey, interview) from pig producer, veterinarian; secondary data from company (sales data),
veterinarian (prescription data), government, level of data (national or specific small-scale farm level)
2.3 Sampling technique, if it is a primary data collection: simple random sampling, stratified sampling, cluster sampling,
systematic sampling, Probability Proportional to Size (PPS), quota sampling, convenience sampling, purposive sampling, self-
selection sampling, snowball sampling
2.4 Sample size: number of respondent, response rate (%)
2.5 Methods for antimicrobial use measurement and indicators
Comments (including strengths, weaknesses)
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Table A2
Quality assessment of included studies.
Clearly focused
issue


















Carmo et al. (Carmo et al., 2017) Y Y CT CT Y Y Y Y Y Y Y H
Dupont et al. (Dupont et al., 2016) Y Y Y Y Y Y Y Y Y Y Y H
Sjolund et al. (Sjolund et al., 2016) Y Y N N Y Y Y Y Y Y Y H
2015
Krishnasamy et al. (Krishnasamy
et al., 2015)
Y N N CT CT CT Y N Y Y Y M
Rennings et al. (van Rennings
et al., 2015)
Y Y Y N Y Y Y Y Y Y Y H
Sjolund et al. (Sjolund et al., 2015) Y Y Y N Y Y Y Y Y Y Y H
Taverne et al. (Taverne et al.,
2015)
Y Y Y Y Y Y Y Y Y Y Y H
Van Boeckel et al. (Van Boeckel
et al., 2015)
Y Y N Y CT CT Y CT Y Y Y M
2014
Ferner et al. (Ferner et al., 2014) Y Y N N Y N N N Y Y Y M
Fertner et al (Fertner et al., 2015) Y CT N N Y N Y Y Y Y Y M
Filippitzi et al. (Filippitzi et al.,
2014)
Y Y CT N CT CT Y Y Y Y Y M
Hauck et al. (Hauck et al., 2014) Y Y Y CT CT Y Y Y Y Y Y H
Hosoi (Hosoi et al., 2014) Y Y CT N N N Y Y Y Y Y M
Trau"er et al. (a) (Trau"er et al.,
2014a)
Y Y N N Y N Y Y Y Y Y M
Trau"er et al. (b) (Trau"er et al.,
2014b)
Y Y N N Y N Y Y Y Y Y M
2013
Bondt et al. (Bondt et al., 2013) Y Y Y CT CT Y Y Y Y Y Y H
Bos et al (Bos et al., 2013) Y Y Y Y Y Y Y Y Y Y Y H
2012
Callen et al. (Callens et al., 2012) Y Y Y N Y Y Y Y Y Y Y H
Eagar et al. (Eagar et al., 2012) Y Y N N Y N Y Y Y Y Y M
Merle et al. (Merle et al., 2012) Y Y N Y Y Y Y Y Y Y Y H
Jensen et al. (Jensen et al., 2012) Y Y N N Y Y Y Y Y Y Y H
2011
Vieira et al. (Vieira et al.,
2011)
Y Y Y Y Y Y Y Y Y Y Y H
2006
Timmerman et al.
(Timmerman et al., 2006)
Y Y Y Y Y Y Y Y Y Y Y H
2004
Arnold et al. (Arnold et al.,
2004)
Y Y Y N Y Y Y Y Y Y Y H
2001
Mitema et al. (Mitema et al.,
2001a)
Y Y CT N Y CT Y N Y Y Y M
CT: Cannot tell.






Summary of unit of measurement from included studies.
Definition and unit of
measurement












A. Volume of antimicrobial use
(kilogram)
1. Number of animals
2. Estimated (medicated) feed)
consumed per day
3. Duration that swine received
antimicrobial
4. Dose of antimicrobial
NA Y (medicated
feed)
Dose in the feed N Y Y N Krishnasamy et al., 2015
B. Volume of antimicrobial use
per biomass (mg/PCU; 1
PCU=1 kilogram of biomass




1. Number of slaughtered
animals
2. Number of livestock
3. Number of imported/
exported animals
4. AW
Y N N Y N Average weight
at treatment
Carmo et al., 2017
(mg/PCU) Active substance Numbers of live animals x (1+
production period) x ratio of
carcass weight to live weight of
animals





(mg/biomass) Active substance (sold) Carcass weight Y N Carcass N N N Hosoi et al., 2014
Daily dose and weight at treatment
C. Product-related Daily Doses
(PrDDkg) or Daily Product
Dose (DPD)
Active substance (prescription)/
80% of maximal dose




Y N N Trau!er, 2014a,b; Ferner
et al., 2014




(average maintenance dose per
day per kg animal of a drug use for
main indication in the target
species)






Y N N Dupont et al., 2016; Taverne
et al., 2015; Fertner et al.,
2015; Ferner et al., 2014;
Trau!er et al., 2014a;b;
Bondt et al., 2013; Jensen
et al., 2012
Definition and unit of
measurement








variable• ADD-LU (livestock unit; LU)
(mg/500 kg LU biomass/day)
ADD x 500 NA N N N N N ADD Ferner et al., 2014
• Number of animal daily doses
per livestock unit (nADDsLU)
ADD-LU Number of treated LUs (total
number of LU produced in one
year by all farm, in which at
least treatment was recorded)
N N N N N N Ferner et al., 2014






Definition and unit of
measurement











E. Defined Daily Doses per
animal year (DDDA) or
Animal Defined Daily Dose
(ADDD) or Daily Dose per
animal year (nDDay)
Active substance (prescription) Recommended dose x total
animal mass that can be treated
for one day with the supplied
antimicrobials x mean total






Y N N Taverne et al., 2015; Bos
et al., 2013; Merle et al.,
2012
Daily dose and treatment period
F. Used Daily Doses per kg
biomass (UDDkg) (mg/
kilogram biomass/ day)
Active substance (administered) Number of treated animals x




Y Y N Timmerman et al., 2006;
Trau!er et al., 2014a, b
G. Prescribed Daily Dose (PDD)
(mg/kg* day)
Active substance (prescription) Average weight of the animals x




Y Y N Arnold et al., 2004
H. Treatment frequency UDD Population size N N N Y N UDD Van Rennings et al., 2015
I. Treatment incidence rate ADD Sum of delivered animals in the
period * 112 (112= days of
fattening period) OR 100
slaughter pig-days at risk
N N N Y N N Vieira et al., 2011
Daily dose and period at risk of being treated
J. Treatment incidence- DDA
(TI-DDA), UDDA (TI-UDDA)






Sjolund et al., 2016;2015;
Filippitzi et al., 2014;








Structured Database Search (Search terms and results)
• MEDLINE: N=401 articles• (antibiotic or antimicrobial).mp. [mp= title, abstract, original title, name of substance word, subject heading word, keyword heading word,
protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms] (251,939)• (“use” or “utilisation” or “consume*” or “practice” or “administration” or “oral” or “feed” or “injection” or “amount” or “quantit*” or “qua-
lit*”).mp. [mp= title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier, synonyms] (5,584,129)• (“livestock” or “swine” or “pig” or “farrow” or “weaner” or“sow”).mp. [mp= title, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier,
synonyms] (285,470)• (“measurement” or “indicator” or “surveillance” or “survey” or “report” or “method”).mp. [mp= title, abstract, original title, name of substance
word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique
identifier, synonyms] (3,766,673)• Sciencedirect: N=636 articles:
“Antibiotic” AND (“swine” OR “pig”) AND (“use” OR “survey” OR “surveillance” OR “consumption”)
Filter: Topics, "pig”, “animal”; Content type, "Journal”.• Scopus: N= 630 articles:
(TITLE-ABS-KEY (antibiotic OR antimicrobial OR antibacterial) AND TITLE-ABS-KEY (livestock OR swine OR pig OR farrow OR weaner OR
finisher OR sow) AND TITLE-ABS-KEY (use OR utilisation OR consume* OR consumption OR practice OR administration OR provision) AND
TITLE-ABS-KEY (measure* OR indicator OR surveillance OR survey OR monitor)):• Web of Science: N=691 articles:
TOPIC:(antibiotic OR antimicrobial OR antibacterial) AND TOPIC: (livestock OR swine OR pig OR farrow OR weaner OR finisher OR sow)
ANDTOPIC: (use OR utilisation OR consume* OR consumption OR practice OR administration OR provision) AND TOPIC: (measure* OR in-
dicator OR surveillance OR survey OR monitor)
Filter: DOCUMENT TYPES: (ARTICLE) AND WEB OF SCIENCE CATEGORIES: (VETERINARY SCIENCES OR MICROBIOLOGY OR AGRICULTURE
DAIRY ANIMAL SCIENCE)
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4.2 Potential factors influencing the use of antibiotics in livestock 
As described in Chapter 1, my previous study demonstrated that the use of antibiotics in the 
agricultural sector could be influenced by complex determinants at different levels including: 
(1) farmer lack of knowledge of antibiotics and awareness about AMR; (2) health
professionals lack of AMR information and diagnostic tools to guide prescription; and (3)
loose regulatory systems such as no requirement for prescriptions to acquire antibiotics.
In addition, I reviewed the literature on antibiotic use in livestock and factors influencing 
antibiotic use, searching online electronic databases including MEDLINE, ScienceDirect, 
Scopus and Web of Science between January-November 2017. The review showed that a 
wide range of factors have been described, and different stakeholders across different levels. 
Farmers are likely to have a limited understanding of antibiotics, particularly in LMICs. Poor 
knowledge and lack of understanding among farmers about the impact of antibiotic use might 
lead to inappropriate use of antibiotics. One study in Cambodia showed that none of the 
farmers demonstrated an understanding of the action and indication for antibiotics (115). 
Another study in Sudan found a significant association between farmers’ poor knowledge of 
antibiotic use and the low education of farmers; only a quarter of farmers in the study had 
heard about antibiotic resistance (116). One study in smallholder dairy farms in India showed 
that among farmers, a low level of knowledge relating to antibiotics was associated with the 
presence of active informal service providers (117).  
Antibiotic use was found to be related to pig production system. In my systematic review of 
the pattern of antibiotic use in pigs (section 3.1.1), the frequency of antibiotic use on different 
farms is associated with the type of pig production. Farm characteristics are associated with 
antibiotic use, such as the type of farm, size of farm and vaccination status. Studies in 
European and Asian countries demonstrated that large farms (111,118,119) and industrial 
production systems (111) are more likely to use medicated feeds compared with smaller-sized 
farms. Another relevant study showed that antibiotic use on Dutch farms located in densely 
pig-populated areas and a high number of sows present on the farm are positively correlated 
with the volume of antibiotic consumption (119). In addition, farm management is associated 
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with the use of antibiotics, such as farm biosecurity practices5, animal density, stress levels in 
the herd, vaccination status, quality of feed, and disease prevalence rates. Good farm 
biosecurity is identified as common practice in herds which leads to a reduction in disease 
transmissions and lower antibiotic use (120). Vaccination is recommended to optimise 
antibiotic usage (121). 
Veterinarians play important roles in the antibiotic utilisation system including dispensing, 
prescribing, providing information and taking responsibility for control over farmer practices. 
However, one prior study demonstrated that the decisions made by veterinarians to prescribe 
antibiotics are based on “expert opinion” or on other colleagues’ views who are “opinion 
leaders” or from internet sources, rather than scientific and peer-reviewed data (122). 
Antimicrobial sensitivity testing is an important tool to identify bacteria and select 
antibiotics. Nevertheless, nearly half of all veterinarians in European countries (44.3%) 
seldom collect a sample for bacterial diagnosis in a laboratory. Pharmaceutical companies 
have common marketing strategies to increase their sales (123,124), which may influence the 
higher use of antibiotics by farmers.  
Antibiotic use by farmers also relies on policies and regulations. Previous studies have shown 
that access to antibiotics also influence farmers’ use of antibiotics. A study in Ghana showed 
that easy access to antibiotics by poultry farmers facilitated the use of antibiotics (125). In 
India, dairy farmers reported the direct marketing of drugs and easily available antibiotics 
which contributed to self-administered use of antibiotics (117). Cambodian farmers reported 
that antibiotics can be purchased without a veterinary prescription from any animal feed 
retailer, where not all of them are employed trained veterinarians (115). 
Based on the review of the literature, factors can be categorised into three levels: individual 
level, systems level, and policy and regulation level. Individual-level factors include the 
knowledge, attitudes and practices of farmers and communities in relation to antibiotic use. 
Systems-level factors are defined based on a relationship between farmers and systems 
including pig production systems and antibiotic supply systems (production, distribution, 
prescription, sale and use of antibiotics). Factors also include association among farmers and 
key stakeholders such as veterinarians, pharmaceutical actors and pork consumers who 
 
5 OIE defines bio-security as a set of management and physical measures designed to reduce the risk of 
introduction, establishment and spread of animal diseases, infections or infestations to, from and within an 
animal population (108)  
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contribute to antibiotic use on farms. Policy-level factors include drivers that are associated 
with the government, regulations and policies concerning the use of antibiotics in pig farms. 
4.3 Conclusions and knowledge gaps 
Drawing on the literature presented above, it is evident that antibiotics have been used 
routinely in livestock production to treat, control and prevent disease, and to increase 
productivity for many decades. Due to the possible association between antibiotic use in 
livestock and AMR in humans, there are concerns that their level of use is unnecessarily high 
including for sub-therapeutic use for growth promotion and disease prevention, and 
particularly for the use of antibiotics that are important in humans. Many classes of 
antibiotics used in animals are also used in humans, particularly Critically Important 
Antimicrobials for human medicine. These uses are considered as important drivers to the 
selection of resistant bacteria. 
The literature review shows that the use of antibiotics in pigs is complex and associated with 
interrelating domains including knowledge and attitudes of farmers and communities. 
Antibiotic use is also related to pig production and antibiotic utilisation systems under the 
government, regulations and policies controlling the use of antibiotics in pig farms.  
However, data about antibiotic use are scarce. There is a lack of explicit information 
concerning how much, and how different types of antibiotics are being used, and which 
determinants contribute to antibiotic use in pig production, particularly in LMICs. This gap in 
knowledge limits understandings of both the barriers and facilitators which can be addressed 
to optimise the use of antibiotics in livestock.  
The empirical research in this thesis aims to contribute to closing the gaps identified in the 
literature by exploring the use of antibiotics, and factors influencing the use of antibiotics in 
pig production. This will enhance understanding of the use of antibiotics in pig production, 
and lead to recommendations for optimising the use of antibiotics in pig production. The 
following chapter will develop the aims and methods of the empirical research.
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SECTION B: RESULTS 
Chapter 5 Mixed-methods study: Pattern of antibiotic use 
in pig farms and the total amount of antibiotics used in pig 
production in Thailand 
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Key questions
What is already known?
 ► Rising global concern about antimicrobial resistance
has drawn attention to the use of antibiotics in an-
imals, in particular the use of last- resort antibiotics
normally reserved for severe infections in humans.
 ► Low- and middle- income countries are large live-
stock producers and consumers. There are many
studies about the use of antibiotics in livestock in
high- income countries yet very few have been con-
ducted in low- and middle- income countries.
What are the new !ndings?
 ► Over half of the farmers used antibiotics for disease
prevention in pig production.
 ► The total amount of active ingredients mixed into
medicated feed for pigs was estimated to be 843
tonnes in 2017.
 ► Amoxicillin was the most common antibiotic used for
disease prevention and mixed into medicated feed.
 ► Half the oral and injectable antibiotics used in farms
and two- thirds of antibiotics added in medicated
feed belonged to the category of Critical Important
Antimicrobials (CIA).
What do the new !ndings imply?
 ► Alternative approaches need to be sought to main-
tain herd health and productivity in order to protect
the effectiveness of antibiotics. These solutions need
to be tested and demonstrated to farmers to show
their relative cost- effectiveness.
 ► We recommend progressive restriction in the use of
antibiotics in pigs with an emphasis on CIA. This can
be achieved by controlling the distribution of certain
antibiotics for animal use with medicines available
only on prescription.
ABSTRACT
Background Rising global concern about antimicrobial 
resistance has drawn attention to the use of antibiotics in 
livestock. Understanding the current usage of antibiotics 
in these animals is essential for effective interventions on 
the optimisation of antibiotic use. However, to date few 
studies have been conducted in low- and middle- income 
countries. This study aimed to explore the use of antibiotics 
and estimate the total amount of antibiotics used in pig 
production in Thailand.
Methods This was a mixed- methods study including 
a cross- sectional questionnaire- based survey of 84 pig 
farmers, secondary analysis of data from a survey of 31 
feed mills to estimate the amount of antibiotics mixed in 
pig feed and interviews with "ve veterinarians involved 
in the feed mill industry to gain an understanding of 
medicated feed production.
Findings Half of the farmers reported using antibiotics 
for disease prevention. Use was signi"cantly associated 
with farmers’ experience in raising pigs, farm income, 
having received advice on animal health and belonging 
to a farm cooperative. The estimated total amount of 
active ingredients mixed into medicated feed for pigs for 
the whole country was 843 tonnes in 2017. Amoxicillin 
was the most commonly used antibiotic reported by both 
pig farms and feed mills. The use of Critically Important 
Antimicrobials including colistin was common, with one- 
third of farmers reporting their use as oral or as injectable 
medication, and accounting for nearly two- thirds of 
antibiotics contained in medicated feed.
Conclusion A majority of antibiotics used in Thai pig 
farms belonged to the category of Critically Important 
Antimicrobials. Progressive restriction in the use of 
antibiotics in pigs is recommended through using 
prescriptions to control the distribution of certain 
antibiotics. The government should strengthen veterinary 
services to improve access of farmers to animal health 
advice and explore alternative interventions.
BACKGROUND
Rising global concern about antimicrobial 
resistance (AMR)i has drawn attention to the 
i In general, this study focuses on antibiotics. The 
term antimicrobials are used when we refer to 
standard terminology such as antimicrobial resis-
tance, WHO Critically Important Antimicrobials 
or when we refer to published literature which use 
antimicrobials.
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use of antibiotics in livestockii with an estimated 70% 
of the antibiotic consumption in Europe being in the 
animal sector.1 Many of the antibiotics commonly used 
in animals are categorised as Critically Important Antimi-
crobials (CIA) for treating humans according the WHO 
list of Critically Important Antimicrobials for Human 
Medicine (WHO CIA list). The WHO CIA list catego-
rises Medically Important Antimicrobials into three 
categories: Important, Highly Important and Critically 
Important, and further divides the last category (CIA) 
into ‘high priority’ CIA including aminoglycosides, amin-
openicillins and carbapenems; and ‘highest priority’ CIA 
including cephalosporins (third, fourth and fifth gener-
ation), glycopeptides, macrolides, polymyxin (colistin) 
and quinolones.2 3 Of particular concern has been the 
use of CIA, the last- resort antibiotics normally reserved 
for the most severe infections in humans.4–6 Indeed there 
is emerging evidence of the threat including a recent 
report describing the discovery of a plasmid- mediated 
colistin- resistant gene in commensal Escherichia coli from 
tests on pigs, pork products and humans in China.7
The use of antibiotics in pigs is complex and associ-
ated with the interrelating domains of animal health, 
animal welfare and economics. Antibiotics have been 
used routinely in farm animal production since the 1950s 
to treat, control and prevent disease and to increase 
productivity. Based on the predicted continued rise in 
global demand for livestock products, global antimicro-
bial consumption of livestock is predicted to increase by 
two- thirds over the next 10 years.8 Within this sector, anti-
microbial consumption is estimated to be highest in pigs, 
compared with chicken and cattle.8 It has been a common 
practice for decades to use subtherapeutic doses of antibi-
otics in food- animals for a number of reasons: to control 
the spread of symptomatic infections between animals in 
close contact some of which may be subclinically infected; 
to prevent disease at points of high risk prior to the onset 
of symptoms, particularly when animals are under stress 
(eg, extreme weather, post vaccination or moving pen) 
and to improve production performance.9 10 In pigs, 
antibiotics can be applied to whole groups including by 
mixing antibiotics into feed (medicated feed) or adding 
antibiotic powder or solution into drinking water (medi-
cated water).11–15
In order to design and implement effective interven-
tions that will reduce the unnecessary use of antibiotics 
in livestock, an understanding of current usage is essen-
tial. However, while data are available from high- income 
countries on the use of antibiotics in pigs, there are few 
studies from low- and middle- income countries. In 2018, 
Thailand was the first middle- income country in Asia 
to publish data on the total consumption of antimicro-
bials and reported that 3690 tonnes of antimicrobials 
were used in livestock production in 2017.16 However, 
these data do not help understand use by animal species, 
ii Domesticated animals kept mainly for meat, milk, egg and 
wool production.
production system or indications. To address this knowl-
edge gap, this study aimed to explore the use of antibi-
otics and to estimate the total amount of antibiotics used 
in pig production in Thailand. A better understanding 
of antibiotic use in pigs, particularly in low- and middle- 
income countries, can help design appropriate inter-
vention strategies to optimise the use of antibiotics in 
livestock production.
METHODS
Thailand has very diverse livestock production systems, 
including large agro- industrial conglomerates, contract 
farming (where the buyer of fatteners also provides 
piglets, feed, vaccines and technical support to the 
contract farmers) and smallholder farms. A few large 
agro- industrial companies dominate the livestock 
production business with integrated operations including 
animal breeding, feed production and processing meat 
products. In 2017, about 19.5 million pigs were raised 
by 180 000 pig farmers, of whom 40% were smallholder 
farmers (less than 50 pigs per farm) raising indigenous 
pig breeds.16 17
In order to determine the patterns and total amount 
of antibiotic use in pig production in Thailand, mixed 
methods were used: a survey of farmers, secondary data 
analysis of a survey of feed mill operators and inter-
views with veterinarians. Data collection was carried out 
between March 2018 and December 2018.
Survey of pig farmers
Questionnaire development
To guide the development of the questionnaire, a litera-
ture review and exploratory interviews with five veterinar-
ians were conducted. Following piloting, some questions 
were modified to suit the local context of pig production. 
The questionnaire consisted of both closed and open- 
ended questions covering general information about the 
farms (type of farm, number of workers, current number 
of pigs at different stages, health management), pig 
production, antibiotic use for prevention of infectious 
diseases, the source of antibiotics and medicated feed 
and farmers’ knowledge and awareness about antibiotics 
and antibiotic resistance (online supplementary file 1).
Study site and sample population
The cross- sectional study was conducted in a province 
in the central region of Thailand, which has one of the 
highest pig populations, accounting for about 20% of 
total annual Thai pig production. The province has an 
area of about 5000 square kilometres subdivided into 10 
districts, some with many pig and cattle farms, and some 
with very few. Based on the best available data and discus-
sions with each district health office, the three districts 
with the highest number of pig farms were purposively 
selected and within each district, the two subdistricts with 
the highest number of pig farms were selected. Due to 
practical and budgetary constraints, a census and random 
sampling were not possible.
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Selection and recruitment process
Within the six selected subdistricts, all pig farmers were 
invited to participate in the study via an official letter. Village 
health volunteers and public health staff in the subdistrict 
health centres also encouraged pig farmers to participate.
Data collection
Between March 2018 and December 2018, interviews with 
pig farmers took place in the local health centres and 
were conducted face- to- face in Thai by 10 interviewers 
with a healthcare background, who were provided with 
basic information about pig farming as well as specific 
data collection training. Most interviews took between 
45 and 60 min. Data were collected on tablets offline 
and synchronised onto a cloud- based server when the 
internet was available.
Data management and analysis
The data were exported into Microsoft Excel and Stata/
SE 15 for cleaning and analysis. Based on the number of 
pigs on the farm at the time of the study, farms were cate-
gorised by size as per the Department of Livestock Devel-
opment (DLD) definition: smallholder farm (less than 
50 pigs), small commercial farm (from 51 to 500 pigs), 
medium commercial farm (from 501 to 5000 pigs) and 
large commercial farm (more than 5001 pigs). The farms 
were grouped by type into farrow- to- finish (breeder, suck-
ling piglet, nursery pig, fattener), fattening (fattener- 
only) and breeding (breeder- only). Pig farms were also 
classified according to whether they held a Good Agricul-
ture Practice (GAP) certificate from the DLD, indicating 
they had satisfied a certain practice standard. Farms 
were also classified into a contract or non- contract farm. 
Contract farmers provide animal housing and labour 
while the contracting company provides pigs, feed, medi-
cines and technical support to farmers. Non- contract 
farmers are independent of contracting companies. Pig 
farms were also grouped based on whether they were 
members of a district or provincial cooperative.
Descriptive analyses including examination of means 
and frequencies were conducted to describe the char-
acteristics of participants, reported pig health problems 
and the use and source of antibiotics on the farm. Univar-
iate analysis was used to assess the association between 
the dependent variable (the use of antibiotics in pigs) 
and each independent variable (size of farm, type of 
farm, etc).
Survey of feed mills
To estimate the total amount of antibiotics mixed in pig 
feed in Thailand, we used data from a 2017 national 
survey of feed mills conducted by the International 
Health Policy Program (IHPP), Ministry of Public 
Health, which estimated the total national consumption 
of medicated feed by food- producing animal species.16 
The target population was the 238 feed mills registered 
with the DLD in 2018. IHPP met representatives of the 
53 feed mills who were members of the Thai Feed Mill 
Association (TFMA) to explain the study in March 2018 
prior to sending the survey form via email and fax. The 
official letter and survey form were also sent to the non- 
TFMA members (185 feed mills). In May 2018, all non- 
responders were followed up by phone.
The respondents were asked to extract the volume 
of antibiotics added to feeds from the feed production 
records which were usually kept in an electronic format. 
They were asked to fill in separate forms for each animal 
species for the calendar year 2017. For the secondary 
data analysis for this study, we extracted the data from 
the forms related to pigs and used the following variables:
► Name of the antibiotic (added to the medicated
premix) according to the veterinary anatomical ther-
apeutic chemical (ATCvet) classification system.
► Thailand Food and Drug Administration (Thai- FDA)
market authorisation identification number.
► Trade name of the medicated premix and the market
authorisation holder.
► Type and amount of the antibiotic added to the feed.
► Stage of pig production for which the medicated feed
was intended.
Data management and analysis
Data from survey forms were entered into in Microsoft 
Excel and checked for completeness. Descriptive statis-
tical analyses were performed using Stata/SE 15 software. 
Antimicrobial consumption was measured by kilograms 
of active ingredient per year (2017) and calculated as the 
volume of active ingredients multiplied by the strength 
of each antibiotic according to Thai- FDA market author-
isation identification number. The market authorisation 
identification number and ATCvet codes were used to 
categorise different active ingredients of antibiotics used 
in the medicated feed and verified with Thai- FDA data-
base. Consumption of each active ingredient was classi-
fied into different stages of pig production: breeding pig, 
pig less than 25 kg and fattener.
Interviews with veterinarians in the feed industry
To gain a deeper understanding of medicated feed we 
conducted in- depth interviews with veterinarians working 
in the feed mill industry. As there was no list or system-
atic way to approach all potential participants directly, we 
solicited the help of the TFMA to identify veterinarians 
fulfilling the following criteria: (1) they could provide 
information about the use of antibiotics in animal feed, 
(2) they had worked in the animal feed area for more
than 10 years and (3) they were willing to be interviewed.
Five veterinarians have met these criteria identified by
the TFMA.
All interviews were conducted face- to- face in Thai by 
the researchers (AL and VT) between October 2018 and 
December 2018 using a semi- structured interview guide 
with three sections: common antibiotics mixed in feed 
including type, dosage and duration of use; common 
diseases and pathogens and common conditions in pigs 
that require the use of antibiotics. The interviews were 
and. Protected by copyright.
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Table 1 Use of antibiotics and medicated feed, and their 





Use of antibiotics or medicated 
feed
► Use 62 (73.8) 11 (13.1)*
► Do not use 22 (26.2) 18 (21.4)
► Do not know – 19 (22.6)
► Not willing to respond – 36 (42.9)




16 (25.8) 2 (18.2)




► In- house mixing – 8 (72.7)
► Internet, online – –
► Others 6 (9.7) 1 (99.1)
*At least one feed formula at farm.
audio- recorded and lasted between 1.5 to 2 hours. The key 
informants were also asked to complete a one- page closed- 
ended questionnaire and return it online within 14 days.
Data management and analysis
The interview audio recording was transcribed verbatim 
and anonymised by AL. The questionnaire data were 
transferred to Microsoft Excel and Prism 8 for data 
management and visualisation. The information in rela-
tion to the use of antibiotics was plotted over a period of 
pigs’ age in weeks according to different stages including 
suckling piglet, nursery pig and fatteners. The maximum 
or minimum dose range was reported if there were 
different reports from more than one veterinarian. The 
information was returned to the informants for review.
Consent and ethical considerations
Prior to the interviews, pig farmers and feed mills’ repre-
sentatives were provided with a participant information 
form and asked to sign an informed consent form if they 
agreed to participate. Veterinarians working at feed mills 
gave their verbal consent to take part in an interview. 
Permission was requested to record the interview and 
written notes were also taken.
The data were manually checked for completeness 
and for entry errors by the researcher (AL). Information 
including the name of respondents and feed mills were 
deleted from the data set. Data were protected by access 
authentication with only the researcher (AL) able to 
access the survey and interview data.
Patient and public involvement
No patients were involved in this study.
RESULTS
Pig farmer survey
Characteristics of farmers and farms
In total, 84 of 102 farmers agreed to participate (response 
rate 82.4%). Over half (59.5%) were female and over 
two- thirds (72.6%) owned the farm that they worked on. 
About two- thirds (69.0%) of respondents were running 
commercial farms and the remainder were running 
smallholder farms. Over 60% of the farms were farrow- 
to- finish farms and over 30% were fattening farms. Thir-
ty- six per cent of the farms had a GAP certificate. Twenty 
per cent were members of cooperative farms and only 
9.5% were contract farms.
One- third reported a monthly income of less than 
THB 10 000 (US$ 317; US$ 1=31.5 THB) and over half 
reported a significant reduction in income over the last 
3 years due to oversupply and lower market prices for 
live pigs. Of the 84 farmers, 21.4% reported spending 
an average of more than THB 50 000 (US$ 1590) per 
month on purchasing feed and a third (36.9%) reported 
spending an average of less than THB 1000 (US$ 32) on 
medicines. Marketing of the animals was variable with 
a third of farmers using brokers (32.1%), a fifth using 
pork retailers (21.4%) and 14.3% using both brokers and 
retailers. The remainder used a mixture of routes that 
mainly related to local consumption (online supplemen-
tary table A1).
Across all pig age groups, gastrointestinal infections, 
respiratory infections and lameness were reported at 
least occasionally in the previous 12 months by more 
than half of respondents. In suckling piglets and nursery 
pigs, gastrointestinal infections were reported to have 
occurred regularly, 34.0% and 12.2%, respectively. In 
sows, reproductive infections were also reported as occur-
ring by half of farmers (online supplementary figure A2).
Use of antibiotics at farm
Three- quarters of farmers reported using antibiotics, but 
most farmers were not willing to say that they used medi-
cated feed or did not know whether or not the feed they 
used contained antibiotics. Pharmaceutical companies 
and pharmacies were common sources of antibiotics. 
The majority of farmers reported adding antibiotics to 
feed in- house. No farmer reported buying antibiotics or 
medicated feed online (table 1).
Oral and injectable antibiotics for disease prevention
About half of farmers reported using oral antibiotics 
(oral solution or adding solution or powder to drinking 
water, excluding medicated feed) and injectable antibi-
otics for disease prevention for the whole group. Overall, 
one- third of farmers reported using oral and injectable 
antibiotics in the CIA group. Half of the farmers used 
only one active ingredient in each stage of pig produc-
tion (table 2A,B).
In total, farmers reported using 11 different antibi-
otic active ingredients for disease prevention. Although 
amoxicillin was the most commonly reported, about half 
and. Protected by copyright.
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Table 2 Number of farms, by type of pig, reporting (A) use of oral and injectable antibiotics for prevention, (B) number of 
different types of active ingredient used and (C) active ingredient categorised by WHO CIA list from the farmer survey
(A) Number (%) of farms
All farms
(n=84)







Reporting any use of antibiotics for 
prevention
48 (57.1) 31 (36.9) 26 (31.0) 17 (20.2) 26 (31.0)
Reporting any use of Critically 
Important Antimicrobials for human 
medicine for prevention











(B) Number (%) different types of active ingredient used
 One active ingredient 24 (50.0) 21 (67.7) 19 (73.1) 9 (52.9) 15 (57.7)
 Two active ingredients 12 (25.0) 3 (9.7) 5 (19.2) 6 (35.2) 5 (19.2)
 Three active ingredients 6 (12.5) 4 (12.9) 2 (7.1) 2 (11.8) 2 (7.7)
 Four active ingredients 6 (12.5) 3 (9.7) – – 4 (15.4)
(C) Number of farms (%) reporting use of named active ingredients (WHO ATCvet code)
(I) Critically important antimicrobials - highest priority
 Ceftiofur (QJ01DD90) 2 (4.2) – – – 2 (7.7)
 Enro!oxacin (QJ01MA90) 11 (22.9) 4 (12.9) 6 (23.1) 5 (29.4) 9 (34.6)
(II) Critically important antimicrobials - high priority
 Amoxicillin (QJ01CA04) 19 (39.6) 15 (48.4) 5 (19.2) 7 (41.2) 7 (26.9)
 Gentamicin (QJ01GB03) 1 (2.1) – – – 1 (3.8)
 Kanamycin (QJ01GB04) 3 (6.3) 3 (9.7) 2 (7.7) 0 3 (11.5)
 Streptomycin (QJ01GA01) 1 (2.1) 1 (3.2) – –
(III) Highly important antimicrobials
 Chloramphenicol (QJ01BA01) 1 (2.1) 1 (3.2) 1 (3.8) – –
 Lincomycin (QJ01FF02) 5 (10.4) 3 (9.7) 1 (3.8) 4 (23.5) 4 (15.4)
 Penicillins, combinations with 
other antibacterials (QJ01RA01)
6 (12.5) 5 (16.1) 4 (15.4) 1 (5.9) 4 (15.4)
 Tetracycline (QJ01AA07) 6 (12.5) 5 (16.1) 1 (3.8) 2 (11.8) 2 (7.7)
(IV) Important antimicrobials
 Tiamulin (QJ01XQ01) 3 (6.3) 2 (6.5) – – 1 (3.8)
 Unknown 22 (45.8) 11 (35.5) 10 (38.5) 8 (47.1) 11 (42.3)
*Number of farms reporting raising pigs in this stage.
†Number of farms reporting antibiotic use for prevention.
ATCvet, veterinary anatomical therapeutic chemical; WHO CIA list, WHO list of Critically Important Antimicrobials for Human Medicine.
of farmers could not specify the name of the antibiotic 
used, either by trade name or active ingredient (table 2C)
Source of advice
Of all farmers, 81% reported having received advice on 
animal health, 77.4% on antibiotic administration and 
42.9% on the use of feed. It is worth noting that most 
farmers sought advice on animal health management 
(45.6%), antibiotics (45.8%) and feed (44.4%) from 
‘others’. These were unqualified sources such as relatives, 
peers, other farmers or someone they called ‘doctor’ who 
may or may not have been a veterinarian. Pharmaceutical 
companies and feed mills were also a source of advice for 
farmers (online supplementary file 2 table A2).
Factors associated with the use of antibiotics for prevention
The farmers’ characteristics that appear to be risk factors 
for using antibiotics for prevention in the past 12 months 
are shown in table 3. The use of antibiotics for prevention 
of disease was significantly associated with farmers’ expe-
rience in raising pigs, farm income, farm type, having 
received advice on animal health and belonging to a farm 
cooperative.
Feed mill survey
Characteristics of feed Mills
Of the 238 questionnaires distributed, 31 were returned 
(response rate 13%). However, it is estimated that the 31 
feed mills that did participate in the survey, account for 
and. Protected by copyright.
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Table 3 Factors associated with the use of antibiotics for prevention of disease in the past 12 months from the farmer survey
Characteristics Categories
Number of farms 
with data available
Use of antibiotic 
for prevention (%) OR (95% CI) P- value
Farmer’s highest 
level of education
Primary school 37 17 (46.0) rv
Secondary school 
and higher
47 30 (63.8) 2.28 (0.92–5.65) 0.10
Farmer’s experience !10 years 37 16 (43.3) rv
>10 years 47 31 (66.0) 2.82 (1.01–8.08) 0.04*
Farmer’s knowledge 
a
Score<60% 29 14 (48.3) rv
Score"60% 52 32 (61.5) 1.86 (0.72–4.75) 0.19
Size of farm Smallholder farm 26 11 (42.3) rv
Commercial farm 58 36 (62.1) 2.54 (0.96–6.71) 0.05
Type of farm Farrowing to 
#nisher farm
54 37 (68.5) rv
Fattening 30 10 (33.3) 0.33 (0.12–0.87) 0.02*
GAP certi#ed farm No 53 26 (49.1) rv
Yes 31 21 (67.7) 2.54 (0.96–6.71) 0.05
Member of 
cooperative farm
No 67 33 (49.3) rv
Yes 17 14 (82.4) 7.73 (1.49–40.01) 0.01*
Contracted farm No 76 42 (55.3) rv
Yes 8 5 (62.5) 1.28 (0.28–5.80) 0.75
Household income 
per month
Less than BHT 
50,000
47 21 (44.7) rv
More than BHT 
50,000
23 18 (78.3) 4.46 (1.32–15.05) 0.01*




16 5 (31.3) rv
Receiving advice 68 42 (61.8) 3.78 (1.12–12.73) 0.02*
*Statistically signi#cant at p<0.05.
†Knowledge: #ve true/false statements in relation to the use of antibiotics and AMR, taken from the AMR module in the 2017 National Health 
Welfare survey form.
AMR, antimicrobial resistance; GAP, Good Agriculture Practice; rv, reference value.
approximately 80% of the total national production of 
pig feed (data from a market survey via personal commu-
nication). Twenty- five out of the 31 participating feed 
mills reported that they had added antibiotics to some 
feeds in 2017, while the remaining 6 feed mills denied 
having done so.
Use of medicated feed
Based on the analysis of the feed mill survey data, the 
total amount of active ingredients mixed into medicated 
feed for pigs was 843 tonnes in 2017 (table 4). Among 
these, the top three active ingredients were amoxicillin, 
contained in almost half of feeds, then halquinol and 
tiamulin. Of the total production, 64.3% of medicated 
feed contained antibiotics on the CIA group, including 
an estimated total of over 40 tonnes of colistin.
Of the total amount of antibiotics added in medi-
cated feed, 39.7% was targeted at suckling and nursery 
pigs, followed by fatteners (37.3%) and breeding pigs 
(23.0%). Regarding choices of antibiotics across the 
different stages of pig production, the majority of colistin 
(87.2%) and haquinol (60.4%) were intended for suck-
ling and nursery pigs, while the majority of tylosin (81%), 
lincomycin (61.7%) and tiamulin (44.3%) was added to 
feed for fatteners. Most bacitracin (87.6%) and oxytetra-
cycline (83.5%) were added to feed for sows (figure 1).
Feed industry veterinarian interviews
All five of the animal feed industry veterinarians who 
were interviewed had practised in the animal feed field 
for more than 20 years (maximum=37 years). They were 
asked to explain the use of common antibiotics in rela-
tion to common diseases and common management at 
different stages of pig production (by week) (figure 2). 
Amoxicillin and tiamulin were commonly recommended 
for use at all stages; the dose range was between 300 and 
and. Protected by copyright.








ealth: first published as 10.1136/bm





Lekagul!A, et!al. BMJ Global Health 2020;5:e001918. doi:10.1136/bmjgh-2019-001918 7
BMJ Global Health
Table 4 Amounts of active ingredients mixed in medicated feed from the feed mill survey, categorised by WHO CIA list
Active ingredient (WHO ATCvet 
code)
Amount of antibiotic added to medicated feed in kg
All feeds
(kg, %)
By stage of pig production
Feeds for breeding 
pig (sow)
Feeds for pigs <25 kg 
(suckling and nursery pigs)
Feeds for 
fatteners
(I) Critically important antimicrobials
highest priority
145 805.3 (17.3) 18 487.3 62 399.5 64 918.6
 Colistin (QA07AA10) 40 378.5 (4.8) 2251.7 35 209.4 2917.4
 Fosfomycin (QJ01XX01) 767.2 (0.1) 79.6 11.2 676.4
 Kitasamycin (QJ01FA93) 9435.4 (1.1) 2153.7 588.9 6692.9
 Tilmicosin (QJ01FA91) 54 738.9 (6.5) 10 271.0 21 045.6 23 422.3
 Tylosin (QJ01FA90) 38 507.1 (4.6) 1764.2 5543.5 31 199.4
 Tylvalosin (QJ01FA92) 1978.2 (0.2) 1967.1 0.9 10.2
(II) Critically important antimicrobials
high priority
395 971.6 (47.0) 102 994.7 152 266.0 140 710.9
 Amoxicillin (QJ01CA04) 395 950.1 (47.0) 102 994.7 152 244.5 140 710.9
 Apramycin (QJ01GB90) 21.5 (<0.1) – 21.5 –
(III) Highly important antimicrobials 48 328.3 (5.7) 17 851.5 11 247.7 19 229.0
 Chlortetracycline (QJ01AA03) 32 889.4 (3.9) 11 853.7 7515.2 13 520.4
 Doxycycline (QJ01AA02) 2686.6 (0.3) 1661.2 881.7 143.7
 Lincomycin (QJ01FF02) 7881.0 (0.9) 270.9 2749.2 4860.9
 Oxytetracycline (QJ01AA06) 4871.3 (0.6) 4065.7 101.6 704
 Sulfadimidine (QJ01EQ03) 240.2 (0.1) – 24.0 216.1
(IV) Important antimicrobials 128 519.1 (15.3) 41 809.6 33 433.7 53 275.9
 Bacitracin (QA07AA93) 9285.3 (1.1) 8136.5 710.1 438.7
 Tiamulin (QJ01XQ01) 119 233.8 (14.2) 33 673.1 32 723.6 52 837.2
(V) Antimicrobial classes currently not
used in humans
123 707.1 (14.7) 12 763.9 74 844.6 36 098.7
 Avilamycin (QA07AA95) 281.5 (<0.1) – 143.0 138.6
 Bambermycin (QA07AA96) 78.2 (<0.1) – 78.2 –
 Halquinol (QA07A!91) 123 347.4 (14.6) 12 763.9 74 623.4 35 960.1
Total 842 571.7 193 906.9 334 215.5 314 449.2
ATCvet, veterinary anatomical therapeutic chemical; WHO CIA list, WHO list of Critically Important Antimicrobials for Human Medicine.
400 ppm (1 ppm equivalent to 1 mg of active ingredient 
per 1 kg of feed) and 150 and 200 ppm, respectively. 
Halquinol and colistin were commonly recommended 
for addition to medicated feed for suckling piglets and 
nursery pigs for the prevention of gastrointestinal tract 
infection. Tylosin, tilmicosin and chlortetracycline were 
recommended for fatteners. According to the indica-
tion label on feed packages and veterinary supervision, 
the duration of antibiotic use was commonly about 4 to 
6 weeks. No medicated feed was said to be provided to 
fatteners 1 month prior to slaughter (20th to 24th week).
The veterinarians reported that the choice of active 
ingredients in the feed was designed for both treatment 
and prevention of common diseases and animal health 
management at different stages of pig production, partic-
ularly when the animals are under stress or prone to infec-
tion. For example, during the first week, piglets undergo 
teeth and tail clippings and castration. During the second 
week, pigs start having feed and are weaned in the fourth 
week. The feed is changed at the fifth, ninth, thirteenth 
and nineteenth weeks. Between the second and seventh 
week, pigs are vaccinated against common infectious 
diseases. These procedures, including handling animals 
and movement between pens, cause pigs stress.
DISCUSSION
Use of antibiotics by different active ingredients
To our knowledge, this is one of the first studies to assess 
in detail antibiotic use in pig production in a low- or 
middle- income country. This study indicated that amox-
icillin, a broad- spectrum antibiotic, was the most used 
oral and injectable antibiotic for prevention of disease 
(39.6% of total farms) and in the medicated feed (47% 
of the total amount of antibiotics). The national surveil-
lance consumption data confirm that amoxicillin was 
and. Protected by copyright.
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Figure 1 Amount (tonnes) of active ingredients mixed in 
medicated feed from the feed mill survey, by stage of pig 
production (antibiotics including 1 tonne at less of the active 
ingredient).
Figure 2 Common active ingredients in medicated feed, dose and duration of use, synthesised from the interview with 
veterinarians.
the most used antibiotic in both humans and animals, 
and that a quarter (24.6%) of total consumption was in 
animals.16 In animals, amoxicillin is reportedly widely 
used for prophylaxis and treatment of generalised infec-
tions in many countries. 18 19 However, when given orally 
to pigs via medicated feed, absorption and bioavailability 
are low 20–23 . This may lead to chronic exposure of gut 
microbiota to amoxicillin and an associated high selec-
tive pressure in the intestine of animals, making them 
more likely to develop antibiotic resistance. 24
Our previous reviews observed differences in antibi-
otic use among stages of pig production, mainly due to 
differences in diseases, epidemiology and administration 
route of the available drugs.19 In this study, gastrointes-
tinal infection reportedly mostly affects suckling piglets 
and nursery pigs. These are periods when pigs are most 
susceptible to getting diarrhoea from common patho-
gens such as post- weaning E. coli and salmonellosis. The 
use of colistin in pigs has been shown to lead to the devel-
opment of a plasmid- mediated colistin- resistant gene 
in humans in China.7 25 Consequently, in 2018, DLD 
restricted the use of colistin for disease prevention in live-
stock, and farmers replaced it with halquinol. Halquinol 
is not used in humans and not listed on the WHO CIA 
list. It is now widely used in pig and poultry produc-
tion for prevention control and treatment of diarrhoea 
caused or complicated by E. coli and Salmonella spp in 
pigs. However, the maximal residue limit of halquinol has 
not been established by Codex Alimentarius due to a lack 
of information about the characterisation of residues in 
animal tissues.26 27
Feed industry veterinarians considered that the use 
of antibiotics in the fattening period for disease preven-
tion was crucial for farms, particularly those which could 
not effectively control common diseases. Antibiotics 
were used in the medicated feed for fatteners, including 
lincomycin, tiamulin and tylosin. Tylosin belongs to the 
macrolides class of antibiotics and is classified as a highest 
priority CIA. Macrolides are used to treat infections in 
humans and are also reserved as second- line treatments 
and. Protected by copyright.
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for patients who are allergic to penicillins.28 Resistance to 
macrolides in human enterococci and enterococci from 
animal sources in Europe 29 30 has been well documented. 
High levels of resistance to tylosin in several bacteria 
including zoonotic pathogens are also reported in pigs 
in many European Union countries; for example, 43% 
to 59% of Streptococcus suis isolates are tylosin resistant in 
the UK,31 and 69% of all pathogens collected from pigs 
in 2017 are resistant to tylosin in France.32 In Thailand, 
a high level of S.suis isolates resistant to erythromycin 
(belonging to macrolides class) (80.9%) were found in 
human patients and pigs.33 Other potential zoonotic 
bacteria such as Salmonella spp showed a high level of 
resistance to common antibiotics including tetracycline 
(82.6%) and ampicillin (81.4%) in Thailand. In food 
chain, 53.7% of Salmonella and 60.6% of E. coli are resis-
tant to ampicillin. Resistance of E. coli to colistin is low, 
3% and none are resistant to meropenem.34
Use of antibiotics at farm level
Our results show that 57.1% of farmers reported the 
use of oral and injectable antibiotics for prevention. 
Common sources of antibiotics for farmers were pharma-
cies and pharmaceutical companies. In Thailand, most 
antibiotics are classified as dangerous drugs, which do 
not require a prescription but do need to be dispensed by 
licensed pharmacists or veterinarians at licensed pharma-
cies; a few are classified as ‘special control medicines’ and 
require a prescription. In 2017, there were about 24 000 
retailers and wholesalers licensed for pharmaceutical 
sales.35 This large number of antibiotic sellers serving 
human health needs provides easy access to antibiotics 
for use in animals. In addition, pharmacists may have 
limited knowledge about pig disease and farm manage-
ment due to the absence of veterinary medicine content 
in the pharmacist undergraduate syllabus.
Pharmaceutical companies can sell antibiotics to 
livestock producers through veterinarians (mostly in 
commercial farms). Therefore, veterinarians are likely to 
play a dual role as animal healthcare providers and drug 
distributors leading to a conflict of interest where they 
make a direct profit from the sales of medical products 
including antibiotics. In the Netherlands, the govern-
ment decoupled the functions of prescription from the 
selling of drugs by veterinarians.36 There is currently no 
similar intervention in Thailand to address the potential 
financial incentives for both veterinarians and pharma-
cists to sell medical products for animals.
Factors in!uencing the use of antibiotics in farms
Farmers’ number of years’ experience and belonging to 
a farm cooperative were associated with the use of antibi-
otics for prevention. Experienced farmers may have an 
established protocol or programme of using antibiotics 
without a detailed examination of animals’ health condi-
tions. Belonging to a farm cooperative probably increased 
the opportunity among farmers to exchange information 
about animal health and antibiotic use. Some studies 
have found that the opinions of peers affected farmers' 
decision- making on antibiotic use.37–39 In addition, farms 
with higher incomes were more likely to use antibiotics 
for prevention, perhaps reflecting greater ability to 
purchase.
The majority of farmers reportedly received advice 
on animal health and antibiotic use from unqualified 
sources, possibly contributing to the positive correla-
tion between advice on animal health and high level of 
antibiotic use for prevention in this study. Other studies 
have shown that farmers perceive veterinarians to be the 
most trusted information source on disease control40 and 
influence their decisions.38 41
However, other risk factors with a lower impact may 
not have been detected. Possible factors associated with 
antibiotic use for prevention reported in other studies 
include the density of pig population in the area and the 
number of pigs on the farm,42–44 production systems,45 
the type of farm13 46 47 and pig age groups.12 48 49
Medicated feed
In this study, based on data from the feed mill survey, the 
largest proportion of medicated feed was applied to suck-
ling and nursery pigs (39.7%) and fatteners (37.3%), 
similar to some other studies.48–50 This study estimated 
that at a national level, the total volume of antibiotics 
mixed into pig feed was around 843 tonnes. The 2017 
national antimicrobial consumption report16 states that a 
total 3690 tonnes of veterinary antimicrobials were used 
by all food- producing animals, of which 2007 tonnes 
(54%) was premix for medicated feed however these 
data do not provide a breakdown by animal type. Our 
estimation from the feed mill survey is likely to be an 
underestimate of the true volume of antibiotics in medi-
cated feed due to a number of reasons. One being that 
many farmers add antibiotics to the feed in- house at the 
farm level. For example, the farm survey indicated that 
72.7% of farmers produced their own medicated feed 
using mixers. In addition, the mix of medicated feed in 
farms implies a lack of quality control in ensuring homo-
geneous distribution of antibiotics in the feed, a concern 
also in Europe.51 This is an area which requires effective 
regulation.
Policy implications
The majority of antibiotics added to the medicated feed 
(64.3% of total amount of medicated feed) and used as 
oral and injectable medications at farm level (31% of 
total farms) belonged to the category of Critically Impor-
tant Antimicrobials for human health. Recently in March 
2018, in response to the AMR threat, the DLD stipulated 
that medicated feed can only be produced, sold and 
used with a veterinary prescription. It also prohibited the 
addition of five classes of antibiotics (polymyxin, penicil-
lins, fluoroquinolones, fosfomycin and cephalosporins) 
to medicated feed for disease prevention. Additionally, 
cephalosporins are not allowed in medicated feeds for 
any indications.52
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In order to promote antibiotic stewardship in animal 
health, the use of antibiotics should be based on guide-
lines with clear guidance on the indication for use, choice 
of antibiotic, dose and duration and these should be 
based on local microbiological surveillance data. Where 
possible non- WHO CIA list antibiotics should be recom-
mended, and where this is not possible then antibiotics in 
the lower tiers on this list should be recommended first. 
Ideally, the use of antibiotics in the CIA category should 
be limited to treatment, with specific indications and only 
when there is no lower tier alternative. However, one chal-
lenge is that there are currently very few such guidelines 
available in veterinary field, especially in low- and middle- 
income countries.53 The development and dissemination 
of such guidelines is an important priority.54
For disease prevention, ideally the use of antibiotics 
should be avoided according to the WHO and Euro-
pean Union guidelines for the use of antibiotics in 
animals.10 55 For alternatives to antibiotics, farmers may 
consider improving husbandry and farm management 
such as good ventilation, good feed quality and water 
and farm bio- security. Vaccinations are likely to play an 
important role in reducing the risk of infection and the 
need for antibiotics for prevention. The use of probiotics 
or prebiotics and immunomodulators such as natural 
herbal remedies have also been proposed as alternatives.56
Limitations
This study had some limitations. First, as described in our 
recent review, there is no standard approach to collecting 
data on the volume of antibiotics used on farms, and a 
wide range of methods have been applied for example 
farm- based survey, inspection of discarded antibiotic 
packaging in bins and veterinary prescription data.57 In 
high- income countries where recording systems are avail-
able at farms, antibiotic prescription or treatment records 
are the most common sources of farm- level data on anti-
biotic use. These provide accurate data on the type of 
antibiotic, indications, doses and duration, the number 
of animals receiving antibiotics and can inform the rela-
tionship between antibiotic use and antibiotic resistance. 
However, none of these data collection methods were 
applicable in this study: antibiotic treatment and medi-
cated feed use were often not recorded; feed packages 
lacked labels and counting discarded packages of antibi-
otics was not feasible (online supplementary figure A1). 
The collection of on- farm data is thus a great challenge 
in a country such as Thailand, and demanded the mixed 
methods used here. Changing the regulations to require 
a prescription is critical to improved audit data.
Second, apart from the large proportion of farmers 
who did not know if they used antibiotics in feed as the 
feed package did not label antibiotic content, a large 
proportion of farmers were not willing to disclose this. In 
2018, the DLD issued a new regulation which mandated 
all feed mills to print on all medicated feed the antibi-
otics’ names and concentration (PPM), and all farmers 
were required to keep records of veterinary prescriptions 
and administration. This should help in the monitoring 
of antibiotic use on farms, if the regulation is effectively 
enforced and monitored.
The third challenge was the sample representative-
ness. For reasons of feasibility, the survey of pig farms was 
conducted in only one province. Additionally, the list of 
pig farms was out of date and many farms especially small-
holder farms had closed down due to a significant reduc-
tion in the market price for pigs over the last few years. 
This meant that it was difficult to conduct a random selec-
tion of farms across the province and instead a complete 
sampling of farms in selected subdistricts was carried 
out. However, the full range of farm types was included: 
from smallholder farms with only a few pigs through to 
large commercial farms with thousands of pigs and the 
province with one of the highest number of farms was 
chosen. Moreover, an outbreak of African swine fever 
was reported in neighbouring countries58 over the data 
collection period, probably affecting the willingness to be 
part of the study. Due to a small sample size, only univar-
iate analysis could be conducted, and it revealed that the 
use of antibiotics in pig farms was significantly associated 
with certain farm characteristics such as belonging to a 
farm cooperative, type of farm and farmer’s income.
Nonetheless, this study covered 84 pig farms with a 
high response rate of 82.4%. Of 18 farmers who did not 
participate in the study, 12 smallholder farmers (26%, 
12/46 farmers in the studies areas) and 6 commercial 
farmers (11%, 6/56 farmers in the studies areas). In 
terms of geographical distribution, among six subdis-
tricts, the response rate in two subdistricts was 100% and 
about 90% in other three subdistricts. The response rate 
was low in only one subdistrict (38%) (online supple-
mentary file 3 tableA1). The results are therefore likely 
to represent a significant proportion of pig production in 
the province, and meaningful conclusions about farmers’ 
antibiotic use in the studied province can be drawn.
Besides, the farm survey data was supplemented by 
data from the feed mill survey. Although only 31 feed 
mills participated, they included the large agro- industrial 
conglomerates responsible for an estimated 80% of the 
national production of medicated feed and are therefore 
an important target for future interventions.
CONCLUSION
This is one of the first studies outside high- income coun-
tries to obtain information on the critical question of 
antibiotic use in pig farming. It used multiple approaches 
to investigate the use of antibiotics in pig production 
in Thailand. From the data, we established patterns of 
antibiotic use and estimated consumption of antibiotics 
through farmer and feed mill surveys. Our results clearly 
show the majority of antibiotics used in Thai pig farms 
are considered the Highest and High Priority Critically 
Important Antimicrobials for human health according to 
the WHO- CIA list, with concerning implications in terms 
of the potential for AMR in pigs and humans.
and. Protected by copyright.
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We recommend progressive restriction in the use of 
antibiotics, in particular, those highest tier on the WHO 
CIA list. This includes through controlling distribution by 
reclassifying certain antibiotics as prescription- only medi-
cines and restricting the use of CIA for specific indica-
tions and guided by local microbiological and sensitivity 
evidence. The DLD should strengthen the veterinary 
service system at all levels to improve access of farmers, 
smallholder farms in particular, to quality animal health 
information and potential alternative interventions to 
antibiotic use including farm management improve-
ment, vaccines and immunomodulators.
Alternative solutions need to be carefully tested for 
their cost- effectiveness in comparison to the antibiotics 
they would replace. Those solutions with the greatest 
impact need to be demonstrated to the farmers in order 
to build confidence in new solutions. Future studies 
about factors contributing to the use of antibiotics are 
required to fill these important knowledge gaps and 
introduce effective policies.
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Chapter 6 Qualitative study: Factors contributing to the 
use of antibiotics in pigs in Thailand  
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Angkana Lekagul1,2* , Viroj Tangcharoensathien2, Marco Liverani1,3,4, Anne Mills1, Jonathan Rushton5 
and Shunmay Yeung1
"CTUSBDU 
Background: Antimicrobial resistance (AMR), recognised as a serious and growing threat to global health, is pro-
moted by multiple drivers, including antibiotic use in the livestock sector. Thus, understanding factors influencing 
antibiotic use in livestock production is essential to the design and implementation of e!ective interventions to 
reduce AMR. This qualitative study aimed to explore the experiences and views of the key actors associated with the 
use of antibiotics for pig farming in Thailand, from local farmers to o"cers in central government institutions.
Methods: A total of 31 in-depth interviews were conducted with di!erent categories of actors: pig farmers (n = 13), 
drug retailers (n = 5), veterinarians (n = 7), government o"cers (n = 3) and representatives of animal and human 
health associations (n = 2). Themes emerging from the interviews were identified and explored using thematic analy-
sis. In addition, direct observations were conducted in the pig farms.
Results: The findings highlight the multi-faceted nature of the views and practices that may contribute to misuse 
or overuse of antibiotics in the study locations, including misconceptions about the nature of antibiotics and AMR 
(particularly among smallholders), lack of facilities and financial means to establish an antibiotic-free farm, lack of 
su"cient training on AMR and antibiotic prescribing for veterinarians, the profit motive of pharmaceutical companies 
and their ties to farm consultants, and lack of su"cient regulatory oversight.
Conclusions: Our study indicates a clear need to improve antibiotic use for pig production in Thailand. Farmers need 
better access to veterinary services and reliable information about animal health needs and antibiotics. Innovative 
investments in biosecurity could improve farm management and decrease reliance on antibiotics, although the cost 
of these interventions should be low to ensure wide uptake in the livestock sector. Lastly, further development of pro-
fessional training and clinical guidelines, and the establishment of a code of conduct, would help improve antibiotic 
dispensing practices.
© The Author(s) 2021. 0QFO"DDFTT This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco 
mmons .org/publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
*OUSPEVDUJPO
Antimicrobial resistance (AMR), recognised as a serious 
and growing threat to global health, is driven by many 
factors including antibiotic use not only in humans but 
also in animals. In many countries, antibiotics are widely 
applied to promote growth in livestock in addition to 
preventing and treating infections [1]. !is practice has 
potential risks to human health that need to be addressed 
[2–4]. Of great concern is the emergence of resistance to 
those antibiotics categorised by the WHO as Critically 
Important Antimicrobials (CIA), such as colistin, which 
are reserved for treating the most severe human infec-
tions [5].
In the pig sector, intensive use of antibiotics has pro-
moted resistance of both commensal and pathogenic 
bacteria [6, 7], particularly in low- and middle-income 
countries (LMICs) [8, 9]. In view of this, research e"orts 
have been made to explore the factors influencing 
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antibiotic use in pig farms [10–16]. A recent systematic 
review showed that antibiotics are commonly used dur-
ing the suckling and post-weaning stages of production; 
in addition, the same review found that specific farm 
characteristics (such as the density of pigs) influence 
the use of antibiotics [16]. Apart from the factors asso-
ciated with pig production, knowledge and understand-
ing of antibiotics among farmers are also important. A 
number of studies found that farmers may have limited 
knowledge of the names of antibiotics and their correct 
usage [10, 12]. For example, a study in China found an 
association between poor knowledge of antibiotics and 
inappropriate use in the farms [11]. Findings about the 
impact of legislation and government policies on anti-
biotic use have been mixed. In five European countries, 
farmers were worried about the implications of legal pro-
visions to reduce antibiotic use, particularly their impact 
on farm maintenance and costs [13]. In two other surveys 
in Europe, legislation regarding veterinary drugs was per-
ceived to influence prescribing practices more than the 
price of antibiotics, market demand or clinical guidelines 
[14, 15].
Despite these studies, our knowledge of practices influ-
encing the agricultural use of antibiotics is still scarce, 
especially in countries where resources to conduct 
research and evaluation are more limited. Considering 
this gap in knowledge, this article reports findings from a 
study which aimed to explore the experiences and views 
of key actors associated with the use of antibiotics for pig 
farming in !ailand, from local farmers to o"cers in cen-
tral government institutions. After a description of the 
study#context, methods, and the presentation of findings, 
implications of the study for the design and implementa-
tion of action plans on AMR are discussed.
.BUerials and!methoET
Study context
!e !ai agricultural sector accounts for approximately 
10% of GDP (USD 42 billion in 2018) with livestock pro-
duction, including pigs, contributing around USD 400 
million [17]. In 2017, nearly 19.5 million pigs were raised 
and slaughtered, mainly for the domestic market [18, 
19]. Since the 1960s, pig production in the country has 
increasingly shifted from smallholder farming for house-
hold consumption to intensive commercial production 
for the growing urban markets. !e pig sector is domi-
nated by a small number of large agro-industrial con-
glomerates although a diversity of production systems 
coexist [20], characterised by di$erent levels of bio-secu-
rity [21]. In smallholder farms, pigs receive a variety of 
feed including leftover food and vegetables. Such farms 
have often limited access to veterinary services and anti-
biotics, while in commercial farms antibiotics are usually 
applied to whole groups of pigs through medicated feed, 
either commercial or mixed in the farm. In 2017, it was 
estimated that about 3,690 tonnes of antibiotics were 
given to food-producing animals, of which about 50% 
belonged to the CIA group [19]. To improve farm man-
agement, the !ai Department of Livestock Development 
(DLD) grants Good Agriculture Practices (GAP) cer-
tificates to farms which comply with standards of animal 
husbandry [22]. GAP-certified farms are required to have 
designated veterinarians to supervise the control, preven-
tion and treatment of animal diseases, including the use 
of antibiotics. GAP certification is voluntary.
Study design
!is qualitative# study was conducted between March 
2018 and January 2019 in a province in the central region 
of !ailand, which accounts for about 20% of annual 
domestic pig production and hosts di$erent production 
systems, from smallholders to large industrial farms. !e 
study was part of a larger project which included a cross-
sectional survey of antibiotic use among pig farmers in 
six sub-districts with the highest number of pig farms in 
the same province [23]. !e research design for the quali-
tative study was meant to capture the diversity of actors 
in the pig farming sector that may influence antibiotic use 
at di$erent level of analysis, from disease prevention and 
control in the farms to the wider regulatory environment. 
In practice, data collection primarily involved inter-
views with farmers to explore their views and practices 
related to antibiotic use. In parallel with the interviews 
with farmers, observations were conducted to gain a bet-
ter understanding of management practices in the same 
farms. In order to capture the diversity of perspectives, 
interests, and incentives which may influence antibiotic 
use, veterinarians, drug retailers, industry representa-
tives, and government o"cers were also interviewed.
Participant selection
Participants in this study were recruited from the larger 
sample of 84 farmers included in the cross-sectional 
survey [23]. In total, 11 out of the 84 farmers agreed to 
participate in the study reported here. Two farmers who 
did not use antibiotics were purposively selected through 
a snowball sampling technique. In addition, informants 
who could provide further insight into the use of anti-
biotics for pig production were approached at relevant 
organisations, including government o"ces, the !ai 
Feed Mill Association, and associations of human and 
animal health professionals. !e first author contacted 
potential informants to ask if they were able and willing 
to participate in the study.
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Data collection
Drawing from previous studies [10, 24], the guidelines 
for the interviews with farmers covered: (a) animal health 
and farm management, (b) pig production and market 
demand, (c) relationships with other farmers, veterinar-
ians, pharmaceutical companies, and (d) regulation and 
policy on antibiotic use (see Additional file! 1). Inter-
views with other categories of participants were tailored 
to their role and the expertise they could bring to this 
study. Interviews were conducted face-to-face by the first 
author and lightly structured to let participants express 
their own views. Interviews were conducted either in 
the farms or the o"ces or shops of key informants. On 
average, interviews lasted two hours. Written field notes 
were taken and, where permission was given, the inter-
view was audio-recorded. After the interviews with pig 
farmers, the researcher sought permission to conduct 
observations in their farm. During the observations, the 
researcher examined activities of farm workers, the feed 
labels, the medicines used in the farm, and general sani-
tation and farm management practices. In addition, the 
researcher walked through the farms and engaged in 
casual conversations with farmers and farm workers. To 
prevent cross-infection between farms, farm visits were 
restricted to no more than one a week.
Data processing and!analysis
#e interview audio recordings were transcribed verba-
tim and anonymised by the researcher (AL). Data were 
imported into the software NVivo 12 for qualitative 
analysis. #e researcher (AL) generated initial codes 
after iterative reading of the transcripts. #e field notes 
were reviewed in parallel with the transcripts. #en two 
researchers (AL and VT) identified and organised themes 
and sub-themes. To reduce subjective bias, the research-
ers (AL, ML, SY and VT) discussed emerging findings 
and their interpretation throughout the process of analy-
sis. In qualitative data analysis, themes are considered 
robust when they are cohesive and meaningful within 
the entire data set [25]. #us, consistency both within the 
individual interviews and across respondents by triangu-
lation was assessed.
3FTVMUT
Pro"les of!participants and!studied farms
Table! 1 shows the profiles of the 31 participants inter-
viewed, which consisted of farmers, animal drug retail-
ers, veterinarians, and informants at government o"ces 
or relevant professional associations. Table! 2 shows the 
characteristics of the 13 farms, which ranged from a 
smallholder farm with only one sow and five piglets to a 
large commercial farm with more than 10,000 pigs and a 
monthly income of more than US$15,900. Six farms were 
DLD GAP-certified, one was a contracted farm and five 
farms were members of a cooperative. #ree were fat-
tening farms and ten were farrow-to-finish farms. Two 
farms were antibiotic-free. Research observations were 
allowed in six farms with variable characteristics, includ-
ing “backyard” production and large commercial farms.
Use of!antibiotics in!pig production: views and!experiences 
of!di#erent actors
#e analysis of the interviews revealed diverse and at 
times competing views of di$erent actors in the agricul-
tural sector about antibiotic use – the pig farmers, health 
professionals, and the pharmaceutical industry, consid-
ered in turn in the sections below.
Pig farmers
Perceived health bene!ts and"economic value of"antibiotics
All the pig farmers interviewed believed that some form 
of medication, including antibiotics, was necessary to 
maintain animal health, and control and prevent disease.
Medicines are really important in my farm. With-
out medicines, my pigs would be very ill. Antibiot-
ics protect my pigs from becoming worse. [Fs02, 
female, > 40!years old, non-GAP farm]
5BCMF 3FTQPOEFOUTQSPGJMF





1. Pig farmers 13 10 3 47.9 (35–66) 22.7 (5–50)
2. Animal drug retailers 5 3 2 40.8 (30–48) 15.1 (3.5–24)
3. Veterinarians 8 5 3 49 (31–61) 22.8 (5–37)
4. Government o!cers 3 2 1 37.3 (31–50) 10 (4–20)
5. Representatives of health and animal 
professional associations
2 1 1 62.5 (60–65) 10 (8–12)
Total 31 21 10 47.8 (30–66) 16.1 (3.5–50)
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At the suckling and nursery stages, the piglets are 
so vulnerable. I usually apply antibiotics to 100% 
of them. Whether or not they are sick, I must use 
antibiotics for prevention… [Fc07, male, > 50!years 
old, GAP-certified farm]
Many farmers explained that antibiotics! are an 
affordable approach to reduce pig mortality. One 
farmer estimated that medicated feed cost only 2.7% 
more than non-medicated feed and administering 
antibiotics to the whole herd via medicated feed was 
less labour intensive than individual treatment.
I think that antibiotic use is a cheap solution…
and affordable… The cost of production is not 
really different whether we add medicine [anti-
biotics] or not. For example, now the cheapest 
medicine is chlortetracycline. For nursery pigs, the 
feed mixed with chlortetracycline is baht 22.60 
compared with baht 22 per kilogram of regular 
feed [without antibiotics]. It doesn’t add much to 
my budget. [Fc12, male, > 30! years old, non-GAP 
farm]
Pig farmers’ knowledge of!antibiotics and!awareness of!AMR
Knowledge of antibiotics di"ered greatly amongst pig 
farmers. None of the three smallholder farmers under-
stood the word “antibiotics”! (yaa-pati-cheewana) 
while commercial farmers could generally di"erentiate 
between antibiotics and other medicines. Most farmers 
who understood the meaning of antibiotics said they 
used them according to the indications on the pack-
age labels or following the recommendations of phar-
macists. However, some farmers routinely used high 
potency antibiotics without clinical justification:
For the treatment of common diseases, I apply 
a broad-spectrum antibiotic such as amoxycil-
lin. If there is no improvement, I will change to 
cepha(losporin), cefo(xamine) or enrofloxacin…
I believe in higher potency antibiotics. If there is 
no price di"erence, I always select higher potency 
antibiotics [Fc12, male, > 30! years old, non-GAP 
certified farm]
Commercial farmers also understood the concept of 
antibiotic resistance but they were elusive when the 
researcher raised the issue that excessive antibiotic use 
in the farm was an important contributing factor:
Our pigs are good, clean. I know resistant patho-
gens, but I don’t think that we (farmers) are 
involved in it. [Fs03, male, > 40! years old, non-
GAP certified farm]
Farm management
All interviewed farmers agreed that sound farm man-
agement was key to animal health and consequently to 
reducing the need for antibiotics.
I give more attention to prevention than treatment. 
Water quality, low pig density and good air ventila-
tion are essential for healthy pigs…. When the pigs 
are healthy, I don’t need to use antibiotics. [Fc09, 
female, 45!years old, GAP farm]
#e government o$cers in this study also believed that 
GAP certification contributes to the optimised use of 
antibiotics. Indeed, the antibiotic-free farms in our study 
were GAP-certified farms with bio-security measures 
such as change of clothing and boots and disinfection of 
all vehicles before entering the farm (Fig.! 1). However, 
only! six of the farms in the study were GAP certified. 
Some farmers were concerned that improving infra-
structure and biosecurity to meet GAP standards would 
require large financial investments.
A closed system housing of 300  m2 costs more than 
1 million THB (US$ 31,700) …the closed system 
would improve the health of my pigs and minimise 
the introduction of pathogens in the farm… so it 
would reduce the need for antibiotics. But this adds 
to the production cost. I can’t a"ord it. [Fc06, male, 
40!years old, non-GAP-certified farm]
Limited availability of farm veterinarians and gaps in 
the monitoring system were seen as further challenges to 
the implementation of GAP requirements.
#e GAP criteria are quite strict. #ey require a 
farm veterinarian to monitor antibiotic use in the 
farm. If antibiotic residue is found in pork prod-
ucts, the farm veterinarian must take responsibility. 
When the farm veterinarian is not available, farm-
ers often give antibiotics to their animals without 
prescription. [GO3, male, 31!years old].
With the GAP certification, the farmer must report 
on administrative records all medicines used in the 
farm and declare they were prescribed by the farm 
veterinarian. However, farmers may choose to not 
follow veterinarian’s prescription. We cannot really 
monitor this. [GO2, female, 50!years old]
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'JH Pigs in the outdoor area at the antibiotic free farm
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Textbox!1: antibiotic-free farm
!e antibiotic-free farm A was a 5000-fattener farm 
covering 8,000  m2. Eight barns were lined up in an 
east–west direction to minimize direct sunlight. Each 
barn had an indoor area of 400  m2, with access to an 
outdoor area of 800  m2 for two to three hours during 
the day, allowing the pigs to move in and out freely. 
!ere were no inside partitions, so all 400 pigs (per 
barn) could live together. !e barn floors were made of 
concrete and cleaned daily by farm workers. Weaning 
pigs were sourced from another farm, located 17 kms 
away and owned by the same farmer. If sick pigs were 
found, they were isolated for treatment or culling.
Observations found that all barns were clean. !e 
researchers also observed pigs roaming around, dig-
ging up the ground in search for roots, and also eat-
ing fruits from trees that the farmer grew outside 
the barn. !e owner said this farming concept was 
intended to raise “happy and healthy pigs” because 
the animals could express their natural behaviour and 
were not stressed. He said this was a feasible alter-
native to using antibiotics. !e farm received many 
visitors, with walls lined with photos of international 
guests and actors.
Lack of!market demand and!production facilities 
for!antibiotic-free pork
!e owner of an antibiotic-free farm expressed con-
cerns that market demand for antibiotic-free pork 
was still low. Another participant pointed out that 
antibiotic-free standards cannot be fully met in !ai-
land since most slaughterhouses do not have facilities 
to separate antibiotic-free pork and medicated pork, 
causing possible contamination. However, a farmer 
explained that large companies would not face this 
problem since they usually control the whole supply 




Antibiotics and other medicines used in the farms were 
provided by di"erent categories of actors working in the 
agricultural sector, including veterinary practitioners, 
veterinarians in pharmacies, representatives of phar-
maceutical companies and animal husbandry special-
ists. Most farmers in our sample relied on the advice of 
veterinarians regarding the selection and use of anti-
biotics. However, only one out of 13 farms hired a full-
time licensed veterinarian, while the others hired “farm 
consultants” who were academics, reportedly# tied to 
pharmaceutical companies. Smallholder farmers had 
limited access to veterinary services, due to lack of pub-
lic veterinary health facilities and district veterinarians, 
while most animal clinics served companion animals 
only. All smallholder farmers received advice on anti-
biotic use from other farmers or the pharmacies where 
they purchased antibiotics.
Training
Interviews with key informants from the veterinary 
and pharmacy councils confirmed that courses on the 
prudent use of antibiotics were not included in the vet-
erinary and animal husbandry curriculum, while the 
pharmacy curriculum did not cover use of antibiotics 
in animals. A key informant from a veterinary associa-
tion mentioned that their association provided in-service 
training and clinical practice guidelines for disease man-
agement. However, veterinarians expressed concern over 
lack of clinical guidelines, lack of protocols for sample 
collection, di$culties in laboratory sample transporta-
tion, delays in receiving lab results and high cost of bacte-
rial culture and drug sensitivity testing.
Awareness of!AMR
Most veterinarians were aware of government policy on 
reducing the use of antibiotics. However, some of them 
became defensive when the researcher raised the issue of 
AMR. !ey said antibiotics were used only when neces-
sary, and not indiscriminately as perceived by the public.
Of course, we use a large amount of antibiotics in 
livestock, but I believe that other sectors such as doc-
tors, pharmacists and orchards use more. Patients 
who don’t take the full dose are the cause of the 
resistant bacteria … I don’t believe that people will 




Commercial farmers explained they could buy antibiotics 
easily at pharmacies or from representatives of pharma-
ceutical companies who visited their farms. Respondents 
from the three commercial farms also reported that rep-
resentatives of pharmaceutical companies encouraged 
the purchase of antibiotics and other medicines through 
discounts and gifts such as leisure travel.
All pharmaceutical companies o"er sales promo-
tions. You can choose either 10% discount or interna-
tional leisure travel awards. In previous years, I have 
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travelled to the US, Iceland, Spain, Japan. I feel like 
I have to order more medicines to gain the award. 
[Fc13, male, > 40!years old, GAP certified farm]
Representatives of pharmaceutical companies 
o"ered me a dinner or presents such as a liquor… 
and they asked me to help them achieve their sales 
target… [Fc10, male, > 40! years old, GAP certified 
farm]
In addition, government o!cers noted that indiscrimi-
nate sales were di!cult to control due to lack of su!cient 
human resources.
We have only a few inspectors. We cannot inspect 
all pharmacies in our catchment area, particularly 
the animal pharmacies. It is not our priority as the 
governor gives priority to the control of illegal drugs 
[GO1, male, 37!years old]
Relationship between!pharmaceutical companies, farmers, 
and!academia
Farmers who hired academic lecturers as farm consult-
ants felt “obligated” to follow their recommendations 
on various aspects of farm mangement, including advice 
on the choice of antibiotics. Two farmers believed that 
academic consultants would receive gifts from the phar-
maceutical companies they recommended, such as equip-
ment for their faculty or honoraria.
Most lecturers are linked with pharmaceutical com-
panies. #ey support lecturers by providing equip-
ment to their university (…) When these lecturers 
come here and recommend to purchase the anti-
biotics from a company, it is di$cult to deny their 
advice. [Fc10, male, > 40! years old, GAP certified 
farm]
%JTDVTTJPO
"is qualitative study aimed to deepen understanding of 
the complex set of factors influencing the use of antibi-
otics for pig farming in a#particular context of livestock 
production. As described above and summarised in 
Fig.#2, the findings highlight the multi-faceted nature of 
antibiotic use and the complexity of influencing factors, 
ranging from perceptions (and misunderstandings) about 
the health benefits of antibiotics to the various inter-
ests of the multiple actors involved. A remarkable find-
ing from this study is that many farmers recognised that 
good farm management practices (such as safe and clean 
housing and routine vaccination) could greatly reduce 
disease prevalence and therefore the need for antibiot-
ics. However, only a few farmers could a$ord the capital 
investment that is needed to build and maintain an anti-
biotic-free farm. By contrast, from a farmer’s perspective, 
intensive use of antibiotics provides a reliable and cost-
e$ective solution to protect animal health and maximise 
profit. In line with our study, a survey of pig production 
'JH Factors related to the use of antibiotics for pig production in the study locations
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costs in Spain found that the cost of drugs and vaccines 
was less than 4.2% of the total [26].
Our findings also showed that farmers, particularly 
smallholders, may have inadequate understanding of 
antibiotics and antibiotic resistance. As emerged in some 
interviews, this can partly be explained by the existence 
of di!erent ways to refer to “antibiotics” in "ai, including 
yaa-kha-chue (“drug that kills germs”), yaa-khae-akseab 
(“anti-inflammatory drug”) and yaa-pati-cheewana 
(“drug that fights microbes”). "e term yaa-kha-chue is 
particularly confusing since it can also be used to indicate 
other types of drugs such as antifungal, anthelmintic, and 
antiprotozoal drugs. In addition, yaa-pati-cheewana is a 
technical term which is often used in AMR campaigns 
but is not commonly understood by lay people as we 
found in our study. "at said, we should bear in mind 
that a good understanding of antibiotics does not neces-
sarily translate into appropriate use. For example, a study 
in Lithuania found no correlation between knowledge 
of antibiotics and their use for self-medication [27]. "e 
cross-sectional survey of 84 pig farmers we conducted 
as part of this project also found no association between 
antibiotic understanding and use [23].
Further considering our findings, we can draw some 
lessons on policy and regulatory issues that need to be 
addressed to improve antibiotic use in the pig sector. In 
most countries, it is recognised that veterinarians and ani-
mal health authorities should play a key role in providing 
information about antibiotics and their appropriate use 
[24, 28]. In "ailand, the Department of Livestock Devel-
opment (DLD) is mandated to prevent and control animal 
disease, enforce legal provisions and promote good prac-
tices in livestock production [29]. To this end, the DLD 
relies on a network of farm veterinarians and o#cers. 
However, our study suggests that the availability of vet-
erinary services may be insu#cient due to gaps in human 
resources, particularly for smallholders [30]. In addition, 
lack of e!ective surveillance systems for infectious dis-
eases in livestock and limited AMR information were per-
ceived to hamper appropriate dispensing of antibiotics 
by veterinarians. Similarly, a study in European countries 
found that veterinarians seldom used sensitivity tests to 
inform decisions about antibiotic use due to the excessive 
time lag between testing and results [15]. Veterinarians 
were also found to have business concerns. such as the 
need to maintain good relationships with clients and the 
cost of laboratory diagnosis [31], which are not conducive 
to appropriate antibiotic dispensing [24, 31–33]. "ese 
problems are also apparent in the human health sector, 
where conflicts of interest between healthcare providers 
and pharmaceutical companies may lead to inappropriate 
prescribing behaviour and create negative public percep-
tions towards health professionals [34–37].
Lastly, the role of pharmaceutical companies and mar-
ket incentives to promote antibiotic use, including the 
provisions of gifts and other rewards, deserves particular 
attention [36–38]. In some countries, codes of conduct 
and ethical guidelines to regulate the behaviour of phar-
maceutical companies are in place [39, 40]. In the UK, for 
example, the Code of Practice for the Promotion of Ani-
mal Medicine restricts the advertisement of animal medi-
cines [41]. In "ailand, the production and use of certain 
veterinary antibiotics was regulated in 2019. Specifically, 
farmers need a veterinary prescription to produce farm-
mixed medicated feed and to use other types of antibiot-
ics in their farms such as injections or medicated water 
with quinolones and derivatives, cephalosporins, mac-
rolides or polymyxins [42]. However, implementation of 
this regulation has been slow and compliance is not yet 
monitored. In addition, there are no codes of conduct or 
ethical guidelines to regulate advertisement and market-
ing practices.
In the future, rules on market access could help 
increase safety standards for the production, processing 
and sale of pig products [43, 44]. In recent years, private 
food safety standards have been implemented in "ai-
land, including those related to antibiotic residue test-
ing in food products and antibiotic-free pork production, 
particularly in large commercial farms. By law, animals 
that are given antibiotics cannot be slaughtered until the 
withdrawal period ends [45] and the maximum residue 
limit of veterinary drugs in food is set by the Food and 
Drug Administration [46]. When residue violations are 
detected, the "ai-FDA or DLD must take legal action 
against violators and remove the contaminated products 
from the market.
Yet tighter restrictions on the use of antibiotics may 
have a negative impact on the financial viability of small-
holders. First, a large farm has higher capacity to replace 
antibiotic use with other preventive measures such as 
vaccination and improved infrastructure, while small-
holders may not be able to a!ord these additional costs. 
Second, as we have seen, the pig production and supply 
chain in "ailand is structured in a way that limits access 
of smallholder farmers to the premium markets of antibi-
otic-free products. Large farm owners can produce anti-
biotic-free pork in their own farms, process the meat in 
their slaughterhouses and pack the final product in their 
retail shops, ensuring supply to premium markets from 
the farm to the fork. In contrast, interviews with farmers 
revealed that antibiotic-free pork and other pork are not 
processed and packed separately at external slaughter-
houses. As a result, those who cannot a!ord the mainte-
nance of a slaughterhouse may find it di#cult to produce 
antibiotic-free meat.
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Study limitations
To our knowledge, this is the first qualitative investiga-
tion of factors influencing the use of antibiotics in pig 
production in!a middle-income country. "e study aimed 
to unpack the complexity of interactions among actors 
involved in antibiotic use, in the wider policy and regu-
latory context. However, limitations should be noted. 
Since AMR is a sensitive issue in "ailand, the number of 
farmers who agreed to participate in the study was rather 
small. In addition, findings cannot be generalised widely 
although we hope this study can provide useful insights 
to better understand antibiotic use in many other settings 
with similar livestock production systems, markets and 
regulatory environments.
Policy recommendations
Our study highlights the need to improve antibiotic 
use for pig production in "ailand. Given that farm-
ers had limited knowledge and awareness of antibiot-
ics and AMR, access to veterinary services and reliable 
information about animal health needs to be improved, 
particularly for smallholder farmers. Innovative low-
cost investment in biosecurity could result in better 
farm management leading to e#ective disease control, 
improved animal health and decreased reliance on anti-
biotics. Poor antibiotic prescribing could be addressed 
through continued professional development and train-
ing, stronger undergraduate curricula, and monitoring 
adherence to clinical guidelines. Controlling the com-
mercial interests of the industry and health professionals 
in promoting antibiotics will also require the establish-
ment, enforcement and monitoring of a code of conduct. 
Finally, the combination of private market access rules 
and control through regulations could be another e#ec-
tive instrument to govern the use of antibiotics where 
other approaches are ine#ective.
4VQQMFNFOUBSZ*OGPSNBUJPO
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SECTION C: DISCUSSION AND CONCLUSION 
Chapter 7 Conclusions and Reflections  
Conclusions   
This thesis set out to investigate the patterns of antibiotic use and determinants influencing 
antibiotic use for pig production in Thailand in order to contribute to the development of 
policies aimed at optimising the use of antibiotics in pig production. The thesis has four main 
objectives:  
1) To critically review the literature on the use of antibiotics in pigs, and to identify the 
methods and measurements used to quantify antibiotic use in pigs;  
2) To describe the patterns of antibiotic use and estimate the total amount of antibiotics 
used in pig production in Thailand;  
3) To explore the practices and views of pig farmers and other stakeholders about 
determinants influencing antibiotic use in pig production in Thailand; and  
4) To identify potentially effective policy options to optimise the use of antibiotics in 
pig production.  
This PhD comprised the following: two systematic reviews on antibiotic use in pig 
production and its associations; and methods and measurements for quantification of 
antibiotic usage in pig production (objective 1); a mixed-methods study using questionnaire 
surveys of pig farmers and feed mills, and interviews with veterinarians in the feed industry 
to describe the patterns of antibiotic use and estimate the total amount of antibiotics used in 
pig production in Thailand (objective 2); and a qualitative study to explore the practices and 
views of pig farmers and other actors about determinants influencing antibiotic use in pig 
production in Thailand (objective 3). Evidence generated from the above is synthesized to 
identify relevant policies and interventions to optimise the use of antibiotics in pig production 
(objective 4). 
This chapter is divided into three parts. The chapter begins with a discussion on the 




this, section 2 describes a summary of the key findings of the thesis based on objectives 1-3. 
The present investigation is concerned with how and why are antibiotics used in pig 
production. Therefore, these areas are addressed in section 3 which discusses practices of 
different actors associated with the use of antibiotics in pig production, and the complex 
determinants of antibiotic use in pig production through interconnections across different 
levels of factors. The discussion regarding objective 4 on the policy and other implications of 
the study are presented in chapter 8. 
7.1 Limitations of the thesis 
Some limitations should be considered in regard to the scope of the thesis, the outcome 
investigated, and the methods used, which are described below. 
7.1.1  Scope of the thesis  
Although there have been many studies exploring the both the positive and negative 
associations between antibiotic use and AMR in food-producing animals (126). The scope of 
this thesis was limited to the use of antibiotics in pigs, excluding AMR.  As research in 
Thailand on the use of antibiotics in the context of AMR in pig farms is a sensitive subject. 
When the Thai government introduced the AMR policy in 2016, there were widespread mass 
media reports about the use of antibiotics in pigs, in particular, reports that colistin resistant 
bacteria had been found in pigs in three provinces of Thailand (97). Concerns were 
highlighted about the possibility of AMR transmission from pigs to humans, leading to panic 
among the general public about AMR in the food chain (Figure 7.1). Unfortunately, this 







Figure 7.1 Cover page of the newspaper on 23 January 2017 (left) and 25 January 2017 
(right).   
Translated as “Terror of ‘Colistin’ added in pig feed. Illegal drug used in pig farms. The 
world is in fear that new drug resistant genes will spread” (23 January 2017); and “The 
Plasmid-mediated Colistin Resistance Genes (mcr-1) in commensal Escherichia coli from 








7.1.2  Methodological limitations  
Systematic reviews: lack of data from LMICs 
In the systematic review of the 36 studies which documented patterns of antibiotic use in 
global pig production, most of the studies were conducted in Europe and North America, 
particularly in HICs where there are higher research capacities and data availability. Only 
two studies in LMICs, Vietnam and Sudan, were available for inclusion in this review. This 
limits the relevance of the findings to which may have very different and highly diverse pig 
production systems and regulations regarding antibiotics across countries. Moreover, there 
were different approaches for data collection in different countries. In HICs, veterinary 
prescription records or antibiotic application records are commonly available to provide data 
on antibiotic consumption in farm animals either from veterinary medicine authorities or at 
the farm level. These data provide accurate information on the type of medicine, indication, 
dose, duration, and the number of animals being treated. However, in LMICs settings, this is 
generally not the case.  
Lack of sampling frame  
One of the main limitations in conducting the empirical research was that farm-level data 
collection was conducted in only one province in Thailand, and the selection of farms was 
not done at random. Due to budgetary and time constraints, it was only possible to include 
one province with the highest pig population accounting for about 20% of Thailand’s annual 
pig production and hosts different production systems, from smallholders to large agro-
industrial conglomerate farms. Random sampling was not possible because I could not access 
the lists of pig farmers in the study area to create a sampling frame. The DLD has authority 
over livestock production in Thailand and has lists of livestock farms and farmers in the study 
area. Initially, I sent an official letter to the DLD asking for their support to provide lists of 
pig farmers and farms in the study area however they made it a prerequisite that they review 
the study findings prior to submission for any publication.  
I therefore decided not to receive the lists from the DLD as the International Ethical 
Guidelines for Health-Related Research Involving Humans states clearly that, “Researchers 




ability to analyse the data independently, prepare manuscripts, or publish them” (127)6. The 
process for seeking DLD support for data collection delayed the study by about four months. 
Consequently, the selection of the pig farmers was not done using a systematic random 
approach but instead relied on the purposive sampling of districts and sub-districts. I 
contacted the provincial health office and asked the district-level public health staff to 
identify the three districts and two sub-districts with the highest amount of pig production. 
Therefore, the study may be subject to selection bias and generalization to the rest of the 
province and beyond needs to be done cautiously.  
Lack of on-farm records on the use of antibiotics  
The lack of availability of data on actual antibiotic use on farms in Thailand was a great 
challenge. I had initially planned to collect data to measure the volume of antibiotics on 
farms from any of three potential sources at farm level: antibiotic prescription records, 
treatment records or antibiotic invoices, whichever were available. However, I realised that 
no data were available from these three potential sources. As mentioned earlier in the 
findings from the systematic review, no prescription is required for antibiotics in Thailand, 
therefore data on antibiotic prescription were not available for analysis. There was no system 
for recording the use or purchase of antibiotics at the farm level and I felt that there was too 
much potential for recall bias if I relied solely on interviews with farmers.   
Several attempts to estimate antibiotic use in animals have been reported in LMICs. In 
Vietnam, the “bin collection” method was applied in which farmers were asked to retain 
antimicrobial packaging over a six-week period in order to calculate the volume of antibiotic 
use at farm through discarded antimicrobial packaging (128). Another approach was through 
data collected from internet-based survey of sales data of commercial feed products in 
Vietnamese pig and chicken production (129). However, I could not apply these approaches 
in this study because the commercial medicated feed did not include information on the 
antibiotic content on the feed labels. In addition, the lists of animal commercial feed products 
 
6 The International Ethical Guidelines for Health-related Research Involving Humans of the Council for 
International Organization of Medical Science states that “Sponsors must not prevent researchers from 
publishing unwelcome findings that restrict their freedom of publication. As the persons directly responsible for 
their work. Researchers must not enter into agreements that interfere unduly with their access to the data or their 




destined for livestock as listed in the Animal Feed Quality Control Act did not cover 
information about the ingredients of feed (whether it contains antibiotics or not, type or 
concentration of antibiotics. Moreover, the previous study showed that the bin collection 
method was an inefficient method of collecting quantitative antibiotic use data on farm. 
There was poor understanding of the methodology by many participants and, consequently, 
few farms retained antibiotic packaging for the full six-week study (128) 
According to my systematic review (130), several studies reported that more than 90% of 
antimicrobial substances given to pigs are administered orally as  medicated feed or water 
(70,71,131). Therefore, analysis of data from a survey of feed mills is used in this study to 
estimate the total volume of antibiotics used in pig production in Thailand. The data used in 
this study have substantial limitations. For example, the resulting estimates tend to 
underestimate the total volume of antibiotics used in Thailand because they cannot capture 
antibiotics in other pharmaceutical dosage forms such as powder for use in drinking water. 
Moreover, they do not include data on medicated feed mixed in-house by farmers who prefer 
not to purchase commercial medicated feed.  
In addition, data from feed mill survey was not able to capture data on dose, duration and 
indications of medicated feed. To gain more of an understanding about the use of medicated 
feed I conducted supplementary interviews with veterinarians working in the animal feed 
industry, focusing on questions about: 1) the common diseases and conditions which require 
antibiotics in pig production; 2) the common antibiotics used for each clinical condition; and 
3) the dose and duration of each antibiotic used at different production stages. 
Willingness of respondents to participate in the study  
Due to concerns about the possibility of AMR transmission from pigs to humans, it has 
potentially affected the willingness of farmers to participate in the study. A further problem 
that affected the willingness of farmers and government officers to participate in the study 
was the outbreak of African Swine Fever in neighbouring countries during the study’s data 
collection period (January 2018 - January 2019) (132).  When I contacted the provincial 
farmer cooperative in the study province, they did not give any positive signals about 




high levels of antibiotic consumption in pig production and that as a consequence there 
would be a negative impact on the sales of livestock products. 
Position of the researcher in data collection process 
Gill Walt et al. (133) advised that we need to reflect on the positionality of researchers when 
conducting health policy analysis, given its implications for access to data and the 
construction of knowledge. In this regard, the connection with my background is worth 
discussing. In the farmer survey, the health centre staff introduced me to the participants as a 
research fellow with a veterinary background. Therefore, most farmers in the study perceived 
that I was an animal health professional who could provide information about animal care. 
The farmers’ expectations of me being able to give animal health advice created a tension 
between my clinical duty in response to animal health demands and my role as a researcher. 
For example, some farmers sought my advice on the use of antibiotics on their farms, 
particularly smallholder farmers who had limited access to animal health services. Some 
farmers asked for my comments and suggestions on whether their practices were good or not 
when I asked about their practices on pig health management and antibiotic use. My 
positionality could also trigger a dual-role confusion both internally (feelings of conflict 
between different roles) and externally (clarifying my role to others) (134). Therefore, my 
positionality and how it may influence data collection and interpretation needs to be 
considered. 
In addition, it was challenging to conduct interviews with veterinarians since I was perceived 
as a Ministry of Public Health staff member who may be involved with the regulation of 
antibiotics. This became particularly clear when I raised the issue of AMR in animals and the 
potential effects on human health. Most veterinarians became quite defensive of their practice 
saying that antibiotics were used more in other sectors such as by doctors, and pharmacists, 
for which the Ministry of Public Health should be responsible. Building rapport and 
establishing comfortable and natural interactions were very important in the interviews with 
key informants. I approached the respondents with an open and curious attitude, stating 
specifically why I was interested in a specific point of view. The interview aimed to explore 
their views and pass no judgment or opinion about whether their practices were right or 
wrong. I enhanced this sense of rapport with them and built considerable relationships and a 




Outcome investigated: lack of measurement of appropriate antibiotic use and agreed metrics 
to measure the use of antibiotics 
As revealed in the literature review, there is a lack of a universal standard about what 
constitutes ‘appropriate’ use of antibiotics in livestock production. This presented a 
significant challenge to the interpretation of the study findings. Efforts to define the term 
‘appropriate use’ are complicated by the array of scenarios for which antibiotics are given. 
According to the OIE’s guidelines, ‘prudent use’ of antibiotics in livestock is promoted with 
the purpose of optimising both their efficacy and safety (135,136). In the human sector, the 
term ‘rational use’ of medicines used to be used quite commonly. It was endorsed by 
resolution WHA54.11 on the medicines strategy in 2011. The WHO definition of rational 
medicine use is: “Medicine use is rational (appropriate, proper, correct) when patients 
receive the appropriate medicines, in doses that meet their own individual requirements, for 
an adequate period of time, and at the lowest cost both to them and the community. Irrational 
(inappropriate, improper, incorrect) use of medicines is when one or more of these 
conditions is not met.” (137).  
Therefore, in this thesis, I chose to focus on the practices associated with antibiotic use in pig 
production, which may contribute to the emergence and threat of AMR to people, particularly 
the use of antibiotics for disease prevention and antibiotics in the CIA category. Although 
most international organisations recommend the avoidance of certain uses of antibiotics in 
livestock the specific uses  (51,138,139). The WHO states that the use of any class of 
antibiotics for disease prevention and the use of highest priority CIA for treatment should be 
avoided in livestock production (51). The FAO recommended that antibiotics should not 
replace good husbandry, including hygiene and biosecurity measures for disease prevention 
(139). 
Moreover, as found in the systematic review of the methodological approaches for measuring 
antibiotic use in animals, there is a lack of standard measurements which hampers cross-
study comparisons. In this study, antibiotic used was reported in total volume of active 
ingredients. However, it should be noted that the unit of measurement of volume of active 
ingredients does not take into account the number of animals in a population; therefore, it 




7.2 Key findings of the thesis  
7.2.1 Objective 1: To critically review the literature on the use of antibiotics in 
pigs and to identify the methods and measurements used to quantify antibiotic 
use in pigs.  
I first conducted a systematic review on the patterns of antibiotic use in global pig production 
(140); the review assessed the evidence for patterns of antibiotic use in pigs on the basis of 
papers published in peer-reviewed journals in English between 2000 and 2017. The result of 
the quality assessment of 36 studies showed that 21 (58%) and 15 (42%) of studies are of 
high and medium quality respectively. The majority of studies were conducted between 2010 
and 2017. Most of the studies were conducted in Europe and North America.  
Penicillin and Tetracycline groups were the most commonly used antibiotics in many 
countries. The most commonly used antibiotics in the CIA category were the following: 
macrolide: tylosin, tilmicosin; polymyxin: colistin; cephalosporins: 3rd and 4th generation 
cephalosporins; and fluoroquinolones: enrofloxacin (130). Several studiers reported a 
positive correlation between antibiotic use and farm characteristics such as a large size of 
farm (111,118,119,141), high pig density in the farm (111,118) and an industrial production 
system (141). Good farm biosecurity was identified as common practice in farms with low 
antibiotic use (120).  
For the second review on the methods for quantification of the use of antimicrobials in global 
pig production, a total of 25 studies were included based on the eligibility criteria. The 
majority of the studies (20/25) were conducted in European countries. The two main sources 
of antimicrobial use data were farm surveys and national sales data of antibiotics. The review 
indicates that there is no harmonised approach for measuring antibiotic use in animals. Ten 
different units of measurement were identified in the review (140) because of different 
approaches between studies and different data recording systems. Global consumption of 
antibiotics in food animal production was estimated at 63.1 million kilograms, which average 





7.2.2 Objective 2: To describe the pattern of antibiotic use in pig farms and 
estimate the total amount of antibiotics used in pig production in Thailand. 
The findings from the questionnaire survey of 84 pig farmers indicated that 73.8% (62/84) 
used antibiotics, of which 57.1% of farmers (48/84) reported the use of antibiotics for the 
prevention of disease. Amoxicillin was the most commonly used antibiotic for disease 
prevention on farms. Antibiotics in the CIA category were commonly used, reported in one-
third of farmers (31%). 
The feed mill survey data showed that the estimated total amount of active ingredients of 
antibiotics mixed into medicated feed for pigs for the whole country was estimated at 843 
tonnes (842,571.7 kilograms) in 2017. Among these, the top three active ingredients were 
amoxicillin, contained in almost half of feeds, then halquinol and tiamulin. Nearly two-thirds 
of antibiotics (64.3%) contained in medicated feed were in the CIA category.  
Based on the analysis of feed industry veterinarian interviews, amoxicillin and tiamulin were 
commonly recommended for use at all stages; the dose range was between 300 and 400 ppm 
and 150 and 200 ppm, respectively. Halquinol and colistin were commonly recommended as 
an addition to medicated feed for suckling piglets and nursery pigs for the prevention of 
gastrointestinal tract infections. Tylosin, tilmicosin and chlortetracycline were recommended 
for fatteners.  
A number of farmer characteristics were found to be associated with the use of antibiotics in 
pig production. Farmers appearing to use the greatest levels of antibiotics for disease 
prevention and antibiotics in the CIA group7 were those who: received advice on animal 
health; had higher education levels; were more experienced; belonged to a farm cooperative; 
had more farm’s income a; owning commercial farma; and having received GAP 
certificationa. There was no correlation between farmers’ knowledge about antibiotics and 
their usage. (This point will be further discussed in section 7.3.2.) 
 
7 The analysis on the use of antibiotics in CIA category was presented in the American Society Tropical 
Medicine and Hygiene Annual Meeting 2019, USA, entitled “The use of “Critically Important Antimicrobials” 
in Thai pig production: survey of 84 pig farms and 31 feed mills” (Appendix 6.4); a: variable that had positive 




7.2.3 Objective 3: To explore the practices and views of pig farmers and other 
relevant stakeholders associated with the use of antibiotics in pig production in 
Thailand. 
This study explores the practices and views of pig farmers and other stakeholders regarding 
antibiotic use in pig production in Thailand through semi-structured interviews (31 key 
informants) and direct observations in six pig farms. Thematic analysis based on practices, 
views and interests of stakeholders showed that many factors seemed to be associated with 
antibiotic use including lack of knowledge and awareness about antibiotics and AMR; 
economic incentives; and loose regulatory frameworks. This information seems to contradict 
the findings of the farmer survey (The discussion is in the section 7.3.2). Farmers considered 
that using antibiotics was a worthwhile investment in pig production. Veterinarians stated 
that they faced challenges in diagnosis and lacked antibiotic prescribing guidelines. 
Pharmaceutical companies used promotion strategies to increase sales.  
7.3 Reflections from the thesis 
To my knowledge, this is one of the first studies to assess in detail the use of antibiotics 
during pig production in a LMIC. Evidence generated from the study aims to contribute to 
the development of policies to optimise the use of antibiotics in pig production. The details of 
the study findings are discussed focusing on the main research question: how and why are 
antibiotics used in pig production? In the first section, the discussion focuses on three 
practices associated with the use of antibiotics in pig production, including: (1) antibiotic use 
for disease prevention; (2) volume of antibiotics used through medicated feed; and (3) 
antibiotic use in the CIA category.  
The second section discusses determinants of antibiotic use in pig production through 
interconnections across different levels of factors. Based on the study framework (described 
in chapter 4), I have categorised the factors into three levels: farmer level; pig production 
systems and antibiotic supply level; and policy and regulations level. The farmer level 
includes farmers’ attributes such as their educational level; experience in raising pigs; 
understanding of antibiotics; awareness of AMR; attitudes on antibiotic use; receiving advice 
on animal health; being members of a farm cooperative; and the income and size of farm. 




management; health status of pigs on farms; farm productivity; and the role of consumers and 
food retailers; access and availability of antibiotics and roles of relevant stakeholders 
involved in the supply of antibiotics such as the pharmaceutical industry and veterinarians. 
Factors in relation to the policy and regulations level (grey shaded box) are presented in 
chapter 8, in parallel to a discussion on relevant policy recommendations for optimal use of 
antibiotics in pig production. Figure 7.2 shows the mapping of the study findings based on 








• Government and relevant stakeholders
- Private food standards
- Regulations regarding of antibiotics
- Veterinary services to farmers
Pig production systems
• Industrial farming systems are likely to contribute to 
increase the use of antibiotics.
• Good farm management are key factors contributing 
to animal health and consequently reducing need for 
antibiotics
• Low level of consumer demand for antibiotic-free 
pork.
Antibiotic supply
• Farmers had easy access to antibiotics and medicated feed through 
several outlets.
• Pharmaceutical industry: Promotion of sale of antibiotic, use 
academia as mediators between pharmaceutical industry and 
farmers 
• Health professionals: Lack of training on antibiotic use in 
undergraduate curricula and continued professional education, 
limited access to laboratory facilities, lack of clinical practice 
guidelines to support appropriate prescription of antibiotics
Patterns of antibiotic use in pig production focusing practices, which are hazardous to the possibilities of the emergence of AMR
- High proportion of pig farmers using antibiotics for disease prevention
- Large volume of antibiotics being administered in the form of medicated feed
- High proportion of pig farmers using antibiotics in the CIA category.
• The use of antibiotics for disease prevention was significantly and positively associated with farmers’ 
experience in raising pigs, having received advice on animal health, being members of a farm cooperative, 
farmer’s income, owning commercial farm 
• The use of CIA was significantly and positively associated with farmers’ educational level, experience in 
raising pigs, having received advice on animal health, having received good agricultural practice 
certification, being members of a farm cooperative, farmer’s income, owning commercial farm 
• Poor understanding about antibiotics
• Lack of awareness on AMR





























• Health professional communities 
- Antibiotic prescription guidelines




7.3.1 How are antibiotics used in pig production?  
My study found several practices associated with antibiotic use in pig production in Thailand, 
which may contribute to the emergence and threat of AMR to people including a high 
proportion of pig farmers using antibiotics for disease prevention; a large volume of 
antibiotics being administered in the form of medicated feed; and a high proportion of 
antibiotics used in the CIA category. 
The survey results of the pig farmers showed that more than half of the pig famers (57.1%; 
48/84) reportedly used antibiotics for disease prevention (Chapter 5). This trend reflects 
findings from my systematic review, which documented a wide use of antibiotics in pig 
production to prevent and control disease by applying a sub-therapeutic dose (130). Several 
studies reported that more than 90% of antimicrobial substances were administered for 
disease prevention in pig production in some European countries (69–71,131).  The sub-
therapeutic use of antibiotics in agriculture has been a major challenge for decades, as its 
mechanism is to inhibit the growth of microorganisms, both commensal and pathogenic 
bacteria, in gastrointestinal tracts (42,43).  This leads to selective pressure favouring the 
survival and growth of resistant bacteria (142). Both WHO and European Union guidelines 
state that the use of antibiotics for disease prevention should be avoided in livestock 
production (51,138).  
Findings from the survey of pig farmers revealed the significant use of CIA, especially those 
reserved as a last resort for the most severe human infections such as colistin (Chapter 5). 
Nearly one-third of farmers (31%; 26/84) reported the use of antibiotics in the CIA group; 
and of all the antibiotics added to commercial medicated feed, almost two-thirds are classed 
as CIAs (64.3%; 541,776.9/842,571.7 kilograms), of which 17.3% (145,805.3 kilograms) 
were in the category of highest priority CIA and 47% (395,971.6 kilograms) in the category 
of  high priority CIA. Similarly, data from the national surveillance of antimicrobial 
consumption in Thailand (Thailand-SAC) showed that 15.7% of total antibiotic consumption 
in food-producing animals belonged to the highest priority CIA group (81). Even though it is 
difficult to compare with other studies, of the total antimicrobials used in food-producing 
animals in European countries in 2016, 14.9% reportedly belonged to the highest priority 
CIA group: third- and fourth-generation cephalosporins (0.2 %), quinolones (2.6 %), colistin 




In the analysis of data from the survey of feed mills, I estimated that 842,571.7 kilograms of 
active ingredients were used through medicated feed for pig production in Thailand in 2017. 
However, it was difficult to compare data from this study with other sources due to the lack 
of standardized metrics to quantify antibiotic use in pigs, as found in the systematic review 
(140). The total annual antibiotic use per year ranged from 15,000 kilograms to 34 million 
kilograms depending on species included in the study (pigs only or all food producing 
animals) and studied areas (some farms in country or per country). For example, a study on 
antibiotic use in Chinese pigs estimated 34 million kilograms of antimicrobials in medicated 
feed in 2012 due to the massive number of livestock (143), while only 15,000 kg of 
antimicrobials were used in one year in all animal species in Kenya (144). Therefore, the use 
of different units of measurement and the unavailability of data by animal species limits the 
ability to compare studies across settings. 
7.3.2 Why are antibiotics used in pig production?  
There are various factors influencing the use of antibiotics. This section discusses the three 
levels of factors: farmers’ attributes, pig production systems and antibiotics supply. Factors in 
relation to the policy and regulations level are presented in chapter 8. 
Farmer’s attributes influencing antibiotic use  
The farmer survey identified a number of characteristics associated with the use of antibiotics 
in pig production as discussed in the published paper (28) and in Appendix 6.4. For example, 
farmers appearing to use the greatest quantity of antibiotics for disease prevention were those 
with more experience. This may be because experienced farmers are more likely to use 
antibiotics without a detailed examination of their animals’ health conditions.  
The farmers’ motive for making money, and farmers’ understanding and awareness about 
antibiotics and AMR also emerged as important variables in the qualitative study (Chapter 6). 
Farmers perceived antibiotics as a “worthwhile” and “affordable” investment relative to other 
interventions, such as high-cost investment in farm biosecurity. For example, findings from 
the interviews with farmers revealed that the cost of feed only increased by 2.7% when 
antibiotics were added, compared with regular feed (Chapter 6). Similar to the study in 
Belgium, farmers perceived antibiotics as cost-effective, therefore they applied antibiotics for 




that the cost of antimicrobials was low relative to other inputs (128). Analyses of a study in 
pig farms in Spain showed that the total drug and vaccine cost was less than 4.2% of the total 
cost per pig (145). While the cost of investing in capital assets such as buildings and farm 
equipment are larger and often unaffordable, when compared with medicines.  
There was some evidence showing the low levels of understanding about antibiotics in 
farmers.  For example, about 40% (33/81) of farmers in this study did not know what an 
“antibiotic” was; about 80% of farmer respondents incorrectly thought that antibiotics were 
effective against cold and flu; and more than 70% of farmers wrongly understood that 
antibiotics can kill viruses (Appendix 7.1 Additional results from the farmer survey). In 
addition, the qualitative study (Chapter 6) showed that pig farmers, particularly smallholders, 
have poor understanding about antibiotics.  
One reason which contributes to these misunderstandings might be the common use of 
different Thai words to define “antibiotic”. For example, Thai people commonly used a term 
“Ya-Khae-Akseab” (Ya=drug, Khae=anti, Akseab=inflammation) which means drugs that 
have anti-inflammatory effects to describe an “antibiotic”; this word is similar to anti-
inflammatory drugs such as paracetamol. Another term that is used to describe “antibiotics” 
in Thai is “Ya-Pati-Cheewana” (Ya=drug, Pati=anti, Cheewana=microbes) meaning drugs 
that counter microbes. But “Pati-Cheewana” is a medical term which is not commonly used 
and understood by lay people. Moreover, “antibiotic” can be called as “antiseptic” in Thai 
(Ya-Ka-Chua, Ya=drug, Ka=kill, Chua=microbes).  
Another reason contributing to the low level of knowledge about antibiotics among farmers 
could be that they did not have access to information about antibiotics. A recent study of 
households in Thailand found that only a small proportion of Thai people (17.8%) had 
received information about the appropriate use of antibiotics and AMR in the last 12 months 
(146). Low levels of knowledge related to antibiotics among farmers were common as 
indicated in other studies. For example, a number of studies found that farmers have limited 
knowledge of the name of antibiotics or clinical indications for use (115,116). Chen et al. 
found poor knowledge of antibiotics in Chinese farmers, along with a high level of improper 
use of antibiotics (147). 
Although the farmer survey showed no association between the use of antibiotics for 




a univariate analysis to explore the relationship of each factor to the use of antibiotic due to a 
low number of samples. Therefore, it was unable to take a relationship between different 
variable (factor) into account.  
Moreover, findings from the interviews with farmers showed that farmers did not consider 
that their practices on antibiotic use would contribute to AMR (Chapter 6). They doubted 
public health concerns about the association between the use of antibiotics in livestock 
production and the emergence of AMR and its potential transmission from animals to 
humans. In European countries, farmers perceived low to moderate levels of public health 
risk from antibiotic use, and were significantly more worried about financial issues than 
AMR (148).  
Factors which influence the use of antibiotics in pig production systems 
Findings of the farmer survey showed that commercial farms were more likely to use 
antibiotics for disease prevention (Chapter 5) and to use CIA (Appendix 6.4). The higher use 
of antibiotics in commercial farms is possibly related to the prevalence of disease on the 
farms. Particularly in industrial production systems, when pigs catch a disease, it can soon 
spread to the whole herd leading to mortality, reduced production and economic loss. Kim et 
al. found higher volumes of antibiotics were used for disease prevention in industrial pig 
farming than on household farms in Vietnam (141). Otte et al. explored the linkages between 
livestock production and global public health where livestock industrial systems with a high 
concentration of animals of a similar genotype being raised in limited spaces potentially have 
higher contact rates and pathogen transmission within the herd. He suggested biocontainment 
measures should be developed for industrial systems to mitigate animal and public health 
risks. (149). Findings from a study in pig farms in Belgium demonstrated a strong association 
between biosecurity and the low level of antibiotic use (150). In this study, the disease 
prevalence at farm was not included in the variables of farm characteristics due to limited 
information. 
Findings from the interview with farmers showed that farmers agreed that good farm 
management including well-managed housing, and farm sanitation are key factors 
contributing to animal health and consequently reduce the need for antibiotics. Similarly, one 
study in Denmark demonstrated that improved farm hygiene contributes to a reduction in 




management requires a large investment to improve infrastructure and biosecurity (Chapter 
6).  
In Thailand, the DLD established voluntary standards for farm management through the 
certification of GAP. The standards range from farm infrastructure, animal feed quality, farm 
management, and animal health management including the use of antibiotics, animal welfare 
and the environment (151). However, although GAP certification should help to optimise the 
use of antibiotics on farms, this is not guaranteed; the farmer survey found that GAP-certified 
farms had a higher chance of using antibiotics in the CIA group than non-GAP-certified 
farms Appendix 6.4). Compliance might be crucial for the effectiveness of the regulations. 
Some study demonstrated the low compliance with GAP in some agricultural production. The 
study of compliance with GAP in Trinidad found that there was low compliance among 
vegetable farmers with the mean score was 14.4 (a maximum possible GAP compliance score 
of 42) (152). However, such data are not readily available in Thailand.  
Factors which influence antibiotic supply  
Findings for the farmer survey showed that most farmers had received advice on animal 
health and antibiotics from unqualified sources such as relatives, other farmers and lay people 
and from pharmaceutical companies; and they used the higher levels of antibiotics for disease 
prevention and antibiotics in the CIA category than farmers who had not received advice on 
antibiotics (chapter 5, Appendix 6.4). This finding is similar to the study about the 
antimicrobial use in Vietnamese pig farms which showed that it was driven by response to 
advice from others (128). 
In Thailand, antibiotics do not legally require a prescription but must be dispensed by a 
licensed pharmacist or veterinarians in licensed pharmacies or pharmaceutical companies. In 
2017, a large number of medicine outlets including about 24,000 pharmacies and 
pharmaceutical companies were licensed for pharmaceutical sales (Appendix 2) (100). 
Therefore, farmers can buy antibiotics through several channels including distributors, 
wholesalers, retail pharmacies, or medicated feed from either feed mills or feed. The farmer 
interviews showed that all farmer respondents had easy access to antibiotics and medicated 
feed through several outlets (Chapter 6). In most HICs, restriction of access to antibiotics is 




(veterinarians) and dispensers/supplier (pharmacists, veterinarians) (153). Pharmaceutical 
companies commonly promote the sales of medicines, including antibiotics, directly to 
farmers through different marketing strategies. The farmers’ interviews revealed that 
pharmaceutical companies applied market promotion strategies such as cheaper prices and 
international leisure travel awards, to increase sales, which are likely to influence farmers’ 
decisions on antibiotic purchases (Chapter 6).  
Most Thai veterinarians who work for pharmaceutical companies can play dual roles as drug 
retailers and health care providers. Their decisions and the information they provide to 
farmers may be biased in favour of profit-driven sales of pharmaceuticals. In human health, a 
number of studies showed that the physician can boost a patient’s demand for unnecessary 
use of medications and healthcare through the provision of additional information. 
Asymmetric information between physicians and patients exists, as patients do not have 
enough information to determine what health services should be used, which can contribute 
to a bias of supplier-induced demand (154–156). 
Another factor that can potentially influence the use of antibiotics is the relationship between 
pharmaceutical companies and animal health care providers. Findings from the qualitative 
study showed that in some situations, pharmaceutical companies used veterinary professors 
as “academic mediators” to provide advice to farmers on animal health management 
including the use of antibiotics (their products), while the veterinary professors received 
honorariums, support for conference participation and laboratory equipment to their faculty 
in return (Chapter 6). Indeed, many other studies of physicians found that pharmaceutical 
companies often provide economic incentives such as support for social outings, workshops 
and conference registration fees, non-educational gifts, reprints of adverts and personal drug 
samples in order to boost their sale of antibiotics (123,124,157). Support from pharmaceutical 
companies was found to influence health professionals’ decisions on antibiotic prescriptions. 
A study on factors influencing antibiotic prescription showed that Chinese doctors over-
prescribed antibiotics because they earned money through sharing the income and profits 
made by pharmaceutical companies and hospitals (158). To my knowledge, no study has 
assessed the influence of the pharmaceutical industry on veterinarians’ decision-making.  
In terms of limitations of health professionals, findings from the qualitative study shows that 




fact that pharmacists in Thailand are responsible for both human and animal medicines. 
Pharmacists therefore may have limited knowledge about pigs’ diseases and farm 
management in order to prescribe appropriate antibiotics to farmers. Furthermore, the rational 
use of antibiotics is not a topic covered in the curriculum for veterinary and animal husbandry 
studies, and in the existing in-service trainings. In addition, even though there are guidelines 
for veterinary clinical practice, they focus on diagnosis and disease management, and do not 
include the appropriate use of antibiotics (Chapter 6). 
Finding from interviews with veterinarians showed limited laboratory facilities to support 
antibiotic sensitivity testing; a lack of protocols for diagnosis; and a lack of clinical practice 
guidelines for the appropriate prescription of antibiotics (Chapter 6). It is therefore pragmatic 
for veterinarians to prescribe antibiotics to pig farmers based on their experience and their 
understanding of the epidemiological profile of common pathogens for different symptoms, 
while it is considerably more difficult and costly to undertake laboratory diagnoses and 
sensitivity testing. Several studies showed that non-clinical factors including time constraints, 
cost of diagnosis and maintaining a good relationship with clients influence veterinarians’ 
decisions (159–162).  
7.4 Summary 
This chapter will review the study limitations and discuss its findings. It is clear that there is 
high use of antibiotics for prevention through medicated feed, and high use of antibiotics in 
the CIA category in pig production in Thailand, and that this has implications in terms of the 
emergence and spread of AMR.  The use of antibiotics is influenced by some of the complex 
interactions among stakeholders in the context of policy and regulatory environments 
including farmer’s attributes such as profit motive of antibiotic use, and lack of farmers’ 
understanding and awareness about antibiotics; industrial pig production systems and 
antibiotics supply. Policy and other implications of the study are considered in the final 




Chapter 8 Implications for policy and research 
Summary 
This chapter summarises the implications of the thesis for policy and areas where further 
research are needed. In the first section, evidence generated from previous chapters is 
synthesized to discuss the implications for policy and identify relevant policy 
recommendations for optimal use of antibiotics in pig production. A further section is 
dedicated to recommendations for research priorities, and the final section looks at the overall 
conclusions of the thesis.  
8.1 Policy implications and recommendations  
Antibiotics are common-pool resources. When everyone can gain access to antibiotics and 
use them inappropriately, it leads to the loss of antibiotic effectiveness through the 
development of AMR. The control of AMR can be considered a dilemma of a common good 
as all individuals can benefit in the long-term from collective actions in maintaining the 
effectiveness of antibiotics (163).  
This thesis has contributed to the understanding antibiotic use and determinants influencing 
antibiotic use in pig production in Thailand. The empirical findings will hopefully be a useful 
contribution to policy makers in Thailand responsible for making decisions about how to 
optimise the use of antibiotics in pig production. This study may also have implications for 
policy in other contexts, particularly LMICs with similar livestock production, market and 
regulatory environments. The contributions of this thesis are described below.  
8.1.1 Policy implications and recommendations for Thailand 
In Thailand, the National Strategic Plan on AMR (NSP-AMR) was established and endorsed by a 
Cabinet resolution in 2016 (Appendix 9). The policy recommendations for optimal use of 
antibiotics in pig production that are proposed in this thesis are in line with the NSP-AMR 
focusing on the Strategy 2 Regulation of antimicrobial distribution and Strategy 4 AMR 




Based on the evidence generated from previous chapters, I address implications for policy to 
guide the optimal use of antibiotics in pig production. There are several interlinking policy 
interventions and a broad range of instruments for both non-legal norms and regulations to 
optimise antibiotic use through collective actions of relevant stakeholders. The priority 
interventions including (1) private standards; (2) monitoring and enforcement of regulations 
regarding antibiotics; and (3) generating evidence and provision information to relevant 
stakeholders, are presented in the following section. 
8.1.1.1 Private standards in pig production   
Private standards have not been set by regulatory authorities, but by non-governmental 
organisations such  as,  in  the  food  sector,  supermarket  chains,  retail companies, 
manufacturers,  and producers  (164,165). Private food standards have increasingly become 
an important role in determining market access in food trade through setting the minimum 
requirements for products, processes or producers. For example, retail corporations such as 
fast-food companies in the US exerted some leverage over the livestock practices of their 
suppliers and demanded animal products with fewer antibiotics (166). Another relevant 
example can be seen in the UK’s big supermarket chains which set contractual standards to 
livestock producers and banned routine preventive use of antibiotics in livestock (167).  
In Thailand, some private food standards including antibiotic residue testing in food products 
and antibiotic-free pork production have been implemented. One of the big supermarkets 
initiated the ‘Big C Farm Fresh Hygienic’ program, which set up the standard of livestock 
production restricting the use of antibiotic as a growth promotor and traceability systems to 
detect antibiotic residue in livestock products (168). Thailand has a ‘Raise Livestock Without 
Antibiotic Programme’, a farm assurance and food labelling scheme set up by the DLD in 
2018 (169). Under the programme, animals must be certified that they have not received 
antibiotics throughout the production, and pig producers were encouraged to apply preventive 
measures such as vaccination, alternative treatments, and appropriate animal husbandry to 
maintain the health of the animals. However, there were only five large agro-industrial 
livestock producers with 144 pig farms who participated in the Raise Livestock Without 




The findings from this study revealed that the Thai pig production supply chain potentially 
limits access of individual farmers, particularly smallholder farmers to antibiotic-free pork 
markets and food safety program of big supermarkets. The food industries, in cooperation 
with DLD should apply the market access rules to control the use of antibiotic in pig 
production, to produce meat which is either free from antibiotic or antibiotic residue. The 
DLD should consider scaling up the ‘Raise Livestock Without Antibiotic Programme, 
particularly increase enrolment of small farms or farms outside the large company chain 
which are eligible to produce antibiotic-free pork to become involved in the programme. 
8.1.1.2 Monitoring and enforcement of regulations regarding antibiotics 
Enforce the regulations in supplement with the private standards 
A combination of market access rules by the private sector and control through regulation 
could be an effective instrument to govern the use of antibiotic in livestock production.  
As mentioned in the previous section about private standards on antibiotic residue testing in 
pig products, the Notification of the Thai-FDA has set the maximum level limit of veterinary 
drugs residue in foods (170). In addition, the DLD is charged with enforcing the Animal Feed 
Quality Control Act, animals given an antibiotic should not be slaughtered until the 
withdrawal period ends (105). When residue violations are detected, Thai-FDA or DLD will 
take legal action against violators and exclude the contaminated products from the market.  
Establish veterinary antibiotic prescriptions monitoring systems 
Findings from this study demonstrated that the availability and easy access to affordable 
antibiotics including CIAs at pharmacies or on-site sales by pharmaceutical detailers 
potentially contributed to high antibiotic use. Restrictions for veterinary antibiotics have been 
recently introduced in Thailand under the Drug Act. In 2019, pharmacies and pharmaceutical 
companies needed medicine prescription for the sale of four groups of veterinary antibiotics: 
quinolones and derivatives, cephalosporins, macrolides and polymyxins (104). However, 
implementation is still at an early phase and is not being monitored. To assess the 
effectiveness of regulatory implementation, Thai-FDA should establish a prescription system 




pharmaceutical companies. The prescription monitoring system should be established in 
consultation with relevant stakeholders.  
In addition, in 2018 the Animal Feed Quality Control Act mandated that veterinary 
prescription is needed for feed mills before medicated feed production, and for farmers who 
produce farm-mixed medicated feed on farms (105). Well-designed electronic antibiotic 
prescription and submission from feed mills and farms could help facilitate timely monitoring 
and remedial actions. The DLD should accelerate the implementation of this prescription 
system, and in addition, Thai FDA and the DLD should synchronise or integrate their 
monitoring systems.  
Limit the pharmaceutical industry’s influence on the farmers’ and veterinarians’ decision 
on the use of antibiotics. 
Despite continuing concerns regarding the influence of pharmaceutical companies on the 
decisions of farmers and veterinarians over the use of antibiotics, the findings of this study 
clearly showed some evidence of lack of control of pharmaceutical companies regarding the 
sale of antibiotics in Thailand. There is currently no regulation requiring veterinarians and 
pharmacists to reveal financial connections to pharmaceutical companies. 
In European countries, the European Parliament has discussed the possibility of “decoupling” 
which separates the right to prescribe from the right to sell antimicrobials in EU member 
states, thereby eradicating economic incentives for prescribing veterinary medicines (171). 
The Dutch government implemented a regulation decoupling the functions of prescription 
from the selling of drugs by veterinarians along with other interventions; this has been shown 
to be effective with a 56% reduction in antimicrobial use in farm animals between 2007 and 
2012 (172). This approach should be applied to Thailand. The government should intervene 
in the phenomenon of profit-led prescription and sales of antibiotics by the pharmaceutical 
industry. First, Thai-FDA and the DLD should decouple the prescription of antibiotics from 
their sale (delivery) to farmers. Secondly, the Thai-FDA and the DLD may consider 
standardising the conditions of prescription of antibiotics. For example, veterinarians (and/or 
pharmacists) should not be authorised to prescribe antibiotics without clinical examination or 




8.1.1.3 Generating evidence and provision of information to relevant stakeholders  
Farmers: strengthening knowledge about farm management and antibiotic use  
Providing correct knowledge and information to farmers help them make better decisions 
regarding the use of medicine. However, findings from the farmer survey showed that most 
farmers had received advice on animal health and antibiotics from unqualified sources or 
from pharmaceutical companies; and they used higher levels of antibiotics for disease 
prevention and antibiotics in the CIA category than farmers who had not received advice on 
antibiotics. Moreover, the survey also demonstrated that veterinarians from DLD were 
reportedly the least frequent source of advice on animal health and use of antibiotics. 
Farmers, particularly smallholder farmers, reported they had difficulty seeking professional 
advice.  
The DLD should improve access to reliable information about antibiotic use for farmers. 
Veterinary professionals can also be effective in disseminating information to farmers. Health 
professionals including doctors, health workers, and pharmacists played a major role 
contributing about 80% of sources of information on appropriate use of antibiotics and AMR 
for Thai people (146). The DLD is a livestock health authority with a broad mission covering 
prevention and control of animal diseases, enforcement of law related to livestock industries 
and increasing the quantity and quality of animal products (173). The ambition of the mission 
is not matched by the available resources. There are few veterinarians at the provincial level 
and veterinarians are lacking in the district livestock development offices (83). Moreover, 
DLD veterinary laboratories are located at regional level and in the study, farmers and 
veterinarians expressed concerns over difficulties in laboratory sample transportation and 
delays in receiving lab results. An evaluation of the performance of veterinary services in 
Thailand in 2012 reported the lack of personnel and skills of veterinary officers at district 
level, as well as no veterinarian supervising and providing advice on the use of medicines to 
farmers (174). One study on the veterinary workforce in Thailand showed the lack of 
veterinarians working in the government sector; just 10.2% of the total veterinarians working 
in Thailand (175). 
There is an urgent need to reconsider the role of government to respond to demands for 




farmers focusing on animal health management, disease surveillance and laboratories. 
Strengthening the role of public veterinary services requires clear, strong and sustainable 
policies on the veterinary workforce and services in the agricultural sector. 
Apart from veterinary service, having relevant knowledge is important but insufficient for 
behaviour change, as discussed in chapter 7. Specific messages should be targeted such as the 
consequence of AMR to animal production and public health to create an awareness on 
AMR. This recommendation is in line with the recommendation in objective 1 of the GAP-
AMR which aims to improve awareness and understanding of antimicrobial resistance 
through effective communication, education and training (176).  
Although all farmer respondents in this study agreed that good farm management and 
biosecurity contribute to animal health and reduce the need for antibiotics, however the 
findings of this study offer some evidence of the limitations of farmers to improve farm 
management, due to the need to make large investments in infrastructure and biosecurity. The 
DLD should consider providing financial and technical support to farmers to improve farm 
management and biosecurity standards with an affordable cost of investment. For example, 
DLD could provide essential veterinary products, vaccines in particular, at low prices or 
indeed free of charge to farmers, as alternatives to antibiotics. It would be beneficial to 
farmers if the government provides technical support to build cheaper affordable housing 
units with high biosecurity for livestock production.  
Health professionals: antibiotic prescription guidelines and data of antibiotic consumption 
and AMR in pig production  
Findings from the interviews with veterinarians revealed that there is a lack of antibiotic 
prescribing guidelines. There are very little teachings about AMR and the appropriate use of 
antibiotics in animals. The topics are not covered in the curriculum for veterinary, pharmacy 
or animal husbandry studies, nor included in the existing in-service training. In order to 
optimise antibiotic use in animal health, adding teachings on AMR and antibiotic stewardship 
into a core component of professional education, training, certification, continuing education 
and development in the veterinary sector and agricultural practice will help to ensure proper 




In the health care of humans, clinical practice guidelines can contribute to the reduction of 
unnecessary use of antibiotics in humans and are an important tool in antibiotic stewardship 
(177). However, based on an OIE survey in 2018, most countries outside the EU including 
Thailand have not established guidelines on the use of antibiotics in food producing animals 
(178). The Thai-veterinary professional communities should urgently develop guidelines for 
antibiotic prescription in livestock including pigs through collaborative work between 
veterinary professional councils and relevant partners. The guidelines should be in line with 
recommendations of international organisations on the use of antibiotics in food-producing 
animals. For example, Food and Agriculture Organization of the United Nations (FAO) 
suggested that antibiotic use for disease prevention should be applied only in exceptional 
situations, such as when a few animals in a group have been diagnosed with an infection that 
has probably already sub-clinically infected other animals. Mass treatment of groups of 
animals should be avoided, and treatment and care targeted to single or small groups of 
infected pigs in separate pens should be the goal (139). WHO recommends an overall 
reduction in use of all classes of medically important antimicrobials (MIA) and complete 
restriction of routine use of MIA for prevention of infectious diseases that have not yet been 
clinically diagnosed in food-producing animals (51). Ideally, the use of antibiotics in the CIA 
category should be limited to treatment, with specific indications and only when there is no 
lower tier alternative. Where possible non-WHO CIA list antibiotics should be 
recommended, and where this is not possible then antibiotics in the lower tiers on this list 
should be recommended first. 
In addition, guidelines should be based on local microbiological surveillance data. The 
surveillance data can help guide veterinary decisions on antibiotic prescription. Currently, there is 
no existing analysis of the potential association between antibiotic use in animals, and AMR in 
animals and humans. The government should support this analysis, in particular for the CIA group 
of common pathogens. National guidelines on antimicrobial use and antimicrobial stewardship 

























Key policy recommendations for the government: 
1. The food industries, in cooperation with DLD and Thai-FDA should apply a 
combination of market access rules and regulations to control the use of 
antibiotics in pig production. 
2. The DLD should consider scaling up the ‘Raise Livestock Without Antibiotic 
Programme.  
3. The Thai-FDA should establish a prescription for certain groups of veterinary 
antibiotics in pharmacies and pharmaceutical companies. 
4. The DLD should accelerate the implementation of the prescription system for 
medicated feed production at feed mills and on farms.  
5. The Thai-FDA in cooperation with DLD should decouple the prescription and 
sale (delivery) of antibiotics to farmers.  
6. The DLD should improve farmers’ access to information about antibiotics and 
create specific messages to create an awareness on AMR 
7. The DLD should strengthen animal health systems through providing public 
veterinary services including animal health management, disease surveillance 
and laboratories. 
8. The DLD should consider providing financial and technical support to farmers 
to improve farm management and biosecurity standards with an affordable cost 
of investment.  
Key policy recommendations for veterinary communities 
1. The veterinary professionals’ councils should urgently develop guidelines for 
antibiotic prescription in livestock including pigs through collaboration with 
relevant partners. 
2. The health professionals’ councils including both veterinarians and pharmacists 
should support training and education on antibiotic stewardship as a mandatory 
requirement in continuing professional development and relicensing of 





These policy recommendations are in line with the GAP-AMR which all countries adopted 
through decisions taken at the World Health Assembly, the Food and Agricultural 
Organization Governing Conference and the World Assembly of World Organisation for 
Animal Health Delegates (176). Optimising the use of antimicrobials in livestock production 
is one of the GAP-AMR key recommendations. There are several interventions such as 
strengthening agricultural practices, conducting research to identify alternatives to 
nontherapeutic uses of antimicrobial agents in agriculture, promoting vaccination as a method 
of reducing infections in food animals, and effective and enforceable regulation and 
governance for licensing, distribution, use and quality assurance of antibiotics (176). Given 
the possibility of applying evidence from this study to other contexts, the next section 
considers the potential policy implications for other countries and global actors, which are in 
compliance with GAP-AMR. 
8.1.2 Possible policy implications and recommendations for other countries and 
global actors 
8.1.2.1 Promoting good animal production and hygiene practices among farmers, and other 
stakeholders in the animal sector  
As discussed in policy implications for Thailand, improving farm management and standards 
of biosecurity contributes to optimising the use of antibiotics in pig production. I strongly 
agree with three measures including good animal husbandry, effective biosecurity and 
vaccination to prevent infectious diseases without using antibiotics recommended by the 
Food and Agricultural Organization recommendation (139) to be promoted among animal 
producers, and other stakeholders in the food and agriculture sectors. Good animal husbandry 
includes, for instance, safe and clean housing; manure management; good hygiene practices; 
adequate amount and nutrient content of feed; and regular veterinary advice on disease 
prevention and animal health programmes. Effective biosecurity covers both actions taken to 
prevent the introduction of infectious diseases onto the farm such as quarantining all new 
animals; and actions taken to prevent the spread of infections within the farm 
including cleaning and disinfecting tools and equipment when moving between animal 
groups. Routine vaccination programmes should be adapted to the diseases circulating in 
each country. However, the guideline should be widely disseminated to relevant stakeholders 




8.1.2.2 Investing in the research and development of alternatives to antibiotics  
Alternatives to antibiotics such as probiotics or prebiotics could help replace the use of 
antibiotics on farms; however, farmers in the study raised concerns that they were found to 
increase the cost of production. The replacement of antibiotics with cost-effective solutions 
should be explored to the benefit of farmers and reduction in the use of antibiotics. 
Investigating these alternatives requires collaborative work with partner organisations and the 
research community for the development and evaluation of new tools. A number of studies 
have proposed a range of potential immuno-stimulant alternatives to antibiotics including 
probiotics, prebiotics, and plant-derived or crude plant extracts (179–181).  
The development of alternatives to antibiotics requires substantial time and resource 
investments for research undertaken by global collective efforts. Research regarding 
alternatives to antibiotics should be prioritized to ensure limited public resources are invested 
first to areas with potentially maximum impact. This recommendation, in line with the OIE 
strategies on prudent antibiotic use, is to support research into alternatives to using antibiotics 
(182). 
8.1.2.3 Strengthening the knowledge and evidence base through surveillance and research 
Quantifying antibiotic use is important to understand the magnitude and profile of antibiotic 
usage in countries. In order to guide the strengthening of existing antibiotic use monitoring 
systems and the development of new ones to facilitate cross-country comparisons, OIE, 
supported by FAO and WHO within the tripartite collaboration, should support countries, in 
particular LMICs, to develop antibiotic use monitoring systems and integrate them into a 
global database on the use of antibiotics in animals. Data on the quantity of antimicrobial 
consumption should be classified into different types of indication (therapeutic use or growth 
promotion), different animal species group and different routes of administration (183).  
While there has been progress in the monitoring of antibiotic consumption in animals, action 
regarding AMR monitoring in animals has lagged behind. Data on AMR in animals can also 
be used to investigate the association between the use of specific antibiotics and resistant 
bacteria in animals and meat products (184,185). This will help identify the risks between the 




support countries to build up an AMR surveillance system and also include AMR information 
in the global database. In the human sector, WHO supports Member States to participate the 
Global AMR Surveillance System (GLASS) in which GLASS promotes and supports 
standardized national AMR surveillance systems.  
 
 
8.2 Recommendations for research priorities 
This thesis identifies research gaps related to antibiotic use in pig production and suggests 
future avenues of research for achieving optimal antibiotic use across different settings.  
8.2.1 Examining the association between antibiotic use and AMR in food-
producing animals and humans 
Findings from the interviews with farmers showed that farmers did not consider that their 
practices on antibiotic use would contribute to AMR (Chapter 6). They doubted public health 
concerns about the association between the use of antibiotics in livestock production and the 
emergence of AMR and its potential transmission from animals to humans.  However, the 
scope of the thesis does not cover information of AMR in pigs. 
Previous studies exploring the associations between antibiotic use and AMR in food-
producing animals resulted in inconclusive outcomes, having both negative and positive 
associations (186–188). Burow et al. (186) conducted the systematic review of 36 different 
trials and found that a majority of the identified studies showed effects of orally administered 
Key policy recommendations:  
1. Intergovernmental organizations, including FAO, OIE, and civil society 
organizations should promote good animal production and hygiene practices 
among animal producers, and other stakeholders in the food and agriculture 
sectors. 
2. The research community should invest in the research and development of 
alternatives to antibiotics with cost-effective solutions. 
3. The OIE, supported by FAO and WHO within the tripartite collaboration, should 






drugs on AMR in E. coli from pigs; whereas the study of pig farms in Vietnam demonstrated 
that there were no significant correlation between total use of antimicrobials at the farm level 
and AMR in pigs (188).  
Moreover, there have been many studies exploring the associations between antibiotic use in 
food-producing animals and AMR in humans. Some studies have found a positive association 
between antimicrobial consumption in animals and resistance in bacteria in humans. A 2013 
study by the  European Centre of Disease Prevention and Control, showed significant 
positive associations between the consumption of tetracyclines in animals and resistance in 
isolates of Salmonella spp. from humans (189). In addition, possible relationships between 
the occurrence of resistance in Campylobacter coli and Campylobacter jejuni isolates from 
humans and the total consumption of macrolides in food-producing animals were observed in 
2013-2014.  
However, most studies have relied on indirect relationships or molecular microbiology 
techniques, which may not have sufficient capacity to provide evidence of the use of 
antibiotic and an emergence of resistant bacteria in animals and humans. For example, one 
study showed the shared genes between pigs and humans. One study of isolates of patients 
and poultry workers demonstrated significantly higher resistance rates of chicken E. coli to 
common antibiotics used in poultry, such as ampicillin and spectinomycin, than antibiotics 
not used in poultry, such as amoxicillin clavulanate and ceftazidime (190). People who had 
direct contact with pigs which were detected as carrying ESBL-producing E. coli, had 
significantly higher ESBL-producing E. coli in their stools compared with people who had 
contact with pigs which were not detected as carrying ESBL-producing E. coli (191).  
This highlights the urgent need for epidemiological evidence to confirm and characterise the 
relationship between antibiotic use and AMR in livestock and humans. This includes 
confirmation of the association between the emergence of AMR in animals and the use of 
antibiotics on the identified farm, and that infections caused by drug resistant bacteria in 
humans have been transmitted from animals raised in the identified farm using certain 
antibiotics. The molecular approach, including targeted and whole-genome sequencing 
methods, should be added to epidemiological studies to examine the evolutionary origins of 
pathogens in both humans and animals. Such research could also facilitate identification of 
high-risk populations (both humans and animals) for AMR transmission, and provide specific 




8.2.2 Evaluating the effectiveness and cost-benefit of alternatives to antibiotics  
As discussed earlier, intergovernmental organizations and other partners should support 
investment in the research and development of alternatives to antibiotics. However, interview 
with farmers has revealed that the high costs of these new alternatives might be a major 
barrier to rapid uptake by farmers. The challenge for supporting alternative use in animals is 
to prove not only the effectiveness but also the cost-effectiveness of alternatives to 
antibiotics. Future research should cover a cost-benefit analysis of these alternatives, by 
comparing the following: costs of alternatives; cost saving from not using antibiotics; 
economic gains from premium grade antibiotic free pork compared with normal pork; and 
comparing outcomes in term of mortality and productivity such as feed conversion ratio 
between pigs which received antibiotics compared with alternatives. Such research will assist 
policy makers in targeting alternatives to antibiotics and reduce antibiotic use in livestock. 
The beneficial effects of many alternatives to antibiotics have been demonstrated but are so 
far unorganised and scattered. A systematic review of effectiveness of alternatives, 
particularly in LMICs settings, should be conducted to identify the effective alternatives to 
antibiotics. 
At the macro level, prospective studies to compare the benefits of antibiotic use in animals 
and the cost of antibiotics are needed to guide the use of antibiotics in animal farming. The 
financial cost of antibiotics should not only reflect production and marketing costs, but 
should cover both the cost of antibiotic development and the externalities of AMR (192). One 
relevant study on the cost-effectiveness of antibiotic use proposed a framework to analyse the 
costs of antibiotic use through a marginal abatement cost theory, which is derived from the 
economics of pollution control (193). The study applied the approach to compare different 
interventions with the amount of antibiotic use reduction according to the intervention, and 
the implicit mitigation cost. The study also presented interventions to modify the use of 
antibiotics in animals including vaccines, disease eradication, husbandry and restrictions on 




8.2.3 Exploring consumers’ demand for and willingness to pay for antibiotics-
free animal products  
Changes in consumer attitudes and meat consumption preference can have a significant 
influence over the practice of livestock production. One relevant study in the US showed that 
American consumers were willing to pay an additional price for growth-hormone-free animal 
products, and premium prices for safer food and products with quality assurance (194). The 
European Food Safety Authority conducted a survey in farmers, veterinarians and consumers 
which showed that consumer willingness to  pay  an  increased  price  for  antibiotic-free 
products would relieve farmers of some of the economic pressure to use antibiotics (195).  
But the market demand for antibiotic-free pork in Thailand is still limited, as shown by the 
findings of the qualitative study. Further studies are needed to identify context-specific 
measures to stimulate consumer preference, consumer demand for antibiotic-free pork 
products, and their willingness to pay for premium products in Thailand.  
8.3 Concluding remarks 
The work presented in this thesis has fulfilled the aim of the thesis to investigate patterns of 
antibiotic use and determinants influencing antibiotic use in pig production in Thailand in 
order to contribute to the development of policies aimed at optimising the use of antibiotics in 
pig production. Evidence showed several practices, which may contribute to the emergence 
and spread of AMR associated with the use of antibiotics in pig production including: (1) a 
high proportion of pig farmers using antibiotics for disease prevention; (2) a large volume of 
antibiotics used in medicated feed; and (3) a high proportion of the CIA group usage. Factors 
influencing antibiotic use in pig production were the complex interactions among actors 
involved in antibiotic use including farmers, veterinarians, pharmaceutical industry, pork 
retailers and consumers, operating in the context of policy and regulatory environments.  
Collective and synergistic actions towards optimising the use of antibiotics in livestock 
should involve a broad range of strategies to target actors including farmers, veterinarians 
and authorities; and system-oriented approaches to address private standards and voluntary 
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Antibiotic distribution channels in Thailand: results of key-informant 
interviews, reviews of drug regulations and database searches
Angkana Sommanustweechai,a Sunicha Chanvatik,b Varavoot Sermsinsiri,c Somsajee Sivilaikul,d 
Walaiporn Patcharanarumol,b Shunmay Yeunga & Viroj Tangcharoensathienb
Introduction
To address antimicrobial resistance, antibiotics should be 
used appropriately in human medicine. Patients should 
receive antibiotics “appropriate to their clinical needs, in 
doses that meet their own individual requirements, for an 
adequate period of time”.4 Similar rules apply to the prudent 
use of antibiotics by all of the relevant stakeholders involved 
in veterinary medicine.5
!e inappropriate use of antibiotics may involve the use
of antibiotics for a health problem for which antibiotics are 
not indicated or the rational use of antibiotics either in doses 
that are inadequate or in the correct doses, but for an inad-
equate duration. As exposure of susceptible bacteria to low 
doses of antibiotics can lead to the selection of resistance,1 
there is a strong association between antimicrobial resistance 
and inappropriate use of antibiotics at both individual and 
population levels.2,3
In most developing countries, many antibiotics can be 
easily bought without prescription and self-medication with 
antibiotics, mostly bought from drugstores or pharmacies or 
le" over from previous treatments, is common.6,7 Such self-
medication is also found in some high-income countries.8
A major aim of the pharmaceutical market is to respond 
to increased demand. As the number of retail pharmacies 
and other outlets for the distribution of antibiotics increases, 
antibiotics become more widely and easily available. Health 
professionals may also be persuaded to over-prescribe anti-
biotics by #nancial incentives.9
In low- and middle-income countries most drug regula-
tion is focussed on the quality of drugs and the process of 
licensing; relatively little attention is given to distribution, 
price and other aspects of market control. Furthermore, in 
such countries, the enforcement of the drug regulations that 
do exist is o"en poor and the sale of substandard over-the-
counter antibiotics and weak pharmaco-vigilance are o"en 
common.10–12
One of the main aims of the Global Action Plan on Anti-
microbial Resistance, which was adopted by the World Health 
Assembly in 2015, was to optimize the use of antibiotics in 
human and veterinary medicine.13 A key goal of !ailand’s 
subsequent National Action Plan on Antimicrobial Resistance, 
which was developed and endorsed by the !ai Cabinet in 
2016, was to reduce antibiotic consumption, by 20% in human 
medicine and by 30% in veterinary medicine by 2021.
In 2009, the value of the antibiotics imported into !ai-
land or manufactured in the country was about 315 million 
United States dollars and this value represented about 10% of 
the total value of the medicines consumed in the country.15 
!ere appears to be widespread and o"en unregulated use of
antibiotics, not only for human and pet health, but also for the
treatment of livestock both on farms and in household settings.
In 2016, we decided to investigate !ailand’s importation, 
manufacture, distribution and regulation of antibiotics. In 
interviews with key informants, we investigated the multiple 
channels for the distribution of antibiotics, from import and 
manufacture to retail sale, and the various issues that probably 
contribute to the inappropriate use of antibiotics.
Objective To analyse how antibiotics are imported, manufactured, distributed and regulated in Thailand.
Methods We gathered information, on antibiotic distribution in Thailand, in in-depth interviews – with 43 key informants from farms, 
health facilities, pharmaceutical and animal feed industries, private pharmacies and regulators– and in database and literature searches.
Findings In 2016–2017, licensed antibiotic distribution in Thailand involves over 700 importers and about 24 000 distributors – e.g. retail 
pharmacies and wholesalers. Thailand imports antibiotics and active pharmaceutical ingredients. There is no system for monitoring the 
distribution of active ingredients, some of which are used directly on farms, without being processed. Most antibiotics can be bought from 
pharmacies, for home or farm use, without a prescription. Although the 1987 Drug Act classified most antibiotics as “dangerous drugs”, it 
only classified a few of them as prescription-only medicines and placed no restrictions on the quantities of antibiotics that could be sold 
to any individual. Pharmacists working in pharmacies are covered by some of the Act’s regulations, but the quality of their dispensing and 
prescribing appears to be largely reliant on their competences.
Conclusion In Thailand, most antibiotics are easily and widely available from retail pharmacies, without a prescription. If the inappropriate 
use of active pharmaceutical ingredients and antibiotics is to be reduced, we need to reclassify and restrict access to certain antibiotics and 
to develop systems to audit the dispensing of antibiotics in the retail sector and track the movements of active ingredients.
a London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, England.
b International Health Policy Programme, Ministry of Public Health, Nonthaburi 110000, Thailand.
c Food and Drug Administration, Ministry of Public Health, Nonthaburi, Thailand.
d Department of Livestock Development, Ministry of Agriculture and Cooperatives, Phathumtani, Thailand.
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Methods
We investigated antibiotic distribution 
and regulation in !ailand using a com-
bination of key-informant interviews, a 
review of the relevant drug regulations 
and database searches.
Interviews
Between the July and November of 2016, 
we conducted in-depth interviews, last-
ing a mean of 90 minutes, with 43 key 
informants. Each interviewee had been 
selected using a purposive sampling 
technique in which relevant associations, 
i.e. !ailand’s Animal Health Products,
Animal Feed Mill, Community Phar-
macy and Pharmaceutical Manufactur-
ers Associations, were asked to propose
lists of their members who could provide
information about antibiotic distribu-
tion. Each potential informant identi"ed
was asked if they were able and willing
to participate in the study and, if so, they
were asked to give their written informed
consent. Our initial aim was to recruit at
least three consenting informants from
each of six main stakeholder groups, i.e.
animal feed industries, farms, govern-
ment authorities in the "elds of human
and animal health, health facilities, phar-
maceutical industries and pharmacies.
However, using the snowball technique,
more key informants were interviewed
until our data became saturated and no
new information emerged (Table 1). To
ensure consistency, the same individual
(AS) interviewed each key informant.
All of the interviews were con-
ducted face-to-face, in !ai. !ey were 
semi-structured, but based on open-
ended questions. !e informants were 
asked about the processes of antibiotic 
import, manufacturing, distribution, 
dispensing, prescription and use. For 
example, they were asked about the 
sources of active pharmaceutical in-
gredients used in the manufacture of 
"nished products and about their sale 
patterns. All of the interviewees were 
asked about the licensing process and 
requirements for each distributor, the 
registration of medicines and the factors 
that might contribute to the excessive 
and inappropriate use of antibiotics. !e 
informants representing the farming 
industry or health facilities were asked 
about their sources of antibiotics and 
the processes they followed to purchase 
such drugs or active pharmaceutical 
ingredients. !e data recorded in each 
interview were kept con"dential.
Database searches
We estimated the numbers of licensees 
involved in antibiotic distribution in 
the !ai market and in the regulation 
of such distribution by analysing the 
relevant databases held by the !ai 
Food and Drug Administration32 and 
the !ai Department of Livestock De-
velopment.14
Drug regulations
We reviewed all of the regulations pro-
mulgated by both of the Acts that, in 
2016, regulated the use of antibiotics 
and medicated feed through inspection, 
licensing and marketing: the 1987 Drug 
Act30 and the 2015 Animal Feed Qual-
ity Control Act.31 !e 1987 Drug Act, 
enforced by the Food and Drug Admin-
istration of the !ai Ministry of Public 
Health, regulates the "nished products 
used in human and veterinary medicine 
and active pharmaceutical ingredients. 
!e 2015 Animal Feed Quality Control
Act is enforced by the Department of
Livestock Development of the !ai Min-
istry of Agriculture and Cooperatives.
Data analysis
!e data obtained from the key-infor-
mant interviews and document reviews
were summarized to provide an over-
view of the distribution of antibiotics
and identify weaknesses that could
contribute to the inappropriate use of
antibiotics. To assess the accuracy of the
interview data, we used triangulation
across the 43 interviewees. If informa-
tion from one interviewee di#ered
substantially from, and contradicted,
the corresponding information from 
another interviewee, both pieces of 
information were ignored. !ailand’s 
antibiotic distribution channels were 
summarized as a system $owchart. !e 
provincial numbers of licensed private 
pharmacies per 100 000 population were 
mapped using ArcGIS so%ware (Esri, 
Redlands, United States of America).
Ethics
!e study protocol was approved by the
Research Ethics Committee at the !ai
Ministry of Public Health’s Institute for
Development of Human Research. In-
terviewees gave their written informed
consent. Strict con"dentiality was ob-
served and interviewees could opt out
from the interviews at any time.
Results
We created a $owchart, based on data 
from the key-informant interviews and 
reviews of the 1987 Drug Act and the 
2015 Animal Feed Quality Control Act, 
to summarize the antibiotic distribu-
tion channels (Fig. 1). It illustrates the 
complexity of the distribution, of active 
pharmaceutical ingredients, "nished 
products and medicated feed, from the 
importers and local manufacturers to 
"nal consumption by humans, livestock 
or pets.
Import, manufacture and 
distribution
!ailand imported active pharmaceuti-
cal ingredients, for local manufacturing
into "nished products. It also imported
medicated premix for the manufacture
Table 1. Types, ages and years in relevant work of the 43 key informants, Thailand, 2016
Type No. of 
informants
Ages (years) Relevant work experi-
ence (years)a
Mean Range
Regulator 13 35–59 15.9 0.5–32.0
Representative of 
pharmaceutical companyb
14 35–65 17.1 3.0–40.0
Representative of animal feed 
companyc
5 30–61 18.5 3.5–37.0
Health professional from human 
or animal health facility
4 35–54 14.3 1.0–31.0
Wholesaler or owner of retail 
drug store
4 36–70 25.5 11.0–42.5
Farmer 3 37–52 16.6 13.0–19.0
Total 43 30–70 17.2 0.5–42.5
a  Recorded after rounding to the nearest half year.
b  Involved in the import, manufacturer and/or distribution of antibiotics.
c  Running a feed mill or feed store.
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of medicated feed by feed mills. Ac-
tive pharmaceutical ingredients were 
imported either by manufacturers or 
by licensed importers that then sold the 
ingredients to manufacturers. Most of the 
manufacturers either purchased active 
pharmaceutical ingredients from licensed 
importers or imported such ingredients 
themselves – rather than buying them, 
at a greater cost, from drugstores. !e 
antibiotics produced by the manufac-
turers were sold to distributors, retail 
outlets and/or wholesalers. !e imported 
"nished products were distributed, by 
importers who were licensed to distribute 
or by distributors, to drugstores, farms, 
feed mills, health facilities, veterinary 
facilities and/or wholesalers. Our data in-
dicated that the import and manufacture 
of human medicines were very similar to 
those of veterinary medicines, because 
the !ai Food and Drug Administration 
regulated all of these processes.
Several interviewees, representing 
regulators, retailers and wholesalers, 
described the illegal distribution of both 
"nished products and certain active 
pharmaceutical ingredients. !e 1987 
Drug Act stipulates that all active phar-
maceutical ingredients must be used by 
manufacturers to produce "nished prod-
ucts. However, a few informants report-
ed how drug inspectors had con"scated 
active pharmaceutical ingredients that 
were being used directly on livestock in 
farms. !e interviewees that represented 
the farming industry reported how the 
high cost of buying medicated feed had 
persuaded some farmers to mix active 
pharmaceutical ingredients into their 
animal feed. !e farmers who produced 
their own medicated feed did not have 
quality control and, in the interviewees’ 
opinion, the feed they produced was 
unlikely to have an even distribution 
of active pharmaceutical ingredients. 
Although the 2015 Animal Feed Quality 
Control Act prohibited such direct use 
of active pharmaceutical ingredients 
in animal feed, inadequate inspection 
allowed farmers to purchase such ingre-
dients from drugstores or wholesalers.
According to the various ministe-
rial noti"cations and regulations pro-
mulgated by the 1987 Drug Act, most 
antibiotics are classi"ed as “dangerous 
drugs” that can only be dispensed by 
licensed pharmacists in pharmacies, 
but can be obtained, legally, without 
a prescription. Only a few antibiotics, 
e.g. betalactamase inhibitor, carbapen-
ems and fosfomycin, are classi"ed as 
special-control drugs because of the 
high prevalence of resistance to them. 
Such drugs cannot be obtained, legally, 
without a prescription and are reserved 
for hospital use.
According to our interviews with 
key informants representing the coun-
try’s health providers, every private 
and public clinic and hospital had a 
pharmacy section in which antibiotics 
were dispensed to inpatients and out-
patients according to the prescriptions 
of doctors. Although most of these 
prescriptions were not required by law, 
the routine issuing of prescriptions, even 
for drugs that were not, legally, prescrip-
tion-only, had become the tradition of 
most health facilities. Antibiotics were 
also dispensed directly to consumers 











































Finished product, including medicated premix
Medicated feed
API: active pharmaceutical ingredients; FP: finished product.
Note: An integrated farming system covers all aspects of the commercial production of livestock, including breeding, feeding, processing and marketing.
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and pet owners by licensed pharmacists 
in wholesalers or drugstores.
Informants representing animal 
feed companies reported how feed 
mills mostly purchased medicated pre-
mix, from importers, manufacturers 
or distributors, to produce medicated 
feed that was then sold to farms either 
directly or via feed stores. According to 
the key informants from the farming 
industry, most of the antibiotics that 
farmers used were given to livestock in 
medicated feed, either for treatment or 
for prophylaxis during periods of in-
creased vulnerability, e.g. when livestock 
were transferred to new environments.
!e large number of licensed indi-
viduals involved in the antibiotic supply 
chains can be categorized according to 
the type of license granted to them un-
der the 1987 Drug Act or 2015 Animal 
Feed Quality Control Act. According to 
the licenses issued in 2016–2017, these 
chains involved 793 drug importers, 187 
drug manufacturers, 323 animal feed 
importers, 299 animal feed mills, 27 165 
feed stores and about 24 000 other indi-
viduals who were distributors, whole-
salers or retail pharmacies (Table 2). Of 
the 793 importers involved in antibiotic 
distribution, 675 (85%) were located in 
Bangkok, the capital city where the main 
air and sea ports are located.32 From 
Bangkok, many medicines, including 
antibiotics, are distributed throughout 
the country by importers, manufactur-
ers and wholesalers, with sales driven, 
as usual, by market forces. In 2016, 
the provinces of Bangkok, Chonburi 
and Phuket had more than 61 licensed 
private pharmacies per 100 000 popula-
tion (Fig. 2).
Our database searches revealed 
how, in 2015, about 3.1 million !ai 
households raised chickens (n = 2.4 
million), ducks (n = 0.4 million), bu"alo 
(n = 0.2 million) and/or pigs (n = 0.2 
million).14
Market authorization and 
licensing
Overall, 5371 antibiotics were registered 
in the !ai Food and Drug Administra-
tion’s database for 2016.34 Of these, 3371 
(63%) were registered for human use 
and the rest for use on livestock and 
pets, some as medicated premix. !e 
database records did not distinguish 
between imported antibiotics and those 
produced in !ailand.
!e importation of any drugs must 
be registered and pre-approved by the 
!ai Food and Drug Administration. By 
law, active pharmaceutical ingredients 
must only be sold by licensed import-
ers and manufacturers. At customs, the 
licensed importers of active pharmaceu-
tical ingredients are required to notify 
the !ai Food and Drug Administration 
before gaining approval for imports.
!e 1987 Drug Act regulates phar-
macists working in pharmacies, on 
aspects such as working hours and the 
dispensing of special-control drugs. 
However, most of the dispensing of 
antibiotics classi#ed as dangerous drugs 
is not legally regulated and the quality 
of dispensing is largely reliant on the 
competences of the doctors, pharmacists 
and veterinarians involved. Historically, 
there have been no legal requirements 
for the keeping of records on the types 
and quantities of antibiotics dispensed 
within the retail sector. At the time of 
our study, prescriptions were routinely 
issued in hospitals, but no prescription 
audits were required.
Discussion
Our study was triggered by the Global 
Action Plan on Antimicrobial Resis-
tance. In this study, we identi#ed a few 
key challenges, on both the demand 
and supply sides of the market as well 
as in health facilities and the regulatory 
environment, that perhaps made access 
to antibiotics too easy (Fig. 3).
Demand by patients and farmers
Self-medication with antibiotics ob-
tained without a prescription is a com-
mon practice in most developing coun-
tries.16 Although such self-medication 
may appear to be a relatively cheap 
option for the sick and their house-
hold carers, the societal cost of such 
treatment, o$en associated with inap-
propriate drugs or appropriate drugs 
in inadequate or suboptimal doses, and 
with a lack of counselling by the drug 
provider, can be relatively high. In China 
and Viet Nam, inadequate knowledge 
and lack of awareness of antimicrobial 
resistance, in both patients and provid-
ers, were recognized as important fac-
tors contributing to the irrational use of 
antibiotics.17 Inadequate regulation of 
drug distribution and sales may result in 
easy access, especially when, as is o$en 
Table 2. The types and numbers of individuals involved in the distribution of antibiotics 
and other medicines, Thailand, 2016–2017
Type License held No. of 
individuals
Licensed providers 
Medicine importers Pharmaceutical import 793a
Medicine manufacturers Pharmaceutical manufacture 187a
Medicine distributors Pharmaceutical sales NAa
Medicine wholesalers Pharmaceutical sales NAa
Retail drug stores or pharmacies  
    Selling all medicines Pharmaceutical sales NAa
    Selling only ready-packed medicines Pharmaceutical sales – ready-
packed medicines only
3164a
    Selling only ready-packed medicines for animals Pharmaceutical sales – 
ready-packed medicines for 
animals only
763a
Human health facilities Health facility 11 560b
Importers of animal feed Animal feed import 323c
Animal feed mills Animal feed manufacture 299c
Animal feed stores Animal feed sales 27 165c
Animal health facilities Animal health facility 2058d
Unlicensed individuals
Households involved in the rearing of livestock None 3 102 530e
NA: not available.
a  In 2017, according to the Thai Food and Drug Administration’s records, there were 19 934 individuals 
holding full pharmaceutical sales licenses in Thailand.32
b  Data from the Thai Ministry of Public Health’s records for 2016.33
c  Data from the Thai Department of Livestock Development’s records for 2016.35
d  Data from the Thai Department of Livestock Development’s records for 2016.36
e  The estimated number of households involved in the rearing of livestock.14
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the case in !ailand, prescriptions are 
not required. In turn, easy access may 
boost the inappropriate use of drugs by 
households.18,19
Supply problems
Any economic incentives o"ered by 
pharmaceutical companies to boost 
their market share may contribute to 
the excessive provision of antibiotics.17 
Some pharmaceutical companies sup-
port clinicians by sponsoring continu-
ing professional education, #nancing 
international travel for conferences 
and leisure or o"ering generous speak-
ing fees.20–22 In an attempt to break the 
link between such incentives and the 
preferential dispensing of drugs pro-
duced by the company providing the 
incentives, Denmark has decoupled the 
prescribing and dispensing of medicines 
by veterinarians.23 Almost all medicines 
used in the livestock sector in Denmark 
are now sold directly to the farmers by 
pharmacies.23
In much of Asia, the quality of the 
pharmaceutical services provided by 
retail pharmacies is o$en poor. !e 
sta" in such pharmacies may o"er no 
counselling or history taking and may 
recommend inappropriate presump-
tive treatments, e.g. antibiotics for the 
treatment of the symptoms of a common 
cold or in%uenza, or appropriate drugs 
in suboptimal doses.24 Suboptimal doses 
may be all that the patient can a"ord. In 
Peru and central !ailand, private retail 
pharmacies, where dispensing could not 
be guided by the antibiotic-resistance 
pro#les of the causative agents, were 
found to be the most common source of 
antibiotics for the treatment of sexually 
transmitted diseases.25,26
In !ailand, we identi#ed about 
24 000 distributors, retailers and whole-
salers who were fully licensed for phar-
maceutical sales in 2017. At the time 
of our study, the records of the !ai 
Food and Drug Administration did 
not di"erentiate between such licensed 
distributors, retailers and wholesalers. In 
consequence, there was no easy way to 
monitor or control the sale of large quan-
tities of antibiotics to individual patients 
or farmers. We found that, if they could 
a"ord it, !ai farmers could easily buy 
very large amounts of #nished products 
and active pharmaceutical ingredients 
from drug retailers or wholesalers.
Regulatory environment
!e focus of drug regulation in low- and 
middle-income countries, e.g. Ethiopia, 
!ailand, the United Republic of Tanza-
nia and Zimbabwe, is on drug quality 
and licensing rather than availability 
and distribution channels.10–12
In !ailand, the 1987 Drug Act did 
attempt to regulate the availability of 
some antibiotics, by dividing antibiotics 
into a large group of “dangerous drugs 
not requiring prescriptions” and a much 
smaller group of “special-control drugs 
requiring prescriptions”.30 !is categori-
zation meant that most antibiotics could 
be dispensed, by licensed pharmacists 
in retail pharmacies, without a pre-
scription. Furthermore, the Act made 
no attempt to regulate the quantity of 
antibiotics that could be distributed to 
any individual or to control the excessive 
use of antibiotics in livestock. Later, the 
2015 Animal Feed Quality Control Act 
prohibited direct use of active pharma-
ceutical ingredient in the animal feeds. 
However, our interviews indicated that, 
many !ai farmers were, illegally, add-
ing active pharmaceutical ingredients to 
animal feeds, probably as a cost-saving 
measure.
Following a series of public consul-
tations, the !ai Food and Drug Admin-
istration is working on a reclassi#cation 
of antibiotics in which a larger propor-
tion of the drugs will be categorized as 
special-control/prescription-only, in 
line with the recommendations made 
by the World Health Organization in its 
20th Model List of Essential Medicines.27
Compared with access to antibi-
otics, access to active pharmaceutical 
ingredients appears to be less well 
regulated, leading to inappropriate 
use by farmers. In !ailand, all drugs 
have to be registered with the Food and 
Drug Administration before produc-
tion or importation. !ere is, however, 
no corresponding requirement for the 
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registration of active pharmaceutical 
ingredients. Drug distributors and 
retailers can only sell active pharmaceu-
tical ingredients legally to manufactur-
ers. However, a lack of monitoring and 
tracking of active pharmaceutical ingre-
dients and inadequate inspections at the 
drug distributors and retailers mean that 
this legal restriction is generally ignored.
One limitation of our study is that 
the data maintained by the !ai Food 
and Drug Administration do not allow 
any estimation of the national consump-
tion of each major class of antibiotics in 
terms of, for example, the de"ned daily 
dose per 1000 inhabitants per day. !e 
!ai Working Group on the Surveillance 
of Antimicrobial Consumption is work-
ing on the development of a sustainable 
system to monitor annual antimicrobial 
consumption.28
In conclusion, this study appears to 
be the "rst published study in !ailand 
to investigate antibiotic distribution, for 
human and animal health. !e thou-
sands of drug distributors, drug whole-
salers, retail pharmacies and animal feed 
stores that have arisen in the country, as 
a result of market forces, and the small 
number of antibiotics that are classi"ed 
as special-control/prescription-only 
make most antibiotics easily and widely 
available in both the human and animal 
health sectors. Such wide availability 
probably leads to frequent inappropriate 
use. A general lack of enforcement of the 
legislation covering the distribution of 
active pharmaceutical ingredients facili-
tates the direct use of such ingredients 
on farms.
!e unnecessary and inappropriate 
use of antibiotics will probably lead to 
an increase in the problem posed by 
antimicrobial resistance in !ailand. A 
system for recording antibiotic dispens-
ing at retail pharmacies should be estab-
lished29 and then carefully audited by 
pharmacists. !e continued professional 
education of retail pharmacists should 
be promoted, as a means of reducing 
the inappropriate use of antibiotics, and 
other drugs. !e sales of large quantities 
of antibiotics to individuals need to be 
restricted by di#erentiating wholesalers 
from retailers in the licensing system. 
!is includes prohibiting wholesalers 
from selling large quantities of antibi-
otics to farmers, or others who are not 
licensed retail outlets, and carefully 
restricting the sale by retailers of large 
quantities of such drugs to individuals. 
!e ongoing policy to reclassify more 
antibiotics as special-control/prescrip-
tion-only drugs in !ailand should be 
rapidly implemented. A national sys-
tem for tracking active pharmaceutical 
ingredients should be established im-
mediately, to prevent the direct use of 
such ingredients on farms.  !
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Fig. 3. Factors potentially contributing to the excessive and/or inappropriate use of 
antibiotics, Thailand, 2016
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Les circuits de distribution des antibiotiques en Thaïlande: résultats d’entretiens avec des informateurs clés, de revues de la 
réglementation sur les médicaments et de recherches dans des bases de données
Objectif Analyser l’importation, la fabrication, la distribution et la 
réglementation des antibiotiques en Thaïlande.
Méthodes Nous avons rassemblé des informations sur la distribution 
des antibiotiques en Thaïlande à partir d’entretiens approfondis 
avec 43 informateurs clés –provenant d’exploitations agricoles, 
d’établissements de soins, du secteur pharmaceutique et de la 
production d’aliments pour animaux, de pharmacies et d’organismes 
de réglementation privés– et de recherches dans des publications et 
des bases de données.
Résultats En 2016-2017, la distribution d’antibiotiques autorisés 
en Thaïlande a fait intervenir plus de 700 importateurs et environ 
24 000 distributeurs, comme les pharmacies d’o!cine et les grossistes. 
La Thaïlande importe des antibiotiques et des principes actifs 
pharmaceutiques. Elle n’a pas de système de contrôle de la distribution 
des principes actifs, dont certains sont utilisés directement dans les 
exploitations agricoles, sans traitement préalable. La plupart des 
antibiotiques sont en vente dans les pharmacies, pour usage domestique 
ou agricole, sans ordonnance. Bien que la Loi sur les médicaments de 
1987 ait classé la plupart des antibiotiques comme «médicaments 
dangereux», elle n’en a classé qu’une petite partie en tant que 
médicaments soumis à ordonnance et n’impose aucune restriction sur la 
quantité d’antibiotiques qui peut être vendue à une personne. Certaines 
dispositions de cette Loi s’appliquent aux pharmaciens qui travaillent 
dans des pharmacies, mais il apparaît que la qualité de leur délivrance 
et de leur prescription dépend fortement de leurs compétences.
Conclusion En Thaïlande, la plupart des antibiotiques sont très facilement 
accessibles dans les pharmacies d’o!cine, sans ordonnance. Si l’on veut 
réduire l’usage inapproprié des principes actifs pharmaceutiques et 
des antibiotiques, il faudra reclasser certains antibiotiques et en limiter 
l’accès, mettre au point des systèmes pour contrôler la délivrance 
d’antibiotiques dans les o!cines et contrôler les mouvements des 
principes actifs.
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Resumen 
Canales de distribución de antibióticos en Tailandia: resultados de entrevistas con informantes clave, revisiones de 
regulaciones de medicamentos y búsquedas en bases de datos
Objetivo Analizar cómo se importan, fabrican, distribuyen y regulan 
los antibióticos en Tailandia.
Métodos Recopilamos información sobre la distribución de antibióticos 
en Tailandia, en entrevistas en profundidad, con 43 informadores clave 
de granjas, centros de salud, la industria farmacéutica y alimentación 
animal, farmacias privadas y reguladores, y en búsquedas de bases de 
datos y bibliografía.
Resultados En 2016-2017, en la distribución autorizada de antibióticos 
en Tailandia participan más de 700 importadores y alrededor de 24 000 
distribuidores, p.e. farmacias minoristas y mayoristas. Tailandia importa 
antibióticos y sustancias farmacéuticas activas. No existe un sistema para 
controlar la distribución de los ingredientes activos, algunos de los cuales 
se usan directamente en las granjas, sin ser procesados. La mayoría de 
los antibióticos se pueden comprar en farmacias, para uso doméstico 
o agrícola, sin receta médica. Aunque la Ley de Medicamentos de 1987 
clasificó la mayoría de los antibióticos como “drogas peligrosas”, solo 
clasificó algunos de ellos como medicamentos de venta con receta y 
no restringió las cantidades de antibióticos que podrían venderse a cada 
persona. Los farmacéuticos que trabajan en farmacias están cubiertos 
por algunas de las normas de la Ley, pero la calidad de su dispensación 
y prescripción parece depender en gran medida de sus competencias.
Conclusión En Tailandia, la mayoría de los antibióticos están disponibles 
de forma fácil y general en farmacias minoristas, sin receta médica. 
Para reducir el uso inapropiado de sustancias farmacéuticas activas y 
antibióticos, debemos volver a clasificar y restringir el acceso a ciertos 
antibióticos y desarrollar sistemas para auditar la dispensación de 
antibióticos en el sector minorista y llevar a cabo un seguimiento de 
los movimientos de los ingredientes activos.
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Appendix 2 System analysis of antimicrobial utilization in humans and 
animals: International Health Policy Program Working Paper  
I have reviewed laws and regulations, and assessed the enforcement capacities of the 
antimicrobial distribution reporting system in Thailand. It was reported 
in Part 1: Regulation and regulatory enforcement, ‘System analysis of antimicrobial 
utilization in humans and animals: actors and legal framework’. Two main regulations were 
examined in the report:  
1 Drug Act, BE 2530 (1987), BE 2530 (1987) 
2 Animal Feed Quality Control Act, BE 2558 (2015) 
The full report is in the next page. 
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Antimicrobial Resistance (AMR) has recently been recognized as a major threat to global health; its 
increased prevalence and spread of resistant microorganisms affect humans and animals throughout 
the world [0F1]. Worldwide, AMR claims 700,000 human deaths annually; unless effective 
interventions are installed, AMR will claim ten million deaths by 2050 and cost the world up to US$ 
100 trillion, equivalent to 2% - 3.5% of Gross Domestic Product (GDP) [1F2].  
Antibiotic use is a critical factor in the emergence of resistant bacteria, as irrational use of antibiotics 
can speed up the resistance [2F3]. Currently in the world, drug supplies and drug distribution channels 
are dramatically increasing which improves access to medicines. However, equally important parallel 
interventions to support the rational use of medicines are not increasing at the same rate. In 
developed countries, drug prescriptions are under authorization by licensing prescribers. The 
mandatory prescription system can easily track the distribution of drugs and facilitate audits which 
may redress the irrational use of antibiotics.  
However, in developing countries including Thailand, there is no such monitoring. Moreover, 
people’s easy access to antimicrobials without prescription (through dispensing and purchasing of 
antibiotics) is common at private pharmacies. At the farm level, active pharmaceutical ingredients 
and medicated premix can be used without professional supervision.  
In May 2015, the World Health Assembly adopted a Global Action Plan on Antimicrobial Resistance, 
calling on member states to develop a national action plan within two years [3F4]. The World 
Organisation for Animal Health (OIE) and the Food and Agricultural Organization (FAO) also adopted 
AMR resolutions in 2015, fostering tripartite collaboration. Thailand developed a national AMR 
strategy, endorsed by the Cabinet in August 2018, which has gained legitimacy and facilitated multi-
sectoral collaboration. One of the five indicators of the National Strategic Plan is the establishment 
of the Antimicrobial Use (AMU) monitoring system. Antimicrobial consumption monitoring is a key 
instrument for monitoring trends and evaluating the outcomes of interventions which strengthen 
antimicrobial stewardship. It generates evidence on the magnitude and profiles of antimicrobial 
consumption. It can provide entry points for evidence-based policy actions to reduce antimicrobial 
use in the country [4F5, 5F6]. 
The system analysis of antimicrobial utilization - including marketing, distribution, prescription and 
use - supports the development of AMU monitoring systems and contributes to the design of 





B.  Objective 
The overall objective of this study is to describe and analyse the system of antimicrobial utilization in 
humans and animals, the actions of key actors involved in distribution channels and the legal 
frameworks governing distribution and regulatory capacities.  
Specific objectives: 
- To review laws and regulations and assess the enforcement capacities of the antimicrobial 
distribution reporting system  
- To describe the system and process of antimicrobial utilization in humans and animals 


























C. Methods  
Framework of the study 
Key terms and explanations included in this study are defined as follows: 
Antimicrobials: An antimicrobial is considered as a naturally occurring, semi-synthetic or synthetic 
substance that exhibits antimicrobial activity (to kill or inhibit the growth of micro-organisms) at 
concentrations attainable in vivo. Anti-helminthic and substances classed as disinfectants or 
antiseptics are excluded from this definition [7]. In this study, it focuses on antibiotics.  
Drug utilization: Drug utilization research is defined by WHO as the marketing, distribution, 
prescription and use of drugs in a society with special emphasis on the resulting medical, social and 
economic consequences [7F8]. In this study, we focus on distribution as it is governed by two relevant 
Acts responsible by FDA and DLD.  
We began by reviewing what regulations and the processes under which they are enforced mean. 
The research team proposed assessing the regulatory framework and the process of enforcement 
with the application of Kumaranayake [8F9].  Although there are different regulatory goals such as 
product quality, quantity, price and distribution, this study focuses on antimicrobial distribution.  
Regulating quality and quantity is implicitly linked with regulating distribution. For example, 
restricting the number of drug stores in some geographical areas by setting standards and quality 
assurance, or the licensing of medicines to ensure their safety, contribute to the number of 
providers and the quality of products.  
Relevant key actors involved in antimicrobial distribution are also fully covered by this study. There 
are many types of regulatory instruments to control and monitor drug utilization such as legislation, 
incentives and codes of conduct. This study focused on two main pieces of legislation covering 
pharmaceutical products including medicated feed. The two Acts are Drug Act BE 2530 (1987) and 









Figure 1.  The four regulatory questions captured by this study: what to regulate, who is regulated, 
how to regulate and at what level? Target variables can be applied at different levels. This study 
considered antibiotics and organization levels such as the licensing of operators and health facilities. 
Licensing and regulating individual health professionals by related professional councils are beyond 
the scope of this study.   






Figure 1 Scope of regulating antimicrobial distribution captured by this study 
 
In terms of the system and process of antibiotic utilization, the study covered importation, 
manufacturing, and distribution by operators, dispensing and prescription by professionals. The 
study covered numerous actors such as: importers, manufacturers, distributors, wholesalers, 
retailers, feed mills, feed stores and animal health facilities and human health facilities including 
public hospitals, private hospitals, clinics, farmers, and pet owners. 
 
Data collection and analysis 
Mixed methods were applied. This included reviews of relevant literature and in-depth interviews 
with key informants.  
Key document reviews included official papers on licensing operators, medicine marketing 
authorization and inspection under the two Acts which control antibiotic and medicated feed 
(medicine for feed medication used in animals). Firstly, the Drug Act (1987) is responsible by the Thai 
Food and Drug Administration (FDA) of the Ministry of Public Health (MoPH). This Act controls both 
human and veterinary medicine finished products and Active Pharmaceutical Ingredients (API).  
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Livestock Development, Ministry of Agriculture and Cooperatives (MoAC), which controls medicated 
feed. This study reviewed the total 45 relevant laws and regulations ranging from the Act itself and 
accompanying regulations, notifications, and rules (Table 1). 
Table 1 Number of documents related to regulations reviewed by this study  
 MoPH MoA 
Act The Drug Act (1987) The Animal Feed Control Act (2015) 
Ministerial regulation 8 2 
Notification of ministry 18 5 




Rule of the organization 1 - 
Total documents reviewed  36 9 
 
The reviews of regulation were supplemented by data gathered through semi-structured interviews 
with 13 regulators; this gained additional information about the legal resources and how regulatory 
enforcement was interpreted and implemented. The regulators are government officers in MoPH: 
FDA, the Bureau of Drug, Rural and Local Consumer Health Products Promotion and Protection 
Division, Provincial Health Office; MoAC: Animal Feed and Veterinary Products Control (AFVC), and 
Provincial Livestock Office. Interviews with regulators focused on existing antibiotics regulations and 
enforcement, according to the conceptual framework of the study.  On the effectiveness of 
regulation, the study analyzed the content of regulation, and real-life enforcement and regulatory 
capacity. The practices and challenges of regulatory enforcement also covered two levels - national 
and provincial - as certain regulations were devolved to provincial offices. 
Further, this study covered a total of 30 key informant interviews including pharmaceutical 
companies, animal feed companies, health professionals, wholesalers, drug stores and farmers, and 
others from the association in accordance with pharmaceutical production and sale (Table 2). The 
key informants have experience in their respective areas, with an average of 17 years (range 0.5 to 
43). The purpose of the in-depth interviews was to understand how regulation was enforced in real-
life and the extent of their capacity to so. Interviews with key informants who are operators focused 




The interviewees were asked about their roles on drug distribution channels. The interview allowed 
investigators to explore new and other open-ended themes surrounding antimicrobial distribution 
which may be overlooked by the conceptual framework. Themes covered by the interviews 
included: (1) regulations in relation to antimicrobial distribution: (2) its enforcement: responsible 
organization, capacity of organization in term of resources and infrastructure, regulatory activity and 
outcomes; (3) cooperation between these regulatory organizations at different levels and with other 
regulation enforcement agencies; (4) distribution process of antimicrobials; and (5) roles of operator 
in the distribution. 
Table 2 Number and profiles of key informants covered by the study 
 
The data extracted from document reviews and transcripts of the key informant’s interviews were 
summarized, analyzed and presented according to the study framework. The antimicrobial 
distribution in line with roles of key actors was mapped into the system flow chart.  
Consultative meeting 
A consultative meeting took place after initial data sets were analyzed. Its aim was to present the 
preliminary findings and invite workshop participants to review, verify, discuss and propose policy 
recommendations on antibiotic distribution and related regulatory enforcement.  
The workshop participants were invited from the following groups: governmental officers at national 
and provincial level, academia from the faculty of medicine, pharmacy and veterinary science, and 
relevant associations.  
Before the meeting, a draft document and a brief summary of the document were circulated to 






Work experience in 
the organization 
(mean, range; year) 
Regulator 13 (35-59) (15.88, 0.5-32) 





Animal feed company 5 (30-61) (18.5, 3.5-37) 





Wholesaler, drug store (retailer) 4 (36-70) (25.5, 11-42.5) 
Farmer 3 (37-52) (16.6, 13-19) 




opened for multi-stakeholder discussion in order to identify certain policy recommendations and 
improve the study report. Afterwards, participants were encouraged to submit their written 
comments within 30 days following the meeting. The report was revised, taking into account 



























Findings consist of three parts: the first starts with the regulatory environment of antimicrobial 
distributions. The second part concerns actors involved in the distribution channels until antibiotic 
use by consumers and animals. Finally, in part three, reveals the complexity of distribution channels 
and concerned actors.   
 
PART I: Regulation and regulatory enforcement 
Two laws govern antibiotic use in human and livestock: the Drug Act BE 2530 (1987) and the Animal 
Feed Quality Control Act BE 2558 (2015). FDA and DLD are the custodies of these laws respectively. 
However, the authority of law enforcement on the operators operating outside Bangkok was 
delegated to the Provincial Health Office (PHO) and Provincial Livestock Office (PLO) respectively. 
Details are discussed in the supply chain inspection section. 
The Drug Act, BE 2530 (1987) 
The Drug Act BE 2510 (1967) was first legislated in 1967; it has been amended four times in 1975, 
1979, 1984 and the last revision in 1987. The current version is the Drug Act BE 2530 (1987). The aim 
of the law is to assure safety, efficacy and quality of medicines. 
• Regulatory authority 
The FDA was established in 1922; it was the Narcotics Division under the Public Health 
Department, Ministry of the Interior in 1922 and then transformed to assume the functions of the 
current FDA.  Currently, it is the responsible agency under the MoPH with a statutory duty to protect 
consumers' health through ensuring the safety, quality and efficacy of all consumable health 
products that have implications on health of the population. The portfolio of health products 
responsible by the FDA are: foods, drugs, psychotropic substances, narcotics, medical devices, 
volatile substances, cosmetics and hazardous substances. Each product is governed by specific law.  
There are eight laws relating to health products, for which the FDA has responsibility. These are:  
1) Drug Act, B.E. 2510 (1967) and amendment No. 2 (1975), No. 3 (1979), No. 4 (1985) and No. 
5 (1987), 
2) Psychotropic Substance Act B.E. 2518 (1975) and amendment No. 2 (1985), No. 3 (1992) and 
No. 4 (2000) 




4) Narcotic Act, B.E. 2522 (1979) and amendment No. 2 (1985), No. 3 (1987) and No. 4 (2000) 
5) The Emergency Decree on the Prevention of Abuse of Volatile Substances, B.E. 2533 (1990) 
and amendment No. 2 (2000) 
6) Hazardous Substance Act, B.E. 2535 (1992) 
7) Medical Device Act, B.E. 2551 (2008) 
8) Cosmetic Act, B.E. 2558 (2015) 
The FDA is responsible for four international agreements: 1) the Single Convention on Narcotic 
drug 1961; 2) The Convention on Psychotropic Substance 1971; 3) the International Code of 
Marketing of Breast Milk Substitute 1981; and 4) The United Nation Convention Against Illicit Traffic 
in Narcotic Drugs and Psychotropic Substances 1988. 
• Definition and classification of medicines 
In line with the fifth revision of the Drug Act (1987), the FDA is responsible for regulating all 
pharmaceutical products, as defined in Section 4 of the Drug Act. 
Drugs are defined as:  
(1) Substances recognized by pharmacopoeias as notified by the Minister;  
(2) Substances intended for use for the diagnosis, treatment, relief, cure or prevention of 
human or animal disease or illness; 
(3) Substances which are pharmaceutical chemicals or semi–processed pharma chemicals; and  
(4) Substances intended to affect the health, structure or function of the human or animal 
body.  
Substances under (1) (2) or (4) shall not include: 
(a) Those intended for use in agriculture or industry as notified by the Minister; 
(b) Those intended for use as food for human, sport and medical apparatus, cosmetics or device 
for use in the practice of medicine and a component thereof;  
(c) Those intended for use in science laboratory for research, analysis or verification of disease, 
which is not directly done to human body. 
The Drug Act also classifies drugs into different categories; this includes:  
“Modern drug” meaning a drug intended for use in the practice of modern medicine or the cure 
of an animal disease; 
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“Dangerous drug” meaning a modern of traditional drug notified by the Minister as a dangerous 
drug; 
“Special-controlled drug” meaning a modern or traditional drug notified by the Minister 
requiring a specific control mechanism on its distribution and use; 
“External drug” meaning a modern or traditional drug intended for external use. 
“Specific local application drug” meaning a modern or traditional drug intended for use in 
specific areas of human body such as drugs for ears, eyes, nose, mouth, anus, vagina or urinary 
tracks. 
“Household drug” means a modern or traditional drug which is notified by the Minister as a 
household drug; 
“Ready – packed drug” means a modern drug manufactured in a pharmaceutical from, which is 
packed in a closed or sealed package which has all the label as required by this Act. 
It is noted that drugs cover finished products: human medicines, veterinary medicines including 
medicated premix (medicine for animal feed mixing only), and API. The medicated feed (medicine 
for feed medication) is regulated by the Animal Feed Quality Control 2015 responsible by 
Department of Livestock Development, which will be discussed later in Part 1. 
• Instruments for regulating antibiotic distribution
To regulate antibiotic distribution, sale and access by the population, the Drug Act (1987)
classified medicines into two main groups; modern and traditional medicines. All types of antibiotics 
are defined as modern medicine and are classified into four categories including: 
1) Household drug, which does not require a license to sell. There are currently 52 items of all
household drugs according the MoPH notification, and two items are antibiotics:
• Sulfacetamide sodium 10% (eye drops)
• Silver Sulfadiazine 1% (topical use)
2) Dangerous drug (pharmacy dispensing only). This group of antibiotics can be sold without
prescription but must be dispensed by pharmacists in licensed pharmacies. On the front of
the package, there is a red font label with the words “dangerous drug”.  There are more
than 78 items on the list, according the last MoPH notification.  All antibiotics are classified
as dangerous drugs except the following:




• Special-controlled substance drug: Sulfonamides PO, Chloramphenicol for children 
use, for animal registered medicine, for adult (systematic use)) 
• Household drug (Sulfacetamide sodium 10% (eye drop), Silver Sulfadiazine 1% 
(topical use)) 
• Penicillin V Potassium (dry syrup) 
• Phenylsulphathiazole 500 mg (tablet)  
• Sulfamethoxazone 400 mg + Sulfa-trimethoprim 80 mg (tablet/capsule) 
• Sulfadoxine 500 mg + Pyrimethamine 25 mg (tablet)  
• Anti-tuberculosis, anti-malaria, antiprotozoal, anti-virus (except specific local 
application drug), anti-fungus (except specific place drug). 
3) Special-controlled drug, which requires prescription and can only be used in hospitals or sold 
to doctors, dentists, veterinary professionals and drug wholesale licensees. On the front of 
the package, there is a red font label with the words “special-controlled drug”. There are 83 
items of medicines on these lists according the MoPH notification. The special-controlled 
antibiotics are: 
• Sulfonamide PO 
• Chloramphenicol for children use, for animal registered medicine, and for adults 
(internal use)  
• New drug (registered under conditional approval); these can be used by hospitals 
under the Safety Monitoring Program (SMP) for at least two years, where the SMP is 
managed by FDA.  
4) Non-dangerous and non-special controlled drugs (ready-packed drugs), which can be sold by 
health professionals. None of the existing registered antibiotics are categorized as this 
group. 
 In summary, the Drug Act regulates antibiotic distribution by classifying all types of antibiotics 
into groups, and specifies which outlets can patients access.  
• Market authorization 
 According to section 79 of the 1987 Drug Act, any person licensed to produce or import drugs 
who wishes to produce or import drugs is required to apply to the competent officer for registration 





 As of 2016, FDA registered approximately 5,371 antibiotics;  3,371 drugs (63%) were for human 
use and about 2,000 were veterinary antibiotics including medicated premix. However, data does 
not allow differentiation between imported and locally-produced antibiotics. 
Section 79 states that it does not cover API control. Under the MoPH notification, the import and 
manufacture licensees can import and, or produce API on the following conditions 1) use for their 
own production of finished products, 2) sell to drug sale or manufacture licensees, 3) export to 
overseas. The law stipulates that API must be distributed to the production of finished products 
only; it cannot be used directly in humans and animals due to its high concentration. At customs, 
licensed importers are required to notify FDA before API importation. Notification is much weaker 
than registration. In addition, notifications are not kept and reported in the FDA statistics. The 
regulation gaps result in API leakage for direct use in animal and plant sectors, which will be 
addressed later in the Section discussion.  
• Licensing 
All operators should be licensed by the Drug Act 1987. There are six types of licensing which 
cover importation, manufacture and sale. In terms of sale, it can be divided into four sub-categories 
including sales of modern medicines, wholesale, sale of ready-packed modern drugs which are not 
dangerous or special-controlled drugs and sale of ready-packed modern drugs for veterinary use.  
Section 12 stipulates that no persons shall produce or sell a modern drug or import or order a 
modern drug into the Kingdom, unless they obtained a license from the licensing authority, —the 
FDA. The application for and grant of a license shall be in accordance with the rules, procedures and 
conditions prescribed in the Ministerial Regulation. Section 15 clarifies license categories for modern 
drugs are as follows: 
(1) a license to produce modern drugs;  
(2) a license to sell modern drugs;  
(3) a license for modern drug wholesale; 
(4) a license to sell ready-packed modern drugs which are not dangerous or special-controlled 
drugs; 
(5) a license to sell ready-packed modern drugs for veterinary use; 
(6) a license to import or order drugs into Thailand;  
Furthermore, there is complexity on cross licensing, as the regulation stipulates that:  
A licensee under (1) or (6) shall be also de facto deemed to be licensee under (2), authorized to 
sell the drugs which the licensee produces, imports or orders into the Kingdom where applicable.  
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A licensee under (3) shall be also de facto deemed to be licensed under (4) and (5), namely 
authorized for retail sales of the ready-packed drugs for human (which are not dangerous or special-
controlled), and for veterinary use.  
A licensee under (3) shall be also de facto deemed to be licensed under (4) and (5) for wholesale 
only. 
• Supply chain inspection
FDA and provincial health offices (PHO) are two main authorities responsible for the inspection
of the six types of operators licensed above. For all types of licensing including importation, 
manufacture and sale located in Bangkok, inspections are responsible by FDA. The inspections of 
operators operated at provincial level are decentralized to the PHO which represents the MoPH in 
each province. However, operator-held manufacture licenses located in any provinces will be 
inspected by FDA, due to lack of certain technical capacities in the PHO. 
Table 3 Inspection of licenses including importation, manufacture and sale by different geographical 
areas 
Location Importation Licensee Manufacture Licensee Sale Licensee 
Bangkok 
First inspection for license approval, annual inspection, inspection when complaint: 
FDA (Post-marketing surveillance division) 
Other 
provinces 
First inspection for license 
approval: PHO 
Annual inspection: PHO 
Inspection in response to 
complaints: PHO work 
with Post-marketing 
control division, Rural and 
local consumer health 
products promotion 
protection division, FDA 
First inspection for license 
approval, annual inspection, 
inspection when complaint: 
FDA (Post-marketing 
surveillance division) 
First inspection for license 
approval: PHO 
Annual inspection: PHO 
Inspection in responses to 
complaints: PHO work 
with Post-marketing 
control division, Rural and 
local consumer health 
products promotion 
protection division, FDA 
• Control the quality of the process
Importation at point of entry:
The FDA designated 40 air, sea and land ports for pharmaceutical products (among these, ten
are designated for the regulation of API), which are responsible for inspection and approval of the 




pass the inspection by officials at these checkpoints. This practice adheres to Ministerial regulations, 
which appoint official authority and mechanisms to control importation at customs.  
Table 4 Regulation at forty points of entry for finished medicine products and API importation  
No. Checkpoints Province Superintendent 
1 
Food and drug checkpoints of Bangkok International 




2 Food and drug checkpoints of post office divided by customhouse border Bangkok post office*  Bangkok FDA 
3 Food and drug checkpoint of the Actulum private harbor* Samut Prakan FDA 
4 Food and drug checkpoint of Lardkrabang train station* Bangkok FDA 
5 Food and drug checkpoints of Bangkok harbor divided by customhouse border Bangkok harbor* Bangkok FDA 
6 Food and drug checkpoint of private harbor No.10* Samut Prakan FDA 
7 
Food and drug checkpoints of Suvarnabhumi 
international airport (International passengers, 
Warehouse*) 
Samut Prakan FDA 
8 Food and drug  ) harbor( checkpoint of Amphoe Phra Samut Chedi * Samut Prakan FDA 
9 Food and drug checkpoint of Samut Prakan (Uni-Thai) * Samut Prakan FDA 
10 Food and drug checkpoint of Amphoe Bang Sao Thong  Samut Prakan FDA 
11 Food and drug checkpoint of Chiang rai international airport (Mae fah luang) Chiang rai FDA 
12 Food and drug checkpoint of Amphoe Chiangsaen (harbor), Chiang rai province Chiang rai FDA 
13 Food and drug checkpoint of Amphoe Chiangkhong, Chiang rai province Chiang rai FDA 
14 Food and drug checkpoint of Amphoe Maesai, Chiang rai province Chiang rai FDA 
15 Food and drug checkpoint of Lamchabung harbor* Chon buri FDA 
16 Food and drug checkpoint of Amphoe Sadao divided by customhouse Sadao border, Songkhla province  Songkhla FDA 
17 Food and drug checkpoint of Ban Prakob, Songkha province Songkhla FDA 
18 Food and drug checkpoint of Songklha Port Songkhla FDA 
19 Food and drug checkpoint of Hatyai international airport Songkhla FDA 
20 Food and drug checkpoint of Padangbezar city divided by customhouse Padangbezar city border, Malaysia  Songkhla FDA 
21 Food and drug checkpoint of Phuket international airport Phuket FDA 




No. Checkpoints Province Superintendent 
23 Food and drug checkpoint Amphoe Kantang, Trang province Trang PHO 
24 Food and drug checkpoint Chongmek border, Ubon Ratchathani province 
Ubon 
Ratchathani PHO 
25 Food and drug checkpoint of Chiangmai international airport Chiangmai PHO 
26 Food and drug checkpoint of Lampoon province Lampoon PHO 
27 Food and drug checkpoint Amphoe Maesod, Tak province Tak PHO 
28 Food and drug checkpoint of Nong Khai province Nong Khai PHO 
29 Food and drug checkpoint of Ranong province Ranong PHO 
30 Food and drug checkpoint of Samui international airport, Suratthani province Suratthani PHO 
31 Food and drug checkpoint of Wangprachan, Satul province Satul PHO 
32 Food and drug checkpoint of Amphoe Tahlee, Loie province Loie PHO 
33 Food and drug checkpoint of Amphoe Sungai Kolok, Narathiwas province Narathiwas PHO 
34 Food and drug checkpoint of Amphoe Tungchang, Nan province Nan PHO 
35 Food and drug checkpoint of Bungkarn province Bungkan PHO 
36 Food and drug checkpoint of Nakhon Phanom province Nakhon Phanom PHO 
37 Food and drug checkpoint of Mookdahan province Mookdahan PHO 
38 Food and drug checkpoint of Amphoe Aranyaprathet, Srakaew province Srakaew PHO 
39 Food and drug checkpoint of Choomporn province Choomporn PHO 
40 Food and drug checkpoint of Krabi international airport Krabi PHO 
*Ten designated checkpoints for API 
 
Manufacturing: 
To ensure the quality of the manufacturing system, the MoPH has issued additional 
notifications under the Drug Act. The MoPH notification for rules and methods of quality control of 
medicine production covers the areas of quality management, personnel, facilities and 
infrastructure, document processing, production operation, quality control, complaint management 




In addition, the FDA notification establishes guidelines for licensing manufacturers in accordance 
with the Good Manufacturing Practice (GMP) based on the Pharmaceutical Inspection Co-operation 
Scheme (PIC/S) criteria.  
Sale at pharmacy:  
Pharmacies which hold sale licenses are at the forefront of pharmaceutical services with 
close interface with communities. They play a critical role in ensuring quality medicines are provided 
to the population. The MoPH has issued a notification to control the quality of pharmacy premises, 
service equipment, and Good Pharmacy Practice (GPP) in 2014. This notification contributed 
significantly to the improvement of the quality of pharmacies in terms of community pharmaco-
vigilance practice, equipment used in sales, storage and control of drug quality. In addition, it 
contributed to the standardization of pharmaceutical services. As a result, it reduced the problem of 
selling special-controlled drugs without a pharmacist. For example, these pharmacies were 
evaluated as required by notification before the annual renewal of their license. Passing the annual 
evaluation is the precondition for a sales license renewal. However, current license holders who 
were licensed prior to June 25, 2014 have a special provision of “grace period” for the adjustment of 
standards as required. They are waived the standards of premises, equipment, and compliance with 
GPP during this grace period of adjustment. All sales licensees shall have to comply with all 
standards as required by the MoPH notification by 2022, which is eight years grace period since 
2014. 
• Monitoring system of distribution and sales of pharmaceutical products 
According to the Drug Act, operators are legally required to send the report to the FDA. The 
monitoring systems apply to both pharmaceutical products: finished products and API. The 
mandatory report by import, manufacture and sale licensees are described in table 5.  
Finished products 
1) A weekly wholesale report of five potentially abused medicines (this group does not include 
antibiotics) i.e. Tramadol, Dextromethorphan, Antihistamine, Corticosteroids and Sildenafil, 
Tadalafil or Vardenafil by import, produce and sale licensees through a web-based 
information system (sometimes, this is called “FDA reporter”) 
2) A four-monthly report of importation, manufacture and sale of four potentially abused 
medicines (also not include antibiotics), i.e. Tramadol, Dextromethorphan, Antihistamine 
and Sildenafil, Tadalafil or Vardenafil by import, produce and sale licensees. 




produce licensees (which historically does not cover distribution detail). 
API 
1) A four-monthly report of the sale of Corticosteroids, Quinolone and derevatives, 
Cephalosporins, Macrolide [all bold type are antibiotics] by import, produce licensees 
through web based information system  
2) An annual report of importation, manufacture and sale of all pharmaceutical products by 
import, produce licensees. 
 










A weekly report Wholesale Wholesale Wholesale 
Tramadol, Dextromethorphan, 
Antihistamine, Corticosteroids 










Antihistamine and Sildenafil, 
Tadalafil or Vardenafil 













- All medicines 
 
 
The Animal Feed Quality Control Act, BE 2558 (2015) 
The Animal Feed Quality Control Act controls the quality and standard of animal feed including 
complete animal feed (finished product of animal feed), and regulated by the Department of 
Livestock Development, Ministry of Agriculture. The FDA recently issued the notification in 2017 to 
exempt the medicated feed, which was formerly regulated by the Drug Act, to be regulated by the 
DLD. Consequently, DLD of the MOAC would issue a notification to control the quality and standard 
of medicated feed. Note that the overlap between “veterinary antibiotics in particular medicated 
premix” under FDA mandates and “animal feed” under DLD mandates is that the “medicated feed” 




In order to control the medicated feed, the law (Animal Feed Quality Control Act) regulates that any 
operator who wishes to produce special-controlled animal feed must register the “Special-controlled 
animal feed”. This refers to the animal feeds that have a potential impact on the economy or society 
or may be harmful to animals or may affect the consumers of animal products. When registration is 
approved, medicated feed can be produced from the mixture of registered special-controlled animal 
feed and antibiotics, registered by FDA. 
In addition, the Animal Feed Quality Control Act covers licensing and regular inspection of feed mills 
which produce feed and stores which sell medicated feed. Operators who want to produce, import 
and sell animal feed should be licensed by DLD. Since the law was newly legislated in 2015, it is 
under the process of drafting the following notification. In the draft of notification, veterinary 
prescription and GMP inspection for feed mills are required for controlling the importation, sale, 
production and use at feed mills and farms. Members of the EU decided to apply a stepwise 
approach to ban the use of antibiotics as growth promoters before 2000 and implemented a total 
ban policy in 2006. Thailand, having recognised the importance and urgency of the matter, decided 
to introduce this policy before 2000 and enforced the total ban policy in 2015. The direct use of API 
in animal farms is also prohibited and unlawful. 
• Regulatory authority 
The DLD was founded in 1942, and is the National Veterinary Authority of Thailand, responsible 
for animal health, animal production and livestock development, food safety of animal-derived 
products, veterinary public health, animal welfare, environmental impact of livestock farms and 
international animal health matters. DLD is the national counterpart of OIE.  
AFVC is a department under DLD. Based on the mandates given by two Acts - the Animal Feed 
Quality Control Act BE 2558 (2015), and the Hazardous Substance Act BE 2535 (1992) - it regulates 
the operators to comply with the law on: quality animal feed, veterinary products and use of 









• Definition and classification  
According to the section 4, animal feed and special-controlled animal feed are defined as 
follows.  
“Animal feed” means  
(1) materials which are intended for use or feeding animals by eating, drinking, licking or 
entering into animal bodies by any method or; 
(2) materials which are intended for use with or as a mixture in the production of animal feed;  
“Special-controlled animal feed” means animal feed that has impact on the economy or 
society or may be harmful to animals or may affect the consumers of animal products. The 
production or importation of such animal feed for sale must be registered in accordance with 
the notifications prescribed by the Minister taking into account the advice of the Animal Feed 
Quality Control Committee.   
Section 4 links with Section 6 of the Act that the Minister shall, with the advice of the 
Committee, have power to issue notifications on the name, category, type, characteristic, quality 
and standard of special-controlled animal feed and animal feed as well as the rules, procedures and 
conditions of the production for sale, importation for sale or the sale of these products. 
In the past, no provision in the Drug Act explicitly defined the regulation of medicated feed.  
As a result of close consultation and collaboration between the two key agencies - FDA and DLD - 
both finally reached the consensus that the medicated premix should be regulated by FDA through 
the provisions in the Drug Act, while the medicated feed is regulated by the DLD, under the Animal 
Feed Quality Control Act.  
• Instrument for regulating antibiotic distribution in animal sector  
The use of antibiotics as growth promoters was totally banned and enforced in 2015. In 2016, 
the use of pharmaceutical active ingredients in animal farms was also totally prohibited with close 
vigilance.  
In addition, the DLD is in the process of drafting the MoAC notification on the control of the 
production, import, sales and use of medicated feed according to the Animal Feed Quality Control 
Act (2015). It is in line with the FDA, which proposes that the Minister of Public Health should sign 
the notification of the MoPH that animal feed containing antibiotics will be regulated through the 




The details of the ongoing development of MoAC notification would cover the production, 
importation and sale of medicated feed. The key contents cover the following:  
- Prohibit the manufacture, import, and sale of animal feeds which contain (1) unregistered 
drug, (2) Polymyxin group, Penicillin Group, Fluoroquinolones, Fosfomycin for the purpose of 
prophylaxis, or use outside the indications approved by the registration (off-label use), (3) 
medicine in sub-paragraph (2) with a combination of more than two medicines in the 
medicated feed, (4) Use of antibiotics mixed in animal feeds in a lower level than that 
specified in the drug authorization, (5) Cephalosporin group (Draft of MoAC notification, 
Article 4) 
- Prohibit farm mixer systems on the following: a) pig farms having more than 500 pigs, b) 
broiler farms having more than 5,000 animals, c) layer farms having more than 1,000 
animals. Below this benchmark, the farm mixer systems are allowed to produce medicated 
feeds for their own use but are required to keep the prescription and e-signature by farm 
veterinarians for three years for the purpose of DLD inspection. Regarding notification and 
reporting requirements, these farm mixer systems are required to notify the number and 
names of the farm veterinary doctors or animal husbandry under their supervision including 
the farm mixing production systems. They are required to produce annual reports to DLD on 
the total annual production of their medicated feed and laboratory test results of the proof 
of a) homogeneity of the medicated feed, b) no cross contamination of antibiotics to non-
medicated feed production. (Draft of MoAC notification, Article 5). Note that there is a 
consultation among FDA, DLD and relevant stakeholders to issue the notification to control 
the use of such antibiotics in the farm mixer systems under veterinary prescription and 
supervision.  
- Medicated feed producers shall meet the requirements for the production quality such as 
GMP certified manufacture, and production controlled by veterinarians (Draft of MoAC 
notification, Article 6). 
- Prohibit the sale of the following animal feed from mills directly to feed store; these are (1) 
concentrated medicated feed, (2) animal feed containing Polymyxin group, Penicillin Group, 
Cephalosporin, Fluoroquinolones, Fosfomycin, (3) medicated feed for fattening pigs 
weighing 90 kg upwards, last stage of broiler and layer, (4) medicated feed without 
veterinary prescription (except animal feed for pigs weighing less than 25 kg with no more 




- Prohibits the sale of medicated feed by stores to farms without veterinary prescription. 
(Draft of MoAC notification, Article 8) 
• Market authorization of medicated feed 
According to the chapter four of the Animal Feed Quality Control Act, licensees who wish to 
produce or import any special-controlled animal feed, must register with competent officials. After a 
certificate of registration for the animal feed has been granted, they would be able to produce or 
import special-controlled animal feed. Note that the registration covers all animal feed, not specified 
medicated feed. The total of registered animal feed formulas was more than 12,000 items.  
• Licensing of special-controlled animal feeds 
The Animal Feed Quality Control Act regulates the operators who produce or import the 
special-controlled animal feed, in this case, the medicated feed (section 15) and sale (section 17). 
Three types of license are defined in the section 22 of the Law: production, importation and sale.  
- Section 15: Any person, who wishes to produce or import for sale of special-controlled 
animal feed shall apply for a relevant license and shall produce or import for sale when such 
license has been granted by the licensor. The application and issuance of a license under 
paragraph one shall be in accordance with the rules, procedures and conditions prescribed 
in the Ministerial Regulation (MOAC). The licensee under paragraph one must also comply 
with the rules, procedures and conditions for the production or importation for sale of the 
special-controlled animal feed prescribed by the Minister under Section 6.  
- Section 17: Any person, who wishes to sell special-controlled animal feed under Section 6 
(1), shall apply for a license and shall sell the said special-controlled animal feed only after 
such sales license has been granted by the licensor. The application and issuance of a license 
under paragraph one shall be in accordance with the rules, procedures and conditions 
prescribed in the Ministerial Regulation (MOAC). Licensees under paragraph one must 
comply with the rules, procedures and conditions for the sale of the special-controlled 
animal feed prescribed by the Minister under Section 6 (1).  
- Section 22 licenses are classified as follows:  
(1) license to produce special-controlled animal feed;  
(2) license to import special-controlled animal feed;  




The licensees under (1), namely license to produce shall also be the licensees under (3) for sale 
of the special-controlled animal feed that they produce. The licensees under (2) shall also be 
the licensees under (3) for sales of the special-controlled animal feed that they import.  
However certain exceptions remain; section 21 of the Animal Feed Quality Control Act, does 
not apply to (1) Ministries, Government Departments or State enterprises engaging in the 
production or importation of special-controlled animal feed for their own uses; (2) the production 
and importation for sale or the sale of special-controlled animal feed as an samples for academic, for 
the purpose of registration; (3) legally registered cooperatives or farmers’ groups who produce 
special-controlled animal feed for the uses by their cooperative members or for farmers in their 
group.  The MOAC notification will set up rules, procedures and conditions as well as reporting 
requirement of these operators.  
Furthermore, registration requirement does not apply to the licensed animal feed producer for 
the production of these animal feed specifically for the use by their own animals. This de facto refers 
to the application of farm mixer for internal use (including in business scale of integrated farming 
system). The MoAC will also announce the rules, procedures and conditions to control farm mixer to 
ensure quality of production such as homogeneous distributions of antibiotics in the feed. 
• Supply chain inspection  
There are four possible cases for the inspection of operators licensed to produce and sell animal 
feed including 1) inspection before licensing approval, 2) annual inspections, 3) inspection before 
relicensing and 4) inspection in response to complaints.  
There are joint inspections by different authorities at national and local levels. The AFVC is 
responsible for inspection of all types of licensed operator operated in Bangkok. The officers in the 
regional and provincial livestock development offices are responsible for the inspection for license 












Table 6 Inspection of licensee on feed mill and feed store by different areas  
Location Feed mill license Feed store license 
Bangkok Inspection before licensing approval, Inspection before relicensing, annual inspection, Inspection in response to complaints: AFVC  
Other 
provinces 
Inspection before licensing approval: AFVC 
and PLO 
Inspection before relicensing (annual 
inspection): Regional livestock office and 
PLO 
Inspection in responses to complaints: 
AFVC collaborates with regional livestock 
office and PLO  
Inspection before licensing approval and 
inspection before relicensing (annual 
inspection): PLO and district livestock 
office 
 
Inspection in responses to complaints: 
AFVC collaborates with regional livestock 
office and PLO 
 
• Control the quality of the process 
To promote the standard of animal feed mills, the DLD enforces a regulation for establishing a 
voluntary GMP certification for feed mill; the GMP is granted by DLD. For a GMP certified feed mill, 
the DLD will inspect the plant not less than twice a year. For a non-GMP certified feed mill, the DLD 
inspection to the plant is required more frequently, that is three times a year.  
Note that GMP certification is mandatory for animal feed mills which produce medicated feed, 
and it will be named “medicated feed mill” consequently. In addition to GMP by DLD, ISO 
certification is voluntary for feed mills aiming for export to regional markets.  
• Monitoring system of medicated feed 
Currently, the DLD is working on a draft of MOAC notification to control feed mill licensees and 
farm mixers which will mandate them to submit the volume of antibiotic used in medicated feed 











PART II: Key actors and their roles involving in the antimicrobial distribution chain 
 
There are a large number of operators involved in the whole range of supply chains of antibiotics. 
Actors are categorized by types of license granted according to the Drug Act and the Animal Quality 
Control Act (Table 7).  
 
Table 7 Number or operators categorized by the licensee (for all drug (not antibiotics) 
Actors involved in antibiotics Type of licensing Number 
1) Importer  Pharmaceutical import license 7741 
2) Manufacturer  Pharmaceutical manufacture license 1841 
3) Distributor  Pharmaceutical sale license  (15,359)2 
4) Wholesaler  Pharmaceutical sale license  (15,359) 2 
5) Drug store    
- Sale medicines Pharmaceutical sale license (15,359) 2 
- Sale of package medicines Pharmaceutical sale license (only for package medicines) 3,164
2 
- Sale of package medicines for 
animals 
Pharmaceutical sale license (only package 
medicines for animals) 722
2 
6) Human health facility Health facility license 11,5603 
7) Importer (animal feed) Animal feed import license 3234 
8) Animal feed mill Animal feed manufacturer license 
2994 
(73)* 
9) Animal feed store Animal feed sale license 27,1654 
10) Animal health facility Animal health facility license 2,0584 
11) Livestock farms - 1,048,6144** 
* There are 73 animal feed manufacturer licensees who received the GMP standard, which can 
produce medicated feed.  
**Total livestock farms include the following: broiler chicken 35,371 farms, layer chicken 57,286 
farms, pig 191,289 farms and beef cattle 764,668 farms 
Sources:  
1) FDA 2015   
2) FDA 2013    
3) Ministry of Public Health 2015   






The study identified more than one million livestock farms in Thailand. Of these 1,048,614 farms, 
there were 35,371 broiler farms (with 1,473,628,997 animals), 57,286 layer farms (with 104,761,215 
animals), 191,289 pig farms (with 18,804,487 animals) and 764,668 beef cattle farms (with 4,407,108 
animals). 
Competitive market and high-profit-margin markets result in a proliferation of multiple actors: 774 
importers, 184 manufacturers, 323 animal feed importers, 299 feed mills, 27,165 feed stores and 
over 15,000 distributors, wholesalers and retailed pharmacies. Of 774 importers, three groups can 
be identified: 176 importers of finished products, 222 importers of API and 108 of both products, 
while 268 licensed for imports are inactive in the businesses. From the interviews, it was estimated 
that more than 95 percent (15,359 operators) of pharmaceutical sale licensed operators sell 
antibiotics; however, registration records do not support the differentiation between wholesalers 
and retailers.  
Most importers and manufactures are located in Bangkok where main ports (air and sea ports) are 
located. Medicines including antibiotics are distributed throughout the country through the 
marketing force by importers, manufactures and wholesalers. The highest density of private 
pharmacies to population ratio was in Bangkok, Chonburi and Phuket (>61 drug stores/100,000 
population). Figure 2 shows density of pharmacies per 100,000 populations by 77 provinces of 
Thailand. Note that the density is classified by five equal percentiles (quintiles). Note that the 
provinces with red shade denote highest concentration, while the dark green shade denotes the 





Figure 2 Number of pharmacies per 100,000 populations by provinces, 2016 














PART III: Antimicrobial distribution 
 
The distributional system of antibiotic is complex. Figure 3 unpacks the complexity of antibiotic 
distribution including API, finished products and medicated feed from importers and local 
manufactures to human and animal final consumption; see Figure 3. 
 
Figure 3 Antibiotic distributional channels: from importation, manufacture to the end users   
 
How are antibiotics imported, manufactured and distributed? 
Thailand imports API for local manufacturing and finished products for domestic consumption 
(including medicated premix for manufacturing of medicated feed by feed mills). Most API was 
imported for pharmaceutical production, either by manufacturers (A1.2) or by importers (A1.1) who 
are also licensed as API distributors (C1).  
By law, API must be sold by persons who are licensed to produce or import. Most manufactures 
usually purchase API from importers or import by their own (B2.1 or A1.2). They seldom buy API 




manufacturers can sell these antibiotics directly (C2.1), or distributed through distributors (C2.2 and 
C2.3). By law API must be used for the manufacture of finished products. API cannot be directly used 
by humans or animals due to its high concentration. At customs, licensed importers of API are 
required to notify the FDA before approval for imports.  
For finished products, antibiotics can be distributed through importers who are also licensed to 
distribute (C2.1), by manufacturers (C2.1) and by distributors (C2.2, C2.3) to wholesalers, human 
health facilities, animal health facilities, drug stores, feed mills and farms. There was no difference 
between the process of importation and manufacture of human and animal antibiotics.  
How are antibiotics dispensed and prescribed?  
Most antibiotics are classified as dangerous drugs, which mean “pharmacy dispensing only” 
medicine. This means antibiotics can be sold in the retail sector without prescription but dispensed 
by professional pharmacists in licensed pharmacies (mostly private). In practice, pharmacists do not 
keep dispensing records as this is not required by the Drug Act. Oral form of Sulfonamide (due to its 
potential complication of Drug Rash with Eosinophilia and Systemic Symptoms Syndrome) and 
Chloramphenicol (due to severe complications of neutropenia and leukemia) are categorised as 
“special-controlled drugs”, which require prescriptions and can be sold to health professionals only, 
by licensed pharmacies. Sulfacetamide sodium 10% eye drops and Silver Sulfadiazine 1% for topical 
use are classified as “household remedies” which do not require sale licenses.  
All public and private health facilities (hospitals or clinics) have their own pharmacy sections, which 
dispense antibiotics based on prescription by doctors for either outpatients or inpatients. Although 
prescription is not required by law, it has been historically practiced.  
At the community level, antibiotics are dispensed by pharmacists either by wholesalers (D) or drug 
stores (E) to household end users and pet owners. Feed mills (G) produce medicated feed sold to 
feed stores (H) and animal farms (J).  
How are antibiotics used?  
At user level, people have easy access to antibiotics. In addition to prescriptions in health facilities, 
people buy antibiotics from licensed wholesale and retail pharmacies. There is a high level of market 
penetration of private pharmacies in urban communities. However, rural people also have easy 
access to pharmacies in the district town centers. Farmers can buy antibiotics through several 
channels including distributors, wholesalers, drug stores, or medicated feed from either feed mills or 
feed stores. The regulatory framework and enforcement on the use of antibiotics are outside the 





Table 7 summarizes the way legislation categorizes types of operator for licensing requirements, and 
types of product for registration and distribution according to the Drug Act and the Animal Feed 
Quality Control Act. 
Table 7 Laws and regulations: operator, product and distribution 
  Drug Act Animal Feed Quality Control Act 
1. Operator 
1.1 Level of control • Import, manufacture, sale at 
pharmacy 
• Not cover dispensing by health 
professionals and use by people  
•  Import, manufacture, sale, 
prescription at feed mill and farm, and 
use at farm  
• Not cover dispensing and 
prescription by veterinarian 
1.2 Licensing • Pharmaceutical import license  
• Pharmaceutical manufacture license 
• Pharmaceutical sale license  
  
• Animal feed import license 
• Animal feed manufacture license*  
• Animal Feed sale license * 
*Not specific to Medicated feed 
1.3 Control quality of 
the process 
• Import: Point of Entry (Finished 
Products = 40, of which 10 are 
designated for API) 
• Manufacture: GMP, PIC/S, post 
marketing quality surveillance  
• Sale: Good Pharmaceutical Practice 
(GPP) 
Import: NA 
Manufacture: GMP, ISO 
Sale: NA 
2. Product 
2.1 Registration Registration required for all imported 
and produced medicines (including 
antibiotics) 
Required registration for all imported 
and manufactured animal feed, but 
not required for medicated feed 
2.2 Classification All antibiotics are classified as 
dangerous drugs, except such drugs 
including household drug 
(Sulfacetamide sodium 10% (eye drop), 
Silver Sulfadiazine 1% (topical use)), and 
special-controlled drug (Sulfanilamide 
(PO), Chloramphenicol for children, 
animal and systematic use for adult, 




anti-Malaria, antiprotozoal, anti-virus 
(except specific local application drug), 
anti-fungus (except specific place drug)  
Prohibit the use of Cephalosporin, 
Polymyxin, Pennicillin, 
Fluoroquinolones and Fosfomycin for 
prophylaxis and extra-label use* 
2.3 Control of product Withdraw antibiotics registration of 
Chloramphenicol and Nitrofuran for 
animal use 
Total ban the use of antibiotic as 
growth promoter 





  Drug Act Animal Feed Quality Control Act 
3. Distribution 
3.1 Control • Import, distributor, sale: API 
can be sold to manufacture 
license and sale license holders  
• Import: control import 10 
antibiotics, ban import of 
Chloramphenicol, 
Nitrofurazone, Furazolidone, 
Dimetridazole, Ronidazole in 
animal drug registry 
• Prohibit import, manufacture and 
sale of medicated feed containing 
Cephalosporin, Polymyxin, Pennicillin, 
Fluoroquinolones and Fosfomycin; 
prohibit feed containing antibiotics for 
fattening pigs, layer and last stage of 
broiler; prohibit use of medicated feed 
without veterinary prescription 
(except for pig<25 kg at feed store) * 
• Manufacture: prescription only 
(except for pig<25 kg), Using colistin 
and Amoxycillin for medicated feed 
(need drug sensitivity test)* 
• Sale: prescription only* 
• Farm  
• Integrated farm (pig>500, 
broiler>5,000, layer>1,000): 
prescription, licensing* 
• Cooperatives: label and sale animal    
feed for member only 
3.2 Monitoring • Finished product: annual sale report of 
production and importation of all 
pharmaceutical products (including 
antibiotics). 
• API: a four-monthly report of sale of 
Quinolone and derevatives, 
Cephalosporins, Macrolide by import, 
produce licensees; annual report of 
importation, manufacture and sale of all 
pharmaceutical products by import, 
produce licensees. 
*Not included its distribution channel. 
At feed mill: annual report the 
quantity of sale on medicated feed* 
 
At farm levels 
• Farm mixer (for business scale): 
annual report the quantity of use on 
medicated feed* 
• Cooperative: annual report the 
quantity of use on medicated feed* 
*Draft MOAC notification  
 
The Drug Act, BE 2530 (1987)  
After the last revision of the Drug Act in 1987, many regulations and ministerial and FDA 
notifications further contribute to the effective functions of the law. The FDA attempted to revise 
the Drug Act in 2014 but it was defeated due to major professional conflicts about various 
dimensions of the amendments and changes of Government.  
Drug regulations aim to ensure the safety, efficacy and quality of drugs, which contribute to the 
health protection of the consumers. Five regulatory functions include market authorization, 




the quality and efficacy of medicine through licensing operators, quality control of the process and 
registration.  
The Drug Act categorizes types of medicines, including antibiotics, and regulates which channels can 
be used for distribution. There is no regulation with the objective of containing the quantity of 
medicines, including antibiotics, distributed to end users. The quantity of drugs distributed through 
different channels is market oriented, where suppliers are responsive to demand without 
government interference to the market. Hence there is containment neither of the number of 
licensed operators, in particular distributors and pharmacies, nor of the quantity of drugs distributed 
through each channel.  
Despite the fact that all drugs must be registered with their formula before production or 
importation, no registration requirements are enforced for API. Only notification to FDA is needed 
for import formalities required by customs. (Note there are only ten designated gateways for the 
importation of API: see table 4). This can potentially lead to the leak of API for direct use in animal 
farms, while the direct use of API is prohibited. These leakages can be either through legal or illegal 
importation. Drug inspectors at the DLD provide event reports and have previously confiscated 
certain API in farms and aquaculture.  
The FDA is working on the reclassification of certain preserved antibiotics as prescription-only 
medicines. In the context of a laissez-faire capitalist economy, policy is not in favour of containing a 
volume of antibiotic distribution. However, reclassification and differentiation of antibiotics may 
apply to the three groups as recommended by the 20th edition of the WHO Model List of Essential 
Medicine, according to local infectious disease profiles [10].  
• Group one is key access antibiotics (including beta-lactam and other antibacterial). These 
can be classified as dangerous drugs required for dispensing by a pharmacist, but 
introducing a policy to keep dispensing records for audits and peer reviews to improve the 
dispensing performance is likely to be a minor reform; no resistance by pharmacists is 
forseen as it improves their professional services.  
• Group two is watch group antibiotics (including Quinolones and Dluoroquinolones, third 
generation of Cephalosporin, Macrolide, Glycopeptides, Antipseudomonal penicillins and 
bata-latamase inhibitors, Carbapenems, and Penems); these antibiotic classes have higher 
resistant potential and are recommended as first or second choice treatment only for a 
specific limited number of indications. This requires prescription-only medicine and strong 




must not be freely available in retail pharmacies. However, efforts should be given to 
ensure that patients in need have access to these medicines.  
• Group three is reserved antibiotic  (including Aztreonam, 4th generation cephalosporins, 
polymixins, Fosfomycin, Oxazolidinones, Tigecycline and Daptomycin). These are the last 
resort options. Use of these medicines should be tailored to highly specific patients and 
settings, when all alternatives have failed. Undeniably, this antibiotics group should be 
administered by infections experts with strong monitoring and who are key targets for the 
national stewardship program.  
In veterinary medicine, the OIE also classified antibiotics used by animals into three groups including 
Veterinary Critically Important Antimicrobials (VCIA), Veterinary Highly Important Antimicrobials 
(VHIA) and Veterinary Important Antimicrobials (VIA). Specific antibiotics were considered for the 
treatment of a particular disease for different animal species. The current ongoing reclassification by 
FDA, under the Drug Act should be aware of the categorization of veterinary important antimicrobial 
agent as recommended by OIE [11]. 
Prescription and dispensing antibiotics   
Human and animal health facilities are controlled by other Acts such as the Medical Premise Act and 
the Animal Health Facility Act. The regulations include mandatory licensing of private human health 
facilities, while public health facilities are outside the licensing requirement. All private animal health 
facilities are regulated by the Animal Health Facility Act, while public animal health facilities are not 
covered by this Act.  
The prescribing and dispensing of antibiotics in health facilities are the responsibility of professional 
practitioners such as doctors, pharmacists and veterinarians. Professional councils provide standard 
guidelines for the rational use of antibiotics, but are not required to report on antibiotics 
prescription in all settings. Unlike the common practice of high-income countries, the use of 
antibiotics in the retail sector, primary care facilities (public health centers and private clinics) and 
hospitals are neither required to keep records of their dispensing or prescribing, nor are subject to 
audit by regulatory authorities or professional peers. Without such records and stringent audit, the 
excessive and inappropriate uses of antibiotics remain unknown.  
Several non-clinical issues were found to influence the health professional’s decision on antibiotic 
prescription. Economic incentives offered by pharmaceutical companies to boost their market 
contribute to excessive provision of antibiotics [12]. Demand and influences by clients are common 




that a one percent increase in doctor-to-population density is associated with 0.52% to 0.86% 
increase in outpatient use of antibiotics; fee-for-service incentives lead to a higher use than the 
capitation payment method [16].  
The antimicrobial sensitivity testing is an important tool to identify bacteria and for antibiotic 
selection. However, practitioners made their decision about antibiotic use based on individual 
preference and clinical experiences. Some studies show that decision-making by health professionals 
is based on “expert opinion”, other colleagues who are “opinion leaders” or from internet sources, 
rather than scientific and peer-reviewed data [17].  
The poor quality of pharmaceutical services provided by retail pharmacies is commonly reported. 
This includes:  inappropriate presumptive treatment, use of antibiotics for common colds or flu 
symptoms, insufficient history taking, sale of medicines that are neither clinically appropriate nor 
proper doses, sale of incomplete courses of treatment, poor or no labeling, and limited provision of 
counseling [18].  
Several interventions can help to improve professional practice. For example, law enforcement 
which prohibits non-prescription sale of antibiotics, strengthening antimicrobial stewardship 
programs [19] and audits of dispensing records [20].  
In-service training such as thorough continued professional education to pharmacists in the retail 
sector may improve the quality of pharmaceutical services [21]. However, trainings which are 
sponsored by the pharmaceutical industry may undermine the integrity of these courses as they may 
protect the interest of pharmaceutical industry. To redress this challenge, Australia has introduced a 
self-regulatory Code of Conduct where pharmaceutical companies voluntarily adhere to a set of 
principles and behavior for ethical marketing and for the promotion of prescription pharmaceutical 
products [22]. This also requires a strong regulatory environment to shape health professional 
behavior.   
Use of antibiotics by people and farmers  
People and farmers can access medicines, including antibiotics from various sources. There were a 
large number of distributors and retailers for selling medicines resulting from the competitive 
market of medicines. No prescription requirement results in people having easy access to antibiotics, 
which they often use inappropriately use due to the lack of understanding in households. On the one 
hand, availability of medicines supports access to antibiotics, but on the other hand excessive 
availability can lead to excessive consumption and subsequent pressure on the emergence of AMR. 




services provided by full-time pharmacists in retail pharmacies and through audits of dispensing 
records. Significantly, there is no special control for wholesalers and people can buy a large quantity 
of antibiotics from pharmacies.  There is no wholesale license authorized by FDA and no foundation 
for tracking the quantity of total sales by wholesalers.  
Obtaining and using antibiotics in the retail sector without prescription are common in developing 
countries [23]. There is often inadequate regulation on antibiotic distribution and sale [24, 25], and 
inadequate knowledge and lack of AMR awareness. These were recognized as important factors 
contributing to the irrational use of antibiotics in China and Vietnam [26]. Therefore, general public 
knowledge of antibiotic use and awareness on harmful self-medication should be raised. To improve 
knowledge of antibiotics and public awareness of AMR, it is essential to understand the gaps in 
understanding about the proper use of antibiotics and AMR awareness in the communities.  
The special Euro-barometers 338 and 445 [27, 28] fill these gaps. These surveys contribute to the 
prevalence of the self-use of antibiotics and sources in the last 12 months, knowledge of antibiotics 
and awareness of AMR. In Thailand, an AMR module was embedded into the Health and Welfare 
Survey (HWS) in 2017 conducted by the National Statistical Office. It is a national representative 
household survey conducted biannually. Evidence from these surveys will support the precision of 
advocacy messages for effective changes of behaviors. Regular surveys are important to monitor the 
progress of public campaigns on AMR. 
The Animal Feed Quality Control Act, BE 2558 (2015) 
As the Animal Feed Quality Control Act was newly legislated in 2015, it is at an early stage of drafting 
regulations for effective implementation. Literature suggests that pressure from farmers and 
financial gains from antibiotics use affects prescribing behavior in veterinarians. The Act however 
does not control dispensing and prescription by veterinarians. In Denmark, interventions that 
significantly stemmed antibiotic consumption included delinking veterinarian prescribing and 
dispensing and restricting the maximum profit on antibiotic sales to 5%, down from a 25% markup 
prior to regulation [29]. As a result, Denmark managed to curb significantly the total consumption of 
veterinarian antibiotics. 
In many countries, there have been attempts to decouple the prescription and dispensing of 
medicines by veterinarians. Almost all medicines used in the livestock sector in Denmark are now 
sold directly to the farmers by pharmacies [30]. This should be reflected in a MOAC notification in 
order to control the use of antibiotics requiring veterinary prescription in feed mills and feed stores  




feed (medicated feed) for their members. The quality of these local non-GMP productions of 
medicated feeds - in particular the homogeneity of antibiotics from the mix - which may result in the 
emergence of AMR pathogens are policy concerns. In such case, the DLD needs to have close 
vigilance in this area.   
The DLD is developing reporting systems for relevant stakeholders including retail medicated feed 
producers, farm mixers for businesses, co-operatives and farmer groups. The system design should 
be in line with the recommendation by OIE. Without mandatory reporting systems for medicated 
feed, there will be a lack of evidence to support monitoring consumption of certain reserved 
antibiotics in the Thai-SAC.    
Literature on medicines regulations [9] in low- and middle-income countries such as Tanzania, 
Zimbabwe, Ethiopia and Thailand focus more on quality and the process of licensing for entry to the 
market, but lose sight on controlling the quantity of distribution and price [9, 31, 32]. Failure to 
address market promotion results in easy access and inappropriate use of antibiotics. The outdated 
law and lack of functioning regulation in Zimbabwe has led to double problems of poor quality and 
high price [33]. 
Regulatory enforcement 
Various provisions in the law and regulations do not always guarantee good outcomes as intended; 
it requires effective enforcement and institutional capacities to regulate the relevant operators who 
should be guided by M&E evidence in a timely manner. The lack of effective regulatory control can 
lead to the inappropriate use of antibiotics. Many studies indicate ineffective regulatory functions. A 
study in Ethiopia reports no inspection of the supply chain with importers and manufacturers [32]. In 
Zimbabwe, it is indicated that regulators lack significant information about the structure and 
operation of the private sector [33].  
Possible reasons for ineffective law enforcement include the over-centralization of regulation with 
poor cooperation between the national and local levels [32], a lack of knowledge by patients of their 
rights [33], inadequate monitoring and information systems [34, 35] and a shortage of qualified and 
skilled workers for medicine regulation. The latter might be due to low government salaries and that 
the regulators are subsequently employed by private industries; this presents a clear conflict of 
interest resulting in regulatory captures [36]. In order to increase the effectiveness of regulation, 
new approaches are proposed; these include a consumer-oriented approach such as improving 
information for consumers and a market-oriented approach, such as intervening to change the 




FDA and DLD devolved by delegating their inspection authority to provincial offices. However, the 
field observations showed that inspectors are spread too thinly across laws and regulations, and 
inspections focus on quality as the primary concern, but not on the quantity of distributions. The 
laws and regulations on antibiotic distribution are not implemented and enforced effectively in the 
following ways.  
Firstly, there are several regulatory authorities at national and local levels such as FDA, PHO, AFVC, 
and PLO. There are variations in the interpretation of enforcement, intensity and degree of penalty 
for violations. From the in-depth interviews with the regulatory officers in four selected provinces, in 
one province there is no annual inspection of animal drug stores. Furthermore, the Drug Act 
enforcement is decentralized to PHO resulting in non-standardized enforcement on licensing and 
annual inspection or license renewals. Antibiotics are not a main concern of pharmacists at district 
hospitals who inspect all drug stores at district levels. Moreover, at a small community level, 
unavoidably, the relationship between the regulator in district hospitals and the operators may lead 
to sympathy and relaxation.  
Secondly, there is no specific or standard protocol for the inspection of the distribution and use of 
antibiotics. Antibiotics are likely to be used and controlled in a similar way to other medicines. 
However, several classes of antibiotics should be reserved for severe illnesses as a last resort to save 
life. In addition, there are other competing priorities. Interviews with key informants reflect that 
antibiotics are not a main interest of the regulators compared with GMP inspections. In some 
provinces, government officers focus on the inspection of potential drug abuses such as tramadol for 
addiction and the use of beta-agonist group such as Salbutamol as leanness-enhancing agents in 
food animals. These are the immediate concerns for consumer protection by PHO while antibiotics 
are overlooked. 
Thirdly, across the interviews with regulators, a heavy workload was common. For example, in 
Bangkok, there were more than 5,000 drug sale license holders and more than 600 import license 
holders, with only approximately 40 staff members in FDA responsible for annual inspection. At the 
local level, there were about three to five staff members in PHO who enforce six to seven Acts 
delegated by the MoPH to the PHO. These include the Food Act, the Medical Device Act and the 
Cosmetic Act to name a few. 
Fourthly, antibiotics classified as dangerous drugs can be dispensed by pharmacists in private 
pharmacies without prescription. Prescription is the only instrument for auditing inappropriate and 
excessive use of antibiotics. To overcome prescription issues, continued professional education, 




Swedish Strategic Programme Against Antibiotic Resistance (Strama) in Sweden [39]. Given the 
current designation of antibiotics as dangerous drugs (except a few special-controlled items for 
hospital use only), it is technically feasible to require pharmacists to keep electronic dispensing 
records for audits by regulatory authority or professional peers. This is one of the critical entry 
points for rational use of antibiotics, in response to the call by Global Action Plan on AMR.  
This study identified significant information gaps. For example, the study estimated the number of 
operators from the license holders at FDA, but this might be outdated. Information gaps are due to 
the lack of data sharing and timely updating between FDA and provincial health offices responsible 
for drug store annual relicensing. The study could not differentiate between operators among three 
groups - distributors, wholesalers and retailers at drug stores - since they hold the same sale license. 
Interestingly, no operator holds a wholesaler packaged medicine sale license. In addition, this study 
could not identify the number of feed mills and feed stores who produce and sell medicated feed. 
For the number of livestock farms, this study could only identify the number of ’standard farms’ 
registered by the DLD. The number of backyards and small-scale farms which substantially use 
antibiotics are yet unknown.    
This study did not cover an illegal use of unregistered antibiotics and API either through legal 
imported or smuggling.  
Surveillance of antimicrobial consumption  
The existing mandatory monitoring system for antibiotics surveillance covers only an annual sale 
report of the production and importation of all pharmaceutical products (historically FDA has not 
requested distribution details). This applies for any medicines, including antibiotics. The four-
monthly report (FDA reporter) of the sales and distribution of potentially-abused medicines is 
designed for the tighter control of the distribution of medicines to prevent drug abuse; however, 
antibiotics are not covered.  
Currently, there is no system to monitor the consumption of antimicrobials in Thailand. The Thai 
Surveillance of Antimicrobial Consumption (Thai-SAC) is currently developed through multi-
stakeholder involvement to fill the gap and grants from USAID, WHO and FAO were secured in early 
2017. The research team comprises FDA, Department of Livestock Development, universities and the 
International Health Policy Program of the Ministry of Public Health. All medicines in the FDA 
registration database are assigned with the ATC classification code for human drugs and ATCvet for 
veterinary medicinal products. The scope of the surveillance system will cover antimicrobials at least 
for systemic use, J01 in humans and QJ01 in animals. The Thai-SAC will also cover the optional list 




To facilitate the development of the surveillance system, these two existing reports need to be 
revised in such a way as to better track the distribution of antimicrobials from production and 
importation to users. However, the FDA has to issue regulations with reference to provision in the 
Drug Act, to include reserved or watch group antibiotics, as recommended by the WHO Model List of 
Essential Medicines, to the four-monthly report.  Moreover, for monitoring the total annual sales of 
the whole set of human and veterinary antibiotics, research and development of the Thai-SAC will 
have to rely on the mandatory annual report on production and importation of antibiotics, with 
volumes and values of sales by different distribution channels. This will facilitate monitoring the total 
consumption of antibiotics: this is in terms of the defined daily dose per 1000 of the population in 






















F. Conclusion and policy recommendations  
In general, the Drug Act regulated market authorization, licensing, inspection, quality control and 
pharmaco-vigilance. The Act categorizes types of medicines and specific channels that can be used 
for distribution; but regulation does not aim to contain the quantity of medicines, including 
antibiotics, distributed to the end users. The quantity of drugs distributed through different channels 
is market oriented, where suppliers are responsive to demand without government interference to 
the market.  
Prescribing and dispensing of antibiotics in human and animal health facilities are the responsibility 
of professional practitioners such as doctors, pharmacists and veterinarians, yet these professionals 
are not regulated by the Drug Act. Professional councils provide standard guidelines for the rational 
use of antibiotics, but are not required to report on antibiotics prescription in all settings. 
No containment of the number of licensed operators - especially distributors and pharmacies in the 
high profit market - results in a large number of operators who boost their market share. There is 
easy access of antibiotics by people and farmers.  
No systems exist in Thailand to monitor the consumption of antimicrobials and estimate 
antimicrobial usage trends over time. This type of evidence is important for policy to optimize 
consumption and minimize the development of antimicrobial resistance. 
In the context of significant challenges posed by AMR and a global call for serious remedial actions, 
dispensing and prescription audits are entry points which can redress the inappropriate and 
excessive use of antibiotics; these interventions require policy leadership and reform in both human 
and veterinary antibiotics.  
General recommendations are to:  
1) Reclassify the antibiotics for humans and animals that have shown high levels of 
resistance, as special-control drugs and prescription-only medicines with restricted use by 
specialists;  
2) Introduce effective dispensing and prescribing audits in the pharmacies, hospitals, feed 
mills and farms.  
3) Establish the national surveillance of antimicrobial consumption, improve the quality and 
accuracy of annual mandatory report by operators, and ensure its uses for policy decision.  




Recommendations to FDA:  
• Accelerate the policy process of re-classification of antibiotics for human consumption 
according to the WHO Model List of Essential Medicine and the OIE categorization of three 
levels of veterinary important antimicrobial agents for animal consumption.  
• Establish a mandatory dispensing record and auditing system of certain group two 
antibiotics (watch group antibiotics) and group three (reserved antibiotics) in order to 
improve the performance of the use of antibiotics at retail sector. Prescription audits in the 
hospital sector provide evidence for improving antibiotic stewardship through training of 
professionals and other sanctions as appropriate.  
• Strictly control API by revising the regulation in order to track API after importation; this 
should be made mandatory despite no registration requirements for API. In addition, the 
sale licensee should provide mandatory annual reports to the FDA on the API sales and 
distribution channels used.  
• Strengthen the collaboration and data-sharing between national and local levels for 
effective inspection. 
• Develop tools and procedures for the audit of dispensing records kept by pharmacists in the 
retail sector and standard operating procedures for prescription audits in health care 
facilities. Punitive, education, training and incentive measures should be introduced to 
change the course of dispensing behaviour at the retail sector and prescription behaviour in 
hospital settings.  
• Establish the Thai-SAC to monitor the annual consumption of antibiotics at national level. It 
should be measured by DDD per 1000 population-day in humans, and milligram of active 
ingredient per population correcting unit in animals. This will help measure the impact of 
policy outcomes on optimizing consumption in both sectors. There is a need to strengthen 
the quality, accuracy and adequacy of the annual mandatory report by importer and 
manufacturers to cover antibiotic distribution channels and also to expand the mandatory 
annual report of antibiotic sales by distributors and wholesalers and their different 
distributional channels. 
Recommendations to DLD   
• Accelerate the implementation of the Animal Feed Quality Control Act (2015) and finalize 
the draft MOAC regulation to be announced and implemented rapidly 




• Establish a well-designed monitoring system of medicated feed by distributional channels 
and animal species, which should be in line with the Thai-SAC. One potential loophole in the 
quality of medicated feed is the exemption of register requirements for the production of 
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Interview questionnaire for farmers on antibiotic use in pig production in Thailand 
 
ช่ือผู*สัมภาษณ1 (Name of interviewer)  ……………..………….………………….……… 
ช่ือผู*ให*ข*อมูล (Name of respondent)  ……………..………….………………….……… 
วันท่ีสัมภาษณ1 (Date)    ……………..………….………………….……… 
ท่ีอยูOผู*ให*สัมภาษณ1 (Address)  
บ*านเลขท่ี (No)………………หมูOท่ี (Moo) …..……..  ตำบล (Sub-district) 
…………………….……… 
อำเภอ (District)  ………………………….…………  จังหวัดราชบุรี (Ratchaburi) 
โทรศัพท1บ*าน (Tel) ………………………….…………  มือถือ (Mobile) …………………….……… 
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ส_วนท่ี 1 ข5อมูลท่ัวไป (Section A – General) 
1.1 ผู5ให5ข5อมูล (respondent profiles) 
 
1. เพศ (gender)    1. ชาย (male)   2. หญิง (female)   3. ไมOระบุ (NA) 
2. อายุ (age)   ................... ปw (year) 
3. ระดับการศึกษาข้ันสูงสุด (Educational level)     
  1. ประถมศึกษา (Primary school) 
  2. มัธยมศึกษาตอนต*น (Secondary school-grade 9) 
  3. มัธยมศึกษาตอนปลาย/ปวช. (Secondary school-grade 12/ Por Wor Chor) 
  4. ปวส. (Por Wor Sor/Diploma)  
  5. ปริญญาตรีหรือสูงกวOาปริญญาตรี Bachelor degree or higher 
  6 . อ่ืนๆ (other) ระบุ (i.e.) ………………………………………… 
4. จำนวนปwท่ีทำงานเก่ียวกับการเล้ียงสุกร (Years working on the pig farm, in any farm) ........ ปw (year) 
5. สถานะ (Position) 
  1. เจ*าของ (owner) 
  2. ผู*จัดการ (manager)  












1.2 ฟารAม (farm characteristics) 
6. อายุของฟาร1ม (age of farm)    ................... ปw (year) 
7. จำนวนพนักงานในฟาร1ม (เฉพาะท่ีเล้ียงสัตว1) (number of worker)  ...................  
8. เปãนฟาร1มมาตรฐานหรือไมO (Government standard farm)  
   1 . ใชO (yes)    2. ไมOใชO (no)     3 . ไมOทราบ (unknown) 
9. เปãนสมาชิกสหกรณ1หรือไมO (Cooperative member)    
   1 . ใชO (yes) If answer Y, please provide a name of association……………………………..  
    1.1 สหกรณ1ผู*เล้ียงสุกรโพธาราม 
   1.2 สหกรณ1ผู*เล้ียงสุกรบ*านโปèง 
   1.3 อ่ืนๆ........................................... 
  2. ไมOใชO (no)     3 . ไมOทราบ (unknown) 
10. เปãนฟาร1มลูกเล*าหรือไมO (Integrated contracting farming system) 
       1. ไมOใชO (no)  ข*ามไปข*อ 12 Please go to 12.  
     2. ใชO (yes) ถามตOอ ระบุรูปแบบ 
  2.1 ไมOได*รับปëจจัยการผลิต แตOขายผลผลิตให*บริษัทต*นทางโดยกำหนดราคาลOวงหน*า  ข*ามไปข*อ 12  
 No input but sell products at a predetermined price (Please go to 12.) 
  2.2 ไมOได*รับปëจจัยการผลิต แตOขายผลผลิตให*บริษัทต*นทางท่ีราคาตลาด ข*ามไปข*อ 12 
 No input but sell products at market price (Please go to 12.) 
  2.3 รับปëจจัยการผลิต และขายผลผลิตให*บริษัทต*นทางโดยกำหนดราคาลOวงหน*า 
 Some input and purchase products at predetermined price 
  2.4 รับปëจจัยการผลิต และขายผลผลิตให*บริษัทต*นทางท่ีราคาตลาด 
 Some input and purchase products at market price 












11. ชนิดของปëจจัยการผลิตท่ีซ้ือ (Type of input) 
  Type of input Piglets Feeds Medicines  
  1.  สุกรเทOาน้ัน (Only pigs)   *   
  2.  อาหารสัตว1เทOาน้ัน (Only animal feed)  *  
  3.  เวชภัณฑ1เทOาน้ัน (Only medicine)   * 
  4.  สุกรและอาหารสัตว1 (Pigs and feed) * *  
  5.  สุกรและเวชภัณฑ1 (Pigs and medicine) *  * 
  6.  อาหารสัตว1และเวชภัณฑ1 (Feed and medicine)  * * 
  
7.  ท้ังสุกร อาหารสัตว1และเวชภัณฑ1 (Pig, feed and 
medicine) 
























1.3 การผลิตสุกร (productivity)  
12. ในฟาร1ม มีสุกรแมOพันธุ1หรือไมO (Breeding sow) 
  ไมOมี ข*ามไปข*อ 13 No (Please go to 13.)  
  มี )ถามตOอ(  Yes    
จำนวนตัว (Number of breeding sow)    …………………  ตัว 
จำนวนแมOพันธุ1ข้ึนคลอด (Number of breeding sow giving birth per week)   …………………  ตัว/ สัปดาห1  
จำนวนลูกสุกรแรกเกิดท้ังหมด (Number of total born)  …………………  ตัว/ แมOสุกร 
จำนวนลูกสุกรแรกมีชีวิต (Number of born alive)   …………………  ตัว/ แมOสุกร 
จำนวนลูกสุกรหยOานม (Number of weaning piglets)   …………………  ตัว/ แมOสุกร 
13. จำนวนสุกรอนุบาล (ปëจจุบัน) (Number of weaner)    …………………  ตัว 
อัตราการสูญเสีย สุกรอนุบาล (percentage of nursing pigs loss) ร*อยละ ………………… 
14. จำนวนสุกรขุน (ปëจจุบัน) (Number of fattener)    …………………  ตัว 
 อัตราการสูญเสีย สุกรขุน (percentage of fattening pigs loss) ร*อยละ ………………… 
15. จำนวนสุกรขุนท่ีขายตOอเดือน (Number of fattener sold per month) …………………  ตัว 
16. การขายผลผลิต (Destination of pig products including piglets and fatteners) 
   1. ผู*รับซ้ือ/นายหน*า (Broker, Trader)   
   2. เขียงหมู (Fresh pork market) 
   3. ผู*บริโภคโดยตรง (Consumer) 
   4. ฟาร1มอ่ืน (Other farms) 
   5. กินเองในครัวเรือน (Household own consumption)  
   6. อ่ืนๆ (ETC) ระบุ (i.e.) ………………………………………… 
17. รายได*จากการขายสุกรรายเดือน (Average income from selling pigs per month)  
  1. ต่ำกวOา 10,000 บาท (< BHT 10,000) 
  2. 10,000-50,000 บาท (BHT 10,000-50,000) 
  3. 50,001-100,000 บาท (BHT 50,001-100,000) 
  4. 100,001-500,000 บาท (BHT 100,001-500,000) 
  5. มากกวOา 500,000 บาท (>BHT 500,000) 
  6. อ่ืนๆ (ETC) ระบุ (i.e.) ………………………………………… 
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18. แนวโน*มรายได*จากการขายสุกรในชOวง 3 ปwท่ีผOานมา (trend of income from selling pigs in the 
last three year) 
  1. เพ่ิมข้ึนมาก (Significantly increased) 
  2. เพ่ิมข้ึนเล็กน*อย (Slightly increased)  
  3. เทOาเดิม (Equal) 
  4. ลดลงเล็กน*อย (Slightly ddecreased) 
























ส_วนที่ 2 การจัดการอาหารและสุขภาพ 












2) ผสมเองในฟาร1ม  
(In-house mixing) 
3) สหกรณ1 (Cooperative)  
4) บริษัทขายอาหารสัตว1 (Feed 
company) 
5) อื่นๆ 






use/ do not 
know/ do not 
tell) 
19. สุกรแมOพันธุ1  1     
(breeding sow) 2     
เฉพาะระยะอุ*มท*องและคลอด 3     
Only pregnant phase 4     
(ประมาณ 3-4 เดือน) 
(~3-4 months) 
5     
20. สุกรดูดนม  1     
(breeding piglet) 2     
(ประมาณ 1 เดือน) 3     
(1 month) 4     
 5     
21. สุกรอนุบาล  1     
(nursery pig) 2     
(ประมาณ 1-2 เดือน) 3     
(1-2 months) 4     
 5     
22. สุกรขุน  1     
(fattener) 2     
(ประมาณ 3 เดือน) 3     
(3 month) 4     
 5     
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23. แหลOงท่ีมาของการส่ังใช*/แนะนำให*กิน อาหารสัตว) (ผสมยา) (ตอบได*มากกวOา 1 คำตอบ)  
        (Prescription/advise to administration of medicated feed) (Multiple answers possible) 
  ไมOได*รับคำแนะนำในการใช*อาหารสัตว) (Do not get advice about administration of medicated feed) 
  ได*รับคำแนะนำในการใช*อาหารสัตว) (Get advice about administration of medicated feed) 
 1. สัตวแพทย1ประจำฟาร1ม (Farm veterinarian) จำนวน ………… คร้ัง/เดือน 
(Time/month) 
 2. โรงงานผลิต/ บริษัทอาหารสัตว1 (Feed mill or feed company)       
จำนวน ………… คร้ัง/เดือน 
(Time/month) 
 3. บริษัท contract (Contract company)   จำนวน ………… คร้ัง/เดือน 
(Time/month) 
 4. สัตวแพทย1จากกรมปศุสัตว1 (DLD veterinarian) จำนวน ………… คร้ัง/เดือน  
      (Time/month) 
 5. ส่ังซ้ือเอง (Self-medication for their own animals) จำนวน ………… คร้ัง/เดือน  
       (Time/month) 
 6. อ่ืนๆ (Others) ระบุ (i.e.) ……………………………  จำนวน ………… คร้ัง/เดือน  
       (Time/month) 
24. รายจOายจากการซ้ืออาหารสัตว1รายเดือน       
(Average spending on purchasing feed per month)    
  1. ต่ำกวOา 1,000 บาท (< BHT 1,000) 
  2. 1,000-5,000 บาท (BHT 1,000-5,000) 
  3. 5,001-10,000 บาท (BHT 5,001-10,000) 
  4. 10,001-50,000 บาท (BHT 10,001-50,000) 
  5. มากกวOา 50,000 บาท (>BHT 50,000) 











25. ในปwท่ีผOานมา โรคท่ีพบบOอยและการใช*วัคซีน (Common disease and vaccination in the last year) 
ตอบเฉพาะสุกรกลุOมท่ีมีการเล้ียงในฟาร1ม Please answer only animal groups that you have. 
A. สุกรแม_พันธุA (Breeding sow) (เฉพาะระยะอุ5มท5องและคลอด) 
โรค (Disease category) 







1. โรคระบบทางเดินหายใจ (Respiratory system) 
(ไอ จาม หอบ หายใจลำบาก)  
(cough, sneezing, panting, breathing difficulty) 
   
2. โรคระบบทางเดินอาหาร (Gastro-intestinal system) 
(ข้ีไหล ถOายเหลว) (diarrhoea) 
   
3. โรคระบบประสาท (Nervous system)  
(เดินวน ชัก หัวเอียง) (walking in circles, seizure) 
   
4. โรคระบบสืบพันธุ1 (Reproductive system) 
(มดลูกอักเสบ) (Metritis) 
   
5. ขาเจ็บ (lameness)    
6. โปรแกรมยาฉีด/กินเพ่ือป°องกันโรค (Antibiotic program (both injectable and oral antibiotics) for 
prevention) 











intestinal system)  
3. โรคระบบประสาท (Nervous 
system) 
4. โรคระบบสืบพันธุ1 (Reproductive 
system) 
5. ขาเจ็บ (lameness) 
หมายเหตุ  
(remark) 
      
      
      
7. โปรแกรมวัคซีน (ตอบได*มากกวOา 1 คำตอบ) (Vaccination program) (Multiple answers possible) 
    ไมOได*ทำ (No vaccination)    ปากและเท*าเป§•อย (FMD)     ปากและเท*าเป§•อย (FMD)    
    อหิวาต1สุกร (Swine fever)    PRRS        ไมโคพลาสมา (Mycoplasma)  
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    …………………………..…         …………………………..…          …………………………..   
B. สุกรดูดนม (Breeding piglet) 
โรค (Disease category) 







1. โรคระบบทางเดินหายใจ (Respiratory system) 
(ไอ จาม หอบ หายใจลำบาก)  
(cough, sneezing, panting, breathing difficulty) 
   
2. โรคระบบทางเดินอาหาร (Gastro-intestinal system) 
(ข้ีไหล ถOายเหลว) (diarrhoea) 
   
3. โรคระบบประสาท (Nervous system)  
(เดินวน ชัก หัวเอียง) (walking in circles, seizure) 
   
4. โรคระบบสืบพันธุ1 (Reproductive system) 
(มดลูกอักเสบ) (Metritis) 
   
5. ขาเจ็บ (lameness)    
6. โปรแกรมยาฉีด/กินเพ่ือป°องกันโรค 











(Gastro-intestinal system)  




5. ขาเจ็บ (lameness) 
หมายเหตุ  
(remark) 
      
      
      
7. โปรแกรมวัคซีน (ตอบได*มากกวOา 1 คำตอบ) (Vaccination program) (Multiple answers possible) 
    ไมOได*ทำ (No vaccination)    ปากและเท*าเป§•อย (FMD)     ปากและเท*าเป§•อย (FMD)    
    อหิวาต1สุกร (Swine fever)    PRRS        ไมโคพลาสมา (Mycoplasma)  
         …………………………..…          …………………………..…          …………………………..  
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C. สุกรอนุบาล (Nursery pigs) 
โรค (Disease category) 







1. โรคระบบทางเดินหายใจ (Respiratory system) 
(ไอ จาม หอบ หายใจลำบาก)  
(cough, sneezing, panting, breathing difficulty) 
   
2. โรคระบบทางเดินอาหาร (Gastro-intestinal system) 
(ข้ีไหล ถOายเหลว) (diarrhoea) 
   
3. โรคระบบประสาท (Nervous system)  
(เดินวน ชัก หัวเอียง) (walking in circles, seizure) 
   
4. โรคระบบสืบพันธุ1 (Reproductive system) 
(มดลูกอักเสบ) (Metritis) 
   
5. ขาเจ็บ (lameness)    
6. โปรแกรมยาฉีด/กินเพ่ือป°องกันโรค 











(Gastro-intestinal system)  




5. ขาเจ็บ (lameness) 
หมายเหตุ  
(remark) 
      
      
      
7. โปรแกรมวัคซีน (ตอบได*มากกวOา 1 คำตอบ) (Vaccination program) (Multiple answers possible) 
    ไมOได*ทำ (No vaccination)    ปากและเท*าเป§•อย (FMD)     ปากและเท*าเป§•อย (FMD)    
    อหิวาต1สุกร (Swine fever)    PRRS        ไมโคพลาสมา (Mycoplasma)  
        …………………………..…          …………………………..…          …………………………..  
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D. สุกรขุน (Fattener) 
โรค (Disease category) 







1. โรคระบบทางเดินหายใจ (Respiratory system) 
(ไอ จาม หอบ หายใจลำบาก)  
(cough, sneezing, panting, breathing difficulty) 
   
2. โรคระบบทางเดินอาหาร (Gastro-intestinal system) 
(ข้ีไหล ถOายเหลว) (diarrhoea) 
   
3. โรคระบบประสาท (Nervous system)  
(เดินวน ชัก หัวเอียง) (walking in circles, seizure) 
   
4. โรคระบบสืบพันธุ1 (Reproductive system) 
(มดลูกอักเสบ) (Metritis) 
   
5. ขาเจ็บ (lameness)    
6. โปรแกรมยาฉีด/กินเพ่ือป°องกันโรค  











(Gastro-intestinal system)  




5. ขาเจ็บ (lameness) 
หมายเหตุ  
(remark) 
      
      
      
7. โปรแกรมวัคซีน (ตอบได*มากกวOา 1 คำตอบ) (Vaccination program) (Multiple answers possible) 
    ไมOได*ทำ (No vaccination)    ปากและเท*าเป§•อย (FMD)     ปากและเท*าเป§•อย (FMD)    
    อหิวาต1สุกร (Swine fever)    PRRS        ไมโคพลาสมา (Mycoplasma)  
         …………………………..…          …………………………..…          …………………………..  
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2.3 การใช5ยาปฏิชีวนะ (Use of antibiotics) 
26. คำปรึกษาในการจัดการสุขภาพสุกร (ตอบได*มากกวOา 1 คำตอบ) (Source of advice on farming 
pigs, feeding, health management, using medicine (Multiple answers possible)) 
   1. สัตวแพทย1ประจำฟาร1ม (Farm veterinarian)    
   2. สัตวแพทย1จากกรมปศุสัตว1 (DLD veterinarian) 
   3.   บริษัทเวชภัณฑ1สัตว1 
   4.   บริษัท contract (Contract company) 
   5.   อ่ืนๆ (other) ระบุ (i.e.) ………………………………………… 
27. จำนวนคร้ังของการตรวจ/เย่ียมโดยปศุสัตว1จังหวัด ในเดือนท่ีผOานมา  จำนวน ………… คร้ัง  
 (Number of visit/inspection by DLD last month) (visit)    (Time) 
28.  แหลOงท่ีมาของการส่ังใช*/แนะนำให*ใช* ยาปฏิชีวนะ (ตอบได*มากกวOา 1 คำตอบ)  
(Prescription/advise to administration of antibiotic) (Multiple answers possible) 
  ไมOได*รับคำแนะนำในการใช*ยาปฏิชีวนะ (Do not get advice about administration of antibiotics) 
  ได*รับคำแนะนำในการใช*ยาปฏิชีวนะ (Get advice about administration of antibiotics) 
 1. สัตวแพทย1ประจำฟาร1ม (Farm veterinarian)  จำนวน ………… คร้ัง/เดือน  
    (Time/month) 
 2. สัตวแพทย1จากบริษัทยา (Veterinarian from drug company) จำนวน ………… คร้ัง/เดือน  
        (Time/month) 
 3. สัตวแพทย1/สัตวบาลจากบริษัท contract (Veterinarian at contract company)  
        จำนวน ………… คร้ัง/เดือน  
        (Time/month) 
 4. สัตวแพทย1จากกรมปศุสัตว1 (DLD veterinarian)  จำนวน ………… คร้ัง/เดือน  
       (Time/month) 
 5. ส่ังซ้ือยาเอง (Self-medication (for their own animals)) จำนวน ………… คร้ัง/เดือน  
        (Time/month) 
 6 . อ่ืนๆ (Other sources) ระบุ (i.e.) …………………………… จำนวน ………… คร้ัง/เดือน  
264





        (Time/month) 
 
29. แหลOงท่ีมาของการซ้ือยาปฏิชีวนะ (ตอบได*มากกวOา 1 คำตอบ) 
Source of antibiotic purchasing (Multiple answers possible) 
 1. บริษัทยา (Drug company)    จำนวน ………… คร้ัง/เดือน (Time/month) 
 2. ร*านขายยา (คน( (Drug store, human)  จำนวน ………… คร้ัง/เดือน (Time/month 
 3 . ร*านขายสัตว1 (สัตว1) (Drug store, animal)  จำนวน ………… คร้ัง/เดือน (Time/month) 
 4 . อินเตอร1เนท ออนไลน1   (Internet, online)  จำนวน ………… คร้ัง/เดือน (Time/month) 
 5. อ่ืนๆ ระบุ…………………………………………  จำนวน ………… คร้ัง/เดือน (Time/month) 
30. รายจOายจากการซ้ือยาปฏิชีวนะรายเดือน       
        (Average spending on purchasing antibiotics per month)   
  1. ต่ำกวOา 1,000 บาท (< BHT 1,000) 
  2. 1,000-5,000 บาท (BHT 1,000-5,000) 
  3. 5,001-10,000 บาท (BHT 5,001-10,000) 
  4. 10,001-50,000 บาท (BHT 10,001-50,000) 
  5. มากกวOา 50,000 บาท (>BHT 50,000) 









ส_วนที่ 3 ความรู5และความตระหนักในการใช5ยาปฏิชีวนะและเชื้อดื้อยา       
(Section C – Knowledge and awareness of antibiotic use and AMR 
31. จากข*อความตOอไปน้ี ทOานคิดวOาข*อความตOอไปน้ี จริงหรือไมO (For each of the following 
statements Please tell me whether you think it is true or false? Please only indicate 
‘Don’t know’ if you really don’t know.) 
1) ทOานรู*จักยาปฏิชีวนะ/ยาฆOาเช้ือ หรือไมO    1. รู*  (Know)   2. ไมOรู* (Do not know) 
(Do you know “antibiotic”?)  
 
2) ยาปฏิชีวนะ/ยาฆOาเช้ือ ฆOาเช้ือไวรัสได*     1. จริง    2. ไมOจริง   3. ไมOทราบ 
        (Antibiotics kill the viruses)         True        False  Do not know 
3) ยาปฏิชีวนะ/ยาฆOาเช้ือ รักษาไข*หวัดได*     1. จริง    2. ไมOจริง   3. ไมOทราบ 
              (Antibiotics are effective against cold and flu   
4) ยาปฏิชีวนะ/ยาฆOาเช้ือ กับยาแก*อักเสบเปãนยาชนิดเดียวกัน*  
       1. จริง    2. ไมOจริง   3. ไมOทราบ 
   (Antibiotic is anti-inflammation drug.) 
5) การได*รับยาปฏิชีวนะ/ยาฆOาเช้ือ บOอยคร้ัง มีผลข*างเคียง เชOน ท*องเสีย* 
(Taking antibiotics too often has side-effects such as diarrhoea) 
          1. จริง    2. ไมOจริง   3. ไมOทราบ 
หมายเหต:ุ ผู*สัมภาษณ1ให*ข*อมูล 
ยาปฏิชีวนะ หมายถึง ยาที่ยับยั้ง/ฆOา/ต*านเชื้อโรค ที่มักเปãนสาเหตุของการเกิดโรคและอาการเจ็บปèวยในคนและสัตว1 อาจ
เรียกวOา “ยาฆOาเชื้อ” 
ยาปฏิชีวนะ ไม_ใช_ วิตามิน หรือ วัคซีน 
 
Note: Interviewer will provide information about antibiotic to respondent.  
Antibiotics: antibiotic is considered substance that exhibits antimicrobial activity (kill or inhibit the growth 
of micro-organisms) at concentrations attainable in vivo. 
Antibiotics are not Vitamin or Vaccine 
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6) การใช*ยาปฏิชีวนะ/ยาฆOาเช้ือ โดยไมOจำเปãน ทำให*รักษาไมOได*ผล หรือเช้ือด้ือยา*  
       1. จริง    2. ไมOจริง   3. ไมOทราบ 
            (Unnecessary or unreasonable use of antibiotics have negative impacts such as ineffective    
       treatment, AMR) 
7) คุณรู*หรือไมOวOา การใช*ยาปฏิชีวนะ/ยาฆOาเช้ือ ในสัตว1มีโอกาสให*เกิดเช้ือด้ือยาในสัตว1ได*    
(Do you know whether antibiotic use in food producing animals can induce AMR in those animals?) 
          1. รู*  (Know)   2. ไมOรู* (Do not know) 
8) คุณรู*หรือไมOวOามีการแพรOกระจายของเช้ือด้ือยาในฟาร1มสุกรของประเทศไทย**  
       1. รู*    2. ไมOรู* 
(Resistance to antibiotics is widespread in Thai pig farming) 
9) คุณรู*หรือไมOวOารัฐบาลประกาศห*ามใช*ยาปฏิชีวนะ/ยาฆOาเช้ือ เพ่ือเรOงการเจริญเติบโตในสัตว1ท่ีนำมา
เปãนอาหารในประเทศไทย*     1. รู*    2. ไมOรู* 
 (Do you know whether Thailand ban using antibiotic as a growth promoter in food producing   
animals?) 
10) คุณคิดวOายาปฏิชีวนะ/ยาฆOาเช้ือจำเปãนตOอการเล้ียงสุกรของทOานหรือไมO  
    (Do you think the use of antibiotics is necessary for the pig farming? 
      1. จำเปãน (yes)    2. ไมOจำเปãน (no)      3. ไมOแนOใจ (not sure)    
 
* คำถามเดียวกับข*อคำถามในการสำรวจอนามัยและสวัสดิการ (Same questions with the National 
Health Welfare Survey conducted in Thai people) 
** คำถามเดียวกับข*อคำถามในการสำรวจของภูมิภาคยุโรป (Revised from the 2017 EU Insights – 
Perceptions on the human health impact of antimicrobial resistance (AMR) and antibiotics 









ส_วนที่ 4 ปÅจจัยที่ส_งผลกับการใช5ยาปฏิชีวนะ  
(Section D – Factors which influence the use of antibiotics) 
32. กรุณาแสดงความคิดเห็นวOาปëจจัยตOอไปน้ีสOงผลตOอการใช*ยาปฏิชีวนะในฟาร1มของทOานหรือไมO 
Please rate your level of agreement or disagreement with the following reasons contribute 
to the use antibiotics in your pig farm. 
 
ปëจจัยที่สOงผลตOอการใช*ยาปฏิชีวนะ 

































   




   
   
   
   
   
   
   









































ก) การเข*าถึงยาปฏิชีวนะและกฎหมายที่เกี่ยวข*อง (Access to antibiotics and regulation) 
1. การบริการของบริษัทเวชภัณฑ1 โฆษณา และการสOงเสริมการขายเวชภัณฑ1 
      (Services from pharmaceutical company, advertising, promotion of product) 
          
2. กฎหมายที่เกี่ยวข*อง เชOน การตรวจประเมินฟาร1ม การตรวจยาตกค*าง 
  (Legal restriction such as farm inspection, ABO residue testing) 
          
3. นโยบายของรัฐในการลดการเกิดเชื้อดื้อยา 
  (Practice policy on a reduction of AMR) 
          
ข) ประสบการณ1 เพื่อน และสัตวแพทย1 (Experience, peer and veterinarians) 
4. ประสบการณ1ของทOานที่ผOานมาการใช*ยาปฏิชีวนะสามารถการลดการปèวยและการตายของ
สุกร (Past experiences that antibiotic reduced morbidity and mortality rate) 
          
5. คำแนะนำจากสัตวแพทย1 (advice by veterinarian)           
6. ข*อมูล คำแนะนำจากเพื่อนเกษตรกร หรือสหกรณ1ผู*เลี้ยงสุกร  
     (Information, advice and experiences from peer farmers, pig cooperatives) 
          
ค) การจัดการฟาร1ม (Farm management)      
7. การจัดการสุขลักษณะฟาร1ม ความสะอาดและสุขอนามัย ที่ไมOเหมาะสม  
     (Poor farm management i.e. no biosecurity) 
          
8. อาหารสัตว1ที่ไมOมีคุณภาพ 
     (Suboptimal feed quality leading to digestive disorders) 
          
9. การเกิดโรคระบาดในฟาร1มและพื้นที่จังหวัด 
     (Disease outbreaks in farm and province) 
          
10. โปรแกรมวัคซีนที่มีประสิทธิภาพ 
     (Good vaccination program) 
          
ง) ผลผลิต (Farm productivity)      
11. กำไรที่ได*จากการเลี้ยงสุกร เพิ่มผลผลิต  
     (Economic advantage, Increase productivity) 
          
12. แนวคิดและความต*องการ อาหารทีป่ลอดภัยในสังคมไทย เชOน ผู*บริโภคต*องการ 
     เนื้อสุกรที่ไมOมียาปฏิชีวนะตกค*าง (Food safety concern in the society. For example,  
     consumer demand for pork product without antibiotic residue) 
          
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ส_วนที่ 5 อื่นๆ (Section E – Others) 
























Table A1 Characteristics of the 84 pig farmers and farms surveyed in the study 
  




•       Male 34 (40.5) 
•       Female 50 (59.5) 
Age (year, mean±SD) 48.9 (±14.2) 
Farmer’s educational level   
• Primary school 37 (44.0) 
• Secondary school  25 (29.8) 
• Bachelor’s degree or higher 22 (26.2) 
Position  
•      Owner 61 (72.6) 
•      Manager 5 (6.0) 
• Owner's dependent 18 (21.4) 
Years of working at the pig farm (year, mean±SD) 15.1 (±11.2) 
Farm  
Size of farma  
• Smallholder farm  26 (31.0) 
• Commercial farm  58 (69.0) 
Type of farm   
• Farrowing to finisher farm  54 (64.3) 
• Fattening  30 (35.7) 
GMP certified farm b 31 (36.9) 
Member of cooperative farm 17 (20.2) 
Contract farm 8 (9.5) 
Income per month c  
•       Less than BHT 10,000 (<US$317) 28 (33.3) 
•       BHT 10,000-50,000 (US$317-1,590) 19 (22.6) 
•       BHT 50,001-100,000 (US$1,590-3,170) 6 (7.1) 
•       BHT 100,001-500,000 (US$3,170-15,900) 8 (9.5) 
•       More than 500,000 (>US$15,900) 9 (10.7) 
•       No response 14 (16.7) 
Trend of income in the past 3 years   
•       Significantly increased 2 (2.4) 
•       Slightly increased 7 (8.3) 
•       Equal 7 (8.3) 
•       Slightly decreased 15 (17.9) 
•       Significantly decreased 53 (63.1) 
Average spending on purchasing feed per month c  
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•       Less than BHT 1,000 (<US$32) 9 (10.7) 
•       BHT 1,000-5,000 (US$32-159) 14 (16.7) 
•       BHT 5,001-10,000 (US$159-317) 7 (8.3) 
•       BHT 10,001-50,000 (US$317-1,590) 13 (15.5) 
•       More than 50,000 (>US$1,590) 18 (21.4) 
•       No response 23 (27.4) 
Average spending on purchasing medicine per month c  
•       Less than BHT 1,000 (<US$32) 31 (36.9) 
•       BHT 1,000-5,000 (US$32-159)  9 (10.7) 
•       BHT 5,001-10,000 (US$159-317) 1 (1.2) 
•       BHT 10,001-50,000 (US$317-1,590) 8 (9.5) 
•       More than 50,000 (>US$1,590) 7 (8.3) 
•       No response 28 (33.3) 
Destination of pig products   
•       Broker only 27 (32.1) 
•       Pork retailer only 18 (21.4) 
•       Both broker and pork retailer 12 (14.3) 
•       Consumer directly 7 (8.3) 
•       Other farms 8 (9.5) 
•       Household own consumption 2 (2.4) 
 
a: According to the catagorisation by the Department of Livestock Development, there are greater 
than or equal to 50 pigs per farm in commercial farms and smallholder farms with less than 50 pigs 
per farm. 
b: DLD certified Good Agriculture Practice (GAP) for farms with a good standard of animal husbandry  






















Table A2 Source of advice on animal health management, antibiotics and medicated feed from 84 farms 
  
  Health 
(N=84, %) 
  Antibiotic 
(N=84, %) 
  Feed 
(N=84, %)   
Received advice       
• Received advice  68 (81.0)  48 (77.4)  36 (42.9) 
• Did not receive advice  16 (19.0)  36 (42.9)  48 (57.1) 
Source of advice       
• Veterinarian at farm  12 (17.6)  11 (22.9)  7 (19.4) 
• DLD veterinarian  4 (5.9)  2 (4.2)  1 (2.8) 
• Pharmaceutical, feed company, feed mill 8 (11.8)  5 (10.4)  6 (16.7) 
• Contracting company  4 (5.9)  3 (6.3)  4 (11.1) 
• Others  31 (45.6)  22 (45.8)  16 (44.4) 












Number (%) of farms  
participated in the study 
  
Number (%) of farms did not  
participate in the study 
 
Total 
By size of farm   
Total 










District A          
- Sub-distrct A1 30  25 (83.3) 9 (36) 16 (64)  5 (16.7) 2 (40) 3 (60) 
- Sub-distrct A2 16  6 (37.5) 3 (50) 3 (50)  10 (62.5) 9 (90) 1 (10) 
District B          
- Sub-distrct B1 16  16 (100) 4 (25) 12 (75)  0 0 0 
- Sub-distrct B2 14  12 (85.7) 0 12 (100)  2 (14.3) 1 (50) 1 (50) 
District C          
- Sub-distrct C1 12  11 (91.7) 7 (63.6) 4 (36.4)  1 (8.3) 0 1 (100) 
- Sub-distrct C2 14   14 (100) 11 (78.6) 3 (21.4)   0 0 0 
 102  84 34 50  18 12 6 
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Appendix 4 Supplement study paper 2  
A 4.1 Interview guide for antibiotic use and factors influencing the use of antibiotic in pig  
 production with pig farmers  
A4.2   Interview guide for antibiotic use and factors influencing the use of antibiotic in pig 
production with experts  
Version2/Date: May 2, 2018/page 1 
Participant’s code: 
Interview guide: Antibiotic use and factor influencing the use of antibiotics in pig 
production 
THIS GUIDE IS PREPARED TO PROVIDE BACKGROUND IDEA ABOUT THE FACTOR INFLUENCING THE 
USE OF ANTIBIOTIC IN PIGS. I WILL NOT READ THROUGH THE QUESTIONS. 
Topic: Towards an understanding of antibiotic use in swine production systems in Thailand 
Student: Angkana Sommanustweechai 
Supervisor: Dr Shunmay Yeung, Professor Anne Mills, Professor Jonathan Ruston 
Objective of the study 
1) To describe the pattern of antibiotic use and estimate the total amount of antibiotics used in pig
production globally and in Thailand
2) To investigate the regulatory system and analyse its effectiveness in controlling the use of antibiotics in
pig production in Thailand
3) To explore factors contributing to the use of antibiotics in pigs in Thailand
4) To identify potentially effective policy to enhance the rational use of antibiotics in pig production in
Thailand
Interviewer……….………….………………….…….………………….…….……………………….…………..…………………………..……… 
Name of respondent………….…………………………………………………………………………….………………………………………… 
Working address………….………………………………………………………………………………….………………………………………… 
Tel …………………………………………………………………………Mobile phone ……………………………………………………… 
• Qualitative interview introduction
Antibiotic use and factor influencing the use of antibiotics in pig production: semi-structured interview
Length: 45-60 minutes
Objective of the interview: To see things the way you (respondent) see them. It does not aim to assess or 
evaluate your work. More like a conversation with a focus on your (respondent) experience, your 
(respondent) opinions and what you think or feel about the topics covered. 
• Verbal consent
Discussion of confidentiality measures, include mention that subjects will be asked for oral rather than 
signed consent.  
• Background Information
Invite interviewee to briefly tell interviewer about him/herself: general information about background... 
mostly about experiences and perspectives on issues surrounding the use of antibiotics in pig production in 
Thailand.  
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Version2/Date: May 2, 2018/page 2 
Participant’s code: 
1: Animal health and farm management 
Sub-area:   General views and practices related to health management 
1. Can you tell me about health management practices in your farm?
2. What is the main health problem(s) in your farm?
3. Do pigs at different production stages have different health issues?
4. If your pigs get sick, how do you treat them? Do you use any medicines? If so, what kind of
medicines? Do you use them for the prevention of treatment of diseases?
5. <In case the farmer does not use antibiotics> Why did you decide to not use antibiotics?
6. Are your pigs vaccinated? If so, what kinds of vaccination program do you use?
7. Do you think that vaccination helps reducing antibiotic use?
Sub-area: Farm management and antibiotic use 
1. Do you believe that antibiotics are necessary for animal farming? If so, why?
2. Do you think any of these issues may be associated with increased antibiotic use in the farm?
- Poor farm management
- Suboptimal feed quality
3. In this period, is there any disease outbreaks in your farm or other parts of the province?
- If so, does this affect farm management including the use of antibiotics? How?
4. If you work for a larger company, does this company set the standards of health management
including antibiotic use? If so, how?
-
Area 2: Pig production and market demand 
Sub-area: Pig production and antibiotic use  
- In your experience, what is the effect of antibiotics on the morbidity and mortality of pigs?
- Do you think antibiotics are necessary to sustain economic profit?
- What about their cost? Are antibiotics expensive?
Sub-area: food safety, market demand (consumer preference) 
- What do you think about antibiotics and food safety? Is there a way to monitor the antibiotic
residue in your meat?
- What do you think about consumer’s demand for organic food or antibiotic-free pig products? Do
you think this may affect antibiotics use in the farms? If so, how?
Area 3: Relationships with other farmers, veterinarian, pharmaceutical company 
Sub-area: Relations with other farmers 
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Version2/Date: May 2, 2018/page 3 
Participant’s code: 
1. Have you ever talked or shared information about antibiotics with other farmers you know? If so,
can you explain?
2. Do you belong to a cooperative association? If so, has this ever involved the discussion or sharing of
information about antibiotic use? If so, can you explain?
Sub-area: roles of veterinarians in diagnosing disease and prescribing antibiotics 
1. Who does animal health checks and prescribes antibiotics in your farm?
- Do you receive regular visits from farm veterinarians? If so, can you explain?
- Have you ever received visits in your farm from DLD officers? If so, can you explain?
- Do you rely on the service of veterinarian consultants? If so, are they from academia? Which
university are they from? Do they influence your decision on the use of antibiotics?
Sub-area: Sources of antibiotics 
1. Where do you buy the medicines (including antibiotics) and medicated feed?
2. Can you tell me more about how you purchase them?
- What about sale representatives? Do they try to influence the way you use antibiotics in the
farm? If so, how?
Area 4: Regulation and policy on antibiotic use 
Sub-area: Regulations 
1. Do you have an official standard farm certification?
2. Do you receive any inspections from the DLD? If yes, how frequently? What do they monitor?
3. Is there any other organisation inspecting your farm? If yes, who and how?
4. Have you heard about any regulations restricting the use of active pharmaceutical ingredient in
animal feed and antibiotic use for growth promotion?
a. If so, what do you think?
b. Can regulations be applied easily in your farm?
5. The Thai-FDA and DLD are currently working on a new regulation to optimise the use of antibiotics
in livestock to reduce AMR
a. Do you know this? If so, what do you think?
Sub-area: Policy on antibiotic use 
1. Are you aware of the National Strategic Plan on AMR, and the national target to reduce 30% of
antibiotic use in animals? If so, what do you think?
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Version2/Date: May 2, 2018/page 4 
Participant’s code: 
Comments: INTERVIEWER, use this space to summarize how the SSI went, including the mood or 
feelings of the participant during the interview. 
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Regulations on antibiotic use in pig production in Thailand 
Interview guide: Regulations on antibiotic use in pig production in Thailand 
Topic: Towards an understanding of antibiotic use in swine production systems in Thailand 
Student: Angkana Sommanustweechai 
Supervisor: Dr Shunmay Yeung, Professor Anne Mills, Professor Jonathan Ruston 
Objective of the study 
1) To describe the pattern of antibiotic use and estimate the total amount of antibiotics used in pig
production globally and in Thailand
2) To investigate the regulatory system and analyse its effectiveness in controlling the use of antibiotics in
pig production in Thailand
3) To explore factors contributing to the use of antibiotics in pigs in Thailand
4) To identify potentially effective policy to enhance the rational use of antibiotics in pig production in
Thailand
Interviewer……….………….………………….…….………………….…….……………………….…………..…………………………..……… 
Name of respondent………….…………………………………………………………………………….………………………………………… 
Working address………….………………………………………………………………………………….………………………………………… 
Tel …………………………………………………………………………Mobile phone ……………………………………………………… 
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Theme: Regulatory system and its enforcement mechanism 
(Item 1-4, do not ask farmers.) 
1. What is the aim of the regulations (under your responsibility: Drug Act, Animal Feed Quality Control
Act, Pharmaceutical Profession Act, Veterinary Profession Act) in controlling the use of antibiotics?
2. What kinds of regulatory system according to the regulations in controlling the use of antibiotics?
a. Legal requirement for registration of professionals/ prescription control/ control
antibiotic use at farm
b. Organization and structure to control registration of professionals/ prescription control/
control antibiotic use at farm
i. National and local levels of the country
ii. Decentralized activities
c. International standard: related to the WHO/ OIE guidance
d. Quality management system: quality management, relevant to the WHO/OIE guidance
e. Internal planning and procedures: monitoring programs
f. Records and outputs: lists and database of professionals, operators
a. Availability of information: publication of database, data publicly available
3. What is the registration of professional procedure?
a. Process for pharmacist registration
b. Process for veterinarian registration
c. Specific process in relation to antibiotic control
d. Inspection
e. Sanction for non-compliance regulations
4. What is the prescription control procedure?
a. Process for prescription control
b. Specific process in relation to antibiotic control
c. Inspection
d. Sanction for non-compliance regulations
5. What is the control antibiotic use at farm procedure?
a. Process for control antibiotic use at farm
b. Specific process in relation to antibiotic control
c. Inspection
d. Sanction for non-compliance regulations
6. In the light of your experience of the regulatory capacity in prescription control/ control antibiotic
use at farm:
a. Which aspects are working well? (strength)
b. Which aspects are in most need of improvement? (weakness)
7. Please describe any concerns, worries or emotional stress you have about the regulatory system
and enforcement mechanism of antibiotic distribution and use. (Probes: Were you concerned or
worried about the working process, complain or sue by operators, affecting your work in any other
way?)
8. If you were to compare about the regulatory system and enforcement mechanism of antibiotic
distribution and use in Thailand with other countries:
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a. How are they similar?
b. How are they different?
Theme: Factors contributing the effectiveness of regulation 
1. Your opinion on the design of regulation on antibiotic use:
- How appropriate is the intervention given its aim (to ensure the safety, efficacy and quality of
drugs)?
- How appropriate is the intervention given to rational use of antibiotics?
- How clearly specified is the implementation process (e.g. regulatory body?)
- What is the accountability of the regulator? Are there clear complaints mechanisms?
- How passive or active is the monitoring and implementation?
2. Do you know whether (information)?
- The Drug Act classifies most antibiotics as dangerous drugs  which can be accessed without
prescription in retail pharmacies but are dispensed by professional pharmacists in pharmacies
- The Animal Feed Quality Control Act prohibits the direct use of API in animal feed
- Thailand ban using antibiotic as a growth promoter in food producing animals
3. Your opinion on the capacity of regulation on antibiotic use:
- What resources are available to undertake inspection/monitoring (Probes: human resource
(quantity and competency of personnel), financial support, policy support, recording system,
etc.)?
- How much did you like capacity of the regulatory system in terms of registration of
professionals/ prescription control/ control antibiotic use at farm?
- Please describe any concerns, worries or emotional stress you have about the capacity of the
regulatory system. (Probes: Were you concerned or worried about the working process,
complain or sue by operators, affecting your work in any other way?)
- Please describe any actual problems that you experienced while working about the capacity of
the regulatory system. (Probes: Did you experience working problem anywhere else? Please
provide detailed info on where the problem was experienced?)
4. Your opinion on the power/authority of regulation on antibiotic use:
- What is the relative authority of the regulator/regulatee?
- What is the credibility of the judicial system (e.g. is there effective sanctioning)
- What is the strength of consumer groups, media, professional associations?
- What are the sources of power/conflict (e.g. resource availability)?
5. Your opinion on the context of regulation on antibiotic use:
- Political context about the regulation
- Social and cultural context about the regulation
- Economic context about the regulation
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Recommendations 
1. Would you like to change anything about the regulatory system and its enforcement mechanism
in controlling the use of antibiotics in pig production? If so, how?
2. Would you like to change anything about design, information, capacity, authority and context of
the regulatory system in controlling the use of antibiotics in pig production? If so, how?
3. Do you have any other recommendations about the regulatory system and its enforcement
mechanism?
4. Do you have any other recommendations about design, information, capacity, authority and
context of the regulatory system in controlling the use of antibiotics in pig production?
Other 
Comments: INTERVIEWER, use this space to summarize how the SSI went, including the mood or 





Appendix 5 Information sheet and consent form 
A 5.1 Ethical approval document by Institute for the Development of Health Research 
Protections 
A 5.2 Ethical approval document by London School of Hygiene and Tropical Medicine 
 A 5.3 Participant information leaflet and consent for research participation for pig farmers 
A 5.3 Participant information leaflet and consent for research participation for experts 
A 5.4 Participant information leaflet and consent for research participation for pig farmer and 
experts in Thai 
---.......  ,"-...._,,.,._, 
Ethics Committee 
Institute for the Development of Human Research Protections (IHRP) 
Building 8 Floor 7 Room 702 Department of Medical Science Ministry Public Health Nonthaburi Thailand 11000 
- --------------------------------------------------------------
Certificate of Approval 
Title of Project: Towards an understanding of antibiotic use in swine production systems in Thailand. 
(Version 2/ Date: January 24, 2018) 
Principal Investigator: Angkana Sommanustweechai 
Responsible Organization: International Health Policy Program (IHPP), Ministry of Public ,Health. 
The Ethics Committee of Institute for the Development of Human Research Protections (IHRP) had reviewed the 
research proposal. Concerning on scientific, ICH-GCP and ethical issues, the committee has approved for the 
implementation of the research study mentioned above. 
V.............. ¥. .................................... . 
( Dr.Vichai Chokevivat) 
Chairman 
Date of First Meeting: January 23, 2018 
Date of Approval: January 26, 2018 
(Dr.Pramote Stienrut) 
Committee and Secretary 
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Observational / Interventions Research Ethics Committee
Dr Angkana Sommanustweechai 
LSHTM
1 June 2018 
Dear Dr Angkana Sommanustweechai
Study Title: Towards an understanding of antibiotic use in swine production systems in Thailand 
LSHTM Ethics Ref: 14860 
Thank you for responding to the Observational Committee’s request for further information on the above research and submitting revised documentation.
The further information has been considered on behalf of the Committee by the Chair. 
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation
as revised, subject to the conditions specified below.
Conditions of the favourable opinion
Approval is dependent on local ethical approval having been received, where relevant. 
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document Type File Name Date Version
Investigator CV CV-angkana20180112 28/01/2018 1
Protocol / Proposal SSI with experts_20180220_CT 02/02/2018 1
Protocol / Proposal Data sheet for AMU volume collection_20180222 22/02/2018 1
Protocol / Proposal Use of antimicrobial in livestock_EC submission_20180502 02/05/2018 2
Protocol / Proposal SSI with farmers_20180502 02/05/2018 2
Protocol / Proposal Questionaire_ 20180502 02/05/2018 2
Information Sheet Consent form_farmer_20180515 15/05/2018 2
Covering Letter Cover letter to LSHTM EC_20180517 17/05/2018 1
Information Sheet Consent form_expert_20180517 17/05/2018 2
Local Approval EC Eng 21/05/2018 1
After ethical review
The Chief Investigator (CI) or delegate is responsible for informing the ethics committee of any subsequent changes to the application.  These must be submitted to the Committee for review
using an Amendment form.  Amendments must not be initiated before receipt of written favourable opinion from the committee.  
The CI or delegate is also required to notify the ethics committee of any protocol violations and/or Suspected Unexpected Serious Adverse Reactions (SUSARs) which occur during the project
by submitting a Serious Adverse Event form. 
An annual report should be submitted to the committee using an Annual Report form on the anniversary of the approval of the study during the lifetime of the study. 
At the end of the study, the CI or delegate must notify the committee using an End of Study form. 
All aforementioned forms are available on the ethics online applications website and can only be submitted to the committee via the website at: http://leo.lshtm.ac.uk
Additional information is available at: www.lshtm.ac.uk/ethics
Page 1 of 2
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PARTICIPANT INFORMATION LEAFLET AND CONSENT FOR RESEARCH PARTICIPATION 
Study Title: Swine production systems and health management in Thailand 
Principal Investigator: Angkana Sommanustweechai 
I am a graduate student at the London School of Hygiene and Tropical Medicine.  I am planning to conduct 
a research study, which I invite you to take part in.  This form has important information about the reason 
for doing this study, what we will ask you to do if you decide to be in this study, and the way we would like 
to use information about you if you choose to be in the study.   
Respondent: pig farmer 
Why are you doing this study? 
You are being asked to participate in a research study about swine production systems, health 
management and the use of medicines in pig farms in Thailand. Now there is no information about Thai 
swine production. This study will generate information for better understanding about Thai swine 
production and its context such as regulation, the use of antibiotics and pig market.  
What will I do if I choose to be in this study? 
You will be asked to provide information, your opinions, views, experiences about farm management. The 
interview will cover details of productivity of your farm, animal health and illness, market demand, your 
relationship with DLD and other farmers, and regulation.  
You will be asked to provide data through questionnaire and semi-structured interview. After the interview, 
I would like to ask for permission to stay on your farm for 3-5 days to learn more about the farm 
management, husbandry and biosecurity.  
In order to understand about medicines used in your farm, data on the antibiotic use in your farm will be 
explored. Potential sources include antibiotic prescription record, treatment records or antibiotic invoices 
at farms, where they are available. The duration of antibiotic use data will cover the last batch of 
production in breeder in farrowing period (about 1 month), weaner or breeding piglet (about 2 months) 
and fattener (about 3 months).  
For the interview, I would like to record this interview so as to make sure that I remember accurately all the 
information you provide. I will keep these audio file in my laptop and LSHTM database and they will only be 
used by the research team.  
[If respondent may participate without being taped, state so.  If audio/video recording are not optional, 
then clearly state that it is required for participation.] 
Study time:   
The questionnaire will take approximately 30 minutes. 
The semi-structured interview will take approximately 1-1.30 hours 
The observation period and antimicrobial use data collection will take 1-3 days each. 
Study location: All study procedures will take place at Bangkok and Ratchaburi province. 
What are the possible risks or discomforts? 
This research does not involve taking any samples from you or from the farm. We expect that any risks or 
discomforts to you will be minimal. It is unlikely, but possible that some of the topics that we discuss or 
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questions we ask may make you feel uncomfortable, in which case you are free to not answer or to skip to 
the next question. 
What are the possible benefits for me or others? 
You are not likely to have any direct benefit from being in this research study. This study is designed to 
gain more about insight and understanding pig production and health management. The knowledge 
received may be of value to humanity. 
How will you protect the information you collect about me, and how will that information be shared? 
Study data will be handled as confidentially as possible. All information will be kept in secret with the 
primary investigator for their confidentiality. The paper documents will be kept in the locked cabinet at the 
International Health Policy Program to which only the primary investigator will have access. All audio files 
and transcripts will be password protected and kept in the primary investigator's computer which will also 
be password protected.  The files will be encrypted and backed up on LSHTM’s secure FILR system and on a 
password protected portable storage. 
Summary results of this study may be used in publications and presentations.  Individual names and other 
personally identifiable information will not be used. Participants’ names and other information that could 
be used to identify individuals or individual farms will be removed or changed to keep confidentiality.  
Sometimes it is helpful to use direct quotations (i.e. to use the same words that you use in the interview, in 
academic publication or other academic outlets. If we do this, we will make sure that it is completely 
anonymous so that there is no way that individuals can be identified from other information in the 
interview. However, if you would prefer that we do not use direct quotations in this way then we will not.  
We will give you the choice when we ask for your consent. 
What are my rights as a research participant? 
Participation in this study is voluntary.  If at any time and for any reason, you would prefer not to 
participate in this study, please feel free not to. If at any time you would like to stop participating, please 
tell me. We can take a break, stop and continue at a later date, or stop altogether. You may withdraw from 
this study at any time, and you will not be penalized in any way for deciding to stop participation.   
If you decide to withdraw from this study, the researchers will ask you if the information already collected 
from you can be used. 
Who can I contact if I have questions or concerns about this research study? 
You have the right to ask questions about this research study and to have those questions answered by me 
before, during or after the research.  If you have any further questions about the study, at any time feel 
free to contact a researcher at 
Angkana Sommanustweechai 
International Health Policy Program, 
Tivanond Road, 





Ask respondent to provide “I agree” or “I do not agree” options at the end of the consent form. 
I agree to join in 
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   Questionnaire 
   In-depth interview (if yes, you agree if your quote is made available through academic 
     publication or other academic outlets with anonymity. 
       Agree 
       Do not agree 
   Observation 
   Antimicrobial use data collection 
  I do not agree to join in the interview  
Participant: 
I have read the foregoing information, or it has been read to me. I have had the opportunity to ask 
questions about it and any questions that I have asked been answered to my satisfaction.  I consent 
voluntarily to participate as a participant in this research. 
__________________________ __________ ________ ________________________ 
Signature of Participant Date Time Printed Name 
Researcher/person taking the consent: 
I have accurately read out the information sheet to the potential participant, and to the best of my 
ability made sure that the participant understands. I confirm that the participant was given 
an opportunity to ask questions about the study, and all the questions asked by the participant have 
been answered correctly and to the best of my ability. I confirm that the individual has not been coerced 
into giving consent, and the consent has been given freely and voluntarily.  
__________________________ __________ ________ ________________________ 
Signature of researcher/ Date Time Printed Name 
person took this research 
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PARTICIPANT INFORMATION LEAFLET AND CONSENT FOR RESEARCH PARTICIPATION 
Study Title: Swine production systems and health management in Thailand 
Principal Investigator: Angkana Sommanustweechai 
I am a graduate student at the London School of Hygiene and Tropical Medicine.  I am planning to 
conduct a research study, which I invite you to take part in.  This form has important information 
about the reason for doing this study, what we will ask you to do if you decide to be in this study, 
and the way we would like to use information about you if you choose to be in the study.   
Respondent: experts about regulations in relation to the use of antibiotics in pig production in 
Thailand.  
Why are you doing this study? 
You are being asked to participate in a research study about swine production systems and health 
management in Thailand. The aim of the study is to understand how farmers manage the pig 
production, how and why the antibiotics are used in pig production in Thailand.  
What will I do if I choose to be in this study? 
You will be asked to provide your opinions, views, experiences about the regulations in relation to 
antibiotic use. 
Study time:  Study participation will take approximately 1-1.30 hours 
Study location: All study procedures will take place at Bangkok and Rachburi province. 
I would like to record this interview so as to make sure that I remember accurately all the 
information you provide. I will keep these audio file in my laptop and LSHTM database and they will 
only be used by the research team.  
[If respondent may participate without being taped, state so.  If audio/video recording are not 
optional, then clearly state that it is required for participation.] 
What are the possible discomforts? 
This research does not involve taking any samples from you or from the farm. We expect that any 
risks or discomforts to you will be minimal. It is unlikely, but possible that some of the topics that we 
discuss or questions we ask may make you feel uncomfortable, in which case you are free to not 
answer or to skip to the next question. 
What are the possible benefits for me or others? 
You are not likely to have any direct benefit from being in this research study. This study is designed 
to gain more about insight and understanding pig production and health management. The 
knowledge received may be of value to humanity. 
How will you protect the information you collect about me, and how will that information be 
shared? 
Study data will be handled as confidentially as possible. All information will be kept in secret with 
the primary investigator for their confidentiality. The paper documents will be kept in the locked 
cabinet at the International Health Policy Program to which only the primary investigator will have 
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access. All audio files and transcripts will be password protected and kept in the primary 
investigator's computer which will also be password protected.  The files will be encrypted and 
backed up on LSHTM’s secure FILR system and on a password protected portable storage. 
Summary results of this study may be used in publications and presentations.  Individual names and 
other personally identifiable information will not be used. Participants’ names and other information 
that could be used to identify individuals or individual farms will be removed or changed to keep 
confidentiality.  
Sometimes it is helpful to use direct quotations (i.e. to use the same words that you use in the 
interview, in academic publication or other academic outlets. If we do this, we will make sure that it 
is completely anonymous so that there is no way that individuals can be identified from other 
information in the interview. However, if you would prefer that we do not use direct quotations in 
this way then we will not.  We will give you the choice when we ask for your consent. 
What are my rights as a research participant? 
Participation in this study is voluntary.  If at any time and for any reason, you would prefer not to 
participate in this study, please feel free not to. If at any time you would like to stop participating, 
please tell me. We can take a break, stop and continue at a later date, or stop altogether. You may 
withdraw from this study at any time, and you will not be penalized in any way for deciding to stop 
participation.   
If you decide to withdraw from this study, the researchers will ask you if the information already 
collected from you can be used. 
Who can I contact if I have questions or concerns about this research study? 
You have the right to ask questions about this research study and to have those questions answered 
by me before, during or after the research.  If you have any further questions about the study, at any 
time feel free to contact a researcher at 
Angkana Sommanustweechai 
International Health Policy Program, 
Tivanond Road, 





Ask respondent to provide “I agree” or “I do not agree” options at the end of the consent form. 
Participant: 
I have read the foregoing information, or it has been read to me. I have had the opportunity to ask 
questions about it and any questions that I have asked been answered to my satisfaction.  I 
consent voluntarily to participate as a participant in this research. 
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  I agree to join in the interview 
  I disagree to be quoted directly.  
  I agree to be quoted directly if my name is not published. 
__________________________ __________ ________ ________________________ 
Signature of Participant Date Time Printed Name 
Researcher/person taking the consent: 
I have accurately read out the information sheet to the potential participant, and to the best of my 
ability made sure that the participant understands. I confirm that the participant was given 
an opportunity to ask questions about the study, and all the questions asked by the participant 
have been answered correctly and to the best of my ability. I confirm that the individual has not 
been coerced into giving consent, and the consent has been given freely and voluntarily.  
__________________________ __________ ________ ________________________ 
Signature of researcher/ Date Time Printed Name 
person took this research 
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นักวิจัย สพ.ญ. อังคณา สมนัสทวีชัย   
ข้าพเจ้าเป็นนักศึกษาระดับปริญญาเอกจาก London School of Hygiene and Tropical 
Medicine ประเทศสหราชอาณาจักร โดยวางแผนในการเก็บข้อมูลในการศึกษาวิจัยเรื่องการใช้ยาปฏิชีวนะใน
การเลี้ยงสุกรของประเทศไทย โดยขอเชิญท่านเป็นผู้ให้ข้อมูลประกอบการศึกษาดังกล่าว เอกสารฉบับนี้มี





ไทย การศึกษาวิจัยนี้จะทำให้เกิดความรู ้และความเข้าใจเกี่ยวกับการเลี้ยงสุกรในบริบทประเทศไทย เช่น 
กฎหมาย การใช้ยาปฏิชีวนะ และตลาดสุกร 
สิ่งที่ท่านต้องทำในการให้ข้อมูล 
ผู้สัมภาษณ์จะสอบถามข้อมูล ความคิดเห็น มุมมอง และประสบการณ์ในการจัดการฟาร์มของท่าน การ
สัมภาษณ์จะครอบคลุมรายละเอียดเกี่ยวกับผลผลิตสุกรในฟาร์มของท่าน สุขภาพและความเจ็บป่วยของสุกร 
ความต้องการของตลาด ความสัมพันธ์ของท่านและกรมปศุสัตว์ และกฎหมายที่เกี่ยวข้อง 
ผู้สัมภาษณ์จะสอบถามข้อมูลในรูปแบบแบบสอบถาม และการสัมภาษณ์กึ่งโครงสร้าง หลังจากการสัมภาษณ์ 
นักวิจัยอาจจะขออนุญาตที่จะเข้าศึกษาดูงานในฟาร์มของท่านเป็นเวลา 3-5 วัน เพื่อเรียนรู้เกี่ยวกับการจัดการ
ฟาร์ม สุขาภิบาล และความปลอดภัยในการป้องกันโรค 
เพื่อที่จะเข้าใจถึงการใช้ยาในฟาร์มของท่าน นักวิจัยจะขอสำรวจข้อมูลเกี่ยวกับการใช้ยาปฏิชีวนะ จาก
แหล่งข้อมูล ดังต่อไปนี ้ได้แก่ บันทึกการใช้ยาปฏิชีวนะในฟาร์มของท่าน บันทึกการสั่งจ่ายยาโดยสัตวแพทย์ 
หรือใบเสร็จการซื้อยาปฏิชีวนะ ระยะเวลาในการสำรวจข้อมูลการใช้ยาปฏิชีวนะจะครอบคลุมหนึ่งรุ่นย้อนหลัง
ของการเลี้ยงสุกรในแต่ละช่วงอายุ ได้แก ่ประมาณ 1 เดือนในสุกรแม่พันธุ์ ประมาณ 2 เดือนในสุกรดูดนมและ
สุกรอนุบาล และประมาณ 3 เดือนในสุกรขุน 
รายการที ่1 
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บันทึกเสียง สามารถแจ้งผู้เก็บข้อมูล)  
ระยะเวลาในการให้ข้อมูล
- แบบสอบถาม ประมาณ 30 นาที
- สัมภาษณ์เชิงลึก ประมาณ 1-1.30 ชั่วโมง
- การสังเกต ประมาณ 1-3 วัน



















หากต้องมีการอ้างอิงคำพูดของผู้ให้ข้อมูล ในการตีพิมพ์ข้อมูลทางวิชาการ ผู้วิจัยยืนยันว่า จะไม่มีการระบุ
ตัวตนของผู้ให้ข้อมูล หรือข้อมูลที่สามารถสืบค้นย้อนหลังได ้อย่างไรก็ตาม หากท่านไม่สะดวกที่จะให้อ้างอิง
คำพูด ท่านสามารถแจ้งสิทธิ์ได้ในเอกสารส่วนท้าย 
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4 
สิทธิ์ในการให้ข้อมูล 
การให้ข้อมูลนี้เป็นแบบสมัครใจ หากท่านไม่ต้องการให้ข้อมูล ท่านสามารถเสนอความจำนงได้ตลอดเวลา ทั้ง
ก่อน ระหว่าง และหลังการให้ข้อมูล ท่านสามารถหยุดพักระหว่างการให้ข้อมูล หรือยกเลิกการให้ข้อมูล โดยไม่
มีเงื่อนไขใดๆ ทั้งสิ้น หากท่านต้องการยุติการให้ข้อมูล นักวิจัยจะสอบถามความยินยอมในการนำข้อมูลไปใช้
บุคคลที่ติดต่อได ้หากมีคำถามเกี่ยวกับการให้ข้อมูล 
ท่านมีสิทธิ์ในการถามคำถามเกี่ยวกับการให้ข้อมูล ทั้งก่อน ระหว่าง และหลังการให้ข้อมูล โดยหากมีคำถาม
เพิ่มเติม สามารถติดต่อผู้วิจัยได้ที ่





สอบถามผู้ให้ข้อมูลว่า “ยินด”ี หรือ “ไม่ยินด”ี ในการให้ข้อมูล ตามส่วนท้ายของเอกสาร
ข้าพเจ้ายินดีในการให้ข้อมูล 
   แบบสอบถาม 
   สัมภาษณ์เชิงลึก (หากยินด ีท่านสามารถให้มีการระบุคำพูดในเอกสารวิชาการต่อไปหรือไม่ ทั้งนี้ 
     ข้อมูลดังกล่าวจะไม่มีการอ้างอิงถึงผู้ให้ข้อมูล) 
       ยินดี 
       ไม่ยินดี 
   การสังเกต 
   ข้อมูลการใช้ยาปฏิชีวนะ 
  ข้าพเจ้าไม่ยินดีในการให้ข้อมูล  
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__________________________ __________ ________ ________________________ 
      ลงชื่อผู้ให้ข้อมูล วันที่ เวลา ผู้ให้ข้อมูล  )ตัวบรรจง(
ผู้สัมภาษณ์ 
ข้าพเจ้าได้อ่านข้อมูลในเอกสารฉบับนี้อย่างครบถ้วน และเต็มความสามารถแก่ผู้ให้ข้อมูล ข้าพเจ้ายืนยันว่า 
ผู้ให้ข้อมูลมีโอกาสในการสอบถาม และข้าพเจ้าได้ตอบคำถามแก่ผู้ให้ข้อมูลจนพอใจ ข้าพเจ้ายืนยันว่าผู้ให้
ข้อมูลได้ใช้สิทธิ์ในการให้ข้อมูลโดยสมัครใจ  
__________________________ __________ ________ ________________________ 





Appendix 6 Associated publications and conferences presentations 
A 6.1 Lists of associated publications  
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2019-001918 
2. Lekagul, A, Yeung S, and Tangcharoensathien V. Patterns of antibiotic use in global 
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• In agriculture, antibiotics are used to treat 
infections but are also used to increase livestock 
production through the control and prevention of 
disease maintaining food availability.
• However, the increase of antimicrobial resistance 
has given rise to concerns with regards the 
overuse of antibiotic in animals (1,2,3).
• Humans and animals often share the same 
pathogens and the same classes of antibiotics. 
Many common antibiotics used in animals are 
categorised as critically important antimicrobials
for human medicine according to the WHO priority 
list (4).
• While data from High-income countries are 
available, there are few published studies 
investigating the use of antibiotics in pigs in Low 
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Objectives
How antibiotics are used in pig production in Thailand
Angkana Lekagul1,2, Shunmay Yeung1, Anne Mills1, Viroj Tangcharoensathien2
1 London School of Hygiene & Tropical Medicine, UK 2 International Health Policy Program, Ministry of Public Health, Thailand
To describe the pattern of antibiotic use and estimate 
the total amount of antibiotics used in pig production 
in Thailand.
• Questionnaire survey of pig farmers (84 farmers): 
to investigate antibiotic consumption profiles at farm-
level (July-September 2018)
• Survey of feed mills (23 feed mills): to gather data 
on volume of medicated feed at country level. Data 
were collected by International Health Policy Program, 
MoPH. The volume of antibiotics mixed in feed in 
2017 was measured by kg of active ingredient 
(volume of antibiotics x strength) by ATCvet Code.
• Statistical analysis: 
o Descriptive analysis
o Univariate analysis: to assess the association 
between the dependent variable (the use of 
antibiotics in pig farms) and each independent 
variable
• A majority of oral and parenteral antibiotics used at farm level, and antibiotics 
added to medicated feed belong to the category of Critically Important 
Antimicrobials for human medicine (WHO’s list). 
• Farmer with >10 years experience, cooperative farms and farms having received   
animal health advice were significantly associated with higher use of antibiotics.
• Information about medicated feed could not be captured at farm due to              
1) no recording system at farm, 2) recall bias, 3) no antibiotic data in feed 
products, and 4) farmers were not willing to provide information.
• The small sample size of farmers limited the ability to identify the potential risk 
factors of the use of antibiotics. 
B
Findings
Fig. 2 Type of antibiotics in medicated feed from feed mill survey (N=23)
Farmers characteristics that appear to be risk factors for use of antibiotics 
for prevention in the past 12 months (N=84) a
*Statistically significant 
a: Number of farms where information is 
available; b: Knowledge: five true/false 
questions in relation to the use of 
antibiotics and AMR, followed the 2017 
National Health Welfare survey; c: 
According to the catagorisation by the 
government, there are ≥50 pigs per farm 
and smallholder farms as those with <50 
pigs per farm; d: Government certified 
GAP for farms with good standard of 
animal husbandry
+++ Highest Priority Critically important antimicrobials for human medicine, WHO’s list 
++ High Priority Critically important antimicrobials for human medicine, WHO’s list  







































































































*OR = 4.81: 95%CI= 1.2-19.4, P-value=0.01
*OR = 3.55: 95%CI= 1.1-11.4, P-value=0.03











Total active ingredient (AI) = 842.6 tonnes
of medicated feed from farm survey 
Fig. 1 Type of oral and parenteral antibiotics for prevention from farm survey (N=84) 




A 6.4 ASHTM poster 2019: The use of Critically Important Antimicrobials in Thai pig production: survey of 84 pig farms and 31 feed mills  
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Methods
Introduction
• Cross-sectional questionnaire based survey of 84 pig farmers 
to determine the patterns of antibiotic use at farm-level 
(March-December 2018)
• Secondary analysis of data from a national survey of feed mills 
(31 feed mills), having an estimated 80% of total market share 
to estimate the total amount of antibiotics mixed in pig feed in 
2017
• Statistical analysis: 
- Descriptive analysis
- Univariate analysis: to assess the association between the
use of CIA and independent variables of pig farmer
characteristics.
• Consumption of CIA in pig production in Thailand is high, both as oral 
and injectable medications and medicated feed
• The use of CIA was significantly and positively associated with farmers’ 
educational level, experience in raising pigs, farm income, farm size, 
receiving advice on animal health, good agricultural practice farms 
certification, and being members of a farm cooperative membership 
• No correlation was found between the use of CIA and farmers’ 
knowledge about antibiotics and AMR
• Progressive restriction of the use of CIA is recommended guided by the 
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Conclusion and recommendations
Survey of pig farmers
The use of “Critically Important Antimicrobials” in Thai pig production: 
survey of 84 pig farms and 31 feed mills
second line
Angkana Lekagul a, b, Viroj Tangcharoensathien b, Anne Mills a, Jonathan Rushton c, Shunmay Yeung a
a
London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
b
International Health Policy Programme, Ministry of Public Health, Nonthaburi 11000, Thailand.
c
Institute of Infection and Global Health, University of Liverpool, L3 5RF, UK.
• Antimicrobial resistance is recognised as a growing threat to 
global health security and is driven by the use of 
antimicrobials in both humans and animals (1,2,3). 
• Of particular concern is the use in animals of Critically 
Important Antimicrobials (CIA) (4), in particular the Highest 
Priority CIA such as colistin, which are reserved as a last 
resort for the most severe and resistant human infections. 
• In agriculture, antibiotics are used to treat infections, to 
control and prevent disease, and to promote livestock’s 
growth.
• There are few published studies investigating the use of 
antibiotics in pigs in low- and middle-income countries (5).
Note: *Statistically significant at p <0.05, a: Knowledge: five true/false statements in relation to the use of antibiotics 
and AMR, taken from the AMR module in the 2017 National Health Welfare survey
Fig. 3 a) smallholder farm, b) commercial farm (sow barn), c) commercial farm (fattener barn) in the study and d) antibiotics storage in one of the study farms
Objective




(No. of farms with data 
available)




level of education 
Primary school (37) 8 (21.6) 1
Secondary school and higher (47) 24 (51.1) 3.78 (1.43-9.97) 0.01*
Farmer’s  
experience 
≤10 years (37) 8 (21.6) 1
>10 years (47) 24 (51.1) 3.78 (1.43-9.97) 0.01*
Farmer’s  
knowledge a
Score <60% (29) 12 (41.4) 1
Score ≥60% (52) 19 (36.5) 0.82 (0.32-2.07) 0.67
Size of farm 
Smallholder farm (26) 3 (11.5) 1
Commercial farm (58) 26 (50.0) 7.67 (2.07-28.37) 0.01*
Type of farm
Farrowing to finisher farm (54) 25 (46.3) 1




No (53) 14 (26.4) 1
Yes (31) 18 (58.1) 3.86 (1.51-9.87) 0.01*
Member of 
cooperative
No (67) 20 (29.9) 1
Yes (17) 12 (70.6) 5.64 (1.75-18.12) 0.01*
Contracted farm
No (76) 30 (39.5) 1
Yes (8) 2 (25.0) 0.51 (0.10-2.70) 0.43
Household 
income/ month
Less than BHT 50,000 (47) 11 (23.4) 1
More than BHT 50,000 (23) 15 (65.2) 6.1 (2.06- 18.23) 0.02*
Advice on animal 
health
Not receiving advice (16) 2 (12.5) 1
Receiving advice (68) 42 (44.1) 5.53 (1.16-26.22) 0.03
Table 1 Factors associated with the use of CIA for disease prevention in the past 12 
months from the survey of pig farmers
Survey of feed mills

















































Kitasamycin (a macrolide)  1.1%
Tilmicosin (a macrolide) 6.5%
Tylosin (a macrolide) 4.6%






















compound)    
14.6%
Fig. 1 Percentage of farms reporting the use of any CIA 
(one farm can report more than one type of antibiotic.)
Fig. 2 Estimated amount of CIA added to medicated feed in tonnes, 2017
31% (26/84) of farmers reported the use of antibiotics in the CIA lists




A 6.5 LSHTM poster 2019: How are antibiotics used in Thai pig production 
Antibiotic use in livestock
• Antibiotic use is frequently a feature of intensive farming. 
• The purpose of the use of antibiotics in livestock includes: 
treatment, control and prevention of infection; growth 
promotion(2); and increased productivity.  
• Of 26 EU countries, the overall consumption of 
antimicrobials was higher in animals than in  human (3). 
• Many classes of antibiotics that are used for humans are 
also being used in food animals.
• There is increasing debate about the trade-off between the 
benefits of the use of antibiotics, particularly in terms of non-
therapeutic use of antibiotics vs. the AMR threat to humans.
• Global concern: MCR-1 gene (resistant bacteria to colistin-
a last resort antibiotic for treating MDR infections in 
humans) found in patients in Scotland and US (4), and in 
pig farms in China (5) and Thailand (6). 
Improving health worldwide www.lshtm.ac.uk
Methods
Introduction
Antimicrobial Resistance (AMR) 
• Antimicrobial resistance (AMR) has recently been 
recognized as a major threat to global health, causing 
serious implications for health and the economy (1).
• Antimicrobial resistance is a natural phenomenon, but the 
use of antibiotics in humans and animals is considered to 
be a major driving force in the emergence of AMR. 
Fig. 4 Possible factors contributing the use of antibiotics in pigs
Impact
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Objectives
How are antibiotics used and controlled in pig farms in Thailand?
Angkana Sommnustweechai1,2, Shunmay Yeung1, Anne Mills1
1 London School of Hygiene & Tropical Medicine, UK
2 International Health Policy Program, Ministry of Public Health, Thailand
1. To describe the pattern of antibiotic consumption in pig farms
2. To identify factors contributing to the use of antibiotics in 
pig farms 
3. To explore the regulatory system and analyze its 
effectiveness in controlling the distribution and use of 
antibiotics in livestock 
4. To identify relevant policy interventions to enhance 
rational use of antibiotics in livestock
Factors contributing the use of antibiotics in pigs
It is known that there is a wide range of factors that influences 
antibiotic use by farmers: 
• Farm type and farmer: Type of farm, farmers’ knowledge 
and personal attitudes (7-9).
• Pharmaceutical market and veterinarian : Antibiotics are 
public goods; and also it could be said that there is market 
failure in terms of “supplier induced demand” for antibiotics in 
LMICs. Antibiotics prescribed based on the requests from 
farmers (10),  and  individual veterinarian’s preference for 
antibiotics and their experiences, rather than scientific data or 
laboratory findings (11,12). 
• Food consumer: Increasing consumer demand for products 
from livestock raised without antibiotics may affect the 
practices of retailers, e.g. fast-food companies (13).
• Regulation: Regulatory provisions related to medicine in 
LMICs focus on quality, less on market control (14,15). In 
terms of its effectiveness, it requires the commitment of 
government, adequate resources and cooperation. 
Thailand
• Population: 68 million (2017
• GNI per capita (current US$): 5,720*
• Pig farmer: ~190,000 households (2016)
• Pig production: ~9.9 million animals/year (2016)
*Data from World Development Indicators (2015)
To date, there has been little evidence about the use of 
antibiotics in pig farms in Thailand. No research has been 
conducted specifically aiming to understand the factors 
influencing the use and control of antibiotics in pigs.
• Questionnaire survey: to investigate antibiotic consumption 
profiles in pig farms
• In-depth interviews: to identify factors influencing the use of 
antibiotics by pig farmers 
• Semi-structured interviews: to describe the role of 
pharmaceutical industries, veterinarians, consumers and 
regulators and attitudes to use of antibiotics in pig farming
• Document review: to review the regulations regarding to 
antibiotic control 
• Questionnaire survey (adapted from WHO tool): to analyze 
the effectiveness of regulation 
The excessive use of antibiotics in livestock is considered a 
major driver of the emergence of AMR. A better understanding 
of key factors contributing to the use of antibiotics in pigs will 
support the introduction of policies for optimal use of antibiotics 
and other alternatives which lead to the reduction in selective 
pressure on antibiotics and the emergence of AMR. 
Fig. 1  Concerns over illegal antibiotics and    
‘colistin’ widely used, and MCR-1 resistant  
gene found in pig farms
Source: Kom Chad Leuk Newspaper, 23 Jan 2017 
B
Fig. 3 Pigs been injected with antibiotics




A 6.6 LSHTM poster 2020: How and why are antibiotics used in pig production in 
Thailand? 
How and why are antibiotics used in pig production 
in Thailand?
Improving health worldwide www.lshtm.ac.uk
Angkana Lekagul a, b, Anne Mills a, Jonathan Rushton c, 
Viroj Tangcharoensathien b, Marco Liverani a, Shunmay Yeunga
a London School of Hygiene & Tropical Medicine, UK,b International Health Policy Programme, Thailand, 
c Institute of Infection and Global Health, University of Liverpool, UK.
Fig. 1 Antibiotic use and factors influencing the use of antibiotics in pig production
A convergent parallel mixed-methods 
design  (March 2018-January 2019)
Methods
Introduction
• Antimicrobial resistance (AMR) is a growing 
threat to global health security. 
• Selective pressure driven by the use of
antibiotics in humans and animals 
accelerates the emergence of AMR.
• Of particular concern is the excessive, sub-
therapeutic use of antibiotics for disease 
prevention, in particular the Critically 
Important Antimicrobials (CIA), which are 
reserved as a last resort for the most severe 
and resistant human infections. 
• To date, only a few published studies have 
assessed the use of antibiotics for pig 




• Findings from this study found several hazardous practices associated with the use of 
antibiotics in pig production including the high proportion of the CIA group, the large 
volume of antibiotics used in medicated feed, and use for disease prevention by a high 
proportion of pig farmers.
• Factors which trigger high levels of antibiotic use include lack of farmers’ knowledge and 
awareness about antibiotics and AMR, limited veterinary health services, high cost of 
investment in farm biosecurity, economic incentives, and loose regulatory framework. 
• Collective and synergistic actions towards optimising use of antibiotics in livestock should 









Aim To investigate the patterns of antibiotic use and factors contributing to antibiotic 
use in pig production in Thailand. 
MIXED METHODS
Data collection
• Quantitative strand 
⁻ Farmer survey                
(84 farmers)
⁻ Feed mill survey              
(31 feed mills )
• Qualitative strand 







⁻ Interview with farmers and 
other stakeholders including 
animal drug retailers, 
veterinarians, and 





Factors influencing antibiotic 






• Trends in antibiotic use in pig 
farms (including type, route, 
purpose) are described
• The total national amount of 
antibiotics used in pig 
production through 
medicated feed is estimated
• Farmer characteristics are 
associated to the use of 
antibiotics 
• High use of antibiotics in the CIA group
Fig. 2 a) smallholder farm, b) commercial farm (sow barn), c) commercial farm (fattener barn) in the study and d) antibiotics storage in one of the study farms
*Farmers with education higher than primary school, with more years of experience in pig production, belonging to a farm cooperative 
and receiving advice on animal health were more likely to use antibiotics for disease prevention and CIA.
*No correlation was found between farmers’ knowledge of antibiotics and the use of antibiotics for disease prevention and CIA.
Antibiotic utilisation system
Pig production system
• National strategic plan on AMR 
- Well-known among stakeholders
- DLD’s initiative on “Livestock raised without 
antibiotics”
- Improve farmers’ awareness and knowledge 
about antibiotics and AMR
- Establish non-legal norms and standards  
- Strengthen regulations and enforcement
- Support the implementation of the national 
strategic plan on AMR. 
• Antibiotics not requiring a prescription could be easily 
accessed
• Market prices do not reflect the true cost to society of 
producing antibiotics—AMR
• Need the enforcement of recent regulations which 
require farms and feed mills to obtain a prescription 
for medicated feed
Facilitators to appropriate use Drivers of excessive use 
*Farms with higher income, commercial farms, GAP certified farms were positively associated with use of CIA
• More than 25,000 outlets for antibiotic sales
• Health professionals
- Had access to limited laboratory facilities and lack 
of clinical practice guidelines supporting 
appropriate prescription of antibiotics
- Lack of training on the rational use of antibiotics in 
health professionals’ curricula
• Pharmaceutical industry
- Promotion of antibiotics
- Potential conflict of interest between 
pharmaceutical industry and professional
• Access to reliable information sources
• Belief that antibiotic use can be reduced by 
good farm management and bio-security
• Limited knowledge about antibiotics, acquired 
knowledge from unreliable sources
• Limited access to public veterinary health services
• No awareness on AMR 
• Alternatives to antibiotics such as vaccines, 
probiotics, herbs 
Antibiotic use in pig production
• High share of pig farmers 
used antibiotics for disease 
prevention
• Large volume of antibiotics consumed 
through medicated feed
31% of farmers reported the use of CIA on farm
64% contained in medicated feed for pigs were CIA
57% of farmers
Total national amount of active ingredients mixed 
into medicated feed was estimated at 843 tonnes.
• High level of farm biosecurity • High cost investment in farm biosecurity
• Antibiotics were seen as more affordable than 
investments in bio-security




Appendix 7 Additional results from the farmer survey 
A 7.1 Pig farmers’ knowledge about antibiotics and AMR 
Table A7.1 Pig farmers’ knowledge about antibiotics and AMR (n=81)  
 Question  Respondent who 
answered “know” 
Do you know “antibiotic”? 48 (59.3) 
Do you know whether antibiotic use in food producing animals can 
induce AMR in those animals”? 
46 (56.8) 
Resistance to antibiotics is widespread in Thai pig farming 40 (49.4) 
Do you know whether Thailand ban using antibiotic as a growth 
promoter in food producing   animals? 
48 (59.3) 
  Respondent who gave 
correct answer 
Antibiotics kill the viruses (F) 23 (28.4) 
Antibiotics are effective against cold and flu (F) 17 (21) 
Antibiotic is anti-inflammation drug (F) 34 (42) 
Taking antibiotics too often has side-effects such as diarrhea (T) 17 (21) 
Unnecessary or unreasonable use of antibiotics have negative 






Appendix 8 Medically Important Antimicrobials  
Sources: World Health Organization (66)
CRITICALLY IMPORTANT ANTIMICROBIALS HIGHEST PRIORITY 
HIGHEST PRIORITY  HIGH PRIORITY 
• Cephalosporins (3rd and higher generation)    • Aminoglycosides  
• Glycopeptides   • Ansamycins 
• Macrolides and ketolides   • Carbapenems and other penems  
• Polymyxins    • Glycylcyclines  
• Quinolones   • Lipopeptides  
    • Monobactams  
    • Oxazolidinones 
    
• Penicillins (antipseudomonal, 
aminopenicillins, aminopenicillins 
with ß-lactamase inhibitors) 
    • Phosphonic acid derivatives 
    
• Drugs used solely to treat 
tuberculosis/ mycobacterial diseases 
HIGHLY IMPORTANT ANTIMICROBIALS 
• Amphenicols 
• Cephalosporins (1st and 2nd generation) and cephamycins 
• Lincosamides 
• Penicillins (amidinopenicillins, anti-staphylococcal, narrow spectrum)  
• Pseudomonic acids  
• Riminofenazines  
• Steroid antibacterials  
• Streptogramins 
• Sulfonamides, dihydrofolate reductase inhibitors and combinations  
• Sulfones 
• Tetracyclines 
 IMPORTANT ANTIMICROBIALS 
• Aminocyclitols  
• Cyclic polypeptides  
• Nitrofuran derivatives  





Appendix 9 Thailand’s National Strategic Plan on Antimicrobial Resistance 
2017-2021  
 
Source: Ministry of Public Health and Ministry of Agriculture and Cooperatives, National 
Strategic Plan on Antimicrobial Resistance 2017-2021 Thailand. Nonthaburi; 2016 
